<SEC-DOCUMENT>0001178913-12-001000.txt : 20120404
<SEC-HEADER>0001178913-12-001000.hdr.sgml : 20120404
<ACCEPTANCE-DATETIME>20120404162136
ACCESSION NUMBER:		0001178913-12-001000
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20120229
FILED AS OF DATE:		20120404
DATE AS OF CHANGE:		20120404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORAMED PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001176309
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980376008
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50298
		FILM NUMBER:		12742116

	BUSINESS ADDRESS:	
		STREET 1:		2 ELZA STREET
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			93706
		BUSINESS PHONE:		011 972-54-7909058

	MAIL ADDRESS:	
		STREET 1:		2 ELZA STREET
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			93706

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integrated Security Technologies, Inc.
		DATE OF NAME CHANGE:	20040614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IGUANA VENTURES LTD
		DATE OF NAME CHANGE:	20020625
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>zk1211274.htm
<DESCRIPTION>10-Q
<TEXT>
<html>
<head>
    <title>zk1211274.htm</title>
    <!--Licensed to: ZK Global-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Mark One)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">x</font> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the quarterly period ended February 29, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">o</font> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the transition period from _________ to _________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission file number: 000-50298</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in its Charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">98-0376008</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incorporation or Organization)</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Hi-Tech Park 2/5 Givat Ram</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PO Box 39098</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Jerusalem, Israel</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">91390</font></div>
</td>
</tr><tr>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Offices)</font></div>
</td>
<td valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">+ 972-2-566-0001</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's Telephone Number, Including Area Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">x</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">x</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</font></font></div>
</td>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">o</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of April 3, 2012 there were 70,320,583 shares of the issuer's Common Stock, <font style="DISPLAY: inline; FONT-SIZE: 10pt">$.001 par value,</font> outstanding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline"><a href="#part1">PART I &#8211; FINANCIAL INFORMATION</a></font></font></div>
</td>
<td align="right" valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item1">ITEM 1 - FINANCIAL STATEMENTS</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item2">ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item3">ITEM 3 &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item4">ITEM 4 - CONTROLS AND PROCEDURES</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#part2">PART II - OTHER INFORMATION</a></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item12">ITEM 1 - LEGAL PROCEEDINGS</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item22">ITEM 2 &#8211; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"><a href="#item6">ITEM 6 - EXHIBITS</a></font></font></div>
</td>
<td valign="top" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><a name="part1">PART </a>I &#8211; FINANCIAL INFORMATION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item1">ITEM </a>1 - FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;(A development stage company)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AS OF FEBRUARY 29, 2012</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;(A development stage company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AS OF FEBRUARY 29, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TABLE OF CONTENTS</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="92%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:</font></div>
</td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.2pt"></font><a href="#balance">Balance sheets</a></font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.2pt"></font><a href="#operation">Statements of operations</a></font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 3</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.2pt"></font><a href="#equity">Statements of changes in stockholders&#8217; equity</a></font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 4</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.2pt"></font><a href="#cash">Statements of cash flows</a></font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 5</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="92%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.2pt"></font><a href="#notes">Notes to financial statements</a></font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F - 6 - F - 13</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="balance">ORAMED </a>PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(<font style="DISPLAY: inline; FONT-WEIGHT: bold">A development stage company</font>)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(UNAUDITED)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. dollars</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="51%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">August 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="51%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assets</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT ASSETS:</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="51%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,824,141</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,513,365</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="51%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Short term deposits</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">838,738</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,801,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Marketable securities</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">341,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">384,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted cash</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable - other</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,668</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">542,891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,805</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Related parties</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">432</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grants receivable from the Chief Scientist</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,045</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,191</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 39.7pt"></font>T o t a l&#160;&#160;current assets</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,108,283</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,284,082</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LONG TERM DEPOSITS AND INVESTMENT</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,412</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,186</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON&#160;&#160;RETIREMENT</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,101</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,293</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">PROPERTY AND EQUIPMENT</font>, net</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,792</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,376</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T o t a l&#160;&#160;assets</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,142,588</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,325,937</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="51%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="51%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liabilities and stockholders' equity</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="51%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT LIABILITIES:</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">534,907</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">375,538</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Related parties</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,502</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Account payable with former shareholder</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T o t a l&#160;&#160;current liabilities</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">582,159</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">441,292</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LONG TERM LIABILITIES:</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employee rights upon retirement</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,982</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,675</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for uncertain tax position</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">138,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">138,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="51%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">162,036</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">COMMITMENTS </font>(note 2)</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T o t a l&#160;&#160;liabilities</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">744,195</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">602,021</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="51%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCKHOLDERS' EQUITY:</font></div>
</td>
<td valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock of $&#160;0.001 par value - authorized: 200,000,000 shares at February 29, 2012 and August 31, 2011; issued and outstanding: 70,187,583 shares at February 29, 2012 and 70,104,583 at August 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,104</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="26%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,339,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,201,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit accumulated during the development stage</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,011,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,547,299</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T o t a l&#160;&#160;stockholders' equity</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,398,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,723,916</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="51%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">T o t a l&#160;&#160;liabilities and stockholders' equity</font></div>
</td>
<td valign="bottom" width="26%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,142,588</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,325,937</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="operation">ORAMED </a>PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(<font style="DISPLAY: inline; FONT-WEIGHT: bold">A development stage company</font>)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(UNAUDITED)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. dollars</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from April</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12, 2002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(inception)</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Six months ended</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three months ended</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">through</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 28,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 28,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RESEARCH AND DEVELOPMENT EXPENSES</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">894,663</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">627,816</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">710,647</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">341,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,746,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">IMPAIRMENT OF INVESTMENT</font></div>
</td>
<td align="right" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">434,876</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GENERAL AND ADMINISTRATIVE EXPENSES</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">511,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">621,016</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">229,704</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">305,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,469,988</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OPERATING LOSS</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,406,268</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,248,832</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">940,351</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">647,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,651,376</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FINANCIAL INCOME</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,528</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,045</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,574</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,856</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(208,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FINANCIAL EXPENSES</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,043</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,788</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,487</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,432</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">210,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GAIN ON SALE OF INVESTMENT</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,033,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,523</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LOSS BEFORE TAXES ON INCOME</font></div>
</td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,245,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">985,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">642,791</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,860,635</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TAXES ON INCOME</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,558</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS FOR THE PERIOD</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,245,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">985,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">642,791</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,011,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BASIC AND DILUTED LOSS PER COMMON SHARE</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="37%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK</font></div>
</td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,140,610</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,344,880</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,176,638</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,804,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></font></div>

<br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="equity">ORAMED </a>PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(UNAUDITED)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. dollars</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deficit</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">accumulated</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td rowspan="2" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td rowspan="2" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" rowspan="2" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>
</div>
</td>
<td nowrap rowspan="2" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">during the</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">paid-in</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">development</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">stockholders'</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">capital</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">stage</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">equity</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">BALANCE AS OF APRIL 12, 2002</font> (inception)</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,828,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,828</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,872</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CHANGES DURING THE PERIOD FROM APRIL 12, 2002 THROUGH</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">AUGUST 31, 2010 :</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES CANCELLED</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(19,800,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(19,800</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,800</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR INVESTMENT IN ISTI-NJ</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,144,410</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,144</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">433,732</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">434,876</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR OFFERING COSTS</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,752,941</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,753</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,753</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES AND WARRANTS ISSUED FOR CASH&#8211; NET OF ISSUANCE EXPENSES</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,359,230</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,359</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,870,422</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,907,781</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR&#160;&#160;SERVICES</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,730,540</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,731</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">819,606</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">821,337</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTRIBUTIONS TO PAID IN CAPITAL</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RECEIPTS ON ACCOUNT OF SHARES</font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AND WARRANTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">550,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">550</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">274,450</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">275,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,554,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,554,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">615,882</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">615,882</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER COMPREHENSIVE LOSS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">IMPUTED INTEREST</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,986,038</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,986,038</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BALANCE AS OF AUGUST 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,565,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,758,761</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(12,986,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">830,272</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR&#160;&#160;SERVICES RENDERED</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">730,636</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">731</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">226,838</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">227,569</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES AND WARRANTS ISSUED FOR CASH</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,808,626</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,808</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,682,404</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,694,212</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">502,593</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">502,593</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,733</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,733</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">IMPUTED INTEREST</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,782</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,782</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,561,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,561,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BALANCE AS OF AUGUST 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,104,583</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,104</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,201,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,547,299</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,723,916</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES ISSUED FOR&#160;&#160;SERVICES</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SHARES TO BE ISSUED FOR&#160;&#160;SERVICES RENDERED</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,136</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,136</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BALANCE AS OF FEBRUARY 29, 2012</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,187,583</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,339,399</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,011,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,398,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><a name="cash">ORAMED </a>PHARMACEUTICALS INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(<font style="DISPLAY: inline; FONT-WEIGHT: bold">A development stage company</font>)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CONDENSED<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>CONSOLIDATED<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>STATEMENTS OF CASH FLOWS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(UNAUDITED)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">U.S. dollars</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Six months ended</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period from April 12, 2002 (inception date) through</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 28,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,245,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,011,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments required to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,713</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">117,820</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt discount</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exchange differences</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,963</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">295</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock based compensation</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,036</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">335,797</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,783,165</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock issued for services</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,900</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,800</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,072,996</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock to be issued for services</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,435</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on sale of investment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,033,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Impairment of investment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">434,876</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Impairment of available for sales securities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,523</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Imputed interest</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,559</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.35pt"></font>Changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,802</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,124</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(87,140</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted cash</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">140,867</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">107,249</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">534,907</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liability of employee rights upon retirement</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,307</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,982</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Provision for uncertain tax position</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">138,054</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 25.5pt"></font>Total net cash used in operating activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,094,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(695,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(9,638,725</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,129</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(125,612</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acquisition of short-term investments, net</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">961,262</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,677,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,467,120</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Funds in respect of employee rights upon retirement</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,597</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,890</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of&#160;&#160;investment in Entera</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">450,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">450,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of&#160;&#160;Short term investments</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,628,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Lease deposits</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,509</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 25.5pt"></font>Total net cash derived from (used in) investing activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,405,536</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,678,475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(540,131</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font id="TAB1" style="MARGIN-LEFT: 8.5pt"></font>CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of common stock and</font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">warrants - net of issuance expenses</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,106,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,655,693</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receipts on account of shares issuances</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,061</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from convertible notes</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">275,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from short term note payable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments of short term note payable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(120,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shareholder advances</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,243</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 8.5pt"></font>Net cash provided by financing activities</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,106,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,002,997</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INCREASE IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">310,776</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">732,123</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,824,141</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,513,365</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,199,638</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CASH AND CASH EQUIVALENTS AT END OF PERIOD</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,824,141</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,931,761</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,824,141</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non cash investing and financing activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Shares issued for offering costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,753</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="64%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Contribution to paid in capital</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Discount on convertible note related to beneficial</font></div>

<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">conversion feature</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The accompanying notes are an integral part of the condensed consolidated financial statements.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<div>&#160;</div>

<div>
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="notes">ORAMED </a>PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div>
</div>

<div>&#160;</div>

<div>
<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.55pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oramed Pharmaceuticals, Inc. (the &#8220;Company&#8221;) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement (the &#8220;First Agreement&#8221;) with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. The Company has been in the development stage since its formation and has not yet realized any revenues from its planned operations. <font style="DISPLAY: inline; FONT-SIZE: 10pt">On March 11, 2011, Oramed was reincorporated from the State of Nevada to the State of Delaware.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term &#8220;Group&#8221; refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd (the &#8220;Subsidiary&#8221;).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with Accounting Standard Codification ("ASC") No. 915, &#8220;Development Stage Entities&#8221;.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.55pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements as of February 29, 2012 and for the six months then ended, have been prepared in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required for annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. The accounting principles applied in the preparation of the condensed statements are consistent with those applied in the preparation of the annual financial statements, however the condensed statements do not include all the information and explanations required for the annual financial statements. Operating results for the six months ended February 29, 2012, are not necessarily indicative of the results that may be expected for the year ending August 31, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="DISPLAY: inline; FONT-WEIGHT: bold">:</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.55pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Going concern considerations</font></div>

<div align="left">&#160;</div>

<div align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (April&#160;12, 2002) through February 29, 2012 of $16,011,193 as well as negative cash flow from operating activities. Presently, the Company does not have sufficient cash resources to meet its requirements in the twelve months following February 29, 2012. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives as the Company will need to finance future research and development activities and general and administrative expenses through fund raising<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders, as well as on going funding from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel ("OCS").</font></div>
</div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 112pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability<font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Newly issued and recently adopted Accounting Pronouncements</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.55pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2011, the Financial Accounting Standard Board ("FASB") issued an accounting update that amends ASC No. 820, "Fair Value Measurement" regarding fair value measurements and disclosure requirements. The amendments are effective during interim and annual periods beginning after December&#160;15, 2011 and are to be applied prospectively. The accounting update will be applicable to the Company beginning in the third quarter of fiscal year 2012. As applicable to the Company, the adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 76.55pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2011, the FASB issued an update to ASC No.&#160;220, &#8220;Presentation of Comprehensive Income,&#8221; which eliminates the option to present other comprehensive income and its components in the statement of shareholders&#8217; equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The accounting update will be applicable to the Company beginning on September 1, 2012. The adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 2 - </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS</font>:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">a.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the First Agreement with Hadasit (note 1a(1) above), the Company retained Hadasit to provide consulting and clinical trial services. As remuneration for the services provided under the agreement, Hadasit is entitled to $200,000. The primary researcher for Hadasit is Dr. Miriam Kidron, a director and officer of the Company. The funds paid to Hadasit under the agreement are deposited by Hadasit into a research fund managed by Dr. Kidron. Pursuant to the general policy of Hadasit with respect to its research funds, Dr. Kidron receives from Hadasit a management fee in the rate of 10% of all the funds deposited into this research fund. The total amount paid to Dr. Kidron out of this fund was $10,214.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 7, 2009, the Company entered into a second agreement with Hadasit (the &#8220;Second Agreement&#8221;) which confirms that Hadasit has conveyed, transferred and assigned all of its ownership rights in the patents acquired under the First Agreement to the Company, and certain other patents filed by the Company after the First Agreement as a result of the collaboration between the Company and Hadasit.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 8, 2009 the Company entered into a third agreement with Hadasit, Prof. Itamar Raz and Dr. Miriam Kidron ("the Third Agreement"), to retain consulting and clinical trial services from Hadasit. According to the Third Agreement, Hadasit will be entitled to total consideration of $400,000 to be paid by Oramed. $200,000 of this amount was agreed in the terms of the First Agreement, and the remaining of $200,000 will be paid in accordance with the actual progress of the study. The total amount that was paid through February 29, 2012 was $400,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 11, 2011, the Company entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr ("the Fourth Agreement"), to retain consulting and clinical trial services. According to the Fourth Agreement, Hadasit will be entitled to consideration of $200,000 to be paid by the Company, none of which was recognized or paid through February 29, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">b.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 18, 2012, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012. The monthly lease payment will be NIS 3,400 in 2012, NIS 4,225 in 2013 and NIS 5,610 from 2014 onwards, and will be linked to the increase in the Israeli consumer price index (as of February 29, 2012, the monthly payment in the Company's functional currency is $903, the future annual lease payments under the agreement will be $10,836 - $17,878).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As security for its obligation under the lease agreements the Subsidiary provided a bank guarantee in an amount equal to three monthly lease payments. valid until November 30, 2016.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 2 - </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">(continued)</font>:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">c.</font></font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 21, 2009, the Subsidiary entered into a consulting service agreement with<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>ADRES Advanced Regulatory Services Ltd. (&#8220;ADRES&#8221;) (the "Original Agreement") pursuant to which ADRES will provide consulting services relating to quality assurance and regulatory processes and procedures in order to assist the Subsidiary in submission of a U.S. Investigational New Drug (&#8220;IND&#8221;) according to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) regulations. In consideration for the services provided under the agreement, ADRES will be entitled to total cash compensation of $211,000, of which the amount of $110,000 will be paid as a monthly fixed fee of $10,000 each month for 11 months commencing May 2009, and the remaining $101,000 will be paid based on achievement of certain milestones. $160,000 of the total amount was paid through November 30, 2011, $50,000 of which was paid for completing the first three milestones.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 26, 2012, the parties entered into an amendment agreement, according to which the Subsidiary will pay the remaining $51,000 of the Original Agreement upon issuance the amendment agreement. In addition, beginning March 1, 2012 and until submission of the IND, the Subsidiary will pay ADRES a monthly fee of approximately $3,600<font style="DISPLAY: inline; FONT-SIZE: 10pt">. </font>The Company recognized the $51,000 as an expense through February 29, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">d.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 10, 2010, the Subsidiary entered into an agreement with Vetgenerics Research G. Ziv Ltd, a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. The total cost estimated for the studies is &#8364;107,100 ($143,831) of which &#8364;89,293 ($120,029) was paid through February 29, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">e.</font></font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant&#8221;) for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on February 22, 2011 and an option to purchase up to 250,000 shares of common stock, par value $0.001 per share, of the Company at an exercise price of $0.50 per share. The option vest in five annual installments commencing February 16, 2012 and expire on February 16, 2021. The initial fair value of the option on the date of grant was $71,495, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 113.80%; risk-free interest rates of 3.42%; and the remaining contractual life of 10 years. The fair value of the options granted is measured on a final basis at each balance sheet reporting date and is recognized over the related service period using the straight-line method.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 2 - </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">(continued)</font>:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">f.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 13, 2011, the Company entered into a consulting agreement with a third party (the "Consultant&#8221;) for a period of 12 months, pursuant to which the Consultant will provide investor relations services and will be entitled to a cash monthly fee of $4,000, that may be increased up to $10,000 upon the completion of a $5,000,000 capital raise by the Company. In addition, the Consultant received a warrant to purchase up to 32,000 shares of the Company. The warrant has a term of five years and an exercise price of $0.50 per Share and will vest in 12 installments in the period from October 2011 to May 2016. The Company records expenses in respect of this warrant during the term of the services.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 72pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">g.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June 22, 2011, the Subsidiary issued a purchase order to SAFC Pharma for producing one of its oral capsule ingredients in the amount of $600,000, $170,000 of which was recognized through February 29, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">h.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 15, 2011, the Company entered into an advisory agreement with a third party (the "Advisor&#8221;) for a period of nine months, pursuant to which the Advisor will provide investors relations services and will be entitled to a cash monthly fee of $4,000, and an additional $3,000 in the first month. In addition, the Advisor will be issued 249,000 shares of the Company's common stock in three equal installments over the engagement period, commencing November 2011. See also notes 4 and 5.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">i.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 12, 2011, the Subsidiary entered into a Supply Agreement with Swiss Caps AG ("Swiss Caps"), according to which, Swiss Caps will manufacture insulin capsules for a total consideration of CHF 395,000 (approximately $440,600) of which CHF 180,000 (approximately $195,600) was paid through February 29, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">j.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 300,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 750,000 shares of common stock of the Company. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 monthly installments over the term of the agreement. The Company records expenses in respect of this warrant during the term of the services. See also note 5.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">k.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants from Bio-Jerusalem</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Subsidiary is committed to pay royalties to Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $52,733.&#160;&#160;As of February 29, 2012, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the six month period ended February 29, 2012, there were no grants received from the Bio-Jerusalem fund.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 2 - COMMITMENTS </font>(continued):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">l.</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grants from the Office of the Chief Scientist ("OCS")</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Subsidiary is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At the time the grants were received, successful development of the related products was not assured. In case of failure of a product that was partly financed as above, the Subsidiary is not obligated to pay any such royalties.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the Subsidiary's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Subsidiary (dollar linked) with the addition of annual interest at a rate based on LIBOR.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of February 29, 2012, the Subsidiary had not yet realized any revenues from such product and did not incur any royalty liability. The total amount received through February 29, 2012 was $1,078,545.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 75.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the six month period ended February 29, 2012, the research and development expenses are presented net of OCS grants, in the total amount of $57,038.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 3 - FAIR VALUE:</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.699pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 3 - FAIR VALUE</font> (continued):</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Marketable securities consist wholly of equity securities of D.N.A Biomedical Solutions Ltd. which were received in March 2011 as part of the consideration for selling the Company's equity method investee Entera. Those securities are classified as available-for-sale and are recorded at fair value.&#160;&#160;The D.N.A Shares are listed on the Tel Aviv Stock Exchange ("TASE") and their tradability was restricted for a period of 6 months from the closing date of the transaction according to TASE policy with regards to private placements. Until September 30, 2011, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market. As of October 1, 2011, the securities are not restricted and the fair value of the securities is measured based on the quoted prices of the securities on an active market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div align="left">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Transfers in and/or out of Level 3 are recognized in the beginning of the reporting period.</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 8.1pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial items carried at fair value as of February 29, 2012 and August&#160;31, 2011 are classified in the tables below in one of the three categories described above:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="14" valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair value measurements at&#160;reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">date using</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="52%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Marketable securities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">February 29, 2012</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">341,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">341,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="52%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">August 31, 2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">384,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">384,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 39.7pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Six months ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">February 29,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unaudited</font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="85%">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carrying value at the beginning of the period</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">384,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification to level 1</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(384,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carrying value at the end of the period</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS, Inc.</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A development stage company)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)</font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 4 - STOCK HOLDERS&#8217; EQUITY:</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160; On December 12, 2011, the Company issued 83,000 shares of its common stock to the Advisor as remuneration for services provided. The fair value of the shares at the date of grant was $24,900. See also note 2h.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 5 - SUBSEQUENT EVENTS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160; On March 14, 2012, the Company issued 83,000 and 50,000 shares of its common stock, respectively, to two advisory companies as remuneration for services provided. The fair values of the shares at the date of grant were $24,070 and $14,500 respectively. See also notes 2h and 2j.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item2">ITEM </a>2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and in our condensed consolidated financial statements, accompanying notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended August 31, 2011.&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Quarterly&#160;Report on Form 10-Q (including the section regarding Management's Discussion and Analysis of Financial Condition and Results of Operations) contains forward-looking statements regarding our business, clinical trials, financial condition, expenditures, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Quarterly&#160;Report on Form 10-Q.&#160;&#160;Additionally, statements concerning future matters are forward-looking statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although forward-looking statements in this Quarterly<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under "Item 1A &#8211; Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended August 31, 2011, and filed with the Securities and Exchange Commission (the &#8220;SEC&#8221; or the &#8220;Commission&#8221;) on November 29, 2011, as well as those discussed elsewhere in our annual report and in this Quarterly<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>Report on Form 10-Q. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>Report on Form 10-Q. Except as required by law, we undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>Report on Form 10-Q. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this Quarterly<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>Report on Form 10-Q which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As used in this Quarterly Report on Form 10-Q, the terms &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline">we</font>&#8221;, &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline">us</font>&#8221;, &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline">our</font>&#8221;, the &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline">Company&#8221;</font>, and &#8220;<font style="FONT-STYLE: italic; DISPLAY: inline">Oramed</font>&#8221; mean Oramed Pharmaceuticals Inc. and our subsidiary, Oramed Ltd., unless otherwise indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All dollar amounts refer to U.S. dollars unless otherwise indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Overview of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Business Developments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 11, 2011, we entered into a fourth agreement with <font style="DISPLAY: inline; FONT-SIZE: 10pt">Hadasit Medical Services and Development Ltd. </font>("Hadasit"), Dr. Miriam Kidron and Dr. Daniel Schurr (the "Fourth Agreement"), to facilitate clinical trials and provide other services. According to the Fourth Agreement, Hadasit will be entitled to a consideration of $200,000. The terms and conditions of the Fourth Agreement are substantially similar to those of the previous Hadasit agreements, which are described in our Annual Report on Form 10-K for the fiscal year ended August 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 10, 2012, we announced the filing of a provisional patent application with the United States Patent and Trademark Office for a combination therapy of our lead compound, ORMD0801 in combination with our oral exenatide formulation, ORMD0901.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 24, 2012, we announced the issuance of a patent by the Australian Patent Office<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>that covers a part of our technology which allows for the oral delivery of peptides.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 12, 2011, we entered into a Supply Agreement (the "Supply Agreement") with Swiss Caps AG ("Swiss Caps"), according to the which, Swiss Caps will manufacture insulin capsules for total consideration of CHF 395,000 (approximately $440,600).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 26, 2012, we entered into an amendment agreement with ADRES Advanced Regulatory Services Ltd. (&#8220;ADRES&#8221;), according to which we will pay the remaining $51,000 of the original agreement with ADRES upon issuance the amendment agreement. In addition, beginning March 1, 2012 and until submission of the IND, we will pay ADRES a monthly fee of approximately $3,600.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Short Term Business Strategy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We plan to conduct further research and development on the technology covered by the patent application "Methods and Composition for Oral Administration of Proteins", which we acquired from Hadasit, as well as the other patents we have filed since.&#160;&#160;Through our research and development efforts, we are seeking to develop an oral dosage form that will withstand the harsh chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. The enzymes and vehicles that are added to the insulin in the formulation process must not modify the insulin chemically or biologically, and the dosage form must be safe to ingest. We plan to continue to conduct clinical trials to show the effectiveness of our technology.&#160;&#160;We intend to conduct the clinical trials necessary to file an Investigational New Drug (&#8220;IND&#8221;) application with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;).&#160;Additional clinical trials are planned in other countries such as Israel, India and South Africa, in order to substantiate our results as well as for purposes of making future filings for drug approval in these countries. We also plan to conduct further research and development by deploying our proprietary drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other innovative pharmaceutical products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long Term Business Strategy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If our oral insulin capsule or other drug delivery solutions show significant promise in clinical trials, we plan to ultimately seek a strategic commercial partner, or partners, with extensive experience in the development, commercialization, and marketing of insulin applications and/or other orally digestible drugs. We anticipate such partner or partners would be responsible for, or substantially support, late stage clinical trials (Phase III) to increase the likelihood of obtaining regulatory approvals and registrations in the appropriate markets in a timely manner. We further anticipate that such partner, or partners, would also be responsible for sales and marketing of our oral insulin capsule in these markets. Such planned strategic partnership, or partnerships, may provide a marketing and sales infrastructure for our products as well as financial and operational support for global clinical trials, post marketing studies, label expansions and other regulatory requirements concerning future clinical development in the United States and elsewhere. Any future strategic partner, or partners, may also provide capital and expertise that would enable the partnership to develop new oral dosage form for other polypeptides. While our strategy is to partner with an appropriate party, no assurance can be given that any third party would be interested in partnering with us. Under certain circumstances, we may determine to develop one or more of our oral dosage form on our own, either world-wide or in select territories.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Planned Strategic Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to developing our own oral dosage form drug portfolio, we are, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand our current product portfolio. Our goal is to create a well-balanced product portfolio that will enhance and complement our existing drug portfolio.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Product Development</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Orally Ingestible Insulin</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During fiscal year 2007 we conducted several clinical studies of our orally ingestible insulin. The studies were intended to assess both the safety/tolerability and absorption properties of our proprietary oral insulin. Based on the pharmacokinetic and pharmacologic outcomes of these trials, we decided to continue the development of our oral insulin product.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2007, we successfully completed animal studies in preparation for the Phase 1B clinical trial of our oral insulin capsule (ORMD0801).&#160;&#160;In January 2008, we commenced the non-FDA approved Phase 1B clinical trials with our oral insulin capsule, in healthy human volunteers with the intent of dose optimization.&#160;&#160;In March 2008, we successfully completed our Phase 1B clinical trials.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2008, we commenced a non-FDA approved Phase 2A study to evaluate the safety and efficacy of our oral insulin capsule (ORMD0801) in type 2 diabetic volunteers at Hadassah Medical Center in Jerusalem. In August 2008, we announced the successful results of this trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2008 we were granted approval by the Institutional Review Board Committee of Hadassah Medical Center in Jerusalem to conduct a non-FDA approved Phase 2A study to evaluate the safety and efficacy of our oral insulin capsule (ORMD0801) on type 1 diabetic volunteers. In September 2008, we announced the beginning of this trial. In July 2009, we reported positive results from this trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In&#160;April 2009, we entered into a consulting service agreement with ADRES, pursuant to which ADRES will provide services for the purpose of filing an IND application with the FDA for a Phase 2 study according to the FDA requirements. The FDA approval process and, if approved, registration for commercial use as an oral drug can take several years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2009, we commenced a non-FDA approved Phase 2B study in South Africa to evaluate the safety, tolerability and efficacy of our oral insulin capsule (ORMD0801) on type 2 diabetic volunteers. In May 2010, we reported that the capsule was found to be well tolerated and exhibited a positive safety profile. No cumulative adverse effects were reported throughout this first study of extended exposure to the capsule.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, we entered into agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on our oral insulin capsules. In March 2011, we reported that we successfully completed the resulting comprehensive toxicity study for our oral insulin capsule (ORMD0801). The study was completed under conditions prescribed by the FDA Good Laboratory Practices regulations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2010, we reported the successful results of an exploratory clinical trial testing the effectiveness of our oral insulin capsule (ORMD0801) in type 1 diabetes patients suffering from uncontrolled diabetes.&#160;&#160;Unstable or labile diabetes is characterized by recurrent, unpredictable and dramatic blood glucose swings often linked with irregular hyperglycemia and sometimes serious hypoglycemia affecting type 1 diabetes patients.&#160;&#160;This exploratory study was a proof of concept study for defining a novel indication for ORMD0801. We believe the encouraging results justify further clinical development of&#160;ORMD0801 capsule application toward management of uncontrolled diabetes.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We intend to file an IND application with the FDA for Phase 2 clinical studies of our orally ingested insulin during the fourth calendar quarter of 2012. If we do not receive comments from the FDA on our IND application within 30 days from submission, we intend to immediately commence an FDA approved Phase 2 study to evaluate the safety, tolerability and efficacy of our oral insulin capsule (ORMD0801) on type 2 diabetic volunteers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">GLP-1 Analog</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2008 we announced the launch of pre-clinical trials of ORMD0901, a GLP-1-analog.&#160;&#160;The pre-clinical trials include animal studies which suggest that&#160;the GLP-1 analog (exenatide-4) when combined with Oramed&#8217;s absorption promoters is absorbed through the gastrointestinal tract and&#160;retains its biological activity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Glucagon-like peptide-1 (GLP-1) is an incretin hormone - a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The incretin concept was hypothesized when it was noted that glucose ingested by mouth (oral) stimulated two to three times more insulin release than the same amount of glucose administered intravenously. In addition to stimulating insulin release, GLP-1 was found to suppress glucagon release (hormone involved in regulation of glucose) from the pancreas, slow gastric emptying to reduce the rate of absorption of nutrients into the blood stream, and increase satiety. Other important beneficial attributes of GLP-1 are its effects of increasing the number of beta cells (cells that manufacture and release insulin) in the pancreas and, possibly, protection of the heart.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2009, we received approval from the Institutional Review Board in Israel to commence human clinical trials of an oral GLP-1 analog. The approval was granted after successful pre-clinical results were reported. The trials are being conducted on healthy volunteers at Hadassah University Medical Center in Jerusalem. Oramed&#8217;s first-in-humans clinical trial is testing the safety and efficacy of ORMD0901, an encapsulated oral GLP-1 analog formulation. The study monitored the responses of healthy males to a single dose delivered 60 minutes before a glucose load.&#160;&#160;ORMD0901 was well tolerated by all subjects and demonstrated physiological activity, as extrapolated from ensuing subject insulin levels when compared to those observed after treatment with placebo.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="f8k081704_htm__toc30568433"><!--EFPlaceholder--></a><a name="f8k081704_htm__toc30569135"><!--EFPlaceholder--></a>Raw Materials</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our oral insulin capsule is currently manufactured by Swiss Caps, under the Supply Agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, our subsidiary, Oramed Ltd., entered into a Manufacturing Supply Agreement ("MSA") with Sanofi-Aventis Deutschland GMBH ("Sanofi-Aventis"). According to the MSA, Sanofi-Aventis will supply our subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We purchase the raw materials required for the manufacturing of the capsule from third parties, under separate agreements.&#160;&#160;&#160;We <a name="Elo49C"><!--EFPlaceholder--></a>generally depend upon a limited number of suppliers for the raw materials.&#160;&#160;Although alternative sources of supply for these materials are generally available, we could incur significant costs and disruptions in changing suppliers.&#160;&#160;The termination of our relationships with our suppliers or the failure of these suppliers to meet our requirements for raw materials on a timely and cost-effective basis could materially adversely affect <a name="El999O"><!--EFPlaceholder--></a>our business, prospects, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents and Licenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We maintain a proactive intellectual property strategy which includes patent filings in multiple jurisdictions, including the United States and other commercially significant markets. We hold 36 patent applications currently pending, with respect to various compositions, methods of production and oral administration of proteins and exenatide. Expiration dates for pending patents will fall between 2026 and 2032.<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font> We also hold one patent issued by the Australian Patent Office<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>that covers a part of our technology which allows for the oral delivery of peptides.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consistent with our strategy to seek protection in key markets worldwide, we have been and will continue to pursue the patent applications and corresponding foreign counterparts of such applications.&#160;&#160;We believe that our success will depend on our ability to obtain patent protection for our intellectual property.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our patent strategy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Aggressively</font> <font style="FONT-STYLE: italic; DISPLAY: inline">protect</font> all current and future technological developments to assure strong and broad protection by filing patents and/or continuations in part as appropriate;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;</font><font id="TAB2" style="LETTER-SPACING: 9pt; COLOR: black"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Protect</font> <font style="FONT-STYLE: italic; DISPLAY: inline">technological</font> developments at various levels, in a complementary manner, including the base technology, as well as specific applications of the technology; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;<font id="TAB2" style="LETTER-SPACING: 9pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Establish</font> <font style="FONT-STYLE: italic; DISPLAY: inline">comprehensive</font> coverage in the United States and in all relevant foreign markets in anticipation of future commercialization opportunities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The validity, enforceability, written supports, and breadth of claims in our patent applications involve complex legal and factual questions and, therefore, may be highly uncertain. No assurance can be given that any patents based on pending patent applications or any future patent applications filed by us will be issued, that the scope of any patent protection will exclude competitors or provide competitive advantages to us, that any of the patents that have been or may be issued to us will be held valid or enforceable if subsequently challenged, or that others will not claim rights in or ownership of the patents and other proprietary rights held or licensed by us. Furthermore, there can be no assurance that others have not developed or will not develop similar products, duplicate any of our technology or design around any patents that have been or may be issued to us. Since patent applications in the United States are maintained in secrecy for the initial period of time following filing, we also cannot be certain that others did not first file applications for inventions covered by our pending patent applications, nor can we be certain that we will not infringe any patents that may be issued to others on such applications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We also rely on trade secrets and unpatentable know-how that we seek to protect, in part, by confidentiality agreements. Our policy is to require our employees, consultants, contractors, manufacturers, outside scientific collaborators and sponsored researchers, board of directors, technical review board and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific limited circumstances. We also require signed confidentiality or material transfer agreements from any company that is to receive our confidential information. In the case of employees, consultants and contractors, the agreements provide that all inventions conceived by the individual while rendering services to us shall be assigned to us as the exclusive property of our company. There can be no assurance, however, that all persons who we desire to sign such agreements will sign, or if they do, that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets or unpatentable know-how will not otherwise become known or be independently developed by competitors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success will also depend in part on our ability to commercialize our technology without infringing the proprietary rights of others. No assurance can be given that patents do not exist or could not be filed which would have an adverse effect on our ability to market our technology or maintain our competitive position with respect to our technology. If our technology components, products, processes or other subject matter are claimed under other existing United States or foreign patents or are otherwise protected by third party proprietary rights, we may be subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be required to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances that we would be able to obtain such licenses or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore, the failure to either develop a commercially viable alternative or obtain such licenses could result in delays in marketing our proposed technology or the inability to proceed with the development, manufacture or sale of products requiring such licenses, which could have a material adverse effect on our business, financial condition and results of operations. If we are required to defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease the development and commercialization of our technology.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Partnerships and Collaborative Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that working together with strategic partners will expedite product formulation, production and approval.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2006, we entered into an agreement with Hadasit to facilitate clinical trials and provide other services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2006, we entered into a Clinical Trial Manufacturing Agreement with Swiss Caps, pursuant to which Swiss Caps currently manufactures the oral insulin capsule developed by us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During April 2008, we entered into a five year master services agreement with SAFC Pharma, an operating division of Sigma-Aldrich, Inc., a leading developer, manufacturer and distributor of chemicals and biochemicals, pursuant to which SAFC is providing services for individual projects, which may include strategic planning, expert consultation, clinical trial services, statistical programming and analysis, data processing, data management, regulatory, clerical, project management, central laboratory services, pre-clinical services, pharmaceutical sciences services, and other research and development services.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In&#160;April 2009, we entered into a consulting service agreement with ADRES pursuant to which ADRES will provide services for the purpose of filing an IND application with the FDA for a Phase 2 study in accordance with FDA requirements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2009 we entered into an additional agreement with Hadasit, to facilitate additional clinical trials to be performed at Hadassah Medical Center in Jerusalem.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4.1pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, we entered into agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on our oral insulin capsules.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -4.1pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2010, we entered into an additional agreement with SAFC Pharma, to develop a process to produce one of our oral capsule ingredients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, our subsidiary, Oramed Ltd., entered into an MSA with Sanofi-Aventis. Pursuant to the MSA, Sanofi-Aventis will supply our subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May 2011, we entered into a consulting agreement with a third party for a period of 12 months, pursuant to which such consultant will provide investor relations services and will be entitled to a cash monthly fee of $4,000, that may be increased up to $10,000 upon the completion of a $5,000,000 capital raise by us. In addition, the consultant received a warrant to purchase up to 32,000 shares of our common stock. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 installments during the period from October 2011 to May 2016.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2011, we entered into a consulting agreement with a third party for a period of nine months, pursuant to which such consultant will provide investor relations services and will be entitled to a cash monthly fee of $4,000, and an additional $3,000 in the first month. In addition, the consultant will be issued 249,000 shares of our common stock in three installments over the engagement period, commencing November 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2011, we entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Fourth Agreement"), to facilitate clinical trials and provide other services. According to the Fourth Agreement, Hadasit will be entitled to a consideration of $200,000. The terms and conditions of the Fourth Agreement are substantially similar to those of the previous Hadasit agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011, we entered into a Supply Agreement with Swiss Caps, according to the which, Swiss Caps will manufacture insulin capsules for total consideration of CHF 395,000 (approximately $440,600).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2012, we entered into an advisory agreement with a third party (the "Advisor&#8221;) for a period of one year, pursuant to which the Advisor will provide investors relations services and will be entitled to a share based compensation as follows: 300,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing as of February 15, 2012, and a warrant to purchase 750,000 shares of common stock of the Company. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 monthly installments over the term of the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Out-Licensed Technology</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In June 2010, our subsidiary, Oramed Ltd., entered into a joint venture agreement with D.N.A Biomedical Solutions Ltd. (formerly Laser Detect Systems Ltd), an Israeli company listed on the Tel Aviv Stock Exchange ("D.N.A"), for the establishment of a new company to be called Entera Bio Ltd. ("Entera").</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of a license agreement that was entered into between Oramed and Entera in August 2010, we out-licensed technology to Entera, on an exclusive basis, for the development of oral delivery drugs for certain indications to be agreed upon between the parties.&#160; The out-licensed technology differs from our main delivery technology that is used for oral insulin and GLP-1 analog and is subject to different patent applications. Entera's initial development effort is for an oral formulation for the treatment of osteoporosis. The license was royalty-free unless our ownership interest in Entera decreased to 30% or less of its outstanding share capital, in which case royalties would have been payable with respect to revenues derived from certain indications. Under certain circumstances, Entera may have received ownership of the licensed technology, in which case we would have received a license back on the same terms.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">D.N.A initially invested $600,000 in Entera, and Entera was initially owned in equal parts by Oramed and D.N.A. Entera's Chief Executive Officer, Dr. Phillip Schwartz, was granted options to purchase ordinary shares of Entera, reflecting 9.9% of Entera's share capital, upon full exercise.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 31, 2011, we consummated a transaction with D.N.A, whereby we sold to D.N.A 47% of Entera's outstanding share capital on an undiluted basis. As consideration for the Entera shares, we received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, to be paid within four months after closing, and 8,404,667 ordinary shares of D.N.A, having an aggregate market value of approximately $581,977 as of March 31, 2011.&#160; The promissory note was secured by a personal guarantee of the D.N.A majority shareholders and its term was extended by an Addendum to the Share Purchase agreement dated August 11, 2011.&#160;&#160;D.N.A paid off the promissory note in November 2011. The ordinary shares of D.N.A were restricted for six months from the closing. In addition, D.N.A invested $250,000 in our private placement investment round, which closed in February 2011, for which it received 781,250 shares of our common stock and five-year warrants to purchase 273,438 shares of common stock at an exercise price of $0.50 per share.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the transaction with D.N.A, we entered into a patent transfer agreement (to replace the original license agreement upon closing) pursuant to which Oramed assigned to Entera all of its right, title and interest in and to the patent application that it had licensed to Entera in August 2010.&#160;&#160;Under this agreement, our subsidiary, Oramed Ltd., is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 31, 2011, Oramed, Entera and D.N.A terminated the joint venture agreement entered into in June 2010 in connection with the formation of Entera.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2011, Entera reported successful Phase 1 clinical trial results. We believe the Phase 1 data supports the continued development of Entera&#8217;s oral osteoporosis drug. The Phase 1 clinical trial consisted of twelve healthy patients and was conducted at the Hadassah Medical Center in Jerusalem. No adverse events were reported.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Going concern assumption</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The financial statements appearing elsewhere in this quarterly report have been prepared assuming that we will continue as a going concern. We have net losses for the period from inception (April 12, 2002) through February 29, 2012 of $16,011,193, as well as negative cash flow from operating activities. Based upon our existing spending commitments, estimated at $5.7 million for the twelve months following February 29, 2012, and our cash availability, we do not have sufficient cash resources to meet our liquidity requirements through February 28, 2013. Accordingly, these factors raise substantial doubt about our ability to continue as a going concern. Management is in the process of evaluating various financing alternatives, as we will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that we will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The financial statements do not include any adjustments that may be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent on our ability to obtain additional financing as may be required and ultimately to attain profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical accounting policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our significant accounting policies are more fully described in the notes to our condensed consolidated financial statements included in our annual report on Form 10-K for the fiscal year ended August 31, 2011. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Marketable securities</font><font style="FONT-STYLE: italic; DISPLAY: inline">:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Consist mainly of equity securities classified as available-for-sale and are recorded at fair value.&#160; Until September 30, 2011, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market. As of October 1, 2011, the securities are not restricted and the fair value of the securities is measured based on the quoted prices of the securities on an active market. Changes in fair value, net of taxes, are reflected in other comprehensive income (loss).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Factors considered in determining whether a loss is temporary include the extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee based on our intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The loss is recorded as a charge to earnings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Valuation of options and warrants</font>: We granted options to purchase shares of our common stock to employees and consultants and issued warrants in connection with some of our financings and to other certain consultants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We account for share-based payments in accordance with the guidance that requires awards classified as equity awards be accounted for using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. We estimated forfeitures based on historical experience and anticipated future conditions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable, pursuant to the guidance. The fair value of the options granted is measured on each reporting date, and the gains (losses) are recorded to earningsover the related service period using the straight-line method.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Taxes on income</font>: Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We have provided a full valuation allowance with respect to its deferred tax assets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regarding our subsidiary, Oramed Ltd., the guidance prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comparison of six and three month periods ended February 29, 2012 and February 28, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following <font style="DISPLAY: inline; FONT-SIZE: 10pt">table</font> summarizes certain statements of operations data for the Company for the six month and three month periods ended February 29, 2012 and February 28, 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Six months ended</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three months ended</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating Data:</font></div>
</div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">February 29, 2012</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">February 28, 2011</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">February 29, 2012</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">February 28, </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">894,663</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">627,816</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">710,647</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">341,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expenses</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">511,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">621,016</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">229,704</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">305,887</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Impairment of available for sale securities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,111</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial (income) expense, net</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,257</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,913</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,424</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the period</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,463,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,245,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">985,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">642,791</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss per common share &#8211; basic and diluted</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average common shares outstanding</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,140,610</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,344,880</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,176,638</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,804,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and development expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, costs of registered patents materials, supplies, the cost of services provided by outside contractors, including services related to our clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development. All costs associated with research and development are expensed as incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as contract research organizations, independent clinical investigators, and other third-party service providers to assist us with the execution of our clinical studies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical activities which relate principally to clinical sites and other administrative functions to manage our clinical trials are performed primarily by contract research organizations ("CROs"). CROs typically perform most of the start-up activities for our trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical trial and pre-clinical trial expenses include regulatory and scientific consultants&#8217; compensation and fees, research expenses, purchase of materials, cost of manufacturing of the oral insulin capsules, payments for patient recruitment and treatment, costs related to the maintenance of our registered patents, costs related to the filings of patent applications, as well as salaries and related expenses of research and development staff.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2009, Oramed Ltd., our wholly owned Israeli subsidiary, was awarded a government grant amounting to a total net amount of New Israeli Shekels ("NIS") 3.1 million (approximately $813,000), from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel (the "OCS"). This grant was used for research and development expenses for the period of February 2009 to June 2010. The funds were used by us to support further research and development and clinical study of our oral insulin capsule and oral GLP-1-analog.&#160;In December 2010, Oramed Ltd., was awarded another grant amounting to a total net amount of NIS 2.9 million (approximately $807,000) from the OCS, which was designated for research and development expenses for the period of July 2010 to November 2011. We used the funds to support further research and development and clinical study of our oral insulin capsule and oral GLP-1-analog. The two grants are subject to repayment according to the terms determined by the OCS and applicable law.&#160;&#160;See "--Government Grants" below. In December 2011, Oramed Ltd. applied for a third grant. The application is currently being assessed by the OCS committees.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the six months ended February 29, 2012, research and development expenses totaled $894,663, compared to $627,816 for the six months ended February 28, 2011. The increase is a result of two main factors &#8211; the preparation for the FDA approved Phase 2 study that will follow the expected IND filing in the fourth calendar quarter of 2012, that caused an increase of $234,000, and the end of the OCS support on November 30, 2011 that resulted in an increase of $152,000. The increase in development expenses was partially offset by a decrease in stock based compensation costs due to amortization of options granted in the prior period<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">. </font>The research and development costs include stock based compensation costs, which during the six months ended February 29, 2012 totaled $36,820 as compared to $162,896 during the six months ended February 28, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The increase in research and development expenses during the three months ended February 29, 2012, as compared to the three months ended February 28, 2011 is attributable to the same reasons mentioned above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 19.45pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government Grants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the six and three months ended February 29, 2012, we recognized research and development grants in an amount of $57,038 and $15,781, respectively and in the six and three months ended February 28, 2011, we recognized research and development grants in an amount of $208,674 and $56,698, respectively.&#160;&#160;As of February 29, 2012, we had no contingent liabilities to the OCS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Grants from Bio-Jerusalem</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are committed to pay royalties to Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) <font style="DISPLAY: inline; FONT-SIZE: 10pt">in the total amount of $52,733</font>.&#160;&#160;As of February 29, 2012, we had not yet realized any revenues and did not incur any royalty liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the six months period ended February 29, 2012, there were no grants received from the Bio-Jerusalem fund and in the six months period ended February 28, 2011, we received $20,950 from said fund.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and administrative expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">General and administrative expenses include the salaries and related expenses of our management, consulting costs, legal and professional fees, traveling, business development costs, insurance expenses and other general costs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the six months ended February 29, 2012, general and administrative expenses totaled $511,605 compared to $621,016 for the six months ended February 28, 2011. Costs incurred related to general and administrative activities during the six months ended February 29, 2012, reflect a decrease in professional fee expenses of net $81,000 as well as stock options granted to employees and consultants. The decrease in general and administrative expenses was partially offset by an increase in investor relations costs, some of which were paid with share based compensation. During the six months ended February 29, 2012, as part of our general and administrative expenses, we incurred $46,216 related to stock options granted to employees and consultants, as compared to $172,901 during the six months ended February 28, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The increase in general and administrative expenses during the three months ended February 29, 2012 as compared to the three months ended February 28, 2011, is attributable to the same reasons mentioned above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial income/expense, net</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the six months ended February 29, 2012 and 2011, we generated interest income on available cash and cash equivalents which was offset by bank charges and imputed interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From inception through February 29, 2012, we incurred losses in an aggregate amount of $16,011,193. We have financed our operations through the private placements of equity and debt financing, raising a total of $11,655,693, net of transaction costs. We will seek to obtain additional financing through similar sources. As of February 29, 2012, we had $1,824,141 of available cash as well as $838,738 in short term interest bearing investments. We anticipate that we will require approximately $5.7 million to finance our activities during the twelve months following February 29, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management is in the process of evaluating various financing alternatives as we will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that we will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders as well as through additional funding from the OCS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the six month period ended February 29, 2012, cash and cash equivalents increased by $310,776 from the $1,513,365 reported as of August 31, 2011, which is due, mainly, to proceeds from short-term bank deposits and proceeds from sale of investment in Entera, as further detailed below. Cash balances increased in the three months ended February 29, 2012 for the reasons presented below.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Operating activities used cash of $1,094,760 in the six months ended February 29, 2012. Cash used for operating activities in the six months ended February 29, 2012 primarily consisted of net loss partially offset by stock based compensation adjustments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investing activities provided cash of $1,405,536 in the six months ended February 29, 2012. Cash used in investing activities consisted primarily of proceeds from short-term bank deposits and proceeds from sale of investment in Entera.&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were no financing activities during the six months ended February 29, 2012.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the six months ended February 29, 2012 we received approximately $52,155 from the OCS towards our research and development expenses.&#160;&#160;The OCS has supported our activity in the past two years. In December 2011, we filed an application for a third year program for the period December 2011 until November 2012. There is no assurance that the OCS will approve a grant for the third year's R&amp;D activity.&#160;&#160;The amount of such requested grant is also not certain.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the six month period ended February 29, 2012, we issued a total of 83,000 shares of common stock to a third party for services rendered. The value of those shares of common stock was $24,900.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.05pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During fiscal years 2010 and 2011 we issued a total of 927,387 shares of common stock to various third party vendors for services rendered. The aggregate value of those shares was approximately $290,529. We also consummated a private placement by selling 937,500 "units" at a purchase price of $0.32 per unit for a total consideration of $300,000. Each unit consisted of one share of common stock and a five-year warrant to purchase 0.35 of a share of common stock at an exercise price of $0.50 per share<font style="BORDER-BOTTOM: 1pt double; DISPLAY: inline; TEXT-DECORATION: underline">.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have no off-balance sheet arrangements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; DISPLAY: inline">Planned</font> <font style="FONT-STYLE: italic; DISPLAY: inline">Expenditures</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The estimated expenses referenced herein are in accordance with our business plan. Since our technology is still in the development stage, it can be expected that there will be changes in some budgetary items. Our planned expenditures for the twelve months beginning March 1, 2012 are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="85%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.65pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Category</font>:</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.65pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Amount</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development costs</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,570,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expenses</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,118,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="85%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial income, net</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Taxes on income</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="85%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,687,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As previously indicated, we are planning to conduct further clinical studies as well as file an IND application with the FDA for our orally ingested insulin during the fourth calendar quarter of 2012. We expect to have a significant increase in research and development expenses as a result of preparation for the FDA approved Phase 2 study that will follow the IND filing, and during the term of the study. Our ability <font style="DISPLAY: inline; FONT-SIZE: 10pt">to</font> proceed with these activities is dependent on several major factors including the ability to attract sufficient financing on terms acceptable to us and receiving additional grant from the OCS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; DISPLAY: inline">Employment</font> <font style="FONT-STYLE: italic; DISPLAY: inline">and Consulting Agreements</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2012, we entered into an advisory agreement with a third party (the "Advisor&#8221;) for a period of one year, pursuant to which the Advisor will provide investors relations services and will be entitled to a share based compensation as follows: of 300,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing as of February 15, 2012, and a warrant to purchase 750,000 shares of common stock of the Company. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 monthly installments over the term of the agreement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item3">ITEM </a>3 &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a smaller reporting company, we are not required to provide the information required by this Item.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item4">ITEM </a>4 - CONTROLS AND PROCEDURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Disclosure Controls and Procedures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our management, including our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of February 29, 2012. Due to the inherent limitations of our company, derived from our small size and the limited number of employees, the management evaluation concluded that there is a material weakness with respect to segregation of duties. Specifically, our CFO serves as our only qualified internal accounting and financial reporting personnel and as such performs all accounting and financial reporting functions without the benefit of independent checks, confirmations or backup other than bookkeeping functions performed by an outside accounting firm. Based on such review, our chief executive officer and chief financial officer have determined that the Company did not have in place effective controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 19.45pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting that occurred during the three months ended February 29, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="part2">PART </a>II &#8211; OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item12">ITEM </a>1 - LEGAL PROCEEDINGS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time we may become subject to litigation incidental to our business. We are not currently a party to any material legal proceedings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item22">ITEM 2 &#8211; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 36pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 12, 2011, we issued 83,000 shares of our common stock, valued at $24,900, in the aggregate, to a third party for services rendered.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">&#160;</td>
<td align="right" style="WIDTH: 36pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;</font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 14, 2012, we issued 133,000 shares of our common stock, valued at $38,570, in the aggregate, to two third parties for services rendered and to be rendered.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The above issuances and sales were exempt under Section 4(2) of the Securities Act of 1933, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item6">ITEM 6 - EXHIBITS</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibit</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1 *</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification Statement of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.2 *</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification Statement of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1 **</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification Statement of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.2 **</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification Statement of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101 **</font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The following financial statements from the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended February 29, 2012, filed on April 4, 2012, formatted in XBRL: (i)&#160;Consolidated Balance Sheets, (ii)&#160;Consolidated Statements of Operations, (iii)&#160;Consolidated Statements of Changes in Stockholders' Equity, (iv)&#160;Consolidated Statements of Cash Flows and (v)&#160;the Notes to Consolidated Financial Statements.</font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Filed herewith<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">**</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furnished herewith</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ORAMED PHARMACEUTICALS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Registrant</font></div>
</td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;April 4, 2012</font></div>
</td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160;</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; DISPLAY: inline">Nadav Kidron</font></font></div>
</div>
</td>
<td valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nadav Kidron</font></div>
</td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President, Chief Executive Officer and Director</font></div>
</td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;April 4, 2012</font></div>
</td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;&#160;</font></div>
</td>
<td valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;<font style="FONT-STYLE: italic; DISPLAY: inline">Yifat Zommer</font></font></div>
</div>
</td>
<td valign="top" width="22%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yifat Zommer</font></div>
</td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">18</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title>exhibit_31-1.htm</title>
    <!--Licensed to: ZK Global Ltd-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 31.1</font></div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302 OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Nadav Kidron, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Oramed Pharmaceuticals Inc.;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;April 4, 2012</font></div>
</td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; DISPLAY: inline">NADAV KIDRON</font></font></div>
</td>
<td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Nadav Kidron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160; &#160;President, Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;and Director</font></div>
</td>
<td align="left" valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title>exhibit_31-2.htm</title>
    <!--Licensed to: ZK Global Ltd-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 31.2</font></div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302 OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Yifat Zommer, certify that:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of Oramed Pharmaceuticals Inc.;</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td valign="top" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;April 4, 2012</font></div>
</td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; DISPLAY: inline">YIFAT ZOMMER</font></font></div>
</td>
<td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name: Yifat Zommer,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160; &#160;Chief Financial Officer</font></div>
</td>
<td align="left" valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><br>
</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title>exhibit_32-1.htm</title>
    <!--Licensed to: ZK Global Ltd-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the quarterly report of Oramed Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended February 29, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nadav Kidron, President, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;&#160;April 4, 2012</font></div>
</td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; DISPLAY: inline">NADAV KIDRON</font></font></div>
</td>
<td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Nadav Kidron</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160;&#160; President, Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and Director</font></div>
</td>
<td align="left" valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
    <title>exhibit_32-2.htm</title>
    <!--Licensed to: ZK Global Ltd-->
    <!--Document Created using EDGARizer 2020 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 32.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the quarterly report of Oramed Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended February 29, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Yifat Zommer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated:&#160;April 4, 2012</font></div>
</td>
<td align="left" valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; DISPLAY: inline">YIFAT ZOMMER</font></font></div>
</td>
<td align="left" valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160;&#160;Yifat Zommer,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160;&#160;&#160; Chief Financial Officer</font></div>
</td>
<td align="left" valign="bottom" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>ormp-20120229.xml
<DESCRIPTION>INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL on behalf of Z-K Global Ltd http://www.p3xbrl.com-->
<!--version 4.1.0 -->
<!--produced on 2012-04-04 @ 2:34 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:ISO4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ormp-20120229.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">--08-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">2012-02-29</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">0001176309</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.5978.0.0.0.0.0.0" contextRef="as-of-2012-04-03.5978.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70320583</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">ORAMED PHARMACEUTICALS INC.</dei:EntityRegistrantName>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">615882</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5945.3281.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">26733</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5946.3281.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">16900</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">615882</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">26733</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">16900</ormp:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants>
  <ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest id="AdjustmentToAdditionalPaidInCapitalImputedInterest.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">19777</ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest>
  <ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest id="AdjustmentToAdditionalPaidInCapitalImputedInterest.5945.3281.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">3782</ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest>
  <ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest id="AdjustmentToAdditionalPaidInCapitalImputedInterest.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">19777</ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest>
  <ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest id="AdjustmentToAdditionalPaidInCapitalImputedInterest.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3782</ormp:AdjustmentToAdditionalPaidInCapitalImputedInterest>
  <ormp:DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature id="DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature id="DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature id="DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">108000</ormp:DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature>
  <ormp:ImputedInterestExpense id="ImputedInterestExpense.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:ImputedInterestExpense id="ImputedInterestExpense.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1891</ormp:ImputedInterestExpense>
  <ormp:ImputedInterestExpense id="ImputedInterestExpense.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">23559</ormp:ImputedInterestExpense>
  <ormp:IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims id="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">30435</ormp:IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims>
  <ormp:IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims id="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims id="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">30435</ormp:IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims>
  <ormp:ProceedsFromReceiptsOnAccountOfSharesIssuances id="ProceedsFromReceiptsOnAccountOfSharesIssuances.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:ProceedsFromReceiptsOnAccountOfSharesIssuances id="ProceedsFromReceiptsOnAccountOfSharesIssuances.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <ormp:ProceedsFromReceiptsOnAccountOfSharesIssuances id="ProceedsFromReceiptsOnAccountOfSharesIssuances.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">6061</ormp:ProceedsFromReceiptsOnAccountOfSharesIssuances>
  <ormp:ReceiptsOnAccountOfSharesAndWarrants id="ReceiptsOnAccountOfSharesAndWarrants.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">6061</ormp:ReceiptsOnAccountOfSharesAndWarrants>
  <ormp:ReceiptsOnAccountOfSharesAndWarrants id="ReceiptsOnAccountOfSharesAndWarrants.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">6061</ormp:ReceiptsOnAccountOfSharesAndWarrants>
  <ormp:SharesCancelledShares id="SharesCancelledShares.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">-19800000</ormp:SharesCancelledShares>
  <ormp:SharesCancelledValue id="SharesCancelledValue.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">19800</ormp:SharesCancelledValue>
  <ormp:SharesCancelledValue id="SharesCancelledValue.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">-19800</ormp:SharesCancelledValue>
  <ormp:StockIssuedDuringPeriodSharesOfferingCosts id="StockIssuedDuringPeriodSharesOfferingCosts.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">1752941</ormp:StockIssuedDuringPeriodSharesOfferingCosts>
  <ormp:StockIssuedDuringPeriodSharesServices id="StockIssuedDuringPeriodSharesServices.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">1730540</ormp:StockIssuedDuringPeriodSharesServices>
  <ormp:StockIssuedDuringPeriodSharesServices id="StockIssuedDuringPeriodSharesServices.5945.2154.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">730636</ormp:StockIssuedDuringPeriodSharesServices>
  <ormp:StockIssuedDuringPeriodSharesServices id="StockIssuedDuringPeriodSharesServices.5946.2154.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">83000</ormp:StockIssuedDuringPeriodSharesServices>
  <ormp:StockIssuedDuringPeriodValueOfferingCosts id="StockIssuedDuringPeriodValueOfferingCosts.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">-1753</ormp:StockIssuedDuringPeriodValueOfferingCosts>
  <ormp:StockIssuedDuringPeriodValueOfferingCosts id="StockIssuedDuringPeriodValueOfferingCosts.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">1753</ormp:StockIssuedDuringPeriodValueOfferingCosts>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">1731</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5945.2154.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">731</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5946.2154.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">83</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">821337</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">227569</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">24900</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">819606</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5945.3281.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">226838</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServices id="StockIssuedDuringPeriodValueServices.5946.3281.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">24817</ormp:StockIssuedDuringPeriodValueServices>
  <ormp:StockIssuedDuringPeriodValueServicesRendered id="StockIssuedDuringPeriodValueServicesRendered.5946.3281.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">30435</ormp:StockIssuedDuringPeriodValueServicesRendered>
  <ormp:StockIssuedDuringPeriodValueServicesRendered id="StockIssuedDuringPeriodValueServicesRendered.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">30435</ormp:StockIssuedDuringPeriodValueServicesRendered>
  <ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70140610</ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare>
  <ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">60344880</ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare>
  <ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70176638</ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare>
  <ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">62804799</ormp:WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="AccountsPayableAndAccruedLiabilitiesCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">375538</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="AccountsPayableAndAccruedLiabilitiesCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">534907</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">47252</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">47252</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">542891</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">46668</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="AdditionalPaidInCapitalCommonStock.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">18201111</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="AdditionalPaidInCapitalCommonStock.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">18339399</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature id="AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature id="AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="AdjustmentsToAdditionalPaidInCapitalOther.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">18991</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="AdjustmentsToAdditionalPaidInCapitalOther.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">18991</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">3554921</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5945.3281.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">502593</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5946.3281.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">66136</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3554921</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">502593</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">66136</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AmortizationOfDebtDiscountPremium id="AmortizationOfDebtDiscountPremium.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AmortizationOfDebtDiscountPremium id="AmortizationOfDebtDiscountPremium.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AmortizationOfDebtDiscountPremium id="AmortizationOfDebtDiscountPremium.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">108000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:Assets id="Assets.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">4325937</us-gaap:Assets>
  <us-gaap:Assets id="Assets.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3142588</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">4284082</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3108283</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.5943.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2002-04-11.5943.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.5951.0.0.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1199638</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1513365</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1824141</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.5954.0.0.0.0.0.0" contextRef="as-of-2011-02-28.5954.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1931761</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">310776</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">732123</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1824141</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.5952.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.5953.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="CommitmentsAndContingenciesDisclosureTextBlock.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt; &lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"&gt; &lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;NOTE 2 -&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;COMMITMENTS&lt;/font&gt;:&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; a.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Under the terms of the First Agreement with Hadasit (note 1a(1) above), the Company retained Hadasit to provide consulting and clinical trial services. As remuneration for the services provided under the agreement, Hadasit is entitled to $200,000. The primary researcher for Hadasit is Dr. Miriam Kidron, a director and officer of the Company. The funds paid to Hadasit under the agreement are deposited by Hadasit into a research fund managed by Dr. Kidron. Pursuant to the general policy of Hadasit with respect to its research funds, Dr. Kidron receives from Hadasit a management fee in the rate of 10% of all the funds deposited into this research fund. The total amount paid to Dr. Kidron out of this fund was $10,214.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On January 7, 2009, the Company entered into a second agreement with Hadasit (the "Second Agreement") which confirms that Hadasit has conveyed, transferred and assigned all of its ownership rights in the patents acquired under the First Agreement to the Company, and certain other patents filed by the Company after the First Agreement as a result of the collaboration between the Company and Hadasit.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On July 8, 2009 the Company entered into a third agreement with Hadasit, Prof. Itamar Raz and Dr. Miriam Kidron ("the Third Agreement"), to retain consulting and clinical trial services from Hadasit. According to the Third Agreement, Hadasit will be entitled to total consideration of $400,000 to be paid by Oramed. $200,000 of this amount was agreed in the terms of the First Agreement, and the remaining of $200,000 will be paid in accordance with the actual progress of the study. The total amount that was paid through February 29, 2012 was $400,000.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On September 11, 2011, the Company entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr ("the Fourth Agreement"), to retain consulting and clinical trial services. According to the Fourth Agreement, Hadasit will be entitled to consideration of $200,000 to be paid by the Company, none of which was recognized or paid through February 29, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; b.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On March 18, 2012, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012. The monthly lease payment will be NIS 3,400 in 2012, NIS 4,225 in 2013 and NIS 5,610 from 2014 onwards, and will be linked to the increase in the Israeli consumer price index (as of February 29, 2012, the monthly payment in the Company&amp;#39;s functional currency is $903, the future annual lease payments under the agreement will be $10,836 - $17,878).&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; As security for its obligation under the lease agreements the Subsidiary provided a bank guarantee in an amount equal to three monthly lease payments. valid until November 30, 2016.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; c.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On April 21, 2009, the Subsidiary entered into a consulting service agreement with&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/font&gt; ADRES Advanced Regulatory Services Ltd. ("ADRES") (the "Original Agreement") pursuant to which ADRES will provide consulting services relating to quality assurance and regulatory processes and procedures in order to assist the Subsidiary in submission of a U.S. Investigational New Drug ("IND") according to the U.S. Food and Drug Administration (the "FDA") regulations. In consideration for the services provided under the agreement, ADRES will be entitled to total cash compensation of $211,000, of which the amount of $110,000 will be paid as a monthly fixed fee of $10,000 each month for 11 months commencing May 2009, and the remaining $101,000 will be paid based on achievement of certain milestones. $160,000 of the total amount was paid through November 30, 2011, $50,000 of which was paid for completing the first three milestones.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On February 26, 2012, the parties entered into an amendment agreement, according to which the Subsidiary will pay the remaining $51,000 of the Original Agreement upon issuance the amendment agreement. In addition, beginning March 1, 2012 and until submission of the IND, the Subsidiary will pay ADRES a monthly fee of approximately $3,600&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;.&lt;/font&gt; The Company recognized the $51,000 as an expense through February 29, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; d.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On February 10, 2010, the Subsidiary entered into an agreement with Vetgenerics Research G. Ziv Ltd, a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. The total cost estimated for the studies is &amp;euro;107,100 ($143,831) of which &amp;euro;89,293 ($120,029) was paid through February 29, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; e.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on February 22, 2011 and an option to purchase up to 250,000 shares of common stock, par value $0.001 per share, of the Company at an exercise price of $0.50 per share. The option vest in five annual installments commencing February 16, 2012 and expire on February 16, 2021. The initial fair value of the option on the date of grant was $71,495, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 113.80%; risk-free interest rates of 3.42%; and the remaining contractual life of 10 years. The fair value of the options granted is measured on a final basis at each balance sheet reporting date and is recognized over the related service period using the straight-line method.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; f.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On May 13, 2011, the Company entered into a consulting agreement with a third party (the "Consultant") for a period of 12 months, pursuant to which the Consultant will provide investor relations services and will be entitled to a cash monthly fee of $4,000, that may be increased up to $10,000 upon the completion of a $5,000,000 capital raise by the Company. In addition, the Consultant received a warrant to purchase up to 32,000 shares of the Company. The warrant has a term of five years and an exercise price of $0.50 per Share and will vest in 12 installments in the period from October 2011 to May 2016. The Company records expenses in respect of this warrant during the term of the services.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 72pt; text-align: left; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; g.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On June 22, 2011, the Subsidiary issued a purchase order to SAFC Pharma for producing one of its oral capsule ingredients in the amount of $600,000, $170,000 of which was recognized through February 29, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; h.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On August 15, 2011, the Company entered into an advisory agreement with a third party (the "Advisor") for a period of nine months, pursuant to which the Advisor will provide investors relations services and will be entitled to a cash monthly fee of $4,000, and an additional $3,000 in the first month. In addition, the Advisor will be issued 249,000 shares of the Company&amp;#39;s common stock in three equal installments over the engagement period, commencing November 2011. See also notes 4 and 5.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; i.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On December 12, 2011, the Subsidiary entered into a Supply Agreement with Swiss Caps AG ("Swiss Caps"), according to which, Swiss Caps will manufacture insulin capsules for a total consideration of CHF 395,000 (approximately $440,600) of which CHF 180,000 (approximately $195,600) was paid through February 29, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; j.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 300,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 750,000 shares of common stock of the Company. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 monthly installments over the term of the agreement. The Company records expenses in respect of this warrant during the term of the services. See also note 5.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; k.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Grants from Bio-Jerusalem&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The Subsidiary is committed to pay royalties to Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $52,733.&amp;nbsp;&amp;nbsp;As of February 29, 2012, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; For the six month period ended February 29, 2012, there were no grants received from the Bio-Jerusalem fund.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; l.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Grants from the Office of the Chief Scientist ("OCS")&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The Subsidiary is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; At the time the grants were received, successful development of the related products was not assured. In case of failure of a product that was partly financed as above, the Subsidiary is not obligated to pay any such royalties.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Under the terms of the Subsidiary&amp;#39;s funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Subsidiary (dollar linked) with the addition of annual interest at a rate based on LIBOR.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; As of February 29, 2012, the Subsidiary had not yet realized any revenues from such product and did not incur any royalty liability. The total amount received through February 29, 2012 was $1,078,545.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 75.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; For the six month period ended February 29, 2012, the research and development expenses are presented net of OCS grants, in the total amount of $57,038.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70104583</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70187583</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5943.2154.3280.0.0.0.0" contextRef="as-of-2002-04-11.5943.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">34828200</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5951.2154.3280.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">57565321</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5952.2154.3280.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">70104583</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5953.2154.3280.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">70187583</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70104583</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">70187583</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="CommonStockValue.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">70104</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="CommonStockValue.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">70187</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-16</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.5944.4725.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.4725.3280.0.0.0.0" unitRef="USD" decimals="0">-16</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContributionOfProperty id="ContributionOfProperty.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ContributionOfProperty id="ContributionOfProperty.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ContributionOfProperty id="ContributionOfProperty.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">18991</us-gaap:ContributionOfProperty>
  <us-gaap:DepositsAssetsCurrent id="DepositsAssetsCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1801400</us-gaap:DepositsAssetsCurrent>
  <us-gaap:DepositsAssetsCurrent id="DepositsAssetsCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">838738</us-gaap:DepositsAssetsCurrent>
  <us-gaap:Depreciation id="Depreciation.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">11713</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Depreciation.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">15122</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Depreciation.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">117820</us-gaap:Depreciation>
  <us-gaap:DueFromOtherRelatedPartiesCurrent id="DueFromOtherRelatedPartiesCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">432</us-gaap:DueFromOtherRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="DueToRelatedPartiesCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">18502</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="DueToRelatedPartiesCurrent.5953.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">0.01</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueDisclosuresTextBlock id="FairValueDisclosuresTextBlock.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; NOTE 3 - FAIR VALUE:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; &amp;middot;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; &amp;middot;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; &amp;middot;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="text-align: left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify; TEXT-INDENT: 0pt"&gt; Marketable securities consist wholly of equity securities of D.N.A Biomedical Solutions Ltd. which were received in March 2011 as part of the consideration for selling the Company&amp;#39;s equity method investee Entera. Those securities are classified as available-for-sale and are recorded at fair value.&amp;nbsp;&amp;nbsp;The D.N.A Shares are listed on the Tel Aviv Stock Exchange ("TASE") and their tradability was restricted for a period of 6 months from the closing date of the transaction according to TASE policy with regards to private placements. Until September 30, 2011, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market. As of October 1, 2011, the securities are not restricted and the fair value of the securities is measured based on the quoted prices of the securities on an active market.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; Transfers in and/or out of Level 3 are recognized in the beginning of the reporting period.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Financial items carried at fair value as of February 29, 2012 and August&amp;nbsp;31, 2011 are classified in the tables below in one of the three categories described above:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="text-align: right"&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14"&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Fair value measurements at&amp;nbsp;reporting&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; date using&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Level 1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Level 2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Level 3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="#cceeff"&gt; &lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; Marketable securities:&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="10%" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; February 29, 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;341,454&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;341,454&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="#cceeff"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; August 31, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;384,565&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;384,565&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.7pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="text-align: center"&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"&gt; &lt;tr&gt; &lt;td valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Six months ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; February 29,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; 2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Unaudited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="#cceeff"&gt; &lt;td valign="bottom" width="85%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"&gt; Carrying value at the beginning of the period&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;384,565&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"&gt; Reclassification to level 1&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;(384,565&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="#cceeff"&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"&gt; Carrying value at the end of the period&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt; WIDTH: 100%"&gt; &amp;nbsp;&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-2963</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">570</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-295</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments id="GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments id="GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments id="GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.5948.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments id="GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.5949.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments id="GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1033004</us-gaap:GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">511605</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">621016</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">229704</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">305887</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7469988</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1463894</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1245575</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-985375</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-642791</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-15860635</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.5948.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.5949.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">150558</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="IncreaseDecreaseInAccountsPayable.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">140867</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="IncreaseDecreaseInAccountsPayable.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">107249</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="IncreaseDecreaseInAccountsPayable.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">534907</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="IncreaseDecreaseInOtherNoncurrentLiabilities.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="IncreaseDecreaseInOtherNoncurrentLiabilities.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="IncreaseDecreaseInOtherNoncurrentLiabilities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">138054</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPensionAndPostretirementObligations id="IncreaseDecreaseInPensionAndPostretirementObligations.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1307</us-gaap:IncreaseDecreaseInPensionAndPostretirementObligations>
  <us-gaap:IncreaseDecreaseInPensionAndPostretirementObligations id="IncreaseDecreaseInPensionAndPostretirementObligations.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInPensionAndPostretirementObligations id="IncreaseDecreaseInPensionAndPostretirementObligations.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">23982</us-gaap:IncreaseDecreaseInPensionAndPostretirementObligations>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-30802</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">29124</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">87140</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7509</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities id="IncreaseDecreaseInRestrictedCashForOperatingActivities.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities id="IncreaseDecreaseInRestrictedCashForOperatingActivities.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-8</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities id="IncreaseDecreaseInRestrictedCashForOperatingActivities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">16000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
  <us-gaap:InvestmentsAndOtherNoncurrentAssets id="InvestmentsAndOtherNoncurrentAssets.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">10186</us-gaap:InvestmentsAndOtherNoncurrentAssets>
  <us-gaap:InvestmentsAndOtherNoncurrentAssets id="InvestmentsAndOtherNoncurrentAssets.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">9412</us-gaap:InvestmentsAndOtherNoncurrentAssets>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="IssuanceOfStockAndWarrantsForServicesOrClaims.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">24900</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="IssuanceOfStockAndWarrantsForServicesOrClaims.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">119800</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="IssuanceOfStockAndWarrantsForServicesOrClaims.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1072996</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:Liabilities id="Liabilities.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">602021</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">744145</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">4325937</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3142588</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">441292</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">582159</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">160729</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">162036</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent id="LiabilityForUncertainTaxPositionsNoncurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">138054</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent id="LiabilityForUncertainTaxPositionsNoncurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">138054</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
  <us-gaap:MarketableSecuritiesCurrent id="MarketableSecuritiesCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">384565</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent id="MarketableSecuritiesCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">341454</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3106000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">12002997</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1405536</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1678475</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-540131</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1094760</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-695402</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-9638725</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-12986038</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1561245</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1463894</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1245575</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-985375</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-642791</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-16011193</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5944.3282.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-12986038</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5945.3282.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-1561245</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.5946.3282.3280.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-1463894</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1406268</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-1248832</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-940351</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-647215</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-16651376</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">29043</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">6788</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">9487</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3432</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">210300</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">14528</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">10045</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7574</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7856</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">208560</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">24191</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">28045</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.5948.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.5949.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">434876</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">43111</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">43111</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities>
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.5949.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">240523</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3597</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">17890</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">2129</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1475</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">125612</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireShortTermInvestments id="PaymentsToAcquireShortTermInvestments.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-961262</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:PaymentsToAcquireShortTermInvestments id="PaymentsToAcquireShortTermInvestments.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1677000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:PaymentsToAcquireShortTermInvestments id="PaymentsToAcquireShortTermInvestments.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">4467120</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">22675</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">23982</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1670</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">12805</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidPensionCosts id="PrepaidPensionCosts.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">14293</us-gaap:PrepaidPensionCosts>
  <us-gaap:PrepaidPensionCosts id="PrepaidPensionCosts.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">17101</us-gaap:PrepaidPensionCosts>
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">275000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="ProceedsFromIssuanceOrSaleOfEquity.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="ProceedsFromIssuanceOrSaleOfEquity.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3106000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="ProceedsFromIssuanceOrSaleOfEquity.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">11655693</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">120000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromRelatedPartyDebt id="ProceedsFromRelatedPartyDebt.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromRelatedPartyDebt id="ProceedsFromRelatedPartyDebt.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromRelatedPartyDebt id="ProceedsFromRelatedPartyDebt.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">66243</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments id="ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments id="ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments id="ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3628000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
  <us-gaap:ProceedsFromSaleOfEquityMethodInvestments id="ProceedsFromSaleOfEquityMethodInvestments.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">450000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
  <us-gaap:ProceedsFromSaleOfEquityMethodInvestments id="ProceedsFromSaleOfEquityMethodInvestments.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleOfEquityMethodInvestments id="ProceedsFromSaleOfEquityMethodInvestments.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">450000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">17376</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7792</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfNotesPayable id="RepaymentsOfNotesPayable.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:RepaymentsOfNotesPayable id="RepaymentsOfNotesPayable.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:RepaymentsOfNotesPayable id="RepaymentsOfNotesPayable.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">120000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">894663</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">627816</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.5948.0.0.0.0.0.0" contextRef="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0" unitRef="USD" decimals="0">710647</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.5949.0.0.0.0.0.0" contextRef="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0" unitRef="USD" decimals="0">341328</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">8746512</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="RestrictedCashAndCashEquivalentsAtCarryingValue.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">16000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="RestrictedCashAndCashEquivalentsAtCarryingValue.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">16000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-14547299</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">-16011193</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" decimals="0">83036</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.5947.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" decimals="0">335797</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">4783165</us-gaap:ShareBasedCompensation>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="SignificantAccountingPoliciesTextBlock.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; a.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"&gt; General:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 76.55pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; 1.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Oramed Pharmaceuticals, Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement (the "First Agreement") with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. The Company has been in the development stage since its formation and has not yet realized any revenues from its planned operations. &lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;On March 11, 2011, Oramed was reincorporated from the State of Nevada to the State of Delaware.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 112pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd (the "Subsidiary").&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 112pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with Accounting Standard Codification ("ASC") No. 915, "Development Stage Entities".&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 76.55pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; 2.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; The accompanying unaudited condensed consolidated financial statements as of February 29, 2012 and for the six months then ended, have been prepared in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required for annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. The accounting principles applied in the preparation of the condensed statements are consistent with those applied in the preparation of the annual financial statements, however the condensed statements do not include all the information and explanations required for the annual financial statements. Operating results for the six months ended February 29, 2012, are not necessarily indicative of the results that may be expected for the year ending August 31, 2012.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 76.55pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; 3.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; Going concern considerations&lt;/div&gt; &lt;div style="text-align: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (April&amp;nbsp;12, 2002) through February 29, 2012 of $16,011,193 as well as negative cash flow from operating activities. Presently, the Company does not have sufficient cash resources to meet its requirements in the twelve months following February 29, 2012. These factors raise substantial doubt about the Company&amp;#39;s ability to continue as a going concern. Management is in the process of evaluating various financing alternatives as the Company will need to finance future research and development activities and general and administrative expenses through fund raising&lt;font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/font&gt; in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders, as well as on going funding from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel ("OCS").&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 112pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; These condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company&amp;#39;s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability&lt;font style="DISPLAY: inline; FONT-SIZE: 10pt"&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 39.699pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; b.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"&gt; Newly issued and recently adopted Accounting Pronouncements&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 76.55pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; 1.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"&gt; In May 2011, the Financial Accounting Standard Board ("FASB") issued an accounting update that amends ASC No. 820, "Fair Value Measurement" regarding fair value measurements and disclosure requirements. The amendments are effective during interim and annual periods beginning after December&amp;nbsp;15, 2011 and are to be applied prospectively. The accounting update will be applicable to the Company beginning in the third quarter of fiscal year 2012. As applicable to the Company, the adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 76.55pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 36pt"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"&gt; 2.&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In June 2011, the FASB issued an update to ASC No.&amp;nbsp;220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders&amp;#39; equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December&amp;nbsp;15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The accounting update will be applicable to the Company beginning on September 1, 2012. The adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5943.0.0.0.0.0.0" contextRef="as-of-2002-04-11.5943.0.0.0.0.0.0.0" unitRef="USD" decimals="0">53700</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5951.0.0.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.0.0.0.0.0.0" unitRef="USD" decimals="0">830272</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5952.0.0.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3723916</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5953.0.0.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.0.0.0.0.0.0" unitRef="USD" decimals="0">2398393</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5943.2154.3280.0.0.0.0" contextRef="as-of-2002-04-11.5943.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">34828</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5951.2154.3280.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">57565</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5952.2154.3280.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">70104</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5953.2154.3280.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">70187</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5943.3281.3280.0.0.0.0" contextRef="as-of-2002-04-11.5943.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">18872</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5951.3281.3280.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">13758761</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5952.3281.3280.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">18201111</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5953.3281.3280.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">18339399</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5951.4725.3280.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.4725.3280.0.0.0.0" unitRef="USD" decimals="0">-16</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5952.4725.3280.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.4725.3280.0.0.0.0" unitRef="USD" decimals="0">-16</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5951.3282.3280.0.0.0.0" contextRef="as-of-2010-08-31.5951.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-12986038</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5952.3282.3280.0.0.0.0" contextRef="as-of-2011-08-31.5952.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-14547283</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.5953.3282.3280.0.0.0.0" contextRef="as-of-2012-02-29.5953.0.3282.3280.0.0.0.0" unitRef="USD" decimals="0">-16011193</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; NOTE 4 - STOCK HOLDERS&amp;#39; EQUITY:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; &lt;font style="LETTER-SPACING: 9pt"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; On December 12, 2011, the Company issued 83,000 shares of its common stock to the Advisor as remuneration for services provided. The fair value of the shares at the date of grant was $24,900. See also note 2h.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssued1 id="StockIssued1.5946.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssued1 id="StockIssued1.5947.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssued1 id="StockIssued1.5950.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0" unitRef="USD" decimals="0">1753</us-gaap:StockIssued1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">550000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">37359230</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.5945.2154.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">11808626</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets id="StockIssuedDuringPeriodSharesPurchaseOfAssets.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="UShares" decimals="0">1144410</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">274450</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">550</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">275000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">7870422</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5945.3281.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">3682404</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">37359</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5945.2154.3280.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">11808</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">7907781</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.5945.0.0.0.0.0.0" contextRef="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0" unitRef="USD" decimals="0">3694212</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="StockIssuedDuringPeriodValuePurchaseOfAssets.5944.3281.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0" unitRef="USD" decimals="0">433732</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="StockIssuedDuringPeriodValuePurchaseOfAssets.5944.2154.3280.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0" unitRef="USD" decimals="0">1144</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="StockIssuedDuringPeriodValuePurchaseOfAssets.5944.0.0.0.0.0.0" contextRef="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0" unitRef="USD" decimals="0">434876</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:SubsequentEventsTextBlock id="SubsequentEventsTextBlock.5946.0.0.0.0.0.0" contextRef="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"&gt; NOTE 5 - SUBSEQUENT EVENTS:&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"&gt; &lt;font style="LETTER-SPACING: 9pt"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; On March 14, 2012, the Company issued 83,000 and 50,000 shares of its common stock, respectively, to two advisory companies as remuneration for services provided. The fair values of the shares at the date of grant were $24,070 and $14,500 respectively. See also notes 2h and 2j.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <xbrli:unit id="UShares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>ISO4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>ISO4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2011-12-01-to-2012-02-29.5948.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-09-01-to-2012-02-29.5946.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-09-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-09-01-to-2012-02-29.5946.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-09-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-09-01-to-2012-02-29.5946.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-09-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-09-01-to-2012-02-29.5946.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-09-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-12-01-to-2011-02-28.5949.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-12-01</xbrli:startDate>
      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2011-08-31.5945.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2011-08-31.5945.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2011-08-31.5945.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2011-08-31.5945.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2011-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-09-01-to-2011-02-28.5947.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-09-01</xbrli:startDate>
      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2012-02-29.5950.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2010-08-31.5944.0.4725.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2010-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2010-08-31.5944.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2010-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2010-08-31.5944.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2010-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2010-08-31.5944.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2010-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2002-04-12-to-2010-08-31.5944.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2002-04-12</xbrli:startDate>
      <xbrli:endDate>2010-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-04-03.5978.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-04-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-29.5953.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-29.5953.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-29.5953.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-29.5953.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-08-31.5952.0.4725.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-08-31.5952.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-08-31.5952.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-08-31.5952.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-08-31.5952.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-02-28.5954.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-08-31.5951.0.4725.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-08-31.5951.0.3282.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-08-31.5951.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-08-31.5951.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-08-31.5951.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2002-04-11.5943.0.3281.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2002-04-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2002-04-11.5943.0.2154.3280.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2002-04-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2002-04-11.5943.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001176309</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2002-04-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ormp-20120229.xsd
<DESCRIPTION>TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.0 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-04-04 @ 2:36 PM-->
<xs:schema targetNamespace="http://www.oramed.com/20120229" elementFormDefault="qualified" xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xs="http://www.w3.org/2001/XMLSchema">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="ormp-20120229_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="ormp-20120229_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="ormp-20120229_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="ormp-20120229_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" id="ormp-awbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>110 - Disclosure - AGREEMENT WITH D.N.A. BIOMEDICAL SOLUTIONS LTD.</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" id="ormp-ccbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="ormp-ccbsp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" id="ormp-ccscf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" id="ormp-ccso" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/Commitments" id="ormp-comm" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" id="ormp-cscfpar" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" id="ormp-cscse" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/DocumentAndEntityInformation" id="ormp-daei" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/FairValue" id="ormp-fava" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/SignificantAccountingPolicies" id="ormp-sap" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/StockBasedCompensation" id="ormp-sbco" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>112 - Disclosure - STOCK BASED COMPENSATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/ShortTermBankDeposits" id="ormp-stbd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>113 - Disclosure - SHORT TERM BANK DEPOSITS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/StockholdersEquity" id="ormp-steq" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oramed.com/role/SubsequentEvents" id="ormp-suev" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>105 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xs:import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <ormp:element name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" id="ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="AdjustmentToAdditionalPaidInCapitalImputedInterest" id="ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" id="ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="DocumentAndEntityInformationAbstract" id="ormp_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="ImputedInterestExpense" id="ormp_ImputedInterestExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" id="ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="ProceedsFromReceiptsOnAccountOfSharesIssuances" id="ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="ReceiptsOnAccountOfSharesAndWarrants" id="ormp_ReceiptsOnAccountOfSharesAndWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="SharesCancelledShares" id="ormp_SharesCancelledShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="SharesCancelledValue" id="ormp_SharesCancelledValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodSharesOfferingCosts" id="ormp_StockIssuedDuringPeriodSharesOfferingCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodSharesServices" id="ormp_StockIssuedDuringPeriodSharesServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodSharesServicesRendered" id="ormp_StockIssuedDuringPeriodSharesServicesRendered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodValueOfferingCosts" id="ormp_StockIssuedDuringPeriodValueOfferingCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodValueServices" id="ormp_StockIssuedDuringPeriodValueServices" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="StockIssuedDuringPeriodValueServicesRendered" id="ormp_StockIssuedDuringPeriodValueServicesRendered" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
  <ormp:element name="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" id="ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xmlns:ormp="http://www.w3.org/2001/XMLSchema" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ormp-20120229_cal.xml
<DESCRIPTION>TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.0 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-04-04 @ 2:36 PM-->
<link:linkbase xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:href="ormp-20120229.xsd#ormp-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ormp-20120229.xsd#ormp-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ormp-20120229.xsd#ormp-ccbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ormp-20120229.xsd#ormp-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-cscse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ormp-20120229.xsd#ormp-ccscf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:href="ormp-20120229.xsd#ormp-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:href="ormp-20120229.xsd#ormp-awbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/Commitments" xlink:href="ormp-20120229.xsd#ormp-comm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-steq" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockBasedCompensation" xlink:href="ormp-20120229.xsd#ormp-sbco" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/ShortTermBankDeposits" xlink:href="ormp-20120229.xsd#ormp-stbd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/FairValue" xlink:href="ormp-20120229.xsd#ormp-fava" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="ormp-20120229.xsd#ormp-cscfpar" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SubsequentEvents" xlink:href="ormp-20120229.xsd#ormp-suev" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_LiabilitiesCurrent.6082.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.6082.14.6" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DueToRelatedPartiesCurrent.13919.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.6082.14.6" xlink:to="loc_DueToRelatedPartiesCurrent.13919.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.13894.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.6082.14.6" xlink:to="loc_AccountsPayableOtherCurrent.13894.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.8054.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.8054.14.6" xlink:to="loc_LiabilitiesCurrent.6082.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.8718.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.8054.14.6" xlink:to="loc_LiabilitiesNoncurrent.8718.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.13629.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.8054.14.6" xlink:to="loc_CommitmentsAndContingencies.13629.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AssetsCurrent.11042.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.5490.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepositsAssetsCurrent.13499.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_DepositsAssetsCurrent.13499.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_MarketableSecuritiesCurrent.8453.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_MarketableSecuritiesCurrent.8453.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.8067.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.12567.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.8067.14.6" xlink:to="loc_StockholdersEquity.12567.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.8718.14.6" xlink:to="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.8718.14.6" xlink:to="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.8067.14.6" xlink:to="loc_Liabilities.8054.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.4824.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_AccountsReceivableNetCurrent.4824.14.6" order="5.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.9435.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_PrepaidExpenseCurrent.9435.14.6" order="6.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DueFromOtherRelatedPartiesCurrent.5095.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_DueFromOtherRelatedPartiesCurrent.5095.14.6" order="7.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.15266.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.11042.14.6" xlink:to="loc_OtherReceivablesNetCurrent.15266.14.6" order="8.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Assets.11397.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.11397.14.6" xlink:to="loc_AssetsCurrent.11042.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InvestmentsAndOtherNoncurrentAssets.14460.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.11397.14.6" xlink:to="loc_InvestmentsAndOtherNoncurrentAssets.14460.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.9645.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.11397.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.9645.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockValue.5831.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.12567.14.6" xlink:to="loc_CommonStockValue.5831.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.12567.14.6" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.4917.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.12567.14.6" xlink:to="loc_AdditionalPaidInCapitalCommonStock.4917.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.10174.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.12567.14.6" xlink:to="loc_RetainedEarningsAccumulatedDeficit.10174.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PrepaidPensionCosts.9442.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidPensionCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.11397.14.6" xlink:to="loc_PrepaidPensionCosts.9442.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_NetIncomeLoss.8620.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.8620.14.6" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.12608.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.8620.14.6" xlink:to="loc_IncomeTaxExpenseBenefit.12608.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.8862.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:to="loc_OperatingIncomeLoss.8862.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.11299.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.8862.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.11299.14.6" order="1.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.8862.14.6" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.7417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.8862.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.7417.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNonoperatingIncome.8974.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:to="loc_OtherNonoperatingIncome.8974.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.8973.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:to="loc_OtherNonoperatingExpense.8973.14.6" order="4.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:to="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.14.6" order="5.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.14.6" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.14.6" xlink:href="ormp-20120229.xsd#ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.9511.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_ProceedsFromConvertibleDebt.9511.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.9553.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_ProceedsFromNotesPayable.9553.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RepaymentsOfNotesPayable.10022.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_RepaymentsOfNotesPayable.10022.14.6" order="5.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromRelatedPartyDebt.9561.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" xlink:to="loc_ProceedsFromRelatedPartyDebt.9561.14.6" order="6.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.8620.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_NetIncomeLoss.8620.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Depreciation.4943.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_Depreciation.4943.14.6" order="5.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.14.6" order="1.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquireShortTermInvestments.9798.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_PaymentsToAcquireShortTermInvestments.9798.14.6" order="4.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.14.6" order="5.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.7673.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_IncreaseDecreaseInRestrictedCash.7673.14.6" order="6.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" xlink:to="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AmortizationOfDebtDiscountPremium.5284.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_AmortizationOfDebtDiscountPremium.5284.14.6" order="6.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.14.6" order="7.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.6966.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_ShareBasedCompensation.6966.14.6" order="8.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.14.6" order="9.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.14.6" order="10.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.14.6" order="11.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ImputedInterestExpense.33133.14.6" xlink:href="ormp-20120229.xsd#ormp_ImputedInterestExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_ImputedInterestExpense.33133.14.6" order="12.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.14.6" order="13.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.14.6" order="14.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayable.5726.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayable.5726.14.6" order="15.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.14.6" order="16.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.8569.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.14.6" xlink:href="ormp-20120229.xsd#ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.14.6" xlink:to="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.8568.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ormp-20120229_lab.xml
<DESCRIPTION>TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.0 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-04-04 @ 2:36 PM-->
<link:linkbase xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:href="ormp-20120229.xsd#ormp-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ormp-20120229.xsd#ormp-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ormp-20120229.xsd#ormp-ccbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ormp-20120229.xsd#ormp-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-cscse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ormp-20120229.xsd#ormp-ccscf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:href="ormp-20120229.xsd#ormp-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:href="ormp-20120229.xsd#ormp-awbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/Commitments" xlink:href="ormp-20120229.xsd#ormp-comm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-steq" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockBasedCompensation" xlink:href="ormp-20120229.xsd#ormp-sbco" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/ShortTermBankDeposits" xlink:href="ormp-20120229.xsd#ormp-stbd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/FairValue" xlink:href="ormp-20120229.xsd#ormp-fava" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="ormp-20120229.xsd#ormp-cscfpar" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SubsequentEvents" xlink:href="ormp-20120229.xsd#ormp-suev" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-roles-2011-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/newConcept" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-roles-2011-01-31.xsd#newConcept" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:labelLink xlink:title="Label 001 - Document - Document and Entity Information" xlink:role="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_AmendmentFlag.15889.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.15889.11.6" xlink:to="lab_AmendmentFlag.8" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8">Amendment Flag</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.15889.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.15889.11.7" xlink:to="lab_AmendmentFlag.114844" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.114844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.114844">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.15900.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.15900.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.15900.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.15900.11.7" xlink:to="lab_CurrentFiscalYearEndDate.114848" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.114848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.114848">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.33116.11.6" xlink:href="ormp-20120229.xsd#ormp_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.1842267" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.1842267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.1842267">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.33116.11.18" xlink:href="ormp-20120229.xsd#ormp_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.11.18" xlink:to="lab_DocumentAndEntityInformationAbstract18.1842268" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract18.1842268" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract18.1842268">Document and Entity Information [Abstract].</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.15953.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.15953.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.15953.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.15953.11.7" xlink:to="lab_DocumentFiscalPeriodFocus.114849" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.114849" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.114849">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.15952.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.15952.11.6" xlink:to="lab_DocumentFiscalYearFocus.122" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.15952.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.15952.11.7" xlink:to="lab_DocumentFiscalYearFocus.114850" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.114850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.114850">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.15906.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.15906.11.6" xlink:to="lab_DocumentPeriodEndDate.30" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.15906.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.15906.11.7" xlink:to="lab_DocumentPeriodEndDate.114845" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.114845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.114845">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.15957.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.15957.11.6" xlink:to="lab_DocumentType.32" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32">Document Type</link:label>
    <link:loc xlink:label="loc_DocumentType.15957.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.15957.11.7" xlink:to="lab_DocumentType.114854" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.114854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.114854">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.15933.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.15933.11.6" xlink:to="lab_EntityCentralIndexKey.101" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.15933.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.15933.11.7" xlink:to="lab_EntityCentralIndexKey.114847" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.114847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.114847">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.15937.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.15937.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.15937.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.15937.11.7" xlink:to="lab_EntityCommonStockSharesOutstanding.114853" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.114853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.114853">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.15930.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.15930.11.6" xlink:to="lab_EntityFilerCategory.98" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.15930.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.15930.11.7" xlink:to="lab_EntityFilerCategory.114852" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.114852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.114852">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.15932.11.6" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.15932.11.6" xlink:to="lab_EntityRegistrantName.100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.15932.11.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.15932.11.7" xlink:to="lab_EntityRegistrantName.114846" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.114846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.114846">Entity Registrant Name</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrent.12486" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrent.12486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrent.12486">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrent.286015" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrent.286015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrent.286015">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.13894.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.13894.11.6" xlink:to="lab_AccountsPayableOtherCurrent.15954" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.15954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.15954">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.13894.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.13894.11.7" xlink:to="lab_AccountsPayableOtherCurrent.1835981" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.1835981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.1835981">Account payable with former shareholder</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.4824.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.4824.11.6" xlink:to="lab_AccountsReceivableNetCurrent.272" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.272">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.4824.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.4824.11.7" xlink:to="lab_AccountsReceivableNetCurrent7.286004" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent7.286004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent7.286004">Accounts receivable - other</link:label>
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.11.6" xlink:to="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.345" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.345">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.11.7" xlink:to="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax7.286021" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax7.286021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax7.286021">Other accumulated comprehensive income</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.4917.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalCommonStock.4917.11.6" xlink:to="lab_AdditionalPaidInCapitalCommonStock.404" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalCommonStock.404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalCommonStock.404">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.4917.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalCommonStock.4917.11.7" xlink:to="lab_AdditionalPaidInCapitalCommonStock7.286022" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalCommonStock7.286022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalCommonStock7.286022">Additional paid-in capital</link:label>
    <link:loc xlink:label="loc_Assets.11397.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.11397.11.6" xlink:to="lab_Assets.8758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.8758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.8758">Assets</link:label>
    <link:loc xlink:label="loc_Assets.11397.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.11397.11.15" xlink:to="lab_Assets.286011" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.286011" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.286011">T o t a l assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.2510.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.2510.11.6" xlink:to="lab_AssetsAbstract.9477" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.9477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.9477">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.2510.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.2510.11.7" xlink:to="lab_AssetsAbstract.285998" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.285998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.285998">Assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.11042.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.11042.11.6" xlink:to="lab_AssetsCurrent.8038" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.8038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.8038">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.11042.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.11042.11.15" xlink:to="lab_AssetsCurrent.286012" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.286012" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.286012">T o t a l current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.1999.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.1999.11.6" xlink:to="lab_AssetsCurrentAbstract.8037" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.8037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.8037">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.1999.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.1999.11.7" xlink:to="lab_AssetsCurrentAbstract.285999" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.285999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.285999">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.1158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.1158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.1158">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.286000" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.286000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.286000">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.13629.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.13629.11.6" xlink:to="lab_CommitmentsAndContingencies.11903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.11903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.11903">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.13629.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.13629.11.7" xlink:to="lab_COMMITMENTSANDCONTINGENCIESNote.8.286017" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_COMMITMENTSANDCONTINGENCIESNote.8.286017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_COMMITMENTSANDCONTINGENCIESNote.8.286017">COMMITMENTS (note 2)</link:label>
    <link:loc xlink:label="loc_CommonStockValue.5831.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.5831.11.6" xlink:to="lab_CommonStockValue.1498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValue.1498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValue.1498">Common Stock, Value, Issued</link:label>
    <link:loc xlink:label="loc_CommonStockValue.5831.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.5831.11.7" xlink:to="lab_CommonStockValue7.286020" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValue7.286020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValue7.286020">Common stock of $ 0.001 par value - authorized: 200,000,000 shares at February 29, 2012 and August 31, 2011; issued and outstanding: 70,187,583 shares at February 29, 2012 and 70,104,583 at August 31, 2011</link:label>
    <link:loc xlink:label="loc_DepositsAssetsCurrent.13499.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositsAssetsCurrent.13499.11.6" xlink:to="lab_DepositsAssetsCurrent.12244" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositsAssetsCurrent.12244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepositsAssetsCurrent.12244">Deposits Assets, Current</link:label>
    <link:loc xlink:label="loc_DepositsAssetsCurrent.13499.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositsAssetsCurrent.13499.11.7" xlink:to="lab_DepositsAssetsCurrent.286001" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositsAssetsCurrent.286001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepositsAssetsCurrent.286001">Short term deposits</link:label>
    <link:loc xlink:label="loc_DueFromOtherRelatedPartiesCurrent.5095.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DueFromOtherRelatedPartiesCurrent.5095.11.6" xlink:to="lab_DueFromOtherRelatedPartiesCurrent.618" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DueFromOtherRelatedPartiesCurrent.618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DueFromOtherRelatedPartiesCurrent.618">Due from Other Related Parties, Current</link:label>
    <link:loc xlink:label="loc_DueFromOtherRelatedPartiesCurrent.5095.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DueFromOtherRelatedPartiesCurrent.5095.11.7" xlink:to="lab_DueFromOtherRelatedPartiesCurrent.286006" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DueFromOtherRelatedPartiesCurrent.286006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DueFromOtherRelatedPartiesCurrent.286006">Related parties</link:label>
    <link:loc xlink:label="loc_DueToRelatedPartiesCurrent.13919.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DueToRelatedPartiesCurrent.13919.11.6" xlink:to="lab_DueToRelatedPartiesCurrent.12490" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DueToRelatedPartiesCurrent.12490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DueToRelatedPartiesCurrent.12490">Due to Related Parties, Current</link:label>
    <link:loc xlink:label="loc_DueToRelatedPartiesCurrent.13919.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DueToRelatedPartiesCurrent.13919.11.7" xlink:to="lab_DueToRelatedPartiesCurrent7.1835980" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DueToRelatedPartiesCurrent7.1835980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DueToRelatedPartiesCurrent7.1835980">Related parties</link:label>
    <link:loc xlink:label="loc_InvestmentsAndOtherNoncurrentAssets.14460.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsAndOtherNoncurrentAssets.14460.11.6" xlink:to="lab_InvestmentsAndOtherNoncurrentAssets.13061" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsAndOtherNoncurrentAssets.13061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsAndOtherNoncurrentAssets.13061">Investments and Other Noncurrent Assets</link:label>
    <link:loc xlink:label="loc_InvestmentsAndOtherNoncurrentAssets.14460.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsAndOtherNoncurrentAssets.14460.11.7" xlink:to="lab_InvestmentsAndOtherNoncurrentAssets.286009" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsAndOtherNoncurrentAssets.286009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsAndOtherNoncurrentAssets.286009">LONG TERM DEPOSITS AND INVESTMENT</link:label>
    <link:loc xlink:label="loc_Liabilities.8054.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.8054.11.6" xlink:to="lab_Liabilities.4273" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.4273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.4273">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.8054.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.8054.11.7" xlink:to="lab_Liabilities7.107788" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities7.107788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities7.107788">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.8067.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.8067.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.4242" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.4242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.4242">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.8067.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.8067.11.15" xlink:to="lab_LiabilitiesAndStockholdersEquity.286025" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.286025" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.286025">T o t a l liabilities and stockholders' equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.1053.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.4241" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.4241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.4241">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.1053.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.286013" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.286013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.286013">Liabilities and stockholders' equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.6082.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.6082.11.6" xlink:to="lab_LiabilitiesCurrent.1824" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.1824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.1824">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.6082.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.6082.11.15" xlink:to="lab_LiabilitiesCurrent.286016" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.286016" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.286016">T o t a l current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.487.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.487.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.1823" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.1823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.1823">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.487.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.487.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.286014" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.286014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.286014">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.8718.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.8718.11.6" xlink:to="lab_LiabilitiesNoncurrent.5110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.5110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.5110">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.8718.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.8718.11.15" xlink:to="lab_LiabilitiesNoncurrent.1835979" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.1835979" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.1835979">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.1277.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.1277.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.5109" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.5109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.5109">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.1277.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.1277.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.1835977" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.1835977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.1835977">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.11.6" xlink:to="lab_LiabilityForUncertainTaxPositionsNoncurrent.11746" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilityForUncertainTaxPositionsNoncurrent.11746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilityForUncertainTaxPositionsNoncurrent.11746">Liability for Uncertain Tax Positions, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.11.7" xlink:to="lab_LiabilityForUncertainTaxPositionsNoncurrent.285996" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilityForUncertainTaxPositionsNoncurrent.285996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilityForUncertainTaxPositionsNoncurrent.285996">Provision for uncertain tax position</link:label>
    <link:loc xlink:label="loc_MarketableSecuritiesCurrent.8453.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MarketableSecuritiesCurrent.8453.11.6" xlink:to="lab_MarketableSecuritiesCurrent.4731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MarketableSecuritiesCurrent.4731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MarketableSecuritiesCurrent.4731">Marketable Securities, Current</link:label>
    <link:loc xlink:label="loc_MarketableSecuritiesCurrent.8453.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MarketableSecuritiesCurrent.8453.11.7" xlink:to="lab_MarketableSecuritiesCurrent.286002" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MarketableSecuritiesCurrent.286002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MarketableSecuritiesCurrent.286002">Marketable securities</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.15266.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.15266.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12849" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12849">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.15266.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.15266.11.7" xlink:to="lab_OtherReceivablesNetCurrent.286007" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.286007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.286007">Grants receivable from the Chief Scientist</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.11.6" xlink:to="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.12542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.12542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.12542">Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.11.7" xlink:to="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.1835978" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.1835978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.1835978">Employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.9435.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.9435.11.6" xlink:to="lab_PrepaidExpenseCurrent.6063" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.6063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.6063">Prepaid Expense, Current</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.9435.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.9435.11.7" xlink:to="lab_PrepaidExpenseCurrent.286005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.286005" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.286005">Prepaid expenses</link:label>
    <link:loc xlink:label="loc_PrepaidPensionCosts.9442.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidPensionCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidPensionCosts.9442.11.6" xlink:to="lab_PrepaidPensionCosts.6069" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidPensionCosts.6069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidPensionCosts.6069">Prepaid Pension Costs</link:label>
    <link:loc xlink:label="loc_PrepaidPensionCosts.9442.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidPensionCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidPensionCosts.9442.11.7" xlink:to="lab_PrepaidPensionCosts.1835976" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidPensionCosts.1835976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidPensionCosts.1835976">AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.9645.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.9645.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.6369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.6369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.6369">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.9645.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.9645.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.286010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.286010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.286010">PROPERTY AND EQUIPMENT, net</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.11.6" xlink:to="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.6960" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.6960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.6960">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.11.7" xlink:to="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.286003" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.286003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.286003">Restricted cash</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.10174.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.10174.11.6" xlink:to="lab_RetainedEarningsAccumulatedDeficit.7073" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsAccumulatedDeficit.7073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsAccumulatedDeficit.7073">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.10174.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.10174.11.7" xlink:to="lab_RetainedEarningsAccumulatedDeficit7.286023" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsAccumulatedDeficit7.286023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsAccumulatedDeficit7.286023">Deficit accumulated during the development stage</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.209.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.285997" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.285997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.285997">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.12567.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.12567.11.6" xlink:to="lab_StockholdersEquity.10837" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.10837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.10837">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.12567.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.12567.11.15" xlink:to="lab_StockholdersEquity.286024" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.286024" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.286024">T o t a l stockholders' equity</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.1929.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.1929.11.6" xlink:to="lab_StockholdersEquityAbstract.7808" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityAbstract.7808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityAbstract.7808">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.1929.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.1929.11.7" xlink:to="lab_StockholdersEquityAbstract.286019" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityAbstract.286019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityAbstract.286019">STOCKHOLDERS' EQUITY:</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)" xlink:role="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.12450.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.12450.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.10677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.10677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.10677">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.12450.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.12450.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare.286027" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.286027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.286027">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.5828.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.5828.11.6" xlink:to="lab_CommonStockSharesAuthorized.1491" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.1491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.1491">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.5828.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.5828.11.7" xlink:to="lab_CommonStockSharesAuthorized.286028" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.286028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.286028">Common stock, shares authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.5829.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.5829.11.6" xlink:to="lab_CommonStockSharesIssued.10338" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.10338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.10338">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.5829.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.5829.11.7" xlink:to="lab_CommonStockSharesIssued.286029" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.286029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.286029">Common stock, shares issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.5830.11.6" xlink:to="lab_CommonStockSharesOutstanding.1494" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.1494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.1494">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.5830.11.7" xlink:to="lab_CommonStockSharesOutstanding.286030" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.286030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.286030">Common stock, shares outstanding</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.15412.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.15412.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.12855" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.12855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.12855">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.15412.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.15412.11.7" xlink:to="lab_EarningsPerShareBasicAndDiluted7.286073" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted7.286073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted7.286073">BASIC AND DILUTED LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.46" xlink:to="lab_GAINONSALEOFINVESTMENT.286265" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GAINONSALEOFINVESTMENT.286265" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GAINONSALEOFINVESTMENT.286265">GAIN ON SALE OF INVESTMENT</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.7417.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.7417.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.3393" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.3393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.3393">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.7417.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.7417.11.7" xlink:to="lab_GeneralAndAdministrativeExpense7.286060" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense7.286060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense7.286060">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.11.6" xlink:to="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.12570" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.12570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.12570">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.11.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.11.49" xlink:to="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.286083" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.286083" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.286083">LOSS BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.907.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.907.11.6" xlink:to="lab_IncomeStatementAbstract.286053" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.286053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.286053">CONDENSED CONSOLIDATED STATEMENTS OF OPERATION [Abstract]</link:label>
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.12608.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxExpenseBenefit.12608.11.6" xlink:to="lab_IncomeTaxExpenseBenefit.10887" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxExpenseBenefit.10887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxExpenseBenefit.10887">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.12608.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxExpenseBenefit.12608.11.7" xlink:to="lab_IncomeTaxExpenseBenefit7.286069" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxExpenseBenefit7.286069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxExpenseBenefit7.286069">TAXES ON INCOME</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.8620.11.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.8620.11.49" xlink:to="lab_NetIncomeLoss.286084" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.286084" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.286084">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.8862.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.8862.11.6" xlink:to="lab_OperatingIncomeLoss.5320" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.5320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.5320">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.8862.11.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.8862.11.49" xlink:to="lab_OperatingIncomeLoss.286079" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.286079" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.286079">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.8973.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.8973.11.6" xlink:to="lab_OtherNonoperatingExpense.5454" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense.5454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense.5454">Other Nonoperating Expense</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.8973.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.8973.11.7" xlink:to="lab_OtherNonoperatingExpense.286066" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense.286066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense.286066">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingIncome.8974.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingIncome.8974.11.6" xlink:to="lab_OtherNonoperatingIncome.5456" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingIncome.5456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingIncome.5456">Other Nonoperating Income</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingIncome.8974.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingIncome.8974.11.46" xlink:to="lab_OtherNonoperatingIncome46.286080" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingIncome46.286080" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingIncome46.286080">FINANCIAL INCOME</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.7" xlink:to="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.286059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.286059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.286059">IMPAIRMENT OF INVESTMENT</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.7" xlink:to="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities7.1835986" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities7.1835986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities7.1835986">IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.11299.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.11299.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.8474" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.8474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.8474">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.11299.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.11299.11.7" xlink:to="lab_ResearchAndDevelopmentExpense7.286054" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense7.286054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense7.286054">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.6" xlink:href="ormp-20120229.xsd#ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.6" xlink:to="lab_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835982" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835982">Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.7" xlink:href="ormp-20120229.xsd#ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.7" xlink:to="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835984" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835984">WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.18" xlink:href="ormp-20120229.xsd#ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.11.18" xlink:to="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835983" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.1835983">The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" xlink:role="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.3281.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.3281.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.1835987" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.1835987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.1835987">Additional paid-in capital [Member]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.11049" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.11049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.11049">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature7.286189" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature7.286189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature7.286189">DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalOther.13064" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalOther.13064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalOther.13064">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalOther.286182" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalOther.286182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalOther.286182">CONTRIBUTIONS TO PAID IN CAPITAL</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.14359" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.14359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.14359">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.286186" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.286186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.286186">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.6" xlink:href="ormp-20120229.xsd#ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.286145" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.286145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.286145">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.18" xlink:href="ormp-20120229.xsd#ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.18" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants18.286158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants18.286158" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants18.286158">Adjustments To Additional Paid In Capital Share Based Compensation, Stock Options, Requisite Service Period Recognition, Consultants.</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.7" xlink:href="ormp-20120229.xsd#ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants7.286188" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants7.286188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants7.286188">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</link:label>
    <link:loc xlink:label="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.6" xlink:href="ormp-20120229.xsd#ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.6" xlink:to="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest.286149" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest.286149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest.286149">Adjustment To Additional Paid In Capital Imputed Interest</link:label>
    <link:loc xlink:label="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.18" xlink:href="ormp-20120229.xsd#ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.18" xlink:to="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest18.286159" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest18.286159" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest18.286159">Adjustment To Additional Paid In Capital Imputed Interest.</link:label>
    <link:loc xlink:label="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.7" xlink:href="ormp-20120229.xsd#ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.11.7" xlink:to="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest7.286191" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest7.286191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentToAdditionalPaidInCapitalImputedInterest7.286191">IMPUTED INTEREST</link:label>
    <link:loc xlink:label="loc_CommonStockMember.2154.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.2154.11.6" xlink:to="lab_CommonStockMember.8433" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.8433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.8433">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.11.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.5830.11.17" xlink:to="lab_CommonStockSharesOutstanding.286163" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.286163" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.286163">BALANCE, shares</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.11.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.5830.11.16" xlink:to="lab_CommonStockSharesOutstanding.286164" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.286164" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.286164">BALANCE, shares</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.5848.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTax.5848.11.6" xlink:to="lab_ComprehensiveIncomeNetOfTax.1524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTax.1524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTax.1524">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.5848.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTax.5848.11.7" xlink:to="lab_ComprehensiveIncomeNetOfTax.286190" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTax.286190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTax.286190">OTHER COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.3287.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.3287.11.6" xlink:to="lab_EquityComponentDomain.14420" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.14420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.14420">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.8620.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.8620.11.7" xlink:to="lab_NetIncomeLoss7.286192" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss7.286192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss7.286192">NET LOSS</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.11.6" xlink:to="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.12524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.12524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.12524">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.11.7" xlink:to="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent7.286193" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent7.286193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent7.286193">UNREALIZED GAIN FROM AVAILABLE-FOR-SALE SECURITIES</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeMember.4725.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeMember.4725.11.6" xlink:to="lab_OtherComprehensiveIncomeMember.286195" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeMember.286195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeMember.286195">Other comprehensive loss [Member]</link:label>
    <link:loc xlink:label="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.6" xlink:href="ormp-20120229.xsd#ormp_ReceiptsOnAccountOfSharesAndWarrants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.6" xlink:to="lab_ReceiptsOnAccountOfSharesAndWarrants.286125" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReceiptsOnAccountOfSharesAndWarrants.286125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ReceiptsOnAccountOfSharesAndWarrants.286125">Receipts On Account Of Shares And Warrants</link:label>
    <link:loc xlink:label="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.18" xlink:href="ormp-20120229.xsd#ormp_ReceiptsOnAccountOfSharesAndWarrants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.18" xlink:to="lab_ReceiptsOnAccountOfSharesAndWarrants18.286157" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReceiptsOnAccountOfSharesAndWarrants18.286157" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ReceiptsOnAccountOfSharesAndWarrants18.286157">Receipts On Account Of Shares And Warrants.</link:label>
    <link:loc xlink:label="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.7" xlink:href="ormp-20120229.xsd#ormp_ReceiptsOnAccountOfSharesAndWarrants" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.11.7" xlink:to="lab_ReceiptsOnAccountOfSharesAndWarrants7.286183" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReceiptsOnAccountOfSharesAndWarrants7.286183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ReceiptsOnAccountOfSharesAndWarrants7.286183">RECEIPTS ON ACCOUNT OF SHARES AND WARRANTS</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.3282.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.3282.11.6" xlink:to="lab_RetainedEarningsMember.286196" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.286196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.286196">Deficit accumulated during the development stage [Member]</link:label>
    <link:loc xlink:label="loc_SharesCancelledShares.33120.11.6" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledShares.33120.11.6" xlink:to="lab_SharesCancelledShares.286102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledShares.286102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledShares.286102">Shares Cancelled Shares</link:label>
    <link:loc xlink:label="loc_SharesCancelledShares.33120.11.18" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledShares.33120.11.18" xlink:to="lab_SharesCancelledShares18.286103" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledShares18.286103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledShares18.286103">Shares Cancelled, Shares.</link:label>
    <link:loc xlink:label="loc_SharesCancelledShares.33120.11.7" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledShares.33120.11.7" xlink:to="lab_SharesCancelledShares7.286169" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledShares7.286169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledShares7.286169">SHARES CANCELLED, shares</link:label>
    <link:loc xlink:label="loc_SharesCancelledValue.33119.11.6" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledValue.33119.11.6" xlink:to="lab_SharesCancelledValue.286096" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledValue.286096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledValue.286096">Shares Cancelled Value</link:label>
    <link:loc xlink:label="loc_SharesCancelledValue.33119.11.18" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledValue.33119.11.18" xlink:to="lab_SharesCancelledValue18.286100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledValue18.286100" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledValue18.286100">Shares Cancelled, Value.</link:label>
    <link:loc xlink:label="loc_SharesCancelledValue.33119.11.46" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesCancelledValue.33119.11.46" xlink:to="lab_SharesCancelledValue46.286168" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesCancelledValue46.286168" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesCancelledValue46.286168">SHARES CANCELLED</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.3280.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.3280.11.6" xlink:to="lab_StatementEquityComponentsAxis.11418" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.11418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.11418">Statement, Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementLineItems.2511.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.2511.11.6" xlink:to="lab_StatementLineItems.9478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.9478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.9478">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.1920.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.1920.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.1835988" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.1835988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.1835988">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.2467.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.2467.11.6" xlink:to="lab_StatementTable.9237" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.9237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.9237">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.12567.11.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.12567.11.16" xlink:to="lab_StockholdersEquity.286162" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.286162" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.286162">BALANCE</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.12567.11.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.12567.11.17" xlink:to="lab_StockholdersEquity.286165" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.286165" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.286165">BALANCE</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.11706" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.11706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.11706">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.286185" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.286185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.286185">SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.13119.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.13119.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.11686" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.11686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.11686">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.13119.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.13119.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.286176" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.286176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.286176">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesOfferingCosts.286108" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesOfferingCosts.286108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesOfferingCosts.286108">Stock Issued During Period Shares Offering Costs</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.18" xlink:to="lab_StockIssuedDuringPeriodSharesOfferingCosts18.286110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesOfferingCosts18.286110" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesOfferingCosts18.286110">Stock Issued During Period, Shares, Offering Costs.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesOfferingCosts7.286173" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesOfferingCosts7.286173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesOfferingCosts7.286173">SHARES ISSUED FOR OFFERING COSTS, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.13636" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.13636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.13636">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.286171" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.286171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesPurchaseOfAssets.286171">SHARES ISSUED FOR INVESTMENT IN ISTI-NJ, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServices.33125.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServices.33125.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesServices.286114" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServices.286114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServices.286114">Stock Issued During Period Shares Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServices.33125.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServices.33125.11.18" xlink:to="lab_StockIssuedDuringPeriodSharesServices18.286153" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServices18.286153" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServices18.286153">Stock Issued During Period, Shares, Services.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServices.33125.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServices.33125.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesServices7.286178" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServices7.286178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServices7.286178">SHARES ISSUED FOR SERVICES RENDERED, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesServicesRendered.286116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServicesRendered.286116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServicesRendered.286116">Stock Issued During Period Shares Services Rendered</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.18" xlink:to="lab_StockIssuedDuringPeriodSharesServicesRendered18.286155" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServicesRendered18.286155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServicesRendered18.286155">Stock Issued During Period, Shares, Services Rendered.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesServicesRendered7.286181" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesServicesRendered7.286181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesServicesRendered7.286181">SHARES TO BE ISSUED FOR SERVICES RENDERED, shares</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.11.6" xlink:to="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.11681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.11681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.11681">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.11.7" xlink:to="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.286184" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.286184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.286184">SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.13104.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.13104.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.11668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.11668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.11668">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.13104.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.13104.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.286175" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.286175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.286175">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.6" xlink:to="lab_StockIssuedDuringPeriodValueOfferingCosts.286105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueOfferingCosts.286105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueOfferingCosts.286105">Stock Issued During Period Value Offering Costs</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.18" xlink:to="lab_StockIssuedDuringPeriodValueOfferingCosts18.286107" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueOfferingCosts18.286107" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueOfferingCosts18.286107">Stock Issued During Period, Value, Offering Costs.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueOfferingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.11.7" xlink:to="lab_StockIssuedDuringPeriodValueOfferingCosts7.286172" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueOfferingCosts7.286172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueOfferingCosts7.286172">SHARES ISSUED FOR OFFERING COSTS</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.11.6" xlink:to="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.13635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.13635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.13635">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.11.7" xlink:to="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.286170" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.286170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValuePurchaseOfAssets.286170">SHARES ISSUED FOR INVESTMENT IN ISTI-NJ</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServices.33124.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServices.33124.11.6" xlink:to="lab_StockIssuedDuringPeriodValueServices.286113" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServices.286113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServices.286113">Stock Issued During Period Value Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServices.33124.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServices.33124.11.18" xlink:to="lab_StockIssuedDuringPeriodValueServices18.286152" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServices18.286152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServices18.286152">Stock Issued During Period, Value, Services.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServices.33124.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServices.33124.11.7" xlink:to="lab_StockIssuedDuringPeriodValueServices7.286177" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServices7.286177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServices7.286177">SHARES ISSUED FOR SERVICES RENDERED</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.6" xlink:to="lab_StockIssuedDuringPeriodValueServicesRendered.286115" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServicesRendered.286115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServicesRendered.286115">Stock Issued During Period Value Services Rendered</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.18" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.18" xlink:to="lab_StockIssuedDuringPeriodValueServicesRendered18.286154" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServicesRendered18.286154" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServicesRendered18.286154">Stock Issued During Period, Value, Services Rendered.</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServicesRendered" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueServicesRendered.33126.11.7" xlink:to="lab_StockIssuedDuringPeriodValueServicesRendered7.286180" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueServicesRendered7.286180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueServicesRendered7.286180">SHARES TO BE ISSUED FOR SERVICES RENDERED</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.7" xlink:href="ormp-20120229.xsd#ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.7" xlink:to="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836537">Common stock to be issued for services</link:label>
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.18" xlink:href="ormp-20120229.xsd#ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.18" xlink:to="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836536" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836536">Issuance of stock and warrants to be issued for services or claims.</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.15733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.15733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.15733">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.286258" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.286258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.286258">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:label="loc_AmortizationOfDebtDiscountPremium.5284.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfDebtDiscountPremium.5284.11.6" xlink:to="lab_AmortizationOfDebtDiscountPremium.16421" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfDebtDiscountPremium.16421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfDebtDiscountPremium.16421">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:label="loc_AmortizationOfDebtDiscountPremium.5284.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfDebtDiscountPremium.5284.11.7" xlink:to="lab_AmortizationOfDebtDiscountPremium.286261" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfDebtDiscountPremium.286261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfDebtDiscountPremium.286261">Amortization of debt discount</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.16" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.286291" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.286291" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.286291">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.5490.11.17" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.286292" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.286292" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.286292">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.4962" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.4962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.4962">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.11.15" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.286290" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.286290" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.286290">INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_ContributionOfProperty.10924.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContributionOfProperty" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContributionOfProperty.10924.11.6" xlink:to="lab_ContributionOfProperty.7888" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContributionOfProperty.7888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ContributionOfProperty.7888">Contribution of Property</link:label>
    <link:loc xlink:label="loc_ContributionOfProperty.10924.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContributionOfProperty" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContributionOfProperty.10924.11.7" xlink:to="lab_ContributionOfProperty.286295" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContributionOfProperty.286295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ContributionOfProperty.286295">Contribution to paid in capital</link:label>
    <link:loc xlink:label="loc_Depreciation.4943.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Depreciation.4943.11.6" xlink:to="lab_Depreciation.437" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Depreciation.437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Depreciation.437">Depreciation</link:label>
    <link:loc xlink:label="loc_Depreciation.4943.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Depreciation.4943.11.7" xlink:to="lab_Depreciation.286259" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Depreciation.286259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Depreciation.286259">Depreciation</link:label>
    <link:loc xlink:label="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.6" xlink:href="ormp-20120229.xsd#ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.6" xlink:to="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.286248" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.286248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.286248">Discount On Convertible Note Related To Beneficial Conversion Feature</link:label>
    <link:loc xlink:label="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.18" xlink:href="ormp-20120229.xsd#ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.18" xlink:to="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature18.286251" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature18.286251" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature18.286251">Discount on convertible note related to beneficial conversion feature.</link:label>
    <link:loc xlink:label="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.7" xlink:href="ormp-20120229.xsd#ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.11.7" xlink:to="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature7.286296" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature7.286296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature7.286296">Discount on convertible note related to beneficial conversion feature</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.10897" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.10897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.10897">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.11.46" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.286262" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.286262" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.286262">Exchange differences</link:label>
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.6" xlink:to="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.17625" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.17625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.17625">Gain (Loss) on Investments, Excluding Other than Temporary Impairments</link:label>
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.51" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.11.51" xlink:to="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments51.286329" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments51.286329" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments51.286329">Gain on sale of investment</link:label>
    <link:loc xlink:label="loc_ImputedInterestExpense.33133.11.6" xlink:href="ormp-20120229.xsd#ormp_ImputedInterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ImputedInterestExpense.33133.11.6" xlink:to="lab_ImputedInterestExpense.286234" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ImputedInterestExpense.286234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ImputedInterestExpense.286234">Imputed Interest Expense</link:label>
    <link:loc xlink:label="loc_ImputedInterestExpense.33133.11.18" xlink:href="ormp-20120229.xsd#ormp_ImputedInterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ImputedInterestExpense.33133.11.18" xlink:to="lab_ImputedInterestExpense18.286235" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ImputedInterestExpense18.286235" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ImputedInterestExpense18.286235">Imputed Interest Expense.</link:label>
    <link:loc xlink:label="loc_ImputedInterestExpense.33133.11.7" xlink:href="ormp-20120229.xsd#ormp_ImputedInterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ImputedInterestExpense.33133.11.7" xlink:to="lab_ImputedInterestExpense7.286267" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ImputedInterestExpense7.286267" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ImputedInterestExpense7.286267">Imputed interest</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayable.5726.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayable.5726.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayable.1389" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayable.1389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayable.1389">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayable.5726.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayable.5726.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayable7.286272" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayable7.286272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayable7.286272">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.16521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.16521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.16521">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.286269" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.286269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.286269">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.11.6" xlink:to="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.14870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.14870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.14870">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.11.7" xlink:to="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.286273" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.286273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.286273">Provision for uncertain tax position</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.11.6" xlink:to="lab_IncreaseDecreaseInPensionAndPostretirementObligations.11801" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPensionAndPostretirementObligations.11801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPensionAndPostretirementObligations.11801">Increase (Decrease) in Pension and Postretirement Obligations</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.11.7" xlink:to="lab_IncreaseDecreaseInPensionAndPostretirementObligations.1835990" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPensionAndPostretirementObligations.1835990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPensionAndPostretirementObligations.1835990">Liability of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.11.6" xlink:to="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.1379" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.1379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.1379">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.11.46" xlink:to="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets7.286270" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets7.286270" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets7.286270">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.7673.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.7673.11.6" xlink:to="lab_IncreaseDecreaseInRestrictedCash.3717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.3717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.3717">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.7673.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.7673.11.46" xlink:to="lab_IncreaseDecreaseInRestrictedCash.286279" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.286279" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.286279">Lease deposits</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.11.6" xlink:to="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities.17168" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities.17168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities.17168">Increase (Decrease) in Restricted Cash for Operating Activities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.11.46" xlink:to="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities46.286271" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities46.286271" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCashForOperatingActivities46.286271">Restricted cash</link:label>
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.11.6" xlink:to="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.448" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.448">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.11.7" xlink:to="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.286264" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.286264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IssuanceOfStockAndWarrantsForServicesOrClaims.286264">Common stock issued for services</link:label>
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.6" xlink:href="ormp-20120229.xsd#ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.11.6" xlink:to="lab_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.1836535">Issuance Of Stock And Warrants To Be Issued For Services Or Claims</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.8568.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.4896" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.4896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.4896">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.8568.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.8568.11.15" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.286289" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.286289" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.286289">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.16836" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.16836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.16836">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.286281" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.286281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.286281">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.8569.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.4898" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.4898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.4898">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.8569.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.8569.11.15" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.286280" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.286280" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.286280">Total net cash derived from (used in) investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.16837" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.16837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.16837">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.286275" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.286275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.286275">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.8570.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.4900" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.4900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.4900">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.8570.11.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.8570.11.15" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.286274" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.286274" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.286274">Total net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.16838" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.16838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.16838">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.286253" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.286253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.286253">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.8620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.8620.11.6" xlink:to="lab_NetIncomeLoss.4960" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.4960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.4960">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.8620.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.8620.11.8" xlink:to="lab_NetIncomeLoss.286257" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.286257" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.286257">Net loss</link:label>
    <link:loc xlink:label="loc_NoncashInvestingAndFinancingItemsAbstract.4523.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NoncashInvestingAndFinancingItemsAbstract.4523.11.6" xlink:to="lab_NoncashInvestingAndFinancingItemsAbstract.14971" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NoncashInvestingAndFinancingItemsAbstract.14971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NoncashInvestingAndFinancingItemsAbstract.14971">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:label="loc_NoncashInvestingAndFinancingItemsAbstract.4523.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NoncashInvestingAndFinancingItemsAbstract.4523.11.7" xlink:to="lab_NoncashInvestingAndFinancingItemsAbstract.286293" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NoncashInvestingAndFinancingItemsAbstract.286293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NoncashInvestingAndFinancingItemsAbstract.286293">Non cash investing and financing activities:</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.6" xlink:to="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.17604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.17604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.17604">Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.11.8" xlink:to="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet8.286330" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet8.286330" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet8.286330">Impairment of investment</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.6" xlink:to="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.17606" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.17606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.17606">Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.16900" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.16900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.16900">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.11.46" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities46.1835991" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities46.1835991" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities46.1835991">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.6526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.6526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.6526">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.11.46" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment7.286276" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment7.286276" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment7.286276">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireShortTermInvestments.9798.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireShortTermInvestments.9798.11.6" xlink:to="lab_PaymentsToAcquireShortTermInvestments.6541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireShortTermInvestments.6541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireShortTermInvestments.6541">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireShortTermInvestments.9798.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireShortTermInvestments.9798.11.46" xlink:to="lab_PaymentsToAcquireShortTermInvestments46.286278" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireShortTermInvestments46.286278" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireShortTermInvestments46.286278">Acquisition of short-term investments, net</link:label>
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.9511.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromConvertibleDebt.9511.11.6" xlink:to="lab_ProceedsFromConvertibleDebt.6165" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromConvertibleDebt.6165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromConvertibleDebt.6165">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.9511.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromConvertibleDebt.9511.11.7" xlink:to="lab_ProceedsFromConvertibleDebt.286284" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromConvertibleDebt.286284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromConvertibleDebt.286284">Proceeds from convertible notes</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.11.6" xlink:to="lab_ProceedsFromIssuanceOrSaleOfEquity.6190" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOrSaleOfEquity.6190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOrSaleOfEquity.6190">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.11.7" xlink:to="lab_ProceedsFromIssuanceOrSaleOfEquity.286282" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOrSaleOfEquity.286282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOrSaleOfEquity.286282">Proceeds from issuance of common stock and warrants - net of issuance expenses</link:label>
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.9553.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromNotesPayable.9553.11.6" xlink:to="lab_ProceedsFromNotesPayable.6225" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromNotesPayable.6225" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromNotesPayable.6225">Proceeds from Notes Payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.9553.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromNotesPayable.9553.11.7" xlink:to="lab_ProceedsFromNotesPayable.286285" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromNotesPayable.286285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromNotesPayable.286285">Proceeds from short term note payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.6" xlink:href="ormp-20120229.xsd#ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.6" xlink:to="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances.286243" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances.286243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances.286243">Proceeds From Receipts On Account Of Shares Issuances</link:label>
    <link:loc xlink:label="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.18" xlink:href="ormp-20120229.xsd#ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.18" xlink:to="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances18.286246" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances18.286246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances18.286246">Proceeds From Receipts On Account Of Shares Issuances.</link:label>
    <link:loc xlink:label="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.7" xlink:href="ormp-20120229.xsd#ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.11.7" xlink:to="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances7.286283" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances7.286283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromReceiptsOnAccountOfSharesIssuances7.286283">Receipts on account of shares issuances</link:label>
    <link:loc xlink:label="loc_ProceedsFromRelatedPartyDebt.9561.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRelatedPartyDebt.9561.11.6" xlink:to="lab_ProceedsFromRelatedPartyDebt.6237" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRelatedPartyDebt.6237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRelatedPartyDebt.6237">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:label="loc_ProceedsFromRelatedPartyDebt.9561.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRelatedPartyDebt.9561.11.7" xlink:to="lab_ProceedsFromRelatedPartyDebt.286287" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRelatedPartyDebt.286287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRelatedPartyDebt.286287">Shareholder advances</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.11.6" xlink:to="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.12796" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.12796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.12796">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.11.7" xlink:to="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.286238" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.286238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.286238">Proceeds from sale of Short term investments</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.11.6" xlink:to="lab_ProceedsFromSaleOfEquityMethodInvestments.6247" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfEquityMethodInvestments.6247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfEquityMethodInvestments.6247">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.11.7" xlink:to="lab_ProceedsFromSaleOfEquityMethodInvestments.1836539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfEquityMethodInvestments.1836539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfEquityMethodInvestments.1836539">Proceeds from sale of investment in Entera</link:label>
    <link:loc xlink:label="loc_RepaymentsOfNotesPayable.10022.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RepaymentsOfNotesPayable.10022.11.6" xlink:to="lab_RepaymentsOfNotesPayable.6841" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RepaymentsOfNotesPayable.6841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RepaymentsOfNotesPayable.6841">Repayments of Notes Payable</link:label>
    <link:loc xlink:label="loc_RepaymentsOfNotesPayable.10022.11.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RepaymentsOfNotesPayable.10022.11.46" xlink:to="lab_RepaymentsOfNotesPayable.286286" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RepaymentsOfNotesPayable.286286" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_RepaymentsOfNotesPayable.286286">Payments of short term note payable</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.6966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.6966.11.6" xlink:to="lab_ShareBasedCompensation.2850" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.2850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.2850">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.6966.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.6966.11.7" xlink:to="lab_ShareBasedCompensation7.286263" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.286263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.286263">Stock based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.286252" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.286252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.286252">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockIssued1.15369.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssued1.15369.11.6" xlink:to="lab_StockIssued1.14890" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssued1.14890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssued1.14890">Stock Issued</link:label>
    <link:loc xlink:label="loc_StockIssued1.15369.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssued1.15369.11.7" xlink:to="lab_StockIssued1.286294" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssued1.286294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssued1.286294">Shares issued for offering costs</link:label>
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.11.8" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.1835989" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.1835989" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.1835989">Impairment of available for sales securities</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.4413.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.4413.11.6" xlink:to="lab_AccountingPoliciesAbstract.286299" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.286299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.286299">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTextBlock.10803.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTextBlock.10803.11.6" xlink:to="lab_SignificantAccountingPoliciesTextBlock.7722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTextBlock.7722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTextBlock.7722">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTextBlock.10803.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTextBlock.10803.11.7" xlink:to="lab_SignificantAccountingPoliciesTextBlock.286300" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTextBlock.286300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTextBlock.286300">SIGNIFICANT ACCOUNTING POLICIES</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 110 - Disclosure - AGREEMENT WITH D.N.A. BIOMEDICAL SOLUTIONS LTD." xlink:role="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:type="extended">
    <link:loc xlink:label="loc_EquityMethodInvestmentsAndJointVenturesAbstract.4414.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentsAndJointVenturesAbstract.4414.11.6" xlink:to="lab_EquityMethodInvestmentsAndJointVenturesAbstract.286302" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentsAndJointVenturesAbstract.286302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentsAndJointVenturesAbstract.286302">AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD. [Abstract]</link:label>
    <link:loc xlink:label="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.11.6" xlink:to="lab_EquityMethodInvestmentsDisclosureTextBlock.2558" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentsDisclosureTextBlock.2558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentsDisclosureTextBlock.2558">Equity Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.11.7" xlink:to="lab_EquityMethodInvestmentsDisclosureTextBlock.286303" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentsDisclosureTextBlock.286303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentsDisclosureTextBlock.286303">AGREEMENT WITH D.N.A BIOMEDICAL SOLUTIONS LTD.</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 102 - Disclosure - COMMITMENTS" xlink:role="http://www.oramed.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract.4317.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract.4317.11.6" xlink:to="lab_CommitmentsAndContingenciesDisclosureAbstract.286305" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDisclosureAbstract.286305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDisclosureAbstract.286305">COMMITMENTS [Abstract]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.11.6" xlink:to="lab_CommitmentsAndContingenciesDisclosureTextBlock.1479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDisclosureTextBlock.1479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDisclosureTextBlock.1479">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.11.7" xlink:to="lab_CommitmentsAndContingenciesDisclosureTextBlock.286306" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingenciesDisclosureTextBlock.286306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingenciesDisclosureTextBlock.286306">COMMITMENTS</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 104 - Disclosure - STOCKHOLDERS' EQUITY" xlink:role="http://www.oramed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.1930.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.1930.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.286307" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.286307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.286307">STOCK HOLDERS' EQUITY [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.10874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.10874.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.7816" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.7816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.7816">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.10874.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.10874.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.286308" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.286308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.286308">STOCK HOLDERS' EQUITY</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 112 - Disclosure - STOCK BASED COMPENSATION" xlink:role="http://www.oramed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.4354.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.4354.11.6" xlink:to="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.286309" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.286309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.286309">STOCK BASED COMPENSATION [Abstract]</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.11.6" xlink:to="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.9158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.9158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.9158">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.11.7" xlink:to="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.286310" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.286310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.286310">STOCK BASED COMPENSATION</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 113 - Disclosure - SHORT TERM BANK DEPOSITS" xlink:role="http://www.oramed.com/role/ShortTermBankDeposits" xlink:type="extended">
    <link:loc xlink:label="loc_DepositAssetsDisclosureAbstract.565.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositAssetsDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositAssetsDisclosureAbstract.565.11.6" xlink:to="lab_DepositAssetsDisclosureAbstract.286317" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositAssetsDisclosureAbstract.286317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepositAssetsDisclosureAbstract.286317">SHORT TERM BANK DEPOSITS [Abstract]</link:label>
    <link:loc xlink:label="loc_OtherAssetsDisclosureTextBlock.15141.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsDisclosureTextBlock.15141.11.6" xlink:to="lab_OtherAssetsDisclosureTextBlock.14587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsDisclosureTextBlock.14587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsDisclosureTextBlock.14587">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_OtherAssetsDisclosureTextBlock.15141.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsDisclosureTextBlock.15141.11.7" xlink:to="lab_OtherAssetsDisclosureTextBlock.286318" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsDisclosureTextBlock.286318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsDisclosureTextBlock.286318">SHORT TERM BANK DEPOSITS</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 103 - Disclosure - FAIR VALUE" xlink:role="http://www.oramed.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.4322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresAbstract.4322.11.6" xlink:to="lab_FairValueDisclosuresAbstract.286319" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresAbstract.286319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresAbstract.286319">FAIR VALUE [Abstract]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.12036.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.12036.11.6" xlink:to="lab_FairValueDisclosuresTextBlock.9831" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock.9831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock.9831">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.12036.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.12036.11.7" xlink:to="lab_FairValueDisclosuresTextBlock.286320" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock.286320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock.286320">FAIR VALUE</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.7037.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentOwnershipPercentage.7037.11.6" xlink:to="lab_EquityMethodInvestmentOwnershipPercentage.2953" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentOwnershipPercentage.2953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentOwnershipPercentage.2953">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.7037.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentOwnershipPercentage.7037.11.7" xlink:to="lab_EquityMethodInvestmentOwnershipPercentage7.286325" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentOwnershipPercentage7.286325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentOwnershipPercentage7.286325">Joint venture interest sold</link:label>
    <link:loc xlink:label="loc_FairValueOfAssetsAcquired.7118.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueOfAssetsAcquired.7118.11.6" xlink:to="lab_FairValueOfAssetsAcquired.3060" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueOfAssetsAcquired.3060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueOfAssetsAcquired.3060">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:label="loc_FairValueOfAssetsAcquired.7118.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueOfAssetsAcquired.7118.11.7" xlink:to="lab_FairValueOfAssetsAcquired.286326" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueOfAssetsAcquired.286326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueOfAssetsAcquired.286326">Non-cash proceeds from sale</link:label>
  </link:labelLink>
  <link:labelLink xlink:title="Label 105 - Disclosure - SUBSEQUENT EVENTS" xlink:role="http://www.oramed.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:label="loc_SubsequentEventsAbstract.4429.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsAbstract.4429.11.6" xlink:to="lab_SubsequentEventsAbstract.1835974" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsAbstract.1835974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsAbstract.1835974">SUBSEQUENT EVENT [Abstract]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.14907.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.14907.11.6" xlink:to="lab_SubsequentEventsTextBlock.13648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.13648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.13648">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.14907.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.14907.11.7" xlink:to="lab_SubsequentEventsTextBlock.1835975" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.1835975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.1835975">SUBSEQUENT EVENT</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ormp-20120229_pre.xml
<DESCRIPTION>TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.0 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-04-04 @ 2:37 PM-->
<link:linkbase xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:href="ormp-20120229.xsd#ormp-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ormp-20120229.xsd#ormp-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ormp-20120229.xsd#ormp-ccbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ormp-20120229.xsd#ormp-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-cscse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ormp-20120229.xsd#ormp-ccscf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:href="ormp-20120229.xsd#ormp-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:href="ormp-20120229.xsd#ormp-awbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/Commitments" xlink:href="ormp-20120229.xsd#ormp-comm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-steq" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockBasedCompensation" xlink:href="ormp-20120229.xsd#ormp-sbco" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/ShortTermBankDeposits" xlink:href="ormp-20120229.xsd#ormp-stbd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/FairValue" xlink:href="ormp-20120229.xsd#ormp-fava" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="ormp-20120229.xsd#ormp-cscfpar" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SubsequentEvents" xlink:href="ormp-20120229.xsd#ormp-suev" xlink:type="simple" />
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:href="ormp-20120229.xsd#ormp_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.15957.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_DocumentType.15957.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AmendmentFlag.15889.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_AmendmentFlag.15889.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.15906.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_DocumentPeriodEndDate.15906.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EntityRegistrantName.15932.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_EntityRegistrantName.15932.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.15933.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_EntityCentralIndexKey.15933.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.15900.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_CurrentFiscalYearEndDate.15900.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.15953.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_DocumentFiscalPeriodFocus.15953.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.15952.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_DocumentFiscalYearFocus.15952.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EntityFilerCategory.15930.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_EntityFilerCategory.15930.12.7" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.15937.12.7" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.33116.12.7" xlink:to="loc_EntityCommonStockSharesOutstanding.15937.12.7" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsAbstract.2510.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_AssetsAbstract.2510.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.487.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.487.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrent.13892.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.487.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.6082.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.487.12.15" xlink:to="loc_LiabilitiesCurrent.6082.12.15" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_DueToRelatedPartiesCurrent.13919.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.487.12.7" xlink:to="loc_DueToRelatedPartiesCurrent.13919.12.7" order="1.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.13894.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.487.12.7" xlink:to="loc_AccountsPayableOtherCurrent.13894.12.7" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.487.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.1277.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.1277.12.7" xlink:to="loc_LiabilityForUncertainTaxPositionsNoncurrent.13167.12.7" order="1.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.13629.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:to="loc_CommitmentsAndContingencies.13629.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.1929.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:to="loc_StockholdersEquityAbstract.1929.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.8067.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.15" xlink:to="loc_LiabilitiesAndStockholdersEquity.8067.12.15" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.1277.12.7" order="1.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.1277.12.7" xlink:to="loc_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent.13989.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Liabilities.8054.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.1053.12.7" xlink:to="loc_Liabilities.8054.12.7" order="3.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.1999.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.2510.12.7" xlink:to="loc_AssetsCurrentAbstract.1999.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepositsAssetsCurrent.13499.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_DepositsAssetsCurrent.13499.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MarketableSecuritiesCurrent.8453.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_MarketableSecuritiesCurrent.8453.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.10107.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.4824.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_AccountsReceivableNetCurrent.4824.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.9435.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_PrepaidExpenseCurrent.9435.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DueFromOtherRelatedPartiesCurrent.5095.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_DueFromOtherRelatedPartiesCurrent.5095.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.15266.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.7" xlink:to="loc_OtherReceivablesNetCurrent.15266.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.1999.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsCurrent.11042.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.1999.12.15" xlink:to="loc_AssetsCurrent.11042.12.15" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommonStockValue.5831.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.1929.12.7" xlink:to="loc_CommonStockValue.5831.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.1929.12.7" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.4876.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalCommonStock.4917.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.1929.12.7" xlink:to="loc_AdditionalPaidInCapitalCommonStock.4917.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.10174.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.1929.12.7" xlink:to="loc_RetainedEarningsAccumulatedDeficit.10174.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.1929.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.12567.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.1929.12.15" xlink:to="loc_StockholdersEquity.12567.12.15" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.1277.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.8718.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.1277.12.15" xlink:to="loc_LiabilitiesNoncurrent.8718.12.15" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_InvestmentsAndOtherNoncurrentAssets.14460.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.2510.12.7" xlink:to="loc_InvestmentsAndOtherNoncurrentAssets.14460.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.9645.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.2510.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.9645.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.2510.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.11397.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.2510.12.15" xlink:to="loc_Assets.11397.12.15" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_PrepaidPensionCosts.9442.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidPensionCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.2510.12.7" xlink:to="loc_PrepaidPensionCosts.9442.12.7" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)" xlink:role="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.12450.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.12450.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.5828.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_CommonStockSharesAuthorized.5828.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.5829.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_CommonStockSharesIssued.5829.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.209.12.7" xlink:to="loc_CommonStockSharesOutstanding.5830.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeStatementAbstract.907.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.11299.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_ResearchAndDevelopmentExpense.11299.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.7417.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_GeneralAndAdministrativeExpense.7417.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.907.12.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.8862.12.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.49" xlink:to="loc_OperatingIncomeLoss.8862.12.49" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.907.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherNonoperatingIncome.8974.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.46" xlink:to="loc_OtherNonoperatingIncome.8974.12.46" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.8973.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_OtherNonoperatingExpense.8973.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.46" xlink:to="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.12.46" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.12.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.49" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.14098.12.49" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.12608.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_IncomeTaxExpenseBenefit.12608.12.7" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.15412.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.15412.12.7" order="12.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.8620.12.49" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.49" xlink:to="loc_NetIncomeLoss.8620.12.49" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.12.7" xlink:href="ormp-20120229.xsd#ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare.35816.12.7" order="13.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.907.12.7" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" xlink:role="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.1920.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.2467.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.1920.12.6" xlink:to="loc_StatementTable.2467.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.2511.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.2467.12.6" xlink:to="loc_StatementLineItems.2511.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.3280.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.2467.12.6" xlink:to="loc_StatementEquityComponentsAxis.3280.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.2511.12.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.12567.12.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.16" xlink:to="loc_StockholdersEquity.12567.12.16" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.2511.12.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.12.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.17" xlink:to="loc_CommonStockSharesOutstanding.5830.12.17" order="22.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StatementLineItems.2511.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SharesCancelledValue.33119.12.46" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.46" xlink:to="loc_SharesCancelledValue.33119.12.46" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_StatementLineItems.2511.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SharesCancelledShares.33120.12.7" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledShares" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_SharesCancelledShares.33120.12.7" order="3.10" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.12.7" order="3.60" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.12.7" order="3.70" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueOfferingCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.12.7" order="3.80" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesOfferingCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.12.7" order="3.90" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.13104.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.13104.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.13119.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.13119.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServices.33124.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValueServices.33124.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServices.33125.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesServices.33125.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServicesRendered.33126.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServicesRendered" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValueServicesRendered.33126.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.12.7" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServicesRendered" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.12.7" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.12.7" xlink:href="ormp-20120229.xsd#ormp_ReceiptsOnAccountOfSharesAndWarrants" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.12.7" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.12.7" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.12.7" order="12.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.12.7" order="13.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.12.7" order="14.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.12.7" xlink:href="ormp-20120229.xsd#ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.12.7" order="15.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.12.7" order="16.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.5848.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_ComprehensiveIncomeNetOfTax.5848.12.7" order="17.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.12.7" xlink:href="ormp-20120229.xsd#ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.12.7" order="19.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.12.7" order="18.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.8620.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.7" xlink:to="loc_NetIncomeLoss.8620.12.7" order="20.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.12567.12.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.17" xlink:to="loc_StockholdersEquity.12567.12.17" order="21.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.12.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.2511.12.16" xlink:to="loc_CommonStockSharesOutstanding.5830.12.16" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_EquityComponentDomain.3287.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.3280.12.6" xlink:to="loc_EquityComponentDomain.3287.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockMember.2154.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.3287.12.6" xlink:to="loc_CommonStockMember.2154.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.3281.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.3287.12.6" xlink:to="loc_AdditionalPaidInCapitalMember.3281.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeMember.4725.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.3287.12.6" xlink:to="loc_OtherComprehensiveIncomeMember.4725.12.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.3282.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.3287.12.6" xlink:to="loc_RetainedEarningsMember.3282.12.6" order="2.90" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.46" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.5699.12.46" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.46" xlink:to="loc_IncreaseDecreaseInRestrictedCashForOperatingActivities.13045.12.46" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayable.5726.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayable.5726.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.7" xlink:to="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.15349.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:to="loc_ProceedsFromIssuanceOrSaleOfEquity.9528.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.7" xlink:to="loc_IncreaseDecreaseInPensionAndPostretirementObligations.13204.12.7" order="3.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.46" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.9790.12.46" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsToAcquireShortTermInvestments.9798.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.46" xlink:to="loc_PaymentsToAcquireShortTermInvestments.9798.12.46" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.12.7" xlink:href="ormp-20120229.xsd#ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:to="loc_ProceedsFromReceiptsOnAccountOfSharesIssuances.33134.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromConvertibleDebt.9511.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:to="loc_ProceedsFromConvertibleDebt.9511.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.9553.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:to="loc_ProceedsFromNotesPayable.9553.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_RepaymentsOfNotesPayable.10022.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.46" xlink:to="loc_RepaymentsOfNotesPayable.10022.12.46" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ProceedsFromRelatedPartyDebt.9561.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" xlink:to="loc_ProceedsFromRelatedPartyDebt.9561.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.8568.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.15" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.8568.12.15" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.8620.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.8" xlink:to="loc_NetIncomeLoss.8620.12.8" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Depreciation.4943.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_Depreciation.4943.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.8570.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.1228.12.15" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.8570.12.15" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.7" xlink:to="loc_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.15186.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.7673.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.46" xlink:to="loc_IncreaseDecreaseInRestrictedCash.7673.12.46" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.8569.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.15" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.8569.12.15" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.1226.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.12.15" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.15" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.8623.12.15" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.12.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.16" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.16" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.16" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.12.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.17" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.17" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.5490.12.17" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_NoncashInvestingAndFinancingItemsAbstract.4523.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_NoncashInvestingAndFinancingItemsAbstract.4523.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.46" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.8957.12.46" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.1227.12.7" xlink:to="loc_ProceedsFromSaleOfEquityMethodInvestments.9567.12.7" order="2.75" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AmortizationOfDebtDiscountPremium.5284.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_AmortizationOfDebtDiscountPremium.5284.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.12.46" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.46" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.12613.12.46" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensation.6966.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_ShareBasedCompensation.6966.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_IssuanceOfStockAndWarrantsForServicesOrClaims.4951.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.51" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.12.51" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.51" xlink:to="loc_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments.15732.12.51" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.8" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet.15721.12.8" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ImputedInterestExpense.33133.12.7" xlink:href="ormp-20120229.xsd#ormp_ImputedInterestExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_ImputedInterestExpense.33133.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.368.12.7" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssued1.15369.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NoncashInvestingAndFinancingItemsAbstract.4523.12.7" xlink:to="loc_StockIssued1.15369.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ContributionOfProperty.10924.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ContributionOfProperty" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NoncashInvestingAndFinancingItemsAbstract.4523.12.7" xlink:to="loc_ContributionOfProperty.10924.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.12.7" xlink:href="ormp-20120229.xsd#ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NoncashInvestingAndFinancingItemsAbstract.4523.12.7" xlink:to="loc_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature.33135.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.8" xlink:to="loc_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities.15722.12.8" order="7.20" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.12.7" xlink:href="ormp-20120229.xsd#ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.3777.12.7" xlink:to="loc_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims.35981.12.7" order="5.20" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.4413.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTextBlock.10803.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.4413.12.7" xlink:to="loc_SignificantAccountingPoliciesTextBlock.10803.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="110 - Disclosure - AGREEMENT WITH D.N.A. BIOMEDICAL SOLUTIONS LTD." xlink:role="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:type="extended">
    <link:loc xlink:label="loc_EquityMethodInvestmentsAndJointVenturesAbstract.4414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityMethodInvestmentsAndJointVenturesAbstract.4414.12.7" xlink:to="loc_EquityMethodInvestmentsDisclosureTextBlock.6754.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - COMMITMENTS" xlink:role="http://www.oramed.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract.4317.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract.4317.12.7" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock.5820.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - STOCKHOLDERS' EQUITY" xlink:role="http://www.oramed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.1930.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.10874.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.1930.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.10874.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="112 - Disclosure - STOCK BASED COMPENSATION" xlink:role="http://www.oramed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.4354.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.4354.12.7" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.11569.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="113 - Disclosure - SHORT TERM BANK DEPOSITS" xlink:role="http://www.oramed.com/role/ShortTermBankDeposits" xlink:type="extended">
    <link:loc xlink:label="loc_DepositAssetsDisclosureAbstract.565.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherAssetsDisclosureTextBlock.15141.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DepositAssetsDisclosureAbstract.565.12.7" xlink:to="loc_OtherAssetsDisclosureTextBlock.15141.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - FAIR VALUE" xlink:role="http://www.oramed.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.4322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.12036.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.4322.12.7" xlink:to="loc_FairValueDisclosuresTextBlock.12036.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)" xlink:role="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.7037.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_EquityMethodInvestmentOwnershipPercentage.7037.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueOfAssetsAcquired.7118.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.1917.12.7" xlink:to="loc_FairValueOfAssetsAcquired.7118.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="105 - Disclosure - SUBSEQUENT EVENTS" xlink:role="http://www.oramed.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:label="loc_SubsequentEventsAbstract.4429.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.14907.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventsAbstract.4429.12.7" xlink:to="loc_SubsequentEventsTextBlock.14907.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ormp-20120229_def.xml
<DESCRIPTION>TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.0 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-04-04 @ 2:36 PM-->
<link:linkbase xmlns:ormp="http://www.oramed.com/20120229" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.oramed.com/role/DocumentAndEntityInformation" xlink:href="ormp-20120229.xsd#ormp-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheets" xlink:href="ormp-20120229.xsd#ormp-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="ormp-20120229.xsd#ormp-ccbsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="ormp-20120229.xsd#ormp-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-cscse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="ormp-20120229.xsd#ormp-ccscf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SignificantAccountingPolicies" xlink:href="ormp-20120229.xsd#ormp-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/AgreementWithDnaBiomedicalSolutionsLtd" xlink:href="ormp-20120229.xsd#ormp-awbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/Commitments" xlink:href="ormp-20120229.xsd#ormp-comm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockholdersEquity" xlink:href="ormp-20120229.xsd#ormp-steq" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/StockBasedCompensation" xlink:href="ormp-20120229.xsd#ormp-sbco" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/ShortTermBankDeposits" xlink:href="ormp-20120229.xsd#ormp-stbd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/FairValue" xlink:href="ormp-20120229.xsd#ormp-fava" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="ormp-20120229.xsd#ormp-cscfpar" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oramed.com/role/SubsequentEvents" xlink:href="ormp-20120229.xsd#ormp-suev" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" xlink:role="http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_StatementTable.2467.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.3280.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.2467.5.6" xlink:to="loc_StatementEquityComponentsAxis.3280.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.2511.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.12567.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockholdersEquity.12567.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.5830.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_CommonStockSharesOutstanding.5830.7.6" order="22.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.13104.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.13104.7.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.13119.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.13119.7.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServices.33124.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValueServices.33124.7.6" order="6.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServices.33125.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesServices.33125.7.6" order="7.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueServicesRendered.33126.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueServicesRendered" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValueServicesRendered.33126.7.6" order="8.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesServicesRendered" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesServicesRendered.33127.7.6" order="9.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalOther.14463.7.6" order="10.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.7.6" xlink:href="ormp-20120229.xsd#ormp_ReceiptsOnAccountOfSharesAndWarrants" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_ReceiptsOnAccountOfSharesAndWarrants.33128.7.6" order="11.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.13114.7.6" order="12.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities.13134.7.6" order="13.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.15100.7.6" order="14.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.7.6" xlink:href="ormp-20120229.xsd#ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants.33130.7.6" order="15.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature.12707.7.6" order="16.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.5848.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_ComprehensiveIncomeNetOfTax.5848.7.6" order="17.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent.13961.7.6" order="18.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.7.6" xlink:href="ormp-20120229.xsd#ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_AdjustmentToAdditionalPaidInCapitalImputedInterest.33131.7.6" order="19.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.8620.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_NetIncomeLoss.8620.7.6" order="20.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.2511.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.2467.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.9.6" xlink:to="loc_StatementTable.2467.9.6" order="23.00" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.3280.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.3287.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.3280.6.6" xlink:to="loc_EquityComponentDomain.3287.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.3280.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.3287.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.3280.8.6" xlink:to="loc_EquityComponentDomain.3287.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.3287.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.2154.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.3287.7.6" xlink:to="loc_CommonStockMember.2154.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesCancelledValue.33119.7.6" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_SharesCancelledValue.33119.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesCancelledShares.33120.7.6" xlink:href="ormp-20120229.xsd#ormp_SharesCancelledShares" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_SharesCancelledShares.33120.7.6" order="3.10" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValuePurchaseOfAssets.14894.7.6" order="3.60" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesPurchaseOfAssets.14895.7.6" order="3.70" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodValueOfferingCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodValueOfferingCosts.33121.7.6" order="3.80" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.7.6" xlink:href="ormp-20120229.xsd#ormp_StockIssuedDuringPeriodSharesOfferingCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.2511.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesOfferingCosts.33122.7.6" order="3.90" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.3281.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.3287.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.3281.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeMember.4725.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.3287.7.6" xlink:to="loc_OtherComprehensiveIncomeMember.4725.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.3282.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.3287.7.6" xlink:to="loc_RetainedEarningsMember.3282.7.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001178913-12-001000-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-12-001000-xbrl.zip
M4$L#!!0````(`+6"A$!JB6'Y;4```(*N`@`1`!P`;W)M<"TR,#$R,#(R.2YX
M;6Q55`D``U6M?$]5K7Q/=7@+``$$)0X```0Y`0``[%UI=]NXU?[><_H?4+U)
M3W*.)'/1ZDS:*EX2S\1+;:>S?(-(2$)#D2I`VO'\^O=>@*1(BEH<2[(\H]/I
MC$5BN0OPW`67Y`___#;VR!T3D@?^^XI9-RJ$^4[@<G_XOO+EIM:[.3H[JQ`9
M4M^E7N"S]Q4_J/SS'W_]RP]_J]6N[%\^7'\F@4_Z;$2]`0D&Y+?:3^2C%_2I
M1SZ'+AF%X>3PX.#^_KX^L;_UA5=W@G&M%@\0STP:=9B:I)<G(G`CA[DXLF68
M5LUHP#_D7\0ZM!ODZEPWQ-$(T._+0X_[7]]7,G.IF0(Q/+`,PS[`VWTJ625N
M'HCQ)-<\$'3,7"3M`.<S+*N;M,61^(*QN8_"<=*QOXW"L9=K?V^KUF:WVSU0
M=].F,V3GFN+=I*G+IC2H^25SZL/@[@!N(,EFS3!KMIDTCV1M2.F4QP&5?35R
M?*.DR]G-9<,RVXLXE0&V2#KXT;B\L1N*@_!AP@Z@!1/<B3NL(D-0*R$_(..'
MTAFQ,;UF`Z($<8@COJ](/IYX*&MU;238X'T%M5E+U%;_)MT*.=`#@7`.>V/F
MN_#_\-2C0\+=]Y7<E7JSVVC5C>G_*L0)_)!]"Z]Q[(&`U:J%U45YA4%-+TBK
M!G,5^T+O?PRH)]D/!S-33RDZBH3`BUPZU/N547'BN\<T9(JX>3?73F>M9G1`
M_9K2>;-.B3X.G&B<-KD"O0;N*5R3BNJY=]=.]K\M3?'<&>>1C%S-(SB]MW9R
M\789P>F,L^1J7K)KHO3.1DC5M_,$YV:=)?<6]F6.2KRP=N),H_;O/%DXS92:
M$S_DX<,17!?4._-=]NTG]J#(*KVS=OH,`UJW6[81"Z]TUAER@_$X\&_"P/EZ
M,Z*"R<LH5)86K&^6]@7-@)AV9SXC5-:"02TUH?9,<^P0^5RW_J*'KQ"7.7P,
M./:^`JRU#=LRFAT[Q]@"DHI<GG*/B2-8.\-`9%62N[YVA=P`_3`^N6:30(0H
M4*!Y0OV'+!LY$HIT7[,AEZ`^/[P`YR!#>/[&VBF_O.Z=GQR3JT^]Z_/>T<F7
MV[.CWN<;<G9Q5,_2GJ="$X^6\+#G_C>2(6X1>1OT7)>'X&$!1%+NGOE'=,)#
MZBFE?0"/R$6I,%]2;*3T>3G!/^4U^U_$)0_9#1-WW&$:!:Z9$PQ]->(1-(H\
MT'FH$77[TZ+T&G7;ZICXK\7R-]0&`+EK^1O:^.D1C+(Q,IOBN+`A6F:STP%4
M?R9I_UE5W5Q1U:C<S%8SIZIN/EK55JMMVWM-;UG3K54UO1!4'Z=IL]4UC+VF
MMP[?RPSG8N">Y\?L(7LGU-M<[A<M!.M5U;N'Z>>!Z?5YO2\,FN?.?3:>1"&#
MWR&#J"@L:&?5;L_EV9K==KL](^E5J7XN23V'8VBW2\S)K@MJ6];VI2ZC[1BK
M=2V=8RZ=(/+#2T2K.R9"WO?811"R:^91Z'(;?&`^&W"'4T^WP*.64T;#2,09
MNZ>,4&(!ODE^Z'/O?244$5NO08@/3"0O.RZ!=6L>_'+^^48=&=2F)S('NR6N
M]J/%-;/@0%R=F:'^F.)J%CA<#E?3Y93ONPRNC(Z1.AA/HCHCO\*^/?F&CH@6
M3/FME[:?OHO!]E*5?O>2SZNTTS5CA983\T1&MK8V+;O9[*[,B901*NIRH)S=
MGN_^3`5FB"6N6KS+W--`Q$ZOO!1''N5C'4)\9]]MQ@&VT;";B2R^C]SG%]9+
ML@'/(Z*M[:WUKJ<K$3B,N?(42(1(DO%)*"_]GJ.MR4`?DR73:!D]KLM+,Q!;
M$<A+VD[;$,C6-D_+:"46]G%$9@0RMW%F^RDQK-+PV4X#IX)8A<S-LO](W7]O
M-OV[6=;WCG`A>!YS]4_%8^D=39AE-AM/U6G)&$O*'FIF%\."-#`H)7`^:_^A
M7L3*.%,WML78;&:F,X\A1=?3^-G^YJL]AB$T[-J2'T>"^T.=]8WK5P8#AM>.
M`AEONM6;/^<J-=M-J]M(=N/J-*\JE\3A62Z2I.7S2L,VF@UC%6DDY&Y6$,T5
M!;$XL_AX08`<6G9K=^306E4."]W5Q\NA8V<`?#UB4+"R,ES,MGX^J&PW[<6B
MF"5V6^)X!DNX.6FLLD5R#9]/!O82RY$C<Y/L;P,HB^SO#O?;@,<B]YU5EO\V
MF-]6U-*Q3-MN[PC36ZN,L=K-5G='F-Y6HMAJ=)=9_2VN[NV;^H[9A1!]1P3P
M+&6[5JMC=W9$`,]1S6HU.N8&H>Z:^2X3S%U9#DF'YY)'-M7_&'JW*Y?MH.,:
M9/$SX\-1R-S>'1-TR"ZB<9^)R\$'*KG3\]UC[N%!I8ZLOD@\LL1*O"A4A7B7
M@\^!E#"1NJ]$M<;Q-BG)\J>CS(;1,A-SLT9.7HZ\-W6J7R;OEF$W&IW.GUK>
M"Q[XFZYO7-0EZ_OQ3_^9[58K-:9_2GEW5UG?67EGUG?WL>L;3%JCW>UN2M[Q
M"P`.X^,:>44?:-]C,!9<$6`'/G/:YQX/.9/Q4^&ZIG+U]GB4:,T76?I,ZM3%
MRS=?6C_9;.)Z_`Y.MBH">P419`Y?[4>(H&E#A-->OP@NPQ$3"UC.WM^PEAMM
MJVG-Y3!+R%HYVJ#2GLJ1.FJ]P[87+"QCJ:S!AK74;%BJTFX56M?,U28UU6JU
M2@!F!:;*:[@S3\O']>G+FFU8;68'^YI9Q2TE:8.<;E"59L>VNS::T^_G=/D3
M1YE2X6/6#W_FX:B\)GI=@SW;`T)QJ?2ZA?-B1+[,$5S3`S0[(V9EEE:6HVK]
M;&NST\V9HE7IW:)0MK1ZMB:(-3QIN<WG5Y]K9=K-9J-K/5(E:^#W3Z'0YSA?
M:!I6LVOO];D)?3['\4"K96*UU%Z=F\#;[1B]/<9N%&.7*7$]U0I[7-TDKB[5
MX5J.%W<"2\?XSK_?XR0XAD/)8[U7@HUY-([?`[NDU0MZXFH#G+^01ZO6S_G6
M'SQ?F84"QU*RY`5`ZL]-I^1M1.?LL8.:=06B-IC@L\V&U>QT5B$JEUW.7MFT
MW*Q.P^A811++,\C+*=VH,('.CKT2I4=4CGJ^B_\Y`7"^HQYB?"\\HD(\<'\X
M?6!HI98($P7.%B!.PFB\#\V9WAL"F?4SW3174.?4)\XW7X8O9K?;RAZ5KD34
MQCG>Y,%&T[3M5G/7.-[H`8?5,!OFKG&\(.S+ZCAV$)J/>[N4;;9;F^!8>Y5G
MOB,8.*/'3/]W`>/E';9:S&<:[79KF2S*Z=RR2+;U[I>V;9F6_1)$LCU'<S60
M6$DFP7C,=3R'`P#%L,.8[_"X*GK!_1+L7\'$/\(4K,?$/XW!Q_LPCT#^33.(
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MHIIJU.-#_Y!X;`!7BLQ-Z1Z`5F>HX[['?183\/.)'KP?>*[J=W%Y>T(L4L/N
M!]C_$8-EN2D?_>CR_/SL]APHO<E-<*A^S5%>4:XKJ"XO)DQP\<'#7$G1\>2=
MWY>3=V54I'^'6%B4T)33;:ATZX-N1:EN*R``X3*!4$_PW0=R0AWU`:_X]X2Z
M;O+[GKOAZ'W%-(S7%:(8>%]Q&+Y2;*K74)"[^%883#+7W82^G\^.;S\=$KM;
M;W6[V251)M><$E==L$ME=Q"Z"PAK;82HDG6WXGHI7QJTOH2M3;!0W.&:E"_X
MD`<)1PSNB['$+[GACU,N9$AZ0\$8(A,LGW!$/E&7`D:2-WX0,F+2-^9;0OO!
M'7M;59WB+ZT0P4(*%+IIAS`@$Q'<<9>A1<`W+..'6:CO$@=8X0[U2"@X_%LF
MST^1GH1AQI'/A$J+D4&@J4Q:)`.Z8"H3#FA";C6=F4O"\+,I'C0$*EZ!L:P:
MAE$GM]!^(L!5$DBO9%0X6-R!TV3Z'HLZ.>=`VIC\Q%T1^%5"B<L%<T)HB`P$
M@P&0(Q*YQ2+0XP^`-""4<C5W,FP)O00+V%TV"3#5[9+^PY0&'WK2E$(U)`']
MTJ%NAP1JRNKD*A+XKB4E;AP>+#5(SR.3P./.`U*8C*JT"6-.@`]LS4.9GT)6
M,R/#+2R`!)FC"4\'H3$=BH$!`T_85],*_'P53&8:K_$_U//492V,*9.*LW#$
M"S-KR85!"(33,>9`4P%F*`JB4$L<NBN1W%-)7IE&U3(;B_?602@R?R/V3G_N
M#<6Z#46[66_O@IG8'IY>^N1'ZD<(*^TJ`;CIYK%123)9_A3@#`#1S2!!'FBQ
M9^5&MTG!N/*6W(\X[!>X/.`(VN&(AFFG$6P%!RL`'Y@+<Z-?.V`"YT2\HE("
MQ?@#]B5L(=SZP3T`A1SQ"1'XU(E,=O($=C*^BXPZ$"N*'-06[4,,.3&758WM
M3*`=(($JFTL&&W!/0U=6*G00SAD8F%'P!S8CP5@G\#PP.[%AZ+/PGC$_/YR?
MVIX]&NS1X'G1(/(>2$=#P2(D`%LFY@%!E5R)8%`G9R$%AX5<T]_5$I_Q3LB;
M"LYPJX;*X$45]Z?VRE9TP'*F'KPQQX$U@WWBC5Z8HIIQ+0!7^BSG=6EKCA.#
MPQ9O6]C+KQK:&<,F?:;-/.#"I?XF;^JKI88^=@?0U"LQN0E.+?)<-10IOX2-
M@7_D`>=.!D_H5;/#>%1QB@D4K0'EISEAA'Z4"&!4F<XDP\A]*/%7%!HCE=IQ
M&8D@&H[(*>L+91:L;E5]W%C[++$,]C"UAZEGA:D;-@D9/F1*3%.M3W.AWS((
M(@&[8QY<S2)3@E?'U.?,(S?.*!(BQJM3/=B3`*L$HXK#+@:I67BR2N$IY^;X
M@:]B'>V/X886NC;I=_R(N5B"`/M-OSN;?I_2>EI*J[\[*2U`LW.53S`[>I]I
M)+N)^K#!.6[``IAYZB!OBF68!%)QD<KMD`$L0?TL-3H(9U)0YFFS7^R(V0C,
M"Y&).E%#9&BVR3CPPQ'&9.,QGIT`0"41HAGC@!I,-0-?40\ZH0\QKFJHNCB[
M(785O`6D03.%EQI5RVK&EVR%CWBU66V9AG;AX'J#!/X]%9C4P0;)B"#QK[%_
M-L+D37*>J7TJS2;7Z#O&^$V@+#A^TIJ\H<H)F@$T+>B$D80%G@O.U#[X/[O[
M3F5N''WB0AQ5:N0\H`A?=0V[&N>,U.-\U/?1_\H)1I;FT1+>,!74L5ND!G^U
MJYUVY^W:L7;V[">/OFHM_H$!\\_G)?4DIFLBP<.'*43TH95V&:;KL0`+L@@_
M:>J:DC[UOY(A;"(*:E";C_I)','^AZM>[4\8J1P?P.]!=6%J)N0>N0CNM!-G
M&VI'MO8NQN[LF+V+\307PWD.%V/=ZQN<DQZ84H]89C8]/-\YR80_<:Q3B+J^
M\T2^L%C2,_G>\?7)#>FY=Y@#<<DU&T8>#0,@+'T+XN?0K4/HIEI6WL99ZDO!
MAQQ->39//<D<2>D820^O['3)D6":?A+XU;4XED,81,RE4D9"96;0C1%3PB;X
M(1(IH1O>4+_<2&AW3>UU'`43WS(L"AM:R*@_YE+&41\E7^HW=7+FWS'0HX9V
M8`J7R+&(AL`VJ!0XH\5H4W4[#0(W#G6A;<\=0ZPJPSBFU'(Z/>Y!]YAZ?,8%
M)RM$GX\\[,S(M#SS1B4>%DP?L='A+83X$-Y6I_&K&E;;'FQ@FB4I,I6/3TS1
M@'^#>?#L3[77S1F%H50+Q8=IECC`Y_0A7ORSV3D8QYR=MX^/"1%,)#@CSN[T
M\H=9DT.&,?=`81".@SQ?F:U,YK"0G9M)S!5M)NS+5\VT_S2R5YV0(Y2DQ_3J
M1"=5)1QC&SVE8N]O[OW-)\>QTPBKE8VP)E2H<#1O*M!Q9+ZKC\TR^>\L4DTW
M>@8$-1K3A^)&;)K9730+\"2:X/.,\1>>8OB8H4#A&XV?`*S"AH91?`T"*DB/
ML^$(!-J)S0.R"D8OCF?,9$JT1K\,*&DXHA,`S6]\3$,&%U_9U99AK&8J"TNC
MGK>/M[E"ES39A]0E`D.,]`F+/RBY3_^]`'39^^9/\\W=G4K_I5O-U";=6.)D
M^\6#C/^P4%5/<4>"!QR7)WVLD]^`>/!^L0HL/8=(RY<",:1^_!AG-3Y2<",'
M*Z5"0"(G\(+A0WQL@;B)Z0.LS^+H_N)!!YW`'^C`3(\4G0!\"_1$$<?<J6,8
M1J[*1TJ]L%@D@G>FT:[";B!O7ID-N]JQS;=3!V;:JM.M6ET;&UG@Y%C=MRL<
M5>Z=F3W<[!3<L#](*F`*5,WLH>M*V8`"9"45).@;/L2QYI%N354L7CR9&/`[
M1AX`NF2U)$[7&?ND>VG`'H>2$$$['(/.`7?R)[2`64!\C&>9P0I%N32.(PL.
MW*N.#D]%\$`]Y>["Q<[KQ"?T69BYI4LTO(>D5C4]JLW'^DG-:SR&KDF;%FQ(
M6)=(T0D*G2)K4RBTM()T$1VPK5Y0H2J;(P!_3,E&$_QIQ;&CU-^XQ!!5O6(2
M5B$`6Q7U@R`1@;MHU`W#1(WHQM5"$3$!JI0?R83#)8M/8%`R1KUI3/MI^<8$
M8=H".57:C0].U"-!GJ=ST9DH?+KZ6ADG'/Q6+EB.>7W?,O5,'%^]`<,.*$]8
MB0F/:0CT@8\;%P(/!8WC[E=ML]KHPE*/9!(]?_"H\Q7+`0(/I:4&J"&GV&`<
MN,S3AU;0.TT!J*@[\+S@7NT#B#_&^G4AAP2V.ZQ0Z/#`F:>6N?%:KWQ8OVJQ
MOU..N8/6]"[`%(S*+6&]LFG7.\;K=T1P^;4V$"H=KS^YKFJ:E2[M>L.")K-9
M"WS22<2%0AX?Q!70>LJX&GR.N*06$.YQ2<:,XC-5.M,!2L1X"_C&ZJ=09U;Z
MU%/1EAPQW`%L@N^.``*4M)$NGB]"N(OS12JC!A>2)&(,!%--8)X*RS]K"(Y`
M2#@*EGAU^Q!E[S.\')]AL%,A"F9`37N%2JLU6GP`>)V*?:S!YRH;#J/IM#QB
M5IJ:SI84Y*VZ2CL7C7I#&W5E<L<@@_ZT],"-+6B22%;9)5WPK1.N28;^55,-
M@FT<_28I`&BTD/GRK$+BJ<!@ZBA0,"[J@]4EQMRV"K9\YAF?I.]()<:Q$C7O
M6R7^PB(KKC]@D0HR,>&@KISE3JKRM3Y5=<>E$P:8NE:>"="K\^IFJSZ3IA*N
M3#)2<L83`I.1\.&JSP&E9;5IK6M29K=5@]"V9G>XOK;RXZI[>["W!^5+8[A3
M]N#'")RN),B8B0*Y^E07@GF"3^FYYDWO](A<`8*,J0)\P&PW4MYS7)N:YIGB
M_!*0#G;$Y5E,R9SZM32R5K%RJN04+)?RWJ>+]EO])6SUT4YM]5XTA""FD/(I
M]_[0?[GC$HL<5G#^>KIMB>?GJY!NH>\7=RYW_.3Z/+_8'Z+I*T'Q;,[0=:W3
MXW35N<2!RU&)OJ,&1JO1G>^H92I.LZD8/2&&^;K0+N=KI6$S\X?),\Y:G-5L
M!B6M'4!%ULD-#$8]&1!\0%Z2AF*VN8?#/1SN%!SRG8+#8PC$](-'\[R?0D1\
M$TTF@"N%EU/<W`,6D"/P<4CO(WE3F?[&QXEFBR"JV1X*3H#N:(`I//R"3.%,
M+D;4.4\R'GTZA46IHE+RIE!XT&@86'J0.8O#UF;'*&UMPBBJ]?Y0;@\K+PQ6
M_KM3L%(\6K/6X6<5_2H,L3#-4^94R4AY5M/.Z_"LE(,3GX3D*CJIC(]$)*P7
M8]$15/&4J>!*844L__9=WE")R)6W5YI@:R\\)]M8KDW.S;4E_FHYY]ED6*:T
M;5-IMKPKN?<A]V"_8V#_=7?`_B/NJ/B-%1]X4/N1B4A2CXWW>V9?@OVTI75;
M3,,J(\7#4-MC+#^>UJ#`A=SRTV\F`XNFGDAA;KQ$XX=:L8DZU:?I&],:KW45
MM#IZ0I6E!B=-SZKWNHG<^57A54IO_I^]:VM.'$G6[QNQ_T'+.;/1$V%LW27<
M,1-!^])#A-OXV/3.['F346&T*R1&$K;97[^551*40`()I`+<FH=I@R[DEY6W
MNF1FDKE[]="+<WQ_AI]92X0`MZC)9X:BG#.<7_S5W93BR_!D;-G@H[`'!IHP
M!_]#*DV!.WQ%WBR.9FR'WN5XPUE`+Q.^S3&)M%7UO#EKT&CZX33]-CE9BV-?
MFKP41_G(@[RK;#W`:OP&__-\JI3A4BN)JI,#3FLFH8GEFECNJ&(Y]SAC.9)T
M1$MP)+/!L8-&PA,];HHG;I]:_:NGUL^-/C76GV^<!\+X%=8&O"0/E49=Z]$>
M#?/P#71??KGEOD@;(>$1CI5<?YJ\;+DKQ_P(2?H;.E-R%!4'?6_6?'&ZEO.Y
MG"9X:M0G51DEGE[@QY<SE)#&1DE$=`8+HI"F/YJYJ_+.GD]>Z`GL@,"4@:3]
M0T%(2),G1U]&<);:A4D4.0X8/\'670PBDIWNT1H&L%P(9<HSCM607XB+N"QU
M'>8G9/EVH?2-?C7Z=3C]RBG2OY3D=%$MLL^Y"*&2]8"E*UG)J5%^:BOGVD^D
M"#V6?B(1L`Z_YKEBK4UF-T3S_@6KVZ%/?A:4?+?%"T8G/]E0WCE8+%TLJ[#&
M!T&(TB>)+7%^QG(999$D<M?[TG]LU+91VP.ZQ<J6T&@H"1XI<79%%]76RQ,O
M=&]+96+I3#3,,TVM?N^I4:)&B>I=F,N?72TV9XFW@]M(ZAUDDV)=[5\]Q<'K
MV:*X^-J:N7$F*F8U2O&W=OO&L]/]O]9?'']@VOB5ZLNVW@8N;K+^8`7]X"F"
MR)?TRGQ``4U%27J_;;FOVJ:NR5O9'H9*ZU>2))N&OH6L6O%6U]*U?KSD:MB=
M16,_(#YE!>?J]8J;])*WKW2DE,7XOTR$JP15BJS"9KRU(^O%9W&R4-%K',;*
M$"51U=BVX#FT5`*FYN'!8$RC`C#]603]-<D4*Q,1<P/M3BY+FGJNR.86<*LM
MS3,>VP)144W9E#<*($-<M3@UJ2C.U:;FY7%JAJ9KBIQM).O&*1?&N:)YY7$6
MT+_Z<!:6VU6EW`GG-M6L<SP/;4/K',-#F]0BV)@N\RM?5CP^:PW#86PRB<_J
M'%^4X`J9GD&P:90@&$]OQGBR@R?[/6_H3]`]BOJC@?6>T)YW'5R0F@\CNT7Y
MTJRGG]V"J2WI*41Y-%4,3C5D;8-Q*P0QXQTU`/6BP'F>P<)G?_00^'CR&\UC
MC%F7,IIP;^A%7KHG=SV-R7?`:)3&**8P2@2CN?:J(\*HK9"U74`9NR)N!I42
M3<GL=%+15!9!:3S7M(]KV`U#%(57I'M'1.!D7JG9DDNF**ELX)M)Q-X(:C3M
MIF(:BED60(!?0=,_8KH77V28@2KU/LU]R9"4%.D+,DI2;&RG>%<M3E.L2;)<
M!<7\5%0R\-2N$,DS=(M_N0_'$Q_IGOH#+1>=DO%M=]4L[ZK"\G\;,6L(!_Y&
M:#F7:[="FIA&E4-'A7!6AFB#&]QAQ"KQ?#=6``7RPF2U\HL5.L.N9U\[[BR*
MEX6VW%.C,<M:A)7)(BPSDEO(JP5O3:;P:/&:1<87!C5C?,U=\$J'Q=LI,KXL
M7F9\.SSQWEI.0*:7RYVE<+&U1-!NO*-JW?TUWC:[[E\-_OEP(XRCB2L\?/]R
MU[L26NV+B]^5JXN+Z\&U\,=O@V]W@G0N"@-H@1X7&[FXN+EO"1GF;/!X\0[O
MDN#A^,]VQ#QY;D=V2Z!;='_]R^I>,L_=;<J`IP@[@_3.X39*>!XR[][UOMYO
MKLUVWQ_<"(K0%FZ[O4?A']V[[S>7S;'LC6D./]C>/YM='5?&#=DZNO00##$Z
MZ0OQS32'&Y+VZ5E0J%ILD1G5N7"[O-M9J2U,T\;I<5)_YMJ0';\\->,+(1YE
M4C,`7K5L\^L+Q%Z,$-0(6)S`B7OZ$9EQY_06B[2]Q*^-WA#RA(D5_!LQ![R!
MZ#ACCP%"*OQ6=A:GT94/J"M0Y6;FT4YJL.QN!38TC\#CYX1C.//"ZLC800$<
MD9E32<="[P?8U_T'#GT^0R$",NRT+0_SA>--9]!]-:2Z$`LH^V)24H-6UGH.
M?,O&1+XB-SR+TQK@P(6-PF'@/,,!4.3Z;^MFO\G@^=$SXJ#A4GMD31QW?BD\
MS2<X`#F#^AC.J)[&#1N.$DX<V_:S#F8=2-7O0)\$Z5+XOYE/4R9(U9A/,\^R
M(7B$8]/@=;"7>46Q=PFIEI/B)R0-PR':G>UE:)T;XBC!O26^S$'KI>R75N0%
M_QAM=3MV7L9P*CLV*7.P$S'-L?EHCI0VMJ*Q%?QLA7PI])<N/+87"X.P"'YC
MWPYGRO^DIL5?-2-GPO,LPE/X(/"QP)*DJ>=Y$L%BVV$UJMVH=J/:_%1;N12^
M9\3GH-<D1G\;XQDF=MX19'4%4*J"45:8^EJOEN/"HX5\.X[6LUV[4I=K+Q;+
MXV>>`^%BXWSWE/7X!YO-]CP\1X1D1]I=:2F4Z2J.,VC?!#-6N$9W:2,T''O.
MG[/$P4VL=V>"[R'/S6CZ<(:ZX&DN_-;JG5E3WSC_']--TO)]&DLW<O]CR7VV
MW%:[`E]ZN7U+J/.-6'XJ"&@X"\B4CI8SQC;];>Q#!STL]>C/&=AVYA[\Y?7Y
M_7D7RAE-D$W:^SWY[HP6+KV+[/.D1P2;\P^S4-KEF;;.HZGY22KP>L][6%A-
MRF*N%V^/J:*=R>("J@C%S?K`>?EA"A>XP*&+I['.R(FK`"2NKHU_K0T)SK1D
M*"49A-R&*?'2VF161@,O29E!#[F2YUTGC)8KR`/L$+NO6`[(Z4SAYGTXMKP7
M)'QJ#;I/-ZV?DP9R^'>BP+*3I6+:8".,<'R>='MEJ\WJ<0G_96XWK'POFK\E
MW>Z9%>94V6OX:6RN7&<XIUG5`7JQH&`I5#T(G%=XQ]2UAG39_!R'%="-^PE-
M(UJ?6Q'9^MSK[>P8RIE1`$R+KG:I9?8_4ZL724\\.`3R!L5;H8]?1`1MYF6^
M^DQ(ECL6?7'1:,2T=TR>(FOM<^@([LY)'RW(HH5BL+!W``NF-/))/A&2$^\#
M$13EU0A+-FES[E,BA1!["\A49XB#4Q#!+.;?4WR=I9B\"\=@+&G`CJ40G!%Q
M8J9?*S.P\SBM.&G])+&#LB+],)%CJ$NZ%JX/'?.<4VJX6!.10>N1SNN*DE2'
MN<[I7%5@OW00[RZ%=$O)OL!"[\^(M"<A>&+)X@X]<0KK,WIQ/!)'+10CZ1I)
MC0O?.;NFKK/&/)>:MEY''_/4E.&]V)MUL*?!\8@5!,ZJ)P;WG55,@1@UVE%G
M"4V1DF:]Z1`@2>D&L0CIUA-\%S?*(I?(MM40N\(7/+]%(;-314H(5;Y3=4"3
M4U*KL@+?`!K&MBK1MX)*UL$ZQBA5AAX]=*^O>_=?VU_Z@T'_VZ4@3]];"]U[
M]J/(GRS>ILD_+:91L-)43-"W@LGB)KQ^R^)8&<JE.@C/./.S*Y8O_<?KF\<%
ME&?2YAD#@A[;CIT+2]5_@@-B(`GXHJ1FVL%M,^-":E%^OK8#]W904.HX\E3T
M-N>,B\58OX5WW]GN'`-2,J4AW:DWAV_9XK<>4Y54+AP[OP76])<6_?<8E8WU
M-HTE/++!V=L22B)K">73-%?QKG^CM(V,?W`9EQL9;V3\@\NXTLAX(^,?5L8'
M4.BOD?"<Z87P_(('V`]^:?W/<(C0:)2UA+E]);O8U'S;).5(9*OHPGWFMNOF
ME43,4YXFI+2]*&$(CF-&N3I6AU7.ROC="$,C#(TP-,+0"$,C#'D!V]O8B5"Q
M<&TUBE6G[R<2PU4:L*WM,A><%F2PC^]4L-)Y'Z9>L/T9#EN9#;8=YR)E]`KH
M^]\CH95N<.<1VZ'$*JITIFKJ/M/%+9)R;*;F1Q#YLB)[(K"X:T>[T8M&+XX?
M5J,7C5X<C0`U(=+)BWPER^?-?(R01L_W"LFQWA]^-M:XX,8%-RZXT8M&+QJ]
M:$+3?4-34SW3=*T1^4;D&Y'_J"+?U)UJ<ECKS&$EE9-\U_7?2+$%.F:SR<0*
M2'D:TK\>,N.AR@,M5@#%*E:K$D.QIG0MU722%[Z&L$Q-2-DU6OL&?BY=@.E`
MQ53=+85HLM)'UP2L_OQ10\O-'\VQ9J9V%([OU$X4Y]&K?("CPD])+_*0=B$O
MN"!U7(=+*CX@W&A2HTD[Y#,S)VT:+=H[B_=(-*S)C/E02EKB!-R/EQC3:.Q1
M#4ZCL4#O=\^:V4ZT<V3Z\=5V\X;\!F5-%D=VJ_E9<N-<,G<KZ=2&!REU5U80
MD*J'<1FM*+LD'"T$MTU<-@A`?&59$>HX+-H1K0/S6^:5Y!W7>4]U2;=0ND-9
MMWQJFOZ(DE)WP[@4MD];+Q4NP')P]U^/K_]0!P,85/P-RJ>M%F5?FC)$L-SP
M99FIG_>)!7;8*CU%ZY$=)R#/+A<A?/B-Y0]D2@ZS!YW8DA_ID-'!=]UVW_4T
MUXQ-D>EI7O6/>(.8;#-G<9`E_V_M]HUGIUL<KYN?^,.RN_7&=M0KO:W]`&%R
MKV8!E':?#Y:5\[]:CG?GA^$7-,+W#*QWVNFZ^/TU]JQ_NF:[>XNM7_$CNL(P
MH#B57-E14TO[-79HAGCTS-#$K<S`V$456L"ORD;ZV>VRH57`C>1RW^N1OAOD
M0,+-^]"=P09['_HA#,:6-T"3J1]8P;PWF6(UI,<6@#M[/)^A2>^A<^DY[B^M
M*)BA:A7K?>)ZX27^@5\RFL3C09$N_OAV]S0<HXG5AFX/EC?$%%P<%;>,TMS:
M5>\^`K?,'60+!"I#MLR/SZW.#K+%<HN1K<Z'YQ8W*R^)BB**ZM+0[T'W"@.1
MAP++[7IVUX8&:6$$_9I>T<W[%'FD2P]FTN9[>(9"FB3I(N/PMI!6"U9><8XN
M2Z*D'Q:K661<=[.6*:RRW#%2\GT`K)TBX[J;K4MA543--(V#8N5FN`Q5[W1,
M<T>P/6_H3Q#8N5M,U!4FTO%F8-^F<5>Y.)RE]^&@%F$;B%](>J*!U8-^,_>^
M!_`"G_2>Z\&V*G0X!4;5^'ZN\T-)U16SPZA/C<`^U`CQ,N58CU1-,[1FA,J.
M$"\'U.Z8FM(,4/D!XN4UV[HJ&QVI&:"2`\1O)4K23%W4E</I$'Y!'$9\P5'&
MR&'9NW;M!)>==D1Y8LM%.Z(\L66>'5&>V/+,;BCY+:MHHJ:9J_9JC:0U3`&R
M0G2-Z+\]KSLD?87#!VM.^\A3=)OOXCE!D%31U(T4SLW$U8:85\`MB8:L=HX`
M,3=9UA2U(U8YQF01$9POV4R*[AS:P)KTD,X$G__`:?K:>OEQ>EZY5G[PL_F*
M*6KJ)CW)IW,;2QZPT\!1;=>S'_PP"E#DT-3N_K/KO-"`-X<W!9[DZC"4S::D
M`+D'Y]7)*UC='.*F<K+2,>6ZQ2E`4\NQK]$(8:VUXP`.OY%H<Y>67\CA5H%'
MN2[G*J(I;N97`8J/@&&\@CVY(\D;+?II\(N;/IH&GA#4S:]'A#79&4;(OK+"
M<0YGTC=]B#!Q1]PG[ZUVP\UO(U(3-TX'TY25`WOK!_&*IO?2I56`\J/@(H]^
M0$6HA4?<MN_,XJ*33>WAF<5O@J6+XD;OL@N_%F><$B>TG)^E7._6^P"-G,\)
M*VS[HUA2S+8BK=V^==U),G46_%:":D6J%$#*#+-2`FE'E>1]@(;A#`Q)?_04
M^<-_XX=^MX+`PL]C@7A"P:LS1&$_N'(M9Q)#+O,$SWA=5CLI@2]#)W>F<%N`
ME3KFR7"%XSE.0^YT]$K8LKK@MK*>5J.1TT59E)F=^-P5LBTDUFB=#%655*T<
MB9CY9!#&OFNC(+SY<P;5'%?HSKRI9GZKBJQU%",3328]-4&L<;P4294U]IS@
MSA!I[DNT"BK^NNZ1PDZQ(V>BB`G8@^X:V:^9LJ1U=J)[Z>9725]>J3OHTL&L
M9E*_I&%O`#6R7])E4=%W`C#'?N([=B!!9#G>P'I_\$.'+)CFP"IP?]VCM;(!
M4X(RKBRH<[RK8L&R\_S3HO$\:T@V7*]YE!53U73&`6^@I%)(=?HH""G4'2#=
MHPAFN@^!_^K8R/XR_QXBN^?=TNK0:U/\XK>?X#I1K;S@-;E1)#&]R%&<3'[<
MX#>I@1=U.D9M[*"+"X79D7$[Y\-6FL9Z\^)D<N0&O\P'W3!5]F#],;*#WR%I
M314E1:J-&WG+QL5OYYNX)&)ITK<;TJTKQ+6R@YNNZ!TL'O)Q<X.?JG1TQ33D
M[9:C"#N6F0@)XN4W,$QJ65#B(BQ./[L]$:QCZJ)BIE`M:2E-N+:#;":$:Z4(
MUW1(8JN*[L/E1NY']^$R!O>C^V!Y=/N1?;#LLKW(YIASI6/(4D>IBM_JN2*;
M,OQO'VN8\0Z^-K$8B,V6L2R(JNUC00P;K619#"5LY<+KKB#)^)ZSO1=U66=D
M*8.@O9#P]`"FJ<CU(>'G$U11T:3Z@'#T$H8L:;4!X>DW=$U2#+T,E/A0AY_<
MR)8<R;O(]1Q&1U091YA'4D6HN%4!,MAMT9I!\;((^&Z#&RAN=7W4E+&N%12_
MW`U)5-B5[AUA4:.2C8I>X[M$J\F;E(I25`DD?@FO(AM\U@F)EY$P-$/E@XB7
MA3!,3>>"B)]Y$#&D3>8A%],C&B+G%79/0UC78W9X\R_7O&<MJQ*[!)!/1X5P
M:MROQM.^-9-0%$Y.\4B("E'('/9]\`,XH(!?Z[]XSG]@.?;&"J#Q$+Q_B;^:
M]YW@?O>1<_/$THZ.G)LG5H/FR+EY8K5NCIN;W"("5<%SN]4HIQH8M?&[^VHY
M+CC%D1^$%GN>J^J1R/\EGO,?59&DU4"G;GP??O!^7%=Z+"/`:V+:J$\-@_?C
M>OLC&0%^:P:JJ,FK"_5\]>?!FI.WW?K!0^`/$;))A5)"2=Z!PI+/\/3GBL:>
MOBU)Z$$X<V+.D@]7^)W8-LR.6+'`#/SN\,^9$R#\BBD*HOF#:WE1U[,A7V\Z
M25;#BM_.=>M08O/'BM/(D17<-A)2A[6/D14<$QO@3$\-S'@:8R\V0,&$<6S9
M?,BZD^MQF@[F@+Z)!UD4U@Z?FS+HAI%*]#D*^/S6<E3=D.0]X2]J^Q%_DB[P
M=XU&CH?LN,XRJ%&8GYE;R9OJWD*2]93YK(+DH^=GG7M8Z=*1=?"3UKJ+CS&P
M&W>95VI/96>;FV92L#?Y=28VRR;;G:TX_?'`7N$!#5GJV>_K9KTJL^>H,PC8
MB_(ZN6Y(HE2*\F60?^5CPXVGU'C.?(V>$\G)O7Z".[![HCVUF>I>:/FM`1E:
M.J[*)RL?WZ)X4O!DN:@_8LK9;+_MQ"5Y;^P'RY7?3EY]J/E-'25=T_2T/]D=
M]KT?H53GB;R+)R[4I7">L&$N@Y-K&8<\/65IRH?UB%PK0O:#%43S3(>S>L.)
MB^M.>$]8;'?!RTU\=5U6<\SM*EGY",$<?[,BV#.:XTGFE>^Z:`C[3?T16>F(
MLE9M=G_^Q.7_`-PZ8>WASRUNNJ?H>-Z?YSM*TKV9@4FL]`U%8]_>QJ[<N[D>
MMM+R_>I&(KEQXL25JCI.\%M8KTPFLO>?DC.DFVZH>SG-2*67;J*D8E!UEA4V
MV.JNQ3$]HFF\<](?K07_>1=/,#K8&>>)F:!=<1YL,I='TRJL$%G!<(QE^1J]
M(M<GTLRFI&Z\@Z=7-?'MNL("W$!8Y2BY)7_+ABGIAT+)+=%3$G75.!1*?NGA
MDL)F'7-%R;&WF*IK[*&9<C"9QC`P5\#_@%-]Q2$1=!:)KJP@F#O>RS\L=[8`
M7N:9VK=O5ZQN*>(.PHU:RYI7R0VHB8WLY+!O=SB<369D70?V_8=Q4_'MM]4L
M`6VH$0U-/EC<VVBJ$6J-PYM1?*PLU*>Q%:`O5HA%PI^`12#-/@F\[$M<0PPE
M590_FZ`*\'#;B5,T@STG7A<@?K-HPU0DMLA\(43.B^=@480I&VV(C@7UP7>Q
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M[A2_(L(O#_,KR.17"[,HL%$`>B$,D>N&4PLJK2\^3RW;3CZ_.78T_J4EB>)/
M+<%RL93_TAKB<41!:TE*(+S&ER)_RGQO)_3]WKL>_'8I*)USO=-)N)HG`X[G
M8K]04@CB5UJ3Z6?O.9Q^7N/=161O($ROA:@])7--#JWS+;`X00"#U28C?BG\
M:Q9&SFA."?R*/!18[KH>L&1>1`'S-XAQKK0WNK,044,_U[0?277VT!/I$'K"
M*@4X$TI*/[`FR!8><+0QL89H%N$0P0W/A)XW/!<^16,DM"#^L+QYZV?AS0KQ
MKP_]`%(;<1PLX/"I.PT<5Y#D,P%"H3,<XV#Q$^!!UWH+!7]$_L8^-D+PX1Z]
M6K9U+L#N`/,N",0@)G&%;S#!%A3R.OV,/!P30'[>\@3T/G639\+(>D$X1J$W
M(.\%?[3Q>\ES%ISKIQ$!?LY./8A)F3C$&`A3NO0->6M"WQ-NT7,PLX*Y(!E9
M1!#](+\1^4"-]1(@<F0[YM:M$X21T$V^!:XYT5CX#:/&I`C?D`T<%I)^B(0P
M9C%!N,,2_*D5WXZ?AE^A^0F$C"D4C`])C"-,,4_Q$P$]$@!W8G2N.\>TO4"B
M&UG$]<(9%A=AZK@NW/&,A!F.*8613P<I"I#UW_:.KKE-)/E76%T>DBK%%DBR
MY-Q>JAS;R?DVB;TK>ZOV$8F1Q!4"+0-V?+_^NGL&&$`?R!$2)+RD',',]/3T
M=_<TE(Y!C-@NT)MMA4`!`FK+-L<L0,3<*RB8PSF,&7,C/%L*^.)`.)PLK!UP
M7&=AQB>`(UTOT)X9@@W$^#\`!:?T80HW!'1,B2Y@X-(Q71=)3'3?\EP``CEB
MZM$J&U@B(SG@2`5-Z3J>)_XKB1[IR6<I@J;E5Q`LHB[U\Q4@_0DL=,')"%0D
MXAN]LE>]HNM&%;3*`24RTBM(GQY)GT%:^J2(U=2>YA[P^UOO"3F%AV-N`\?Z
M^)IVPWV3.3&M@U@Y:</[-C""S55)Z<N@)C&HPLHGVH/K,,YI?>D%DH28P.(@
MV/'2RI/-F0`0*Q^TUB??"Y<MF'+*?(X\LUJ]".V"ZR&G"TAM!7X5:BE61_'#
MUIO-VK,T-EM/*@V/U8S'4)L1K1;DA4C3C6TO8).YZSG>[%F;VLRQ!!ESY!`@
M4#(-S!4:<1(S,*ASX&$+<[%"R2;Q&%0OKF7Z%O"[1=$:TIRO6Q>C2S`%OGHG
MVKG>;VLMU6`8T?S7,`&:,*TC,<</K8,:WZ:X;V-4Q[>Y)Q]`<AZR5^B:H66C
MZ@1NM3!I1W]QS[$M8?Z)K_J!;<W1T!.55R9Y,;%;8)R3&6D0XT=F-+>_:0O0
MD7-2E^"CP/16&^S=1R9,Y25>9!-^0TX`F(D``&<*UE^"WM5F(E8!YCP\9\L@
M\6L>7-H#V:)<F/\X5IJH8J78RUFY)03;1F:P%QK8U[9G@75]06#!3,XSZ?1G
MS?+(6@>0G-`"7*(+,4>?(FW53STO<#T!"WDJ`B]@OX,GL1*`$[``:"IO:;N1
M.V:Z(,CP<9M6,BT,W0AX7Y-TI=X=^*J+RSNP&MZ"Q=\`0SYZ+6]4,>PR\*\X
M'AE!HTU-VT]@4,Y&[L\ZB2DF?QKF<NG8R1%DD"Q-)$E2*NWX3).PXYITW,'<
MXZS`A!OP!Y3E/8$.\->O7/#LT"<&Q).#E3Z^+2"`KQSU14:U&3J2K#+<0(R0
M9YXV808!C$[))K^5K$O[D44XB&8.YF8`%/*,_BN`S":!`N4SZ&Q<"$&Y"&=`
M-5I7^'I;A%&C#1MM6*XV[%9'&W[RD#]`5DR8[\9R4G#^)HI?.=MF9VA/:;-"
M>,^"5SQKMB?S8(6.-SD/%Z2246RE0I@8AD-GVG9#AI:%J<W4<\D'VEP6:`YU
MCHOEG=#8,E3FHFU`7@)%8I.#B4*R;V`,N#JS^0H3!J3L*_VLC4$Q_;R+\#PQ
M5+VX[$P(XHG)Y]K4\9[$>G$S?$!=W.Y+NT/'R0VDX1##;WE,Q/L(1SR<8MD$
MZD&:%,9XH8\Q4+!<%@PKHH-8!\FB=Z$<`X`*)I`J9>HY``Z"D-L0H0^4ZQ2`
M\WR8S+0YH\`".%8!'ISEA>-`,\=>F#H80ML_NN?_A!,1GZ]'H#8>U)?87D'W
M+U;C'JHS1"P#:1H*5#V">O-"'M$/(L\!V>L2ALG`S-&(RT1$5PR!'85!Z+/U
M#FIR&O1(&H_TMVD!+8(!XHL#9:)<C<=D,0WA)<04`):-L`J>O/_K,S"E'0";
M312%EQ)/:@9NE8B(0J0QIL(QS*8!20/9/F)4E8D+T`OZ%#W:HPY82@@@1IH8
M(MGUB+5\PLAJWAKC<4_P#*:AH]I;@`(@`$)X6[$U80"888],FAAV$$]#FAE.
M@*.5*8+OBD69G"22AC!3\-0]5Y!)\H)E\TG(.1E8$AX;//PEWN`#J/`Z!)*J
M,,:DC<NQ^&,.F&0^0*NP)?"YG#\4]DX<L+Y%YHKMILNYS:;:B+@-YHQ^_B((
MX1G_?^-:(?[=QI(+M!`!@,_`&#X]I)B<]KIU>SG:8\"MB:/]<'$TSG;2EEFW
M!/A6=?14.S_A-@YRP+%2S(YY+#=BT:(*59'R<HATA'+#4-I8;(G>"Z;&7%)-
MBF;PQE@<J"$AB8*CM$20.XC]*>0M$!`V.%[,H0G,@"8`?3$%N2HF?E%ZJTE`
M-45!>^;U_18%C:M>%`3S8.P!#`O)J3Z;D#$+[.U1W$V)T-_YG@M_3X0X:]BM
MB2XT=42XR(W(6HOZ"E34'V/MORJ_]<'#?U^W/EZ,/K3>),RG1E_#)=H1PB0P
M@=TLKEV,+BD+-C0Z;:WU$0.ZXL+(%V:"7R`J;H!_9Z8OK&-\XY'>6"1O"&,;
M[7)PK(57E?B<,@B,ZR4A7#:=XCU_\)ZLD`+.4?"<_"L1))5Q=-#[,]MUR1"8
MPDO:%4B3Q9CYBF?>%X4H8K3/9%U.%!$&FX`OQ7+.<RXF+;$2>RDX:!(90FD+
M*8(C\J+)[_@;'&8$BU(#'$N1*'PJO.<+OGY"<:PD$I4@-8J066B+;(8MO/TX
M0`L3D.=O:FCX^$@,-LPU(8M*1JXWVXN-Y]%(S1\B0[ES+%.:*.LV`?+V/Z'+
M5($+HE01I)'T]"*AF1RA0=)3QNSBE!.RN<_FV&D36%9\Z[+=DB5#S+$7P)X!
MXS)M1Z-@\J68190#495#,H<M/N\9U?G@0\]5XWI),@[65V,>L:,F@T+IL.@$
MBT"Q\8H*`"6W8#:*O6'05%E]`W#HQ&&YXLQAD4^(D;H49"L'4@95"YXP0$29
M.];6QF%`(HU-0I3>[52Z[($*8YE-L"RH&48&"4_DY4:1OS&+]H:EBA@X`ER(
M<E6L7$5Y*P.'8GM+T$=*:"J3K(N5&DP6R>NH'FR!&3-%`?DL\#U3*J`VE<C$
M^@]CT(K>P.B4:V5SR00NG3%&WN1[Q?5B6V[7]`$</U$Y,/O"#@),U`+Y1^/7
MLH!`B^0#J7!`BMJ3:-\6EJFA>XY/%!6/[V-%,#CHE'!VA<LNT[0II@%7P3$Y
M3VIUU&"&7'-J)G&Y#8?S72H>EAIAC0`A1%>"X;55V/NJS?OE[=MKUTI?[\K#
M*/^C7+\K=%\N<QTO@)^D!%.Z>>9_QJMR!2ZSRIN%>N[U+7<)^]V!>E<YO_[+
MP>[K!>[@=I+KQOH.8`^['6-@E`1WB=>DNP.C>ZYVMM@KX"4WI.^J5Y[W"3A0
MK*'W>R==8[@CF:\8MK$5Q5#M1+%G8B^XA2S)[[:%_J"?NOF[7[HONH4,]>^V
MA0&@H%<:!Q3=0H8/=M["<%`:+P`8^@MX8<6P34TJAL/2!*A>=`M97MAQ"]U!
M?S@XTTMCAZ*[R+##K@>!,^AE[:(P.64Y8M===$$]J.T_]DQ1O8'1?P%%K1BV
MN;5':<14=`,98JK*!H@6C)?Q=';8Q@T8Y\.S3K<L-6T4WD:>J7?:!K7#&99D
M,`FN+K2-/%?OM(U<JYO=MX%]]Z[B`'JFU4C1MW^>;B/K"B+W'164"/A!.IKT
ML*/)_>WE;]J_;S]?7?\Q2L*"U[\_W-S_=8!^)H<L92V*G&R=R.?K^_OK/]Z.
M[BXN;[Y^>J=%Q0I*5&357ZFJO"WOKO@++ZK&,3A1;!K%X>+;JB(4-^RV.YV.
M"/!2>%9&@Q=T@1_%AHQK75B/-L>[&E@&N@A=69Y,04<>79BG&_#Q;0TEPR<#
M7'(961QHR?O:,V#7@&Y\OS)Z[?-.YT0;,;P6P:D@B6G&/!^ZJD`8JJ@L72&P
M;PC[>B*3Y0\U[,6[=3\UZ[F[;3\'_'IR/VL'2"C6`GQ%&?`[BO13DS(N/G+%
MJ0V^\L&KS+??OV\*/)G>MD#`:M0DMBO,L"TJ0-!DXS.9#N??MY,=$`L:A1X5
M0&#\ZC$1U1UT^^=&MRBJ8I@/@))^093DY4*$DOZ+4*+KP\[PS,AZ</M$R5WH
M3^8F9[?3"\Y94``SV1''I!E=[_5Z>E&2R4)>"$U4(O1=0JK8#`()6T(SA="X
M6YS&&/1Z_>T8++:)"F*T?,+,1>1_9'3N:%ED$%G4LLA^%?-`6"RD'])O'HMM
M!\-!IV=DX_7;H"T=%?V"J-BL*7=#1?=L:/1R":2CH^(8HH=LJ*HAXA#64_ZS
MHV`Y50T1AY*>@_/.8##,YH^.OOW^UNUOIH"BV^^>G?<,O3S1N(O)O'+`L71&
MKPORH2!>7FXK[PD]AQ>>Z$S4!#F'D2.];F\XV.Y\%D%)..;L[Q"_=_*(A7Z9
MG,^ZITV.YV?*\0Q/]`T].59G>?J8Y7GX,+K^_0&>:M=_PK^;.]67CN'*-#>I
M7T9(MMKM16V>UJ>#L&Z\W]F2&6IC:X7X,E2;$D5/GF:*1-&S;*MHBR8:N^>,
M>*&D$7:?P*Q19R"@?@7;`^<V!5HFG<0U0_3H,/Z;3RN]-!>T3L8*0?UM[#OV
M.]0%))&C:!L]C!_+6W#OQ?_$KG\]33^CV4Z3Z=9,?[5FZIO1+=AN@W?PQLMF
M!I5$L&?FI];43/Z6&O8U7."I>W[\<%>@:,3IIAF5Y:Z8Z]%EF$T+;D-P=L7\
MI-%39=_K<!=WY[5>\#6[-):Q7X@L_U!^M;$-@CW%VQ@<4ULLE?SB;'(R\QY/
M+V]^:[T'?M;UP5FW<QY!FPS.["RUEEQ)W"#)KL]1V5T!5[Y/=A;-DCS+#&*N
M%0V1VT\6MI0!T:_*TM%/$K';<;W!>LE7YQP>XPDB&<F<+-U:`,8WO&5B!U]$
M0M\"!>9B1.Y?K<1VE)<\1"+Z,K[.=?'-YG%BE&:+@<7_1IG1LU/QL/5^W2>V
MQ-J_GJX$*<<VZ;U\-U'1$=:(J/2&J%82U47<D^7.M*T;]])<8N>JAK:*TE;>
MY6YH2\YX2:8I.=$-/16EIYH;&U7#=>$/^-8.UYW=#3NY_?)PO3G%U1AVE3?L
M.KLSL#SG8Q%58]C5Q;"K&6TUAEW%#;N:T5/-C8W*XWI=1?I/@NL2#;OBQ?-U
MPW6TL^HX+)L3V?FKL(U.DC/>8O^B5%<NT93K>`KJ)<35*55H;JVM:3RTJGMH
M-22JQD.KB8=6-]IJ/+1J>VAUHZ>?S9(M"==JXXW>VTX7T#NH8QF%N(\<O$]V
M$D\NG^P34YM;E#2"K1*66)HD5#?P`"31V%$5MJ..1QF-%50]*^AXU%!O)5LJ
MIK:VE6OXIE*Q-(4T,KF$LDFCL;^J;W\=GB0:^ZL>]M>!*:.QORIM?QV8&FIL
M?QT`4S)'WZ]CM"V-*37=OG=,;>W@W$B8JEJJG9*9:&MKZ88TJF:I'IXD&DNU
M'I;J@2FCL50K;:D>F!IJ;'^5C*GMGY5I^*::$C4ZN4-11B-1JRQ1#TT-]96H
M>\"4^`7^^#]02P,$%`````@`M8*$0-K8L;,C#```=I<``!4`'`!O<FUP+3(P
M,3(P,C(Y7V-A;"YX;6Q55`D``U6M?$]5K7Q/=7@+``$$)0X```0Y`0``[5U;
M;^)*$GY?:?\#RSY#,+?@T<R>)4#.0<H$%)B=?5LU=@'6&#?3;9-P?OVI-C8Q
MP8!QW(Y[-5(4;L95]7W5W575%S[_]K*R2QM@W*+.E[)6K95+X!C4M)S%E_*W
M2:4[Z0V'Y1)WB6,2FSKPI>S0\F__^OO?/O^C4ADW_GOW]%"I!"^#^Y2:5;Q1
M:?_VTG77GVYNGI^?J^O&RXS958.N]I^N&34]`\P2?K%>T^J56A/_2O\NU3\U
MVJ7QU]V%MN7\^"3^S0B'$BKM\$^4K=9?RI&[4T968(J[WX@[U>IUO1Q<*\2:
M[OYJ7PO*%GA=K76S^W!_J1!S<-_GAG^MINOZC?]I>.G1E='[-FY"?<MH0:FT
MLX%1&YY@7A*/WYZ&I_07']_TJ>&MP'&[CCEP7,O=#ITY&DU<!!E5\.^W9##_
M4A905$*;JR_<_*?_CDG`"B]TMVLDCUNKM0WETDU*E7K4,<'A8.(33FW+)"Z8
M=\0FC@&3)8#+$REF&#.>MV)CPA#+);B60>S$6JYS4'/BXG]!-!_-1VM@/L%)
M@>14DH91K7I+XBR`#YV)2XT?2VJ;V-0'/SWTR61J<@.;0;Y(]@A?WMOT.3&0
MQCQ;#2?6PK'FZ&W8@@V#>MB$G<48534L2*84)QF[7W?!P,?GN^4N^PZYLRA^
M+AK$A-J>[W8/KIE(-_*<?1->K2S79R\997A]QHRE\V[NPD\)BMP1W[M7:W3S
MY'T^GQD9]PB3)67N%-CJCC@_^K"FW$K($'=G9K:ZW!.+_8?8'B22/R<;\E&]
M3HKA!GN@-6$9D^?-./ST4)7!)G'+XAYL+JN!=AF>[7OF`[X.K[=<&[]0J]5+
ME=(>&7S>&SWV!X^305\\FXP>AOWN%%_<=1^ZC[U!:?+'8#"=A%*%[AD%(CL#
MX,4%_(:YB\5"$VQJ!%?99`;VES*^\;\'B\PLVW*QE^YY3+!8;=<Z]:K6K+8/
MX8M&DW/"9W[HY_'*@I"U"$&U&[!='KXC@-8J-:W2T'RH@[=CY!VJCCH1E[(0
M_+.Z!P,->M^6S&S`R!'?81Z8,49IC8XNSZHK-$ED;L3;NBRT?,[H*CEI+GT?
M2)3AP.!G29@F/8.U6+KAJS6S*,/Q`AV_7/(XFD'70M77ID^8<>34A^E"<,4-
M]U:[&+]B8>,Y!`>O2>0'?0^F]`ELT2JP)SJT2-=T:;2?%IPWRPDA"$BM*T#J
M&[\=X>C"HG[:S*LQ1R5_<.,]"4+`:T,!7B/F5SNUECP:(X(RINU8[Y"O\]PJ
MU*5&#'FDCA'8TKG5.GGP]2KR(YB+-UBAKC.26^)PCS&CR,7!$9DX]AKMNKP!
M\8SDW)A,:KU"?6:7<XSQ]QV_5FM*#&6CLM+'YB(U%/#C@R@N;(CM$^+V"&-;
M),3/:ZNMIEZ3YXQ)5,C"+2_1L_?,:S%1:,`(2R5OL&@T=8GA=YS,/`F];+1"
MH\97PGZ`*\+,">#X=Q#$=)JMAC0:SPC.D\R$]BLT;#P!=YEE8$J8K.?1:EKM
M5AK-5VJ3)_7O`2KPAZ8"_A`)G]#&X_H_QE1M>?Q?DIX^UHBQ1*NW))J24OGD
MT6U">D+_O0"`0EU6B,'VGK)OC@',)98S)2]C,<Z*&;M(<J8UM!S<-8$F&9-_
M+N%^FZY>BY-"$>48'+'`!IN"7_9"RUP&KL7\*98^S"T'S#MP\(D[MHG#XQ'4
M&GI'7@2:B8X?X#[98UO,0%=:CWNB$J%0\PI+RT]@`,8Y&/8^@AN&2LU.77Y]
M/4YRGE%?4@0"4EL*D#IFL":6.7@1RR@@M$5O-EKRNL`XD7G2>-'F@+^V`OSU
M/;A'`/Q..7XVKU73Y7%Y47RNQ95KL`@XOE6`X\"@L,_AD4Y':]7;;6GLGA:<
M)ZT)S0\([2A`Z,YR-+FARTM'=D*R(RI&W?VX>)))A<*;H;,!OI\%\IWN-7(-
M(6@VV_*F'Q)HD`N=UR*A4+5@S.@:4]^MR%'\C0,8M:^%I=BI5/5V4V;4<UIR
M+JPF-5VA\J28N*6[1??!3%@'49<Y51V5E@5KB0J1T7GJ4^8JU-%B%N6M/#\\
MVRU/HJLU@Z4H,&Q@Z!AT!0^4BV%^-)^2%TRL;N6%.%<JDSOG[P"KF`66>)<P
M36LG?XR)V=#ID;7E$COB\-6FKDF,E2[*SY_XJR!1:`A^`E%Y!G-`F&,Y"Q[Q
M<%%'-"Q7S);=RJLF758@=[*OQ$2A(3JHM03EXQ[E&*/H38FKD6($YA1>G36T
M6)WQYYNW-C_@Z^2;5YK)-J],IOCP=?`XG91&]Z71>/#4G0[Q@E"O=-M8SN\'
MO7H_"PZ=K^-HM=.NRTOP#D2EG[U^O8<H=^W6*WK8;;R"<0=SRH+P`*,"X(,7
MEQ'T0<LA;#M$^/Q9&?PFPHRW7PP=%Q@F?6AZ39>W8E>BYEDT\@NN\)H?YX._
M0C']WM2@J!Y,!>*0UZ[)=J<CJ;F[PGF[8[O^2C%Y#%Q8..2K\6B]O!+SL<`L
MZ,NWB]Q7JL^CIU![?@(.>*U8V=:'#=C4KQ0%3HY14%WB(MVSLK-PCD1.'EGI
MEQ")6'J+VLY%+6&Z),X45FN,NM#C5QB^,F&;P$,<9K$O`H\I$^*>P*`+Q_H3
M,!L-$Q51.]1:MW5Y5;<,-<W==V2AK-*(\CN.B(S88A>QN;(<B[L"OPV$+>BV
M*;&N<T%X[@YQ!1BQ%9V"<AQ.$=%#+*H=76(9YX10A:.'RR@J5.8[LB;T<31'
MWLZ04U+_C[PB!L?8>F!!^XK?B>4(#$=.9.P;O!BV)T[5.S=B<C$&-N2E(N_0
M3%WWRHH.A98\9AB5=3?$LL6B)"2&D^@^,#]>DY@VYV&#NEZ=/\4%"\G?6^!O
MIRGP][J3/TKW#Z/O&1;XCXXI3%/?%S<9,[JQ\!MWVV]<4'R/[N482'+7P`@\
M6)??:LLK5B;7(_W,`-[<`##]MC;DW!/'?8W8!-UV-`\F(?5679Z-E^5G5)M-
MS6AD-=052"E4N8L:YB^:76,S<H*="Z/Y9$FP[PPMYM5&0VO$Y6CQ1]]=>?<B
MDGTE)L6:MTW,/':G&\!A#<>M/LQ<]&5-7HGNC.`B>L`9;!3*KZ,6/5(7PA._
MT!R))R^<DEI$GD^AHM#JF2=8DVT0"1V8H]5J$K.+4V*+PG(B6&(STH(610X'
MJ/W.I6W0/[7SZ;O?2BX*W4G146C;W@E8]I,)![#<2EV1E%"/]$E)H1=8I7/?
M1#R%[GO2?H6RBCZL&1B6?YMJ4V_*BS"BDHK"X"GK%2IZGH!A5P8[ZH?E+>Y(
MKL<[JB!!<#"E70-3>08GMSY5]5N)QPDFUT.BHR=B>#_2ID).I84O1Q;N?[XA
M4A$6QDDLDB51H;`><0DOE>8BHX&E*/U]):ZH[6_]4V!M&PQQ?U$?0I/=-R9K
M+:TC;UO:.S0KC.=D!*Y"@RR&>0P(AS[L'H?.X3F!U=NVQ+4/EZ07Q3&N02DV
MI2MJ;Q)TE?>417W?GXN,!4AOR5OY=J4R1?&-=V"HTH*YMWUC..?T%=PE-0]&
M5IFG4B96HS#ND08WA:9PNBNQ%N%/LAL:17VK;W%_EFK,8&5YJVJKWI%XSMHE
M\45)R*_"2:&R('9[J)^S.TG'V$X9<3CQ`Z5PG=9NM8S8Z:_5VYJ\8.(*38KB
M%&G!BST)K*`#AS]5??3+A]6V+O$4L'B916'],B(*'0RV7XDR]X\/P%3I.V'H
MQWY`-`&VL0S@(]:SB;7BU:;>DC<Q=)4J17&&U/@%/J(KX"._%E!+=*",ET-K
M-14&E5^;`3_0XR3O$=14F%U$BSU7&+-;V!WN<!'K\.(BW!-K$^/O4A2>$]@8
M4J9"IGI<Q`L.P.G#'#``#T]7#@^0#,[/P<1>WMQB.IT*XR#O1C3T'R5*8)>J
MP!BPQ<&G-6H2#^E,IU1Q/>AJ2$,74F+Z[MC>-[]^6\7Q4%Y>?%%\<?WB#$ZA
M!Z@YW_;FL.+HCVYHK48SS['GM"K%]8N$\(4^HD))-?[WV<:`:IIO`1"+\^25
M5*_1)`L7>9_ED=6+*1RMF$L;/Q*P"_-<"DU2_=H_G>/^Z8*5&*[;#:W"/JJ8
MM&O_4V>'OW(VFMG68K=G'6/F>DW>/&PJG8KB;>\'5*$-6J<G'*;T#L2G8,9-
M/31:>B>N3'JJM)5.3&%<(@.4BCE`?F1$<6$/5;'ZX),'4@0?B'\S1`'?^0M0
M2P,$%`````@`M8*$0*W=9__Z!P``HE$``!4`'`!O<FUP+3(P,3(P,C(Y7V1E
M9BYX;6Q55`D``U6M?$]5K7Q/=7@+``$$)0X```0Y`0``W5Q=<]I&%'WO3/^#
M2A_ZA$!\&3QQ4PRX8>H8UY"F?>HLT@+;2%IE=V4[_[Y7*PD;(\$:2T)D)D.$
MM+I[[CUGOR]^]_[1L;5[S#BA[D7%T.L5#;LFM8B[O*A\FE;[T\%X7-&X0*Z%
M;.KBBXI+*^]__?&'=S]5J[?-OR_OKJO5Z&MD1VOI8$A;WUX)X9W7:@\/#[K7
M?)PS6S>ILW[J,6KY)K8T>+%1-QK5>@O^:;]IC?-F1[O]&!:TB?OE//B8(XXU
M`.WR<\H<[Z+RS#IER,%68+T66*HW&KU*5#:HUA+KTA(%94LH5V_7PH?KHD$U
M&W8?FK*LT>OU:O)I7'2KY'.[S5J,MP(>:%KH`Z,VOL,++?C_T]TX#7_PN#:D
MIN]@5_1=:^0*(KZ-W04XC00$&2!(>RN&%Q>5(!35V&?]D5L_RSL6PB0N*+YY
M0!XGCF?CBE8[$-*`NA9V.;;@@E.;6$A@ZQ+9R#7Q=(6QX$K`3'/.BP9VBQC$
M<H4%,9&MC-(K`.94P&=`-)\L)AYFDF#50'*:$\+GJ`8KY"XQ'[M30<TO*VI;
MT-1'7WW0I!I,;D(S*#:2`\175S9]4`ZDN<@6X90L7;(`M4$+-DWJ0Q-VE[<`
MU218#11'&<NOOV18QN<S$:NABRX)A>=!@YA2VY>RNQ:6$C;TD'T3=APB)'MJ
ME$'YC!D[3-U<X*\Y`+E$4MV.!S)7[_/YW,RX1YBN*!,SS)Q+Y'X98H]RHL@0
M%W,K6RQ7B+"_D.UCI?H7Z!X=J]<Y8+B!'LA#+&/R_#G'7WV`,KI7;EG<Q_?[
M82!FQDBBR^=@UE,AXHJ:19Q:5*:&[!?A2)D_Q?.R:G`ML3U[,W-4+A7]@X%M
MOIPYMA489*8_QU6X"^K;Z@J4@>ZPE#GJ=0U5BSJ('`HYS4SV>*7YJH.=.6:'
M@DVRD6=D\0+YMGA[:#?MI".&@L0EP6!T#5_CXD384![,:E5MW1G"]6!R,QS=
M3$=#;3KKST8?1S>SJ3:YT@8?^C>_CZ;:^`8>3`9_?)A<#T=WTU^TT9^?QK-_
M8AB!L[G,54/_\*/`\+X5+L]B#VUJ1J5L-,?V105N_+NV/T-S&^N-5N=,;^N=
MQ+C+F"\0G\O`^[RZ1,@+%J1&#=N"QW>";M>HUHUJTY!D1+=?5+6)&*`@05E,
MB1KDT/5@'@'+=XA0_Y%PO=GHUG/W(*EF)8>>5-9GL6L+1ATE,@1]70`H`X'(
MO8]Z1?,8H0Q*@YHKFL\!(O4"'$]#>-0(W]1KA\Y#P=<Q"4T.C^&2ZXVV8>AG
M.=.WKNXM(GS9!'6CT0:^<L.^N\F_36_I\7_2W"Y_\U+:CE%'56/!VHN&/>9T
M!3-7/O&%W/2#):O>[C;K>3&VJ^)BN5,,041BHU%"%B7X,8?INS7T6;#;@`&?
M)1=,-_A!/N&ZT33JK5Q;X#X(1VB4KXE*1''K=!@.!;OAC-$KF.(7&$K!\8ZX
M1"2W3X=D*=@I9O?$!%>:3:.1T(J35_1*)DO!6*J3$5^=T^$K%-^&+^VW$K9I
MLQ2,I;L9479V.I1MJ.\N6!TR6&\&+G4R;6JQZ5(0N-?IB,?NZ?"XJ<D-GQ+6
M'F]I@J5B<K_;$96]$E+9M_[S>7C\,Z-]RR(AE%M$K+$[0!X1R)Z(%6:ZT6IU
MFGG-;I1A%,OX0=&)%YSU$M)]ATU,/,$G;G0X.EF$\NV[UF?$&`)/I7*[R@U6
MQ62QK+W6R9BP,FX1[!H]!M2-DG\FB_!:D+D-@XH))06)9MY'673NA5:*GOOU
M48RE<D+[$*'TE;QL%JT516RE$,L!<8S5TBRA6E2&-NGR5D*$C,]$0H?9SE>?
M<"+BF6P8*NB`Z3+D0C?:1CVW?<R"G"C?I"-C9F*AEG'SK:!P!*DEOBWBN4'2
MWGO*!*AX@-^E'E,(B*59QBU#E<@\&R2&>"Y3`)_&D"N,A,^P#BO%>F['<UFA
M+)_J7AO;6$MEW,X,V@W#J^#(^AZ/79,Z^`;#RF6&'O5VMY6P'LOL*#"MWL)/
M`A4"$%-8QNU-N1.0X$;_'A$[R)I84,;1\\GBD\AC5V\ID[$4@I&Y+X*W9C3,
M:H299:^36P)"SN"+U5*!3,2"+.,^[9-3J5WHV/%\@>&[P+"Z$7+D3=#8WJF/
M:@7'&D0."4!,;1GW;4&EH:2O*>=ZM]/(;8VU45.Q]*4Y&6>#E'&'-<V]WBGD
MC6VG^.4-6SW?\C!5]9+V=U+<C&45;M>$>;OG)H6>X5&,;/G*187CI2/'LPQE
MMY5B_VJQI6=;=LJ:;IKHT`MK0]D>`T?.\G(DL<8L!:E$3:S-??[GELRX,]\_
M0SEVOQ<YYN3($>78?94<N\][S!SEF/0;"54][H"?TV3I</KV)0A_E',2O6&T
M<SNDV:HM`]VI49"0#;SE;XGSN*.CH>!7[[:-PV/%8"&1E`V:EO:28*+@8Z\]
M3D3Q+^-9U@OHX5=YPJ^^BY]HXZ@,;+NQIL`H'P4[3MAO?6:N$,>319]S++AN
MM+J]HZ0EO$12BH/EO3%:T]XY%=I#Z2;ZE)",6T"*02F)WQ^E-?-GI\*\%/-D
ML<#!K0'E4::5^I:BLMU24+C;W35]W5.A+_H-UI9#C6SR=\M'X!Z'UPSV2L=@
MRGYV-&^&&79N1T4[:RY\S:`:A]S6JOD='$8^M,Z2?L*2[['?D<A4CD2)5R-W
M6(`);(T0<Z%/X4]*3.A%LV$QN<K"V=OK^7%_X_FN]L)C&#6^!'_G,+P??`1_
M.!#N_`]02P,$%`````@`M8*$0+ZKXA7N0@``);@#`!4`'`!O<FUP+3(P,3(P
M,C(Y7VQA8BYX;6Q55`D``U6M?$]5K7Q/=7@+``$$)0X```0Y`0``[%UK;^,X
MEOV^P/P';G:!J0;RL/R([=HNS3J.4F6,8WMB5V\W%HN%8C&)T+;DEN14,K]^
M2>IAR7I1$LG0C05FNM/6)>^A>'AX2?'Q\]_>MAOP"AW7M*TO9\IEZPQ`:VT;
MIO7\Y>S[\F*T'$\F9\#U=,O0-[8%OYQ9]MG?U+_\R\__>G&QZ/QZ\S"]N`C^
M,\@'="]11B#Z^<7S=I^OKG[\^'&YZ[P].IO+M;V-GNX<V]BOH0%0PG9+:5^T
MNNA_X#]!^W/G&BSN?<.-:?W^&?_C47<A0*`M][/M;'=?SF*YVXZ^A0;._0KG
MU&JWAV>!+79K>)$U06$[S\BNU;OR'T:FV$TBWQ\=8JL,A\,K\C0T35G&\^U<
MA7C/4`D`\,O@V!OX`)\`_O?WATD>?OSXZM9>[[?0\D:6H5F>Z;U/K"=4:-U#
M+QE!(/F]./#IRQE^%1=AF2_?7./?R"^&#LW0T'O?H<ISS>UN`\_`54U(8]LR
MH.5"`_WAVAO3T#UHW.@;W5K#Y0N$GDL%;+U^=$4#6^@.>I<OT#/7^H8:Y4X`
MS*6'_HDKVIT_S7?0(15,^R)=FQ/".*KQBVX]0W=B+3U[_?N+O3%04]?^V"-.
MTL%TUZ@9B'V38]U]N=O8/ZA?Y/J)+<*E^6R93XAMJ`6OU_8>-6'K>8&@KDU(
M!\K5&=-O].Q`\G[^R_1>;BW]QK31<]P@EO9F3V@W]0PJ;/H/]DUXNS4]4GMT
M58;L&==8/7:['OR#`Y`;G;![NT,TI]=\]W'-6!&6+[;CK:"SO=&MWV_ASG9-
MRAIRO4>#+98[W71^T3=[2.7_27_5/TIU:G0W2(%VNL.X\O:/+OQCCZ!HK]0M
MR]W#U_HPGG3WD01!>_?B6==W/I"-_@@W5_J;Z=[")WV_\9)(XH%9*@.$4+F"
M&\_%O^#<7`Q:N6@I%QV%P,[(ERUP"_Y`5;Z&.[:XT]G6J_9XX#GT<1MPY\`U
MYN<4ER`3=B+IQG&.4U[@["Y04*Y<$[@Y>7+`?(O^P0-W*E]FV"WX7.=E!\F.
M$6?EQAKJ`CJFC886C#%G9\L'/))>Q^,!/YTQZP*L;$_?L(6>SI(UZ!ED_+:/
M,V3^EE$H5UE(2MYR*LM\T*3SF**_0DO3VR!3DAJT6@JX`.$H/_ZG;AG`'_*#
MC#$_QMAXXL#'#-\\B"(:PY^BB%#;Z\"*X/]RAG[XWQ'*T<"YWFWTYTNE-Q@,
M+Q7E\CJ_/W3A^O+9?D6Z;/I=(?KCN`-$/R5S3N)#CG7/=L*7FGBM(R=$^>38
M6SJ0GHWL],<CN\$9L!T4]'\Y4\[`#C5_![VS+V>M,[!W$0A[AU_<(8K3G76J
M"I(S/X'%U=KOVR\V:;8@D\Q2';WX+*PY+$A".,0N2;\.=.V]LX9D#@NYP1-]
MT+KXOCP#II'M4(U^`/B7GZ\."&O3IG\*M.D7TT91NH-N]X2X$P*F)Y"7HW65
M612X;D2E\=[!8ZH[TT5#JM^@[J`8`\=SJ,*&K18C,<ISTHQ@%:"'7,M-TFY)
M3;E"W+REJ\BY&CP$_E.`'Z->U@#8@#43&>C;1S$QI7KY27"CEKOS+,4N1`O+
M4#"D9E'L-WIT/4=?>Y>=CH)BVK1@9L\'4>79C)4U48<,I4JN#+KM]G5?:KI6
M*PAO-:V$1BT9O8#_#I/\#T]&*X.3I/0!=A5.*X/@]<LMPE6+0L]K(\@Y8VC+
MB-\Q7!48?EF/XK[\^S-0=^@W%_?*O0ZCT#;7"QNBTX`_)G=&FG;G)+B<@UR4
M)&>[/S`T""1\`T`LF%.208S[<91,1;D%:7"0-CQ55@;@A<2YI3"X$11'S(<:
M;G-1S,@'2W(6`<^F9BQ%NWU"K#S"+58ID\Y3-"0#+AXD9*Z1HDA8HH^Q%*AE
M]^2>DBJ#_@':F`+!G)+19]AH=B=KQ-^$D`D/;.A8!OJ8C$G[SFG0,`U:E!:F
M/!]8%W3$S2:=<JJ/H0B*XURN`![9X\"F=X*\"X$+%;],"(Q)N$*@2#_69ZQW
M.&,VE,N!>,PT8M8YC1@OPBI*RT*'!_;@7UA0AJ%<\:),KCCY9CBDD/O#="9>
MH5(4]]R$0_X\X!@E=O3-Q#+@V]_A.ZZI#JMYNTP/S5A%"SJD5XY]2Y&:9`6H
M>:M4OFLUF#@.G@'R$*"G3&G'0,/$TRZE:CGV.&R0^SM>,7`A.E<(@2T)[>W6
M]K>&+5]T!&V^]\B.4=-Z)I7+*A`K=\>$GM6*<\35PL0MN0<*M$40))YE."(2
M$T-`+,^!;PMBQOPXS4YEI>!TGOX6)L81E-R?["J40J0R4^#AR?`[<P.=,1IE
M/]N.WP>S6D*9D3\+#I<!3I(V:3V4>X%$'F0Q0IOR&]*./`#A$X8D8Z:;HDB6
MHXQ'UKC1RCU;4P1;H/9E`F#'N@?X;.*%.)8WT[=DUJ3#ZHMPE@,6O"N%G"3>
ML7E+[B\?^:#%*%R&YY!MAT<`/V-)-V8J)XYN.3IW;(X'D=<GR+@`MT"ERT9`
M2[[X#U/T%_W.PC:X`-&Y!.CO\7QVJ\V6VBW^:SF?3FY'*_0?-Z/I:#;6P/*;
MIJV6N6^F_C%`U;<9^D>EN`O]77_<P)%EH%^</32FIOYH;DS/A&ZP6OY2Z0R&
M9<)>O"D?_W+<[H*?JR!IUB2;%3G:FU8EEW9W('?[K5$:WEU)=4AJF`0$:<C"
MX2`5B"4[!T'"BGLKZQ"GH%?ZL[:5]#[."KFT!]<M1>YYNSK%$=('U@!V:#.[
M6)O1@S8#W_!I2+#BDJ@C&'/O!8T^8B3IBNI#XIZ9MH.2(N7P/IFJ-Y3\FS$%
M>L%]0`:$E.:?`V+%1N*SZUF$I`NF;IED)U,-.KWA0.YOT53X/T*4,Y&$+(Y$
M^(?IO0"\TPDZP,7SS_XQ>?7(_`#7T'S%^<Z@%[KN#MK\=3C+,QLVTY7IF,V9
MJ=I]N2<1R\&+DN%<!`<5/IB<`V344(8+:YFK#'\0<W-U."M5GP1QK=.((HH+
M(%2)"Z$<J.Q$9N`"V%BV*Y-XO]UO\%R-+_KV=H>$'`74YBN<6&M["Z>VZR(,
M\Z>5_H8XT"_;,M"(UU7`-*9ZLY+'V%\IHX[D2\-KE4>`NE<&I<82^0$W2"0#
M?CKP":?\B70%P'X"*+F8-L2K;Y"_#67U(%4R\H6P+7UT7Z],HOJ96NA4OR'I
ML::U3C0JDZ2MV((,P_3K:J&;QL0:ZSO3TS>QY3"7W:%2MF2P0:,I]=^PG=0H
M7]0T*-+*'EY1%H%[)T*'0SW8`6R(*`T"T_/$LBMN).?3,\A#\K3^EZ8-!$CR
M47"%8HA1>7I`<=;OD/$%8OW:-Z_(<]>%'M[#W!ER5&SBI"%A\X!&K/0-!OV>
MW$L%$SBYBVC,F>K_1S-^'+X\R4Z0`](CAI#O5))'HTFD%=0GYP!Q>JH$/M45
ML($'=+`!>FW:1*>DM7M*V=KDIN1A<^9;&>XDE2*[8;<O]W:F3+QBQ"?I-!"A
MVF<)YE00GQB,/['2L=61W:`WE'SI>PYB,1%3IN\&'5WT&4UI=3DN3(O[8L&K
M?-A)7H5V@U;G%$B5A"M&KA(^`R;5_>:473<\0RB>G,H+J!+K?R0?\F4"%AA>
M';F.15GKX`#I^M%6D/?A7-_AL.R"#T9T8]E%EI8BDWR1.6JVIQ")9<,6JG!)
MW\=*US!`RZM%CG&:0"[F1&W'YB0<D?O8T6+@`F.X'`CJ^/O#@S9;@=%RJ:V6
MGRO>\J"[+R/+P/_"MX&^ZAODPAUY8]UQWDWKF5Q$>=GK#OD-3JD@-.-JS5)&
MET-0)5<4R:?5JA2#M\Y6P*)B([)"FOP1,S\'N@?"%(`DX<E^+LHL'?O35Z-0
M)2<K>>3>H5FM($*4O1*D0T-8XS_@(4%%UA\NH<:^;7)I-[3PE=V72N>ZS2\D
M+O#<D.*5BA0QNRB5,FS)?>0'!7KN*EX*08V9^!H>-^+`6SXB_:&\32OR_/Y^
MLKI'0=]R-+L=SV>KR>RK-AM/M.7,]N#EP!\\RSW*HR^$&"6FA:/&+,$G"ST#
M[9^J$SGX7!WTO0-$.)ZB&_?6G+'%V./JFK!4NI+/T^<@%J&B:;=J\D`D\N0<
M3%QW#PU&=..FE0+HEA;%(\M@(8CD(6DN:#&BE^<^))^+'^%%Q/\.6I?X+N>=
M[H!7;`HN@+[W7M#K_"<T/@,$Y[SE_]_?.^7BL=D=?'3VNO,.VL-S@"\H\S>'
M[Y_WK@<Z"OE-^0]@$E*39_;AP*_/H-\Z5P;]<U3EI7EBTU:7F"*;(P\5#TR&
M.]LU48><G./O=#G.%6?Z;-9R:(L1G:Z<;=]N2W[];R%NWM)=Y%P-'X)&G\A*
MZI&+AHNG8_JP[TQ[,A*6>V%2,7`ALEX(05TBT?8`RGX+C,"P(B/W\`[5*UDX
M_P#)FOF%[L3/.>BUACU^6EGFOB%1JY<NXFQITFM%[@B8L@3<994*AHK,`*ZX
M8#-48`D"T[IZ2UW_?*17%G:G%;DT*5$8N<]<HB^$&*6FA:.&Y-[YCRMS>F5G
MYZ]TA@K'N#;7<6,:TQ<H1N#<1.WN4.Z18CEX`:)<C(#HL6>ST^'2*N:EP!_&
MV2S1S4G4#PXR.57:QO"+DMI2),U4=F*]0C>:S">:/D/O,%BV$>R]Z':O^2VE
MH$#0C,/UBAB2F2IUIW4M]P"O0BEX2S(]%#5F2B;,_)#Y8`WJK`BO1`<N8BT7
MXU/R39.:1'ARKX&K4@PA8EX!D#J=S[Z"E?9P#VZUQ7PY62W!:'8+)K-?M"7Y
MC%>-\[%C'2\'K1Z_\[QBCII1N!!QR-2X4;?=EWOI0QHL;Z5->51COS0G$!=M
MY$J@E-3%C%!`U>KW!W)/=67B%2)>69[5%=XW`38,2(4$D7S1\T\O=/&Z,N\=
MU=LUO]WK9=Z9T8^R;!F<S$[9;7?EWHY#60*!\E<`(ZZ)),CT'W)B,I]-8I)0
M.;V3K#0I^70O]U%LU&6HH,/U]YO1HHEM0=L<$=R-)?HK69'+FNZ'G36M7MEE
MN_Q8SV;+4/VRTC:"*`>D1W+/(E0LR4<+?!).CM#7WA%7F1B\XV69&D%1I%V<
M`UFQ>C(C.;JRB([0J5"EV@/3?B'ZYMT:\#MP@?4E)C3X,PA].*2]+?>RLUS,
M`I4ZX3C.P9J?W`KJC'NPS9MTA0%UXLP!N1<P%*`6'30?^<\XJ8'%=,;QMN?N
M0,@\!M.]\A6*D\_.0V`P:)],IYZ-7;Q&)@%D:B6+Z#6G=GF'JX+)6A21ID\I
M0.)P:EUY"KWHJ#,'1W36PW0RNIE,)ZN)5O7`AYB3PQ>SRT%?&8A0U8-+9APM
M*D4&/V/F/461>_%,$6R!$GKL.ZF>AZ<LB<@]WA3#Q,*H,V9/%B#UY5X$4()<
M=/29@2'\B&9;S_[^!A;Q9VQ=011#M/M"8M"T:PY<S2]5(66C9#U%\L4K-/`_
M1$V3&/)4E4586E#;O$/3C^%P482:E8P(B-SG)5"60'2D6H`EMO*J>;SZ?F<[
MW]%K=#S=M%;ZVP)O7$/UD>@'.HJ`10X42-A0O%Z1CQE/E8O2[Y[&M%>%THC2
M='I(D<2_XVM&090(7]$%HF3-0^I*Q.':`<C95G)[!YI<R+&+?Y[&$A9':+]1
M`9BZ<.Q7TT4/29O91VW&0VUF%Z2KUDSN=>=WZ.$[)I<0>4O,90^Z'%=9%#AN
MU@HJE2@D?5&B;K\C]_*)<O"\Y;\4@7JP``>3FI_F:&J8BY)_*&=30EV4B*SW
MEWLU)PU\(4),`21.7S<RJL;:8%]S>*6O&[M\6>FUK_G=O)OON!EI*Q4H)&U1
MHO:@*_?L23EXWD);BD`-CW^(3)I<@TY3Q5R4]B,YFQ+:@D1$'^2>*Z%`+T1F
MRW&H7QW]Z-YS<J()2@C&+R9\`LNUB>Q-MR*-%_CZ6ML*=\>A"-MSH&<Z$&^:
MNX5/I@6-&VBA/[P%PN[FS*QWA@-^IT,PP=BL<?!Z36$[8I1_NR?Y/A6FY>3=
MH[`$JP:9Q395)_,#088@R!&0+,\!DX^HC.G+I5_[\[7R5&_)*'\R;R[WKDG&
M)172"[/%K&K;W<9^AQ`XYO,+ZKKW.]3Z#QE6;,`.Q)<3:V\[!!*&P<&PV^%W
M?EZFRX;MBZX447/)-+]N7<N]K+$(-O<N*]^W&CP#P<.:XY[B.N33,XAF8EJX
M,\U);"[W3LIBX&)DM0A"1$KH/ZXX<12D#I1[C!3;197(\;[1#(=,B%A<@B,:
M)HQ1VY9[9B@?M"`Q3'N.6!<&Y>09.^KQ5$$QU,M3P(2Q'^K(_8VS$+=(_<M$
MH([NY]_Q!2%WWV>W&CYL"#QHRX4V7H'Y'=#N%]/Y;YH&'B9?OR&C[XLY?KZ:
M/&C5SR-:./8..MX[#ET]%./B'8H['(C.(.KXKKL\`\E\STT97*5,!RH7I+KN
M2"^GI>CYZVH9!#4T.2?3&%ZT^9N8D6EW#NSE)+L?RMX,(2Y(1?9_R+U9@0J_
M(&$N1Z(N'N8+[6'U&SD+3OO']\D"2^\YL*HR^`&ZGF.N/6A0WFF)W/-;I%@1
M33.B-R]Z2/ZJ.5T/K^5N#?4*Q%O@:Z%2#ZE`P56LM28=:C.(2Y=P&HTGU7-4
MS8D,T>6>:JM;)"']2TUP\7:$+W"MVE+PJD=H:+ICH9S=T7J]W^[):=5X"GMM
MX@-CE#Z_XTC+`31M#S4*>&@"I8G[+<D/-:4N`_]>@@Z(&AJ"T!)\BMF"P+CB
MY9A5>,"I%Y"'Z!E:7Y8XN,/OU+E^*(8@3:<&I`8_`#W&=6/OX#OH\;(=`[["
MC4T&',#U].>*=](O/90A3CQ_NC,MW5J;^B9<'W\X#Z#%;U4.#8!F+:!6$<,6
M0)<8;QZ0>XU:I7+PEOPJ8-3Q?':KS9;:+4!_+>?3R>UHA?[C9C0=S<8:6'[3
MM-6R]K;5C',XE7:/X[X^UF>\4A7@P.:T<6O0D9VZ>:#Y\S3'L[I,G+@7G$<Y
M\E#`_;CW%[%[-KZ1J/(0M:@Z^9Q2(9*0Z0,J\L[!E?L,GP+4%>*'^@=3Y/N/
M'8O6_%3(HN-"AVV>,0&?PU"KE">?H%&:_J`E]_*Y4NSB!30)H(J.,NSB4[7.
M963W@2Q.#>3*#I65^V,E!7HAP[9R'.IR-1___=M\>JL]+/]*OO2L?DN?01'_
M88K^\G],_A:",SU<)@(8H$*`"Q"%S^AONNCXTV*$#W+[IJTFX]'TI]S793OZ
M%AJ7:WOKOZNQ;1EX/96!_G#MC6G@T>>-CE[.&BY?(/1<OVV^0,]<ZT<O%+YY
M$"4WSLJ;Z-C>;FV+O%Z4X=PA)33(?.8".LL7Y`3?^MCC=Y<=!8)FK;9>$</V
M2Y6Z=2WYH3(52L&[9Z*'HOJF@-B>X\X(O6*_#1J`)``H!2!)JG5,E2C!I8N2
MB_6I7HLF-8E[3Y_V83&$]&,5`(7L=WWV[Q#[7PGG=XCS;B/.$S_N:.^]H.KZ
M)^IV>H,VOV-!"QPSHWAYB3*8G4JD=(=RGX91#EZ@>F<C.!)MWP@<K-B3EK<^
MBR=MD1RG$A&YD'LT3`-?M/SF`3F27=?GK\Z*OQ/7W?LUS6\2)\<I8][FE227
MLT$"I=7IG!A=D\B%2VS"?::^G@/?ABTYQ0BK"'*6"VJ0@(B`W%,R9=`_1DB3
M(+)%U&3!T?G><SW=,DSK&55O1\B\1,HS8[86EBF7LO%4*/22^[L-!7KANIJ"
MD*.M,3L.Y!6CLF+)6ZZW\518-#IR+_.FPO\QRIN!)%M^[0(:UY\6[])-BR]7
MZ%]XY\42;XS#6S)&JPDR:#8A'CEVYT_S'71T<KAH[<GP<%%8.!5SH[OF>F09
MM^9F[^$(K-=5^&U-+O'>K-E6+UK8=$M3M@<]N??04Y:`=_]#!T.-UMA&<]OG
M@)B2_1B!<;5^B+KRN?1%<O`ZU265I/27@4J^E)RZ#$*Z)EHTZLUH.1F3#7FW
MD^EWW#U,Y\LE0)T"ZC3N[^<SL/PV>M"JD?RK;EI3VW7GUL1ZA:Y'N@7M;;W9
MXQZ/G`BT>M&M%=SN4-_BO$^V.]UTB!5B2;]#6-+EHNP-H#5K'8S?2=ATOHXF
M,]1WCZ;:_&XR^T5;KG#/CJNW?2UW5U""G**9#/UF8L%G'(#4:RC%*%3\&.!&
M@`QPM'0PJ=@BH(5"H@UJ@2-C:UHF7C#AF:\P.,GELM]5^*VV+7'>D-=52Q8Q
MMR1AIS.46_'I"L`[E*%"H096)&Y)VH5'6/'A,Y<H1@H^IX*8DH1^EROY%FKJ
M,@@)8FC1J%^U&1K$3DD8,[J]G\PFRQ4>U/ZB`>W7!1X"+ZO1>V*AP2[$W?4=
M(@8:YGJFM<?==#2PO8%/M@-]NY7^!E%7CM"AJC4MW'FCH3`YR!"E1&\!9?\\
ML=";0/W^I=)M#?E]X>>(O%F[$OM*PT;)U6N[UY>[.0LH/>_NC7\15#\I^(2=
M_.0?!7[P`PZ.P"/Q!`)[XNL<)+P!XLX_6_C@$(0>)12APVT"_Z]"[-^I"!G"
MG>!`[DA91/$KCQ=7]7<>"2B/2J9A;K2[^8,&5J-?M24>ADYFX_E]Q<D8'T0T
M/1\MUA]R/!(IQR>+MEM>D&2C2]OC-]P[A0:3#UU,KYOK/V\[<LZ7I=J;EJ+V
M$T3\P8GAJ.-&;80S>5->69"7IBA)^F:D:`T&<B_U+D$NAKQY[M5#^!9.?8!/
M@4G%8U-*ZY3+[,?'T#,UW9&3(AB4R[UNJQ2[D.F-,A1JHVY_!KU#F'(YN&ZW
M^(7["5_-B%@&.Z1?THX$37*ONLH&+#)JS42@SK25_\D/19I@]4W#G_XF\]N*
M%[CY@2\.8P]UARJ/WV6#:8?->$=5@NBFM@SC7J<M]V10/FC>'7*N9S5Z$DZJ
M^),P[,C'1^^$LB^M?5G6Y'N^W+UN$6R1.EB`0PW&++.O1!-KW&*)1O5VF'_X
MR6@P[/.[X#K/:T-"4I<E<7ME5HI>MR=WSUR"G+LZ%KH/+EJ-/Z_WQ;:T1OE=
ML"J>G=EWJV:E(+&VW-=NE&(7,EHI0Z'>36:CV7@RFM;\YIIRX,LSKE-^)^SF
M.&5,S[R2Y+(S2(`4X,2HF0`N7#GCWK.$TW_.EI9\EBE^""_3JPMS4G2O_>&C
MY`.>4O"5HTY&TGD,Y/_:N[;FQG%C_5=0><ENE>T2===Y8!4MTS-*/*(BR3,G
M9Y]HB1HSD4F'HF9G\NL/`)(B)=X`$`"AV7U)9F6B\379-P"-[HSM9-GJJ4H>
M1=&M<\BDG"[\`'V5I;/QOWKH%O7,2Y*%4:\.;3#J:F+#`3Y(.:B"L%=VICZ<
M9L%'+XHO\`2P*R^VX0M<GWU:&+,E.@QKDC?,$9GQS7;WJ)K@S@\.]MY9.9MC
M@#ON8@D6=^E$"@_*F`.JURS`4)3//XI:Y8VO(*24^"JNS<"0,'5A?(S/QNS)
MN'\R;]$F_RV^R[`RI\_+V7I&NTI;.@<'?DS4@N4A+;J?K`4UK3L15TRE<NYF
M!H"6K4P?H(IQX_Y([:TO$OBB5W$$&/3DF>C>9:;9`]-6&.''%M7OJF49+NIE
M53XN.HU6?`>7D`,IIIX,B[XT5Z:QG'Z,KEZ:G\TG"W=#9-P\^^*X7U_A`M7X
M!I>87YWY\>W%":S=Q;7/J$K!\P&YE*G_]GX,<;:BM4,^Z%3TL#<8:\,"(^X'
M;UBLNYUN=X*%&OW"<^IF\B_V'23:PG.6R%]WE=8M(?R*]BDB0.L)41!3!1%9
M8.WBH@!&6A0@*;:(B(,9:HI^(H^>1Q.P%LP5(N:C/U7]W#'RER!U7:@07H4[
M6Q&H]2\F:@]O/L`UD[DT/IA@_OSIWERB5512#@'5M@?/JZC#//QQ\8SS!0@*
M*:"1"NBZ-OY3V3,O08RVJWN_0`BOY-J^]3='%!%C<BTK?.\O^OK5`7;LS[W(
MG_N[4YFN`!P]-TS*)>+59Z9T%PA?[1#`)]$WW0+7`QM[OT'="=$?7TZ%@K9Q
M3&`N5G<<RWT-2LM]G=_#F'XTYA_,%3)718TY2C]>:=FO;*FOZ2O\3&C[JJZ#
M%D7M+V.[=2/U6-@N^HSVNQO:^T\.^CQWO>Y8$[;%5#EU,S-&R56RWJ@>%LFQ
MVM=!"#D0O28@@Z&GCX%W^-PMUFK\)/@M>I;R$I.Q_=<QWME=^R4@H&I!&Q2Z
M+WOGP7D)O[CA:_33`3[[Z-CA$;>(&`F\LL<+9E,E$?:R4H7B-876Z:M](,N;
M5?$JRA6OGJ&'6JAE5!N11`X[)GH#,F0!H@M^AX1!2AG$I-O6?2&;TC^K[N>V
MNGE-@?=QM?$?0_M39J5LH'.'K3_,5E/K&9V%H@7['*[LU[/[)[BVM]8F6)I/
M^.[RV@+WYMQ\G.$TK.BQ%;J\_&@:ZV?:"H@D3.!#X3NMWQ^*NQU`C$.\ZI:Q
M2Z.;,8U>9ZCN;AH3+RIXUBP@&M>)QPE7C]8<7SOJP>2Z(AK8[*E]J$3/C#*N
MYPP6*H2Q7L[NGW$!=>1#%L8LVA@V%K.U\<1?+9)ROJCZ^ALZ5,;;6WCWQ<(?
M];!$7:X/;NBLG.";NT'=[%Q_&Z<3H2?NM('6$=>M0Q(7XE52S*NF46@N"/H]
MQ?.&);\)%7PM/W9H/#6>]?8%30NR\]Y$;59`//4-.$T.XME!-#W(S*^X:6LM
M7OCCF3:F6(4'`NR%U4YGEOTJE(F3.#(5]9-')^RXX-@GE"`7%1;++-ZM112#
M?5@:\_@G\]/BR?JG::[B8_FE.5U;2\K,.DF\HE8ZQWUHHW+_O9Y6V$RMY*!>
M/L*KL$_5;U2RJ<J"05+=5[LW0XMOY2>)S@I8.XO4UOE(;7:*U*)`#=SG`K7S
M.(TH3`,9)-=C^0ASE/XT?2ROM#W;IXVQ,@S4;CK<ZGN1D4G5-I,<+"'3DO4F
M:PSSJ5C*6D.R[.P_C2'#&VW/%L;GDW^:PK+7\C,M98L89%W6HI+;ST]K^-_,
M2]E25F<H81:ESL;5Z)'"%&5;UIH@TAEXF9`&'.5-`#$Q'-E?R^8Z-5?REF*T
MT#(!1$W\$!-@;,'21+ZHES#JJTS5$H*46A(%_FQ:D^%+?@A/#Y)=@YCC9GIY
MHXU[U=>@BKB3E%@4/TRTGTQ_4K8DQWW4`%%U%7S!;P8CLJ6YHBSI!&/(MSAZ
MC.\>=+6!N`J7N>F:"3\!^D2T\X^.^SUU[\55018="97,JT>_QUL=;-=/,J2C
MJW%6>H'M;C".]P:%G)973<U-"DF8*I#(_#"DW<.K$<]R_.2R^HY7J:;'6-:2
M!(U^;SP9\ZEY$U^I%"&[HLUF*[);94U+WK;:*=%$^&EE=Q7:02A*>OO-I?<]
M<%X=[^!^BUL!SIW0VJWM[_`[]\4U,*N8N+'HDG.4$=S20=J@J[S4UH"7$!I4
M(]#/GCAOI'(#X+/H0CM\^@8881BX+\<050]$J8(+*-,>Y8X(B0B("B;:$^JB
M2*)T$%XFJ%T:FP2^E&48`1#=6G^,BJ@LEN9'<[Y";=VC,ME0RJW5BK)=4%2<
M`$WL>U#\'_PWV_70_7MQ=ZL+IVPFM81<)/):_+C6[RO>M*H2MVC36S6Y'OT1
MG/X*?HO^3KD\*^YW)\2""N_2E[.29X_%^R=J7TPJ02S%%A;/?6K0QU`XO,"Z
MEI</3G?$$@L<%R+.A@UK/PH:[K3>9"BN#(M@],V$7_ZK/2L3+G+FKNKQN*0W
M(-JSR&$C;H%3N3XXS7@+I[Q%<X)T4I#.>KZ2B.?FLJ*0ID[BFAO\X2U5<4,#
M<3/'WE'MW5II[T!*="*+&_UYOC2-I]G_F0_@@S&;@\>E]2G3PJ!Q!X,R1N*#
ME_ZH.Y`>U_`XF:/EJTY5D^,]]%G4OJU"R$%;3OT<1NR4-V=.>8_J0;.=[RV=
MC>.^AP?+,S8;_^A!38OVLPUO^\4.@B3OM5NTWUR244%"LYFP,J).6Q80#$<O
MO*NVY%+Q(5I^:<#HR</`@E%@]#@J;!Z7/4>5T),A(L69,,=.-7G.Y]&1C$^2
MM]2N]DG)";E0-\N5HX-%(=Z4Z7!T@D*6`*>:>!=TF*D?'J?%JQW2TS$B)2ZG
M@J0OS:DY6Z"ZT'-@3..J>(]@]=%8QM?DOQC+)?W5@J43VJ[G;)-&96E5XZ[`
M=F!%<S85=#(^4LDN?!['>FH7IJA!+C[8J)I>?W!V[L8-@;V!1A]55'>V8`O7
ME;CHN@.VF19@AQ#5;F<+GB--F=KP?>[W2>UX;,@HZB\4$FDFAJ2X$C$L?AZ]
MS([:YRW5P$4+8>7L>NSL3W^.O3]7"2,,8.6+6#Y$+1P0ATP=M=UV'71906@-
MCIS$Q16[:&/,FD]+%E3*%[E<V%CX?!3+#-6^/E2#7$I@6(U!CT.^*<IO?'HR
M']AR'"\F^6SOCP[ZHEI1%U@R2<,TN`I:&:H2.8L>1XT:%0_A*G%+]IUGD^==
M)_XS3]%B<YS"9:O6;>+G$Y.O=NY5#?*6G.8%C`*?&7T2GL+65].0]8DL67\8
MV7RU"TW4("<0MDDD;)[S%:T6N?C,"Q0YGTDI8TG;K(N\PH/QW3V@+09Q)9DK
MIVXHHG1<G22U<IBF]37%Y94$OW`?3`!"/SUT`RYS5@_@-_0D[:9)0O#)]9P9
M_"=<,@\T<<F`^?DX26P%_IR8IL].^J,K$<U+S-+$\6+B5`3!;^A/`/^-5>JL
M7;[5H/%R"`-[$]YID\*=.\Z"6`6!DVS2<9D3U^KAN-?=E0@Q&2?21)L(#FH+
ML;*>9@^XBA-5-TYHD6-JK/JQ1FE5=]W^4-Q]EO.Y.$E\">Z<:$?/3;H]M<_!
M"_%*$]/,I%GKBW^F%JQ+>4?IQ=%7$G/WNJZ5++V(D7"0"EKN:1S_*WZ04HZ:
M7.@:7ZHN1Y%<I>8H>T+RN:7*7G['N^3]J9W%5H&:5O:8BU&48V@@>3/<]OL!
MGSM')1WC#8)3KT%KEVE%F*8^WVD]K2>NID\S<!P$FN>+.9/]!H2U44?Q[7HN
M#(H/(3B@U*.*11$9$-&)ZS$G9YHWV>:Z_NZL`6]*KQVE%>=9KEQIBQT6.V&<
MEG8%SJTYAW*.?+E@3;:Y9ZO5,UR^/EK+;#M<M(2]Z*'+>'1<!7;N_([_A&6O
M\#!9@E*>0`A4OBI&B90L0T`;*MX,BXZ15CW=)1HBCP8'14\(5@7Y_JDE5:#S
M-RD!9,E&/X4N))RT[S]RF/2"K/$SIV&L/MX"5+X"^@ST.UJ%`?-_49U[<R7`
M:5B[G8-^F_J'^#I"4?)YV>$],66!*E#'`9$:G!/!>1*J[_53<].J;RB$5.$@
MDFM#R3B`!XH7?-(<*84EOR"?BIA*G"2D*9YEQ<(/N?@WS+UB`$<4*9VK`FVR
M%H,@$28]*ZP*=+'0&9$HZW>D>)(^`SOM1T7%P`J6T-;CH[F<S3_`U?-J+2+Z
M64`V7NV#8^V,P\&!DJ/UQQ-QI2RHL`C4%@*VB10F3Z<W[%WQ$J*,GU8CIQ)0
M1"XC&8LVBZ/14I1'_EI;">6A\S8Y.M@.JMVBA(VA]CU.&;0"GS.;?S97:Y1Z
MA-*-9JOU[';^-P&N)^YZ%P4K12Z')=Q*B`H4_PK<1&)_&H]#7[4K)](QTJJ7
MN$1#L+1.A@@5:A[KZ5:DFG(5G1!(ZJ%<\;JA@!4EULYY7$0QT.G3"I5S#FOE
M5L2<+F9)QL>+MBO>(LUSTGZ4DL-4$)ZLS.7GV13^MC3G#^:2^0XR"8ZEX\&/
MZVRQM!1E1C>1\H2X!&FOX(-*ZD]TL(^]XG5N*4-*A#"7J"A"&9",E:(-/&.;
M5M6!,=9)""4.^8J3DBI84BKVR>.CBH%.^B$B&,K+%<>@J%7]8`N2$CIQ);DK
MWMDIYTB=H"F'+0F>UA:X-^6%4/C^.U%ZJ"8]V9T,FQ`58WXM-2I'2E<;7J<"
MTO'74OQ&!;+286%*$M/<:<52YLG&%6DKJ8,DI(LM^%5N#5,RV*;[I(-*G>#.
M3SW/<EP[[3A-L;F\M6R2J-59]K7JE8MH^&C3J5V"(7%>G#/:RX1#NBMJ1P>H
M7,M%OO55;DB4,-*ZJ\A!:I;+SD\W\KE_1765Z#8?\H3%"7T=?A+!+TBOOE[A
M+V:F33=0B*AJ7QJ/$I&\7B4QS?:C%1!YXGWH/)&DNJ7J!6[HV6EY_[D*&TDT
M)")KO4J&&NTY*Z`#5/%.42;U%=3<H>.F]<BG&%=MOCH_42],.6UG(2PET9:4
M:1(5*4R?OM[8J(R=-J.C$DPDWD%0@GJ-`$E?.JN@-52.I3AA^BIO!5;ST[IS
M*4-&FIK.3U_.D@.+O`M#+"4TI[$.-8F@G^=-7V76;C$?;3J$2S#U*V6NN>@E
M<L%A>=R&.-,MBB^3I*]W-5#`B0I+X3PLDCB';Q)ZB:0T7_JV(=]4<<E%BO3U
M[O;D&6D]$LE!(DD_YR_/9^EW0[YAB-`L0E(N:.3\/!?Z>I>MI?RH$*9<@B(/
M5_CFF]<($,?XI4T]8(MG+A.?KS<[J((CE>*;/#R:.(=SHGF-2/$+?-I4#*9`
MZ"+M^7IW:,H94B8PRD$C3S'/:4'VAR?XK^C'\]\2'MP0L8[Y`IW.$-R"M#W%
M+4J\>T`9%0^@JH.*L?H('I^L+ZO2]^D']AL4QXW_%KW,J0^Y]0[.%O[CX._=
M+6H1=YKX8.VF]N'U<>__?K%:<+Z'Z#UM_U*O[>A]H[YQ<8,8P]M^L8/`AM37
M_KT3?8U'/TC>OQ5,][;[!M<.@\F8XK"/<9IF-H`?;\@<L%+3QKWA0.&N+XWY
M$FX<FB+4I_[;F^^!`W:>H0]>'.!&+G3G!^#`M/'56+@(8\GKU)SS"+/9!U3W
MEF]COF1$FTU!Z@D!=$`8J9#M;<'O,9%R?8)?#6PB6G2J96S_=3R$V,6M_:6#
M/I.[=^9../.@:W2>_`/\';F^1>!_<Z&?N__Q#)WDS+/>G0"^(.^KL0G=;SAY
M_M3DK#<:B>LL)@)Q,PV6\PZ3,%G(;-I@U%/[-$@DVZ)W901BUS.TD7DX40>0
M/(CH@U_0#+^B/Z-)0#(+>/D!?D$3`=?[%9SF`NEDS*T&A:J$D'R&/YA9R:V^
MA<P&%X[=@=IW<X3R+64M+Y*#,_,2./\YN@$T%]"0!"<[XT$[LX=SH%_1OS?(
MQ!PCJP+\DU&Q3W/\#Z4I>?.#T/TO#L:LW8/S$CZXAXU_],)%X+RYQ[>[07<L
M+CNP=OJ&2D[/W4EC:X=JPWY7[6O@Q#P(=]&$0/3L@RA*1X^"Y%GP2_STKZ)D
M7(SO4T7&\UZI=B@R5,-K%_*$"3G^@A1.3M:W2-:W\<-T$H[\#UP.H_]#O3>_
MV7OD4HQP"I>V/Z!_P#O/=X/^I".N:3`1AF:BSLIF(N]DX]'WF:@M\W2,D,O]
M>U0+A[W_,!4P'1\DH!N?^!^H__IGXPF?,AAK<&]^F,WGZ`*$]0@6YG)F4>:'
M4$J+$-NOGE+DG`#%)U,[_X^.$5JE8&Z,3`6K6B5,^#M798C.)>%*)G#L@_/@
M1/]_!['TA(7\-$A$:`8IS]7Z44*E/U&\33T#-Z(7!_20=+S1AO;N\3\RHVZ2
MU*ID(/@E&4JY:&`2GC0)[0^D,2G33"J#+9_:J29,_%"L-OS0WO-T+M7(]-E\
MNC2-E8DN_I3Z&TIM\;TP<%^.T:IG$:"=J?#'G=:9%%[^X:07A9,VU`!21DZR
M7CQ@-!ZKO3-;B5NXR:^87,_^$:V+DS_SE4@QX7X+$ID/Z(L'8.U7.^F[!KF4
M_9MJ#.?"&?K@W7;Q5OS&?G>A%:>3T0?G/7`V+MX!@I%-7US0G9VIF3A68TYD
M\/PIA7/&BL&*MG^Y&?7L+QR$2(AU$RQ$.4-V]A0^,IM<CQPE>*48K:*9FXA4
MO`EM>9DRGG,_=);.'B7NHG0KS]FYD/@^+?KYZ-CA,7!0#GJ/H@=9H\D:BB%G
M/D^"VX@N^GY]M8-'/@P*M[(\4.JGTT?+.RL>C0B!F!)8^R"EE:TX'5-K1?\(
M\W*O7P'SM\`:$8YN*74':I\!\6*17`N;W1/CA#?51ZA=FXP^>D@?@U@?<2KO
M21\WJ3[N8MEI12');IA<OS[F([DF=$?1XDO=Y'F.',J)%KE@Y:.(='KXZ`>.
M^]6;'H/`\38_UH'M'5#JF^]]L%T/Y>+=.SOXS-K^?J=UAYJX!34%DF8JV8SE
M1`&IJ'3&$[47[`S<B(XUZ2'I\1"0C`&900"-BC/+;Z`&H:$`CI6@+OT_H+[T
M&RD,3NA2^]B7A1T"E9E$*N,Y7Y&Q9_-&#-!T\_OF%=)RP-9%Y53A.-I+CPEM
MRYM!EQ3G8$.R^^/6];Y:X:L3K.$4:^?MW0_LX,?L[=UV`_P4OAO2%>99&B!K
MICE\7TFB2(VHCF#(K[1><>!.M&=J#E'/.",4[&7HW(`3)8!)@1#2`B=B($.M
M!05-U[=_:FC^G7!0T8&&;'*OJ_;&/!\&J?WAFGV)Q@5QI+>H7("]QW>>W1,M
MR@H!;^_'$-UI@HM.2,#\_HYJ>>#U?M$*J^S^?R&59AI!C"R1]9(!*+#HJ5T&
MJ@:Y:#=2/;T>_QDD?P?Q`WP%C;321`N2EM^#+AX1[V0J7C6^%KNL7>,Z(*6"
M1[G#6_=Y"8L#M2!XN<W6X@'1OMU0[8V=.NA2MD=K0)PDSHT?H!2TBZS,F6=L
M\#;J86'_L%_VSMU@5%BIE$_L6CM]0V&EY^XDMK5#M=Y8[3B3E`7AOIH,AUZ0
M)(]RV9*'0?RT*`$7DJ2DC(#G[7+=T,C$*-YSB8(+.=::&(]^DNOWZ"_X!HF]
MV02HWI,3F7G:VFFYV4]E'Z911FA:&V0XEFC5RV#PEGYB=LNUH)2$-APH7F"!
MGAGYIK\&49D32`L6Q>.8JQ71"XTDQZ"*CA!XBE(2."B]MJBHEIN6/$<=+GV*
M3YT.%[5W<*LE[$SVKOWB[EGJ\!2`09M\<_@!\,%8^)22OM,&O?Y$IC,IA<)=
M56B8KE"7"C+]L>*MQUC8:<&MU&$J=2SXF"@="3)#9>B,+.>BE,Z0N)AR,CB`
M5KN`)1,_;;F96F0Z+B87Y<GY`3C"%Q2$Z#`GM+^#=__@TM_IR,-8P/4.)&-X
MVX4/_9P3N@&NQFZ][-VO>+<6-=_L=L1=X&7"Q%M]V%Y#N1X1T=/&G6M;V5#P
M)=\;D8,K<TLQ!1S&G=,`&2)2=4Z2IU)=YPA\%Q&]<6\P4;S01$/.6O)G-!CU
MQ-O]0`D)SMO[WO_A."!PO[["-=3Q'6I@2J"QM@4.NI_]X.P<Z&FW\4D.Q(D]
M<-PB=S"<R%Q+D6#BKFY,[Z%"W4CH:;W1M>U+4/#5@HLC!E?JXB(*R0DY=G71
M:HRE6WI#,1.39GZ%^I;//6<C&)]S7)V#HV*-0.UXY*0WA*DGFI8<*F%5\[&J
M);L>-A>56SK0X;H;R"@J`74W&H[$77FJFYVW%M7Q5JXN%R-[(TWQM!<R#N3[
MG"(89=XE?197Y1,DV;+<1BNB3>(*+H9BBW-M<58)#ZT9]V(\^A.6\JV#-]PX
MF^I'/RAH$`'CMTZ_J':*'#$O!B56^(E?!*E*E!$<:4.UBZHT8ZQMYU")CM!G
MX,WNHDY)<G6O'1^CHO+1.Z1BBOUA9%2O;<^;DC=%'%@=3CVC=AOZ4*VT"V-1
M[\7^9*")\V<T4!IJ4C.N3^I#1T;Q,F`,W`AW4]20SKJ"KDY=09-AV">M,HU`
MHZ$R=$;,^8_J.I,_[J$B@U.U%+_)Q\20G,,=%FCG7:G;[T=->!WU*MM14W@4
MDJ;(BM]";,I;>]Z&#&#J>ZS$]QA9WX/+2H*(#GC,.B*+S1'-G;"H5^6CZT$4
MYXN`\4#@A05R',WTK0F_B891T.B/%2]31\V+:`VB!:2CQLL5?99/`YEW#QA$
M1DS;%X5U)-_RA8((BAH4O\C)P`U%>,;>[H4>%]87W#3X/:,ONY.6V,*U)+UO
MU!5XKYD>CRRE*>>?7G<R=[=@!/&3J-`E4^JXG`MD++Z'^=9<`P$3LF]P10J6
MVT%@H(7-I]K;U0VXDK*7P(XOZH+Y^&1]68''I?4)/,[FQGR*>L$:T_7L\VP]
M,U>4%^Q*T$3EM7)1CKB,4'(<0O2'B-\:O2FB`8-SM?>JJ7EIR0V5`JKS/J>!
MO%<^52(C=>6C@HX0KWR*B&#SIG:")@,W;:Y\*G#I:S0;\)+U#WSE[C>T,0T_
M/_CEF*B->U(;SDNA`FC92&6D@(<1&JE1\4^O3&>QN=KIG>Q,J>.#+I"Q."/>
M2R$2`9.Y%%)1P4B70E6T<-:(V@=%#;AJ<RE$@"^W%)K-/YNKM8BE4%$FV'@P
MZLAV5-RSX)KP6Z,W133ZD\Y5QGCEO+3DADH!U7F?YBFD#"(C=2FD@HX0+X6*
MB&#SIG::#@,W;2Z%*G!=+H7BQ4^VAI5P/<F&)M+S"BKPR%*;<O[IM><L&+_*
M;3<"IM1Q.A?(6+P/[[4/B8#)7/NHJ&"D:Y\J6KCIJ-J5KQIPU>;:AP!?;NUC
M+<RET7CM,_,V_IN#NJO<P7F$+F_2J1IK017JC(!G'NM/ALJO0W)P)5C]RSFQ
M/8]^3)I<&6$8N"_'$%>)#GVPL`/J<C3%WVQ\E9*6ZVUR_AC65^7W8`L`DTO;
M-R=X\1N8P/SD6.SV\`=*L8)O`YK3=.O(VYY.U&>A\Y9:T?Z@*ZX8!#&,AN+(
MSNU)5(E):/V)XC<4J7D1;DXI`>GQ@,P!`;ILE69.X4'LT3*UN(@)DE55CGQ(
M3$P"=_U6/!*F9D9.`$P+"RE)M%'CGFE)4=8N9?A;U3D0.2?GD.DWN/`#]#V7
MSL;_ZKG_15&[:0<>!'"`O@MUE.R*N]O+$6DS+1/[RA)%Y#K+:-A1>VM5`+>B
M/1U_R'I-PUP0D;TY[[<;DP8I;;23FU"_`9"^`B9!R#+GYS8)N346QUEPN\1>
M3^WM`"'\2EKAB<"N9TQ!@^:]'*$9WVQWC_9$=GZ`>@JOG,TQ2#H-C+K=:P@&
MRGE0QB90O68!UJ)J?NBYU+YW)/4]7%'04<N,L'#D!ISFOH63W^)NY.GT=-9L
M8?_`,S_ZP2+P-XZS/3Q"'<38"_.V)P-QF;:48)H9F,:<)Y:"EI`V5#VAB9$C
MT=K+!DM/AN$2*K\D(W'>^J]QO>[F=SU8I4E,;;RK4*1\,3Q*2OUAW`9![4WF
M!EP1:!2/`GCL"/7'H[?%_?O@-._.)N3>A2+!MO:-S7^.D`1$^.X$X8\%9"4T
MO*T)?WU'C]Q-1A-QI\_D./AH$PN_EWI$0&,XZ*H=?U+S(LL+D0)*_4_H@W@(
M2,;`@`^-NL'[T:>!PC5$K-=14$7*?4T]D;@-P<^B)BD[DKT+!31]`6F^HOK&
MT)V\QX]C'7$XZ<CJ%2ZTUD[PEEE](6D1ETI+!(&S8I!Q6:H2A<.'@_YUQ%LD
M;$AW%N58"OT$?OPVA,]GMPE$RKXDU]"V\!,XA*+Q2=%GM9/$:5EIRQ%4P]+Q
M4U%O5N0'#JDNN-DM,X_VA"Z[QIGZD%00NB][Y\%Y@0'#0!-W!E\Q<4/9I^'H
M)/`5@X;:4.T;JO7@A9OV.@3ZV583R#P#T$/\959([E6K,IO+KZH:A.M4J)VG
M00)?2@X5`9`+\=UDQ-?S0^K]T<R$IRJ_P<K>.]8.Q?_A#_C1!5YDJY^?GS23
M\E<DU"5CAYKBG7:)>9!IEJN`7(AWVK0@`.AA%'!$CPN3<^'FNF4YKS3>)6.Q
M[>E>NZ0G7$@WY=5X+D3>S?3IV&0[#J!]EM^3DNFW^)HSRI=)'D^:<+(KQASY
M#[@:0$?84%P&XJY5E,W*3PFJ>2D2_;,1PV[W>@+M`N0RS7E^^@N)Q@^`^`G.
MXBG<6DL4STK+?#8"6XXK%=`$NW0K7(3B0E+Q7@;`>QDHF`;O365VZ6P<]ST\
M6)ZQV?A'+[1VJU<;`D]<PN&NU]-Z??)^+G34^4DL$R=%@DQ`"'V<OMJ7<!@Y
MDFF7R6&E6H#&@60@L#P0#\6-6_#@4TC>(-"@D25M_-.HA9;+?:>CI(VC#Z;X
MD2<K3^2ZL?4W1[3+;"-&!>M("I!-2^[DJ,GHI]&2RBBHGE!T6#W^F;Q'RI+T
MF(D"G'Y2"+ABM6.%P.=#6"%<'FYCCTZY%G80_HCWHX=R3H4N9^:I&74\%:O!
MQ:AA5_'BP`3HY<9&11`N5@/Q0P`_U?!PJ/0["U_`MB"[-2;\8A2V'U<LO0G^
M%HQS,1(=F^A7?P_?)["WWQJ:7;1G^<D.T3V6'X:WG?K[O;-!GP/Y`KA>#B]R
M.;2!-A;7`:L!,GZ2W_R5%&D&-=7N2/$^C!RXD^D5V"!>>`U$Y`8D9/"N?4H(
M-]_FD3S&0QB%NY[KT\]*ST5+%9ECQ>N6\F!/NM]C!'JYUQL?)Z_2/5^7ESHF
M1WR?G/#5WYXE.@Z&`B]JDL+@JVD4W):I53F)8;=_/;$A"2NR'5H-G@+OE299
M@&@0/S]5+RI2G)(RBE'K;\I)1,W5U6XPS,!-*]ZD'E>)\T@]!JX'X$%,-IV&
M+)WW./_:VIV=4&J=CL!2(V73-E,`"F82@2\=,APK?J&E!KEH.U\]O9[^&<EI
M@Q2,^F\JYFY*6Q*:OX)2.@;OMZB]`J_%3B"F/"Z9U.%(KUDE5TJ:IF'@3;![
M^^#`!<(;2HW#IX5WP\E0W.94\9S-)):4CT1:2Y[OC@=JIRI7XA9M3*LFC[93
M;U_07T'VSUSE44C<VX(\YB+:XN>C8\.AVL>T=="EQ*HU(/053@Z.I'/#+ITA
MM.W(`%L[U,;B<>__GBEJ/='$;5I4S=Q04JEX.LEKU2A<U%[M1'@B_,+M*0$(
M?6K-'\SYRGP`\%\KZVGV8*SA?ZS6\/\^F?/U"EB/(-,<A;5<.M80E+#@;%$[
MMY[`MO?9J9H*;R7H5%JSC_7'BM]'*H(K7A9S<\9&,_J1AS")\=Z"A2GOJK./
MX2KM:M_;+,0KQRD7S*ROTDPGU(#=#^!:9N<$J'[=QC_0;IU*KK2J>BGKGZ2@
M[5D*L*2Y45&XL;H;Q9+?`KE]8"Z5+9>CBP+:=C("6R`TY@`.Y65HLS\\P7]%
M/Y[_EO#NANBEX?<!M(X&;L&#>]CL_<,Q<.!_K&8?YK/'V=28KX$QG5K/<]S$
M;@$CN^G,7)6^>OB&WISM'5R\1.]]Y<(7L7,WJ`Q5E$<*7\;"W[N;G+8[WT/'
MVSK;O]3;TSRIM&],7Q-WU[%\WF:&BX:?Q,%7C,%.3%TC08A>="Q9#T&OT0+V
M54R55JRA(MS#I_Y]IW7&'7'"3`:B8;#*RN@IC"4C,((N66EYI^)#^"J*`HR>
M>1BD3X/D<?`;&@#P",%:(&9AIJ`6Y!=S9`10%P[%ZYY3<B)G`4B%J<XI\(O*
MM,YE5&9\6)IX.PU\F:T_@H>[^9UQ!^YGUB?S`0)Z`BOKZ7D]L^8K\+1^N"..
MTHRO@8.W^+ZXX>N#9]^[/OP[?"/[E;\_(H$Y/(5;YG"M)"'#\+9_\UTO_`S_
M`_)W%O,4W:+FH_"48)II?F/.$PM`2P@+J]HND94ET=Z1$9=>I)SENLD<.Y;`
M2^U$:K&&HX%T/2K`(42%B/BMT9XB&MW!0.TT;VI>6M*74D!Z:3YJUMFQAY4,
M`B,DLE1807(!)LTW1.9.[;-^!FZD!)KTN"B="L<=P>YE[#FU/GV:K?%9+G%<
M.?7?WMRB;&R*X#%#`U\0P=&YXZ'8/,67!E`]@>D-5%":*75#KA.]IB.#A4[M
M4E1L#(EV@4RH](Q&,4>#1#.G9F4P[HKKWT.'18)^5/!-I2"9+9K^2.U]=29^
ME%"/"U!Z9E!\\38SC$^DR"A$0J+%*U">7-1(20?;/;53[!DYDA(]LF'+>AF.
MX6$_=V"\MJ9__V@]/9C+U5^!^8_GV?J?Y*?$*`4G*G)Q*"JA3!$NYDFA*PJ9
M5-&>.`=8/3>'M"\*OL[RP,K'82E1^U(N(0?"#\V(8.A8#\"%(C1+=\U-6N@T
M.^.1N,T^8APBA)R,W6J!+Z(Q&FMJ>R-:5MI1@5(\>O;YOR;7T-$0/N$;@[2(
MR^U54CF*LX*):&![IO9..#TS<HZ3:6$5^PR.Y\BYO;QHPGLCNJ_Q:6'.5P;:
M1:0+V&HNHU$$;2DX:Y<E&%=%FZ*,:YR1C:]&)==+,]M?`L^YFF%KIO*\WTMB
M!AK2Q7*K]CX()PY%>U0^,/4R?6:..XEQW6=Q93R0-A!X,ZLA.DDZ2?QJJ+6R
MA/)$4_SHF@^#RNAD%4H]XV_]W=E5\U,M6DSI!F2OI)\J)[!'Q=SD4TBL_'.H
M;BZN;DH9&7)-[<Q-7BQ*B<$Y@2UUK!R#\UXN./]H+==@;2X_P8GG?P</YL):
MS2A.W4\]?^]M[]\/SKM_<!N<O\<$C,/!"8M.,P?#@3A'7SUW0VM`R=A)UVO&
M8=E1>TN5E`7AKI8,AUZF$LSQ+;[5=SEMQM`/M+ZX;@35DS<3:FK&$JFN&]@?
M*%[7G8P!T1)-A$+'3X'H,3Y[H:3?74A0IX)`YT*RFH'8M*B]7"+D0$I`18:E
MU%!S/'G.Q4N/QFP)/AM/SR9QA/1HN\%G>W]TF*.B$X442G;?36"USZJ9FZD:
M'4^)GE6.PG*A]DXA$7[1;H,$A)X*.G/<4S1/QIAV.SUQ!14KY^8ON55L5<EN
M9B-GW%.[:BT)_#8D]P*#CIX!^*&,Y6ZRQT7XO84$.^V+<2[4J1Z'S$=7[;TE
M,@:D!#I$4#*FF%MDT^F,T.9/4FP/W[B@JZGWR\(.X,A7)T0W=W\ECH:F/@QZ
M/'R6ZQW\O;M%6V0G((=,V;^S"9ACI^)K,-;O'OQJK^[[PH%?R`OMK\[=J-,3
M=YN#&$8SI6[`;?7MK"(2W<G@&J]FE;,BVGU1XBF]NW@#3F-`.HC'Q<4J29%X
M;U$!O2"\M5A`8A09;K6O-C%P(\4CTN/2\45Y\"VZ*0]<U$H##@/0N5!6Z#QY
M8VL7;3X8&X@F@-YKI&EC\4N5RVDYQ7?UW.1"N]R07F=X)4%="71I*Y/B^;.K
M$G^7;,8FS_`64[%+$=EB6KX"R0W!)D'M-.MZ\')7'F4P]+GOW6Y@+`Y?X64#
M(XX;K(/<@?3S_<K\QS.ZA&Y^IKK_O3J^')S_'*$?,+\UN@1^22A3,*<KL`)X
MR:P-\[B)>3EE;9>-P&5#1XH7=JX%+]H1U"+0+R6<_;[.Q539D[])1V#CA;)Y
M^8IJ%3MEPIH9TQOVU3YQJ\4N6U0O`>CI`R!ZHLG]F?JO*^:^3&O"FK\/4SX&
MVP:U5XP$Z*5$+O4X<A:6)%Y)?H+_@[)CX2__#U!+`P04````"`"U@H1`6FR;
MH&$:``"3>@$`%0`<`&]R;7`M,C`Q,C`R,CE?<')E+GAM;%54"0`#5:U\3U6M
M?$]U>`L``00E#@``!#D!``#M75N7XCB2?M]S]C]X<Q]FYB$I#)A+GZZ=)8&L
M8CL+Z(3JVGG:XP0!GC(V;9NLS/[U&Y(O&/!%LBW?>L[ITY474HKX(A0*A2)"
M/__][:`*K\@P%5W[>"<VFG<"TM;Z1M%V'^^^+N^'R]%T>B>8EJQM9%77T,<[
M3;_[^W_]^[_]_!_W]XOV_SX\/]W?.]\ZXPB=!@PD>#_>6];QIP\??OSXT3BV
MWUX,M;'6#]YOCX:^.:W11H`_;#7%UGVS`_\)_RVT?FKWA,47^X.JHGW_"?_O
M13:1`$1KYD^Z<3A^O/.-KAOR`6WPZ!_P2,U6:W#G?!9/N[&\3Q,J=&,'GVM*
M'^Q?>A_%TUR,^Z--/BL.!H,/Y+?N1V\^Z1^W_<&E]PXX$`2;!T-7T3/:"OC?
MK\_3,/KQKS^,]?7I@#1KJ&TFFJ58[U-M"TS+%H`,))#Q]@;:?KS#4-R[/#?>
MS,U_DI]L9*2X'[3>CR`\4SD<570G?$A(TDC7-D@ST0:^,'55V<@6VCS(JJRM
MT7*/D&52$;9>OYAY$[:0#<!RCRQE+:O45!YS('-IP?^QH,WY=GY$!A$P+9"F
MSHE"/U6CO:SMD#G5EI:^_K[7U0TL]<GO)]!).C+--2R#?)$<R>;^4=5_4`.Y
MWF9+X5+9:<H6M`U6\'JMGV`):[L%D+I6$!U1IIRQ^@UW!B+X?%.L_5B3'Q0=
M?H\7Q%)73T3MGJP-%6WRC^R7\.&@6$1Z="*#SV<LL63:;5KH=PZ$/,A$NP]'
M4'-ZFV^^K#.V",N];E@K9!P>9.W[&!UU4Z&4D&F];+*EY5%6C-]D]82HYM_*
MKW)15B?!=@,6Z"@;&0OO]&*BWT]`RN25>F69)_0:3\;10"8,253S"7[@_H%B
MJ?`7S:8HW`NN"^/_$EQ)P?9GA`"'!E.=VBNRB49O%@)Q;6S_RR5;U=?.IU3Y
M!:D?[^`'_Q<UZ/#%M`QY;37:;5'L-L16HT>#(M68EP0#);*E&R[,5!2OX"\;
MHC20>@&4^=U=$ZT;._WUPP8IV#T6\1>8:O&^*=ZW14(W_.AB8"KR_'HP-%Q2
MMX9^2(6MI<<PJAM@I\FA!4XM1T/1#1@;%.]..)E`K7[$$YS7GFRL;W3KTE]W
M/O'A2);N_7JOJ%?F"SZ!IT);9!AH\V1+(W0\,I@%>PDBGZ02ZQ!8W6!V'U5Y
M!^SV^X.,Y'HQ<AD$&\ZJ(]E6K23KHK5`P!``MAG#KH$5NAED4]*LW(L9RB#I
M>-8=B;=K)7$;JF>T4S!"FC6#C0QSW6YE)/"@"<H@[UC&'7%W:BCN$<QOR.H4
M'(^W7]`[8;N=J;RO9BB/P*-8=R0NU4KBHY.!)W]43/#Q_X%DPV_:FAD)/6R2
M,LB="@!']-U:B=X%SF;=WM@>X6<F<5&S6O"ALY1!^'00.-+OU5CZ6/'/C&>U
MN8?,43[)![/OR+U?*[G;8#TJ*C)&8.9VNF'O<EG9^H#QRR#O.+8=60]J*&L<
ME-;M:X_E'J@QYR>+W(8JVHY@D%78)7ZZ\F@"-2ANB*99-<WX^4-@B),A^MD2
M[@4O,`Q?C^:S\62VG(SQ5\OYTW0\7,$W#\.GX6PT$9:?)Y/5DCH(2G\/RQP*
M]8B>;Q\5#0948'/',7^_AK2:<6&IK6R^$)A/YOU.EH^V\B/5,MV?7*\"Y\=4
M!"2/FPY-$]`Y,R*)<<8[.2>7<V6R?A-)QXNXA?)>RUCJDR*_*"I`@TPP=[>7
M>QX08C/68T^N!+14%*\>2?"J9:C6!X1SPO58[_3C-OQ,-.5JVA3FSLX\,!?R
MN_RB(I`K_,0X`6XWDS7$=G\0=WI)80SI*<ED*3`(T;./"<&JN_4,P4^4JK(*
M`N37;?9;>3*1DTZ?V0FPZD&\5^3F1;=DE2$^<T(K_1FIV"M>R,;ENAV(_'S7
M\(F+LFF44'@F3"JU&C!>IE_:\[FU1X;??G?RVNS\,Y=D<PL%P_/H*JH)#-`Q
MG@K"+6H`^'7W"6:ZMKYB7FSU<G&.;Z=.[QF\/^K&5VV-#$M6M)7\YAZ:?)/!
M*A&[_!FDH"1K$T(CRVOE9P6LEAN,+V49;,E()RG>2,,)WL!\M\7/T8B8.6OM
M2&@E:;&IB`/*IAA1@`TXJ@7G\%)ZK:`#II;Y0<S@<3^:IH]')F*TT6]V\PD@
M!$Y?S$J(/)C'PU21_*G08WJN7GFT/U-+3V2!-%Q["]B1@QUX8Y:!+,4@EP%C
MM%4TM'E`&GQA+519,P/1PA&!V'SSY`LS$QJ+]'VS![GNIT2P81*_*(MOHI*X
M-R&L>SYNG4R.?9M\'0'!5?*<+]237`O$B3XN+>#R"CV"Z5JN:%S5B`]Q\`]>
M":^R2HYUUD@VC'<XUI&2S(;4&?#+I:`B(4-5B-5K[YS+BDTM-<2M"[X`#[:Z
M#D=K$#AG$2H0SWPMTR2^R,9W9.'+A"4"Y^;BBK'?X9A2$S%Q$>*GQ*&6@:YG
M!.@H:PMMZ.R@V!2;_&+HC-04H2QI`*ME6,R]EWQ&:P0@P"J:(<M=/IU^B_\E
M;=#,1:@&+1(5B04Q!C`,=)25S>0-MSM!+M>#3EOB%X\(FK((P<?R7L\2NA-Z
M!,1(*"4X045J#OA)/W;Z0CQ)%DQJ65KGL.Y:0--G`D6IU8WKE9!<'\(G+D(1
M*&&H995=-%1\+HV21Y;B66B(8K/#,=DT[_/O[556!+L5J0UDRR_U%<`YX9T^
MR(1GKH=_MHPJ1>@S%/PI'6%LUS*J!1[YZ7`BV["=+ZD?8+X]O@9Z15-MK1_0
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MJ(A92!*SO`&)9\`OJRAE0Q3;`XZ[,'^3%!:0O.2L(L<#MNW(N3IT,I-'N@E<
M#SH=?FT\`B;,V<I$,ES5ZN7T#<?:21J."7]=#)\GL]7GR6HZ&C[]S>4L@P9D
M@0]@_*L;6>A%`N`U-\AL&Q)<7R"#--<#SCH2Q[S:>`HR.C&GZ$S%"E,M+R-N
MNBX.3]8>./L#UJ74;_7S4)'KB4NE&E&HU/+0<</[U#1/-M]\*\\#)BVA)MRB
M4<NC1V0W5JD?VYPX0U7(NEMMMOH0@DM%S@4<7,8.G<NX7,$_7\!+7`KS1V&^
MF#P/5U/X0#IG,?K52V9'T;Y8]@;UM&/`,=T\9,[D[N`SR`MT`Z>%C]$K4G42
M/W'R0N$TV^)831,Y=R:KF59$OE1Y2C1JZ>^12.IJ+VLK=#C"DC+>IP<X^AH8
M!)Q`@=]C]2*O"]W`/#ZCM;[3L/,SU=Q;4QQ^$Z5>BU^"4H:4%J)HO)"NI=/Y
M"6E@K%7<''5S4#3RQ).EO")W7?8Z''-98B8O1'L8`*FE_QF#5V=0B:W7<4&T
MW3E#K='O=UO\6`B8,0_]/3/CF;\8UDON(`]LK=70#KN5*];KW&BPNM507N?2
M5;^49*,_L).C^+`1,FLN2MP-W,-C("AY@LVE(C,ZBG[6W9T'>.=7A!TV:W$>
M7`P$M2RB^R0K&C;8<\WGHD[>UNH)ASFB'%O\7%?/?I&3CWE(05HQ)B0S+$M>
MF)?4SIS=`URC:'?T/&%DO.C-`]KJAI/COY+?$*`'F`,<BH;Q`D&07#'X2Z!`
M)48:]!V@;HB=YJ#/VUWD0GHQ/EMNLBAY_58&SA^`X^P63N\V8+W;Y'>=%C)K
M(?LF#0*5?<0M^GD_)V;CWA\_R*:RQI%&13V!)H%![XC\LFAB9B]$%U@0<76B
M7J&M&;+\1^!NJ\EO1[J8JY@]))Q=5[QE#:BGLOK?D++;PY\-7V&KW*'9Z?""
MC/GV2MWM*\.O)H[OX@K&DPW\?(O!\I).VE)?#*KXU(T#D7RKV6H-B-SQ3[*<
MNA`3P0LZ5]_J%1C-\%IA^"HK*FX$`3Z=*?L;C9$+!WX;52X\5/W2AU(Z56W6
MD3[10`I--+C,+1A]'LX^39;"=`:_F(]^^3Q_&D^>EW\1)K]^G:[^P9YPX$\R
M&(&L=UBJ<36!R=)3HTL"R=;*)<Q"14+RT+(W_`HK>*/5L>L5^;)"YLHZ@XA%
M0.>2S3#NBTHY8!$9+$5$#OHXG5[D+S9OOFQ%%Z)Y-S(*9+>H.W@6.=G:B%TE
M72-E=&^*V6BW^CD8C:"IBY%>'`C57'!BF59<"/$15>F<J.=4DT\A!:I:_`*U
MC<U7.R*@##LYAL7242(<)[XE-!EH*U52+Q\V\LMVCA(,4W:SZ$M"*WFHSE;E
MB<9P'Q6!%Y\;S4S-+A':"-?+J:I3R]1HMT7[1=YK^D/B24&#\%;%VWO3>%9*
MGO>6]$(T`J72&](KH=G?8JFU@NI%Z/3/_I:W`MZ^*1C+BJ=_8BGU+T5G*+O&
M:7PRP.POB`FUJR)/QGHOFVB^]1IP\'SNFH64_-4C*4Z>UG3KKS7VH@F$@U_K
M$B9:RJ(W%$AYBM.KO^*0933?PKSP([L=`[:\09M@V"9".W!9-""&94_Z_?I+
MWSEZW&`1="'%)OZ`D<LB_SBF/048U%\!R%J8H1_D-_AA;[%9C)OAT5`6+8E`
MIN0%%1PLQ`4.(N?WSV.)*(N*1&%3\EJ%[(W($AFORMHYN`79D`3N@SMF600>
MSF@MBQ,BU?X"AJ`S1A)_H6P"CV"UY$4"_!;X,TZN@/D)&@S)<RQCET7^\8Q7
M-2DH_<*_@".H9#R-`2B;(E"P7O)*BZ3/&ZR1<K3,N>:\;CC?.FVZM,TWV3!D
MS3D\!=5;A"@`S9BYRYV9T;+G6"=][.2?)R=G<J6'/.]!,B])2VA^U:G4=.2N
M*,D0JF<13M2N.=*U5QB-)([;7UO*RV5N+1R7B@DVQ-)6EFTG`9+U+.V)W):I
M`&KGKFJ4Q)5%UY)@6<_"#QH3[Y;8X:9X!UQ[241#H)T3IL%)_/VDF(KEGA]L
ME)T2!/R)ABB)37[='7/BHI0;<-;2<?6\7B'?G)#$72-/JN5ZT($-34.."OE3
M6%=U#A."J]GU"E33@.K;W<;HQ?JF6/OSYO>(9.M$NI+W.#8@S8K,4BHM,[ZN
M*M8KB![P?*KW=*K4[W!M^QXV<>[Z0@F"JP'U"JJ?%TOH6IGB*FM<E>JT<,$6
MFB$%AWV&`BU&(A!<S:A7=#7L?>7P@N0SC.[Z<4J;AY9E*"\G"__52K<?;X&C
MVJ#+N6TP/^IS5]$\I>'J<[WNC8([DG!1ONS[K["H2BBC;K5.#>.\8=5V_$)J
M^=88!L?)(KAV95WR&Z`$E5ETQ6E<:K0*K=*[*8VB!J(:K>(3U9M>%7:/]8.L
M:+BRFU\CB<`ILY4^7<V^UULM#H,25[?[=/@+P@V?&BU1ZG"3W<UTF<B-4@D#
MUNTMSR665<C)R.$!V.77!21RZB)D2(U%B5N$A!TI'"8Z/3N=D%][]]"YBY`H
M/1I%%1Q39419P"3:N/W#SOK8XB;*X#F+$&$\]]YJS+EZ)JM>9]TDCZJ-ALO/
MPN/3_%N&CZJ-9'/_J.H_4KVI9B#91&-D_SO5O*="'&/J==!J=_O\^B[0TT&E
MTI2\.B]-CQT'V>F0/-0VQ`PY99]2=Q#8L($7XS1$9;*NT\C>UUTZ+:8E[\.3
MHI7^%3+/"-!4UC`*6;>ZX<$]7%O*JYLZT^Q(>:H;#54E5C=V4$M^#L].W^+@
MY=7ZO@!#[B1DFPOYG?2BDWJ!92>\6+R:OJ#E$M3ZGQZGDC?P2?QPW36(SC-"
MZY-AD`B?_**H;B/?=H=?W2H+*>55($KX:EG^/$,6WF,6AOZJ@'?]\&[W/W>>
MK?9O..>NLRV.=HB=GN0F%R99([0A3]'@O&#<B6EN+&45S;?.Q<=`"JSPR8;7
M^/DS63-9B-A=/&R0E=P+SLK\+G!0![#7-@L=`$268MB]FU]496>_:@3>6HMC
MAXE$-)77(+,"ZFWS4HWT+&39VMW]0Y<MQ^<_V0E*89KE=S?+<@UFQ4`P*^B5
M];Y09<T"Q<#&AKRKWACT!DU^3-,3PM-6LPG=,];)0"RYU4YZEKQ!8[G7#6N%
MC(/OP0P,!,>((!4-%5"D6.AJ&H_PNS^AE=.N7V07'#"TA&$;O=2^(2,X)5>7
M9!NX'X^KH@!PDCGVVXV8N-1*$P%2+0,Y?MYGNH6\"-9`DOBU&`B;M=2J$0;/
MOV(RER#FZOES"<H\HZ/C;<RW%U(7F\T6QV>_P^8M>EG<>F-T")6\$5\V'IB*
M_W@APY'&V3`XEGU$S5RTDL3X8N$PU;)_7PH@1:GJ]I-^KD9?LB-R13-=].HY
M\^^K<TD"8D5Z([*].^Q[BM!+S?*]0"CR*Q./FCGS!1*08N%7%'ZW0.ST9%L1
M0"76F(5!"5[)(XN9[C8TD/0KI$]AO`?4`_)B*^/"QRP$%UT8V:^*RK\BXT5/
MW&@$MUN!;5%%%RBL=%9TV[U>3CU',J*X:#6,[D_"02RUC-..$0R_5HB`&IU!
MAU_HS3]3)KJ3SS)TM2L,J&K8N/RV]5S/4[SV=<JYX/S3:Y:!Z:)M,?4A,@[$
MBEQUL!TB4UQ'YWGH2IO+DNNABQ*\6N[9_O@FSC[\@MNJ`5]#;3/2516M+=+)
ME>0I6%=Y"J(D]ODEL*:@K.C$C\@H<AJ4*V+2TN:!7I;M-'K=7KNXHJ>BE8F]
MSND"L))?[":]ODH!:*X.%I>D3OJY<%1]4`:FBUY%U%YE'(@EOPZ.]2IS]:PH
MKUQKN:U1`<EG6?*Y[\%#88<%_L'YSJ_@Q^!B0=(2ZGI+PI';-C\&64C)[[QQ
M:V,20U;R79OC!2B?KG!YKH@AF$+#>`>K1UY?:4B=`<]^=S0TY+@&;EMI,8-4
MC2TV42\\.@PKE`3`*%T^C<I+M@1NNY<S@U2-=+($G4%Q=3C`</:RM8WG)))F
MFAZ<':G%[P*)FHPBHY5)H*I(YA1CD-))TWW4#7\DC;0;"#RO#22.Y9N,U!1]
M\@VO0DL"IQ<$+V>%<!;9T/XB_"_(VF-7W5><YS1PSB7F'4I&T4H5&^&F`M!3
MIIY41F5*^%K'`;?P_T.V0_HX3WRLF*1T;V&@@W(Z-*16GU\'@]CI*Y@OP01I
M+:_IN.+-9YLL+$\L$$#8ZY"RTT:D,]'Z?67(FBF3:[=/LJ)A8A[P\QP(/R@D
MMKHBQPLG!E+*OU9OO8O$2)<\"IS4M0A^>Z_1'73YW9T'SUE^;;I]0B,6O(I$
M2AFOQ-V.4%O2@M[WA#RL+N>%1G-NC%19.9B-SD#B5ZW'1$H%-2PQU-6(4I;)
MSY#$^OL9[AXWUWQGGLG;6CWA)U_($7NUE[45.AQU0S;>IX>CK!ANID^OW>('
M5`K2RK^NSY"Y"SLS290\%GOIEZQ*M-ZYE"^5:[E'J1$F!9D^Y7/>]G,>5?X#
M$^4^@P#T8Z5KB=QPRY#2\EN#F[(R7G*J1KB=N2KMZB55ITT_Z305="<3TH8K
M>)3R:\^MCQ@/AZ,(E7V.LV2`)VF&ZHB@7B_\DD,)/J.@C8B;:'?Y]2#W3Y7-
M_4+RN]Z+)S2#V*]EJ=Q(U^QG?TF<VVTRVA";@Q:_"X/@2<NB`!20U#+@[UYP
MS#5?,S_<I,II0K32'Y"&MLI:D57[$[C1\R/"A27VSB31;]2I)BN+IF2'6,D#
MT2F>BL_&`PY_SYSXQJTJG&'">2B_?\KS=$,I6^_<TRKS$F$_]X0&@['UL/V0
MH+!P6QKT@T+P80>C9-.47S,9HNOT@'J!]E+KVJTY3ON4I-@4A7L!;VNJ;L(>
MA=^5G'Z:31^GH^%L)0Q'H_G7V6HZ^R0LYD_3T71"_W;D4H&E#ULA[EYOMY4&
MN2YT%3;':P/(\%SD[5#G7;LC\DOF#)\W>6`O$J$5@/(`G_H.?FB_R8\Q.B*R
M,0L,LO,.9^P85?78EGHMB\WKM3S\]#PA#\`*WZ:KS\*X,6L,&\+#=/YE,H85
M_B0LYT]?5]/Y;"D\K<8-ZK4]W!F()!M_4ZS]6),?%##K&Y"2NM15<HXRGZQ-
MXD4>DM8'EOU_=$6S?H-O@+\+[>%W=F4D)KDY")GH+-"SNG=[4NX,!]"1B55(
M+6S75"3#[T]K+9JM:VLQFG_Y,EV1]Z*I+<%(/QR4H'QAAN7N&X,TJR`V'FG8
MPI_I.\N_S;&+*1,I*2J::*8YJZO4MUL4%L=RMDL^I<#/<;ND*/YY%WWGQMU?
MS4>_?)X_C2?/R[\(DU^_3E?_H/?Q\8%KKZN`IAGT""*#$;@="L?5?!5,;7Y+
M('KN%`Y^X+A!N@G^:X_?CDY-1T:5:&R2O+B'84;K3[N4Q9O]FRQEX6&XG(SQ
M7KZ8S)9#[-RS+>>8E%Z&)7TF;K[U#^@$RT>Z:9DD^?8%3^E6C/GL/D<G-QUM
MR4T"];P/_GE]JB]*'*]G4U*7B?G(6FO\=S=9(?_G-3KM&Z/S>?Z\$E:3YR]@
M>6:_"./)8KZ<,IP@O.<)'V3M^Q@==5-)<99P!AB:)K*"G$FI&W1GF5G'X*BY
M4V8`7@_KTTQ)[/!+SH^>/)LESRBTBSLI.ES^M"NV>;-B'X?39^&WX=/7"?4:
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M7Z7"H:J&.'P-.K_!_\,A(_C)_P-02P,$%`````@`M8*$0+3;[BI^!P``>3\`
M`!$`'`!O<FUP+3(P,3(P,C(Y+GAS9%54"0`#5:U\3U6M?$]U>`L``00E#@``
M!#D!``#M6E%SXC@2?K^J^P]:7O;V`0C)S%PE-9E=8TSB6H)9[$QVG[:$+8-V
M;,DCR4GFWU]+!F*<D(7$5V09JJ8RMJ1N=W_ZU-T2^OCS?9J@6R(DY>R\T6D=
M-1!A(8\HFYXWKOVFY=NNVT!281;AA#-RWF"\\?.G?__KXP_-YNCD]^YXT&S.
M7^=ZT+L6*$++YIE2V5F[?7=WU\I.[B<B:84\7?9F@D=Y2"($@L='G>/FT3OX
MAWY!QV<G']#HJAAX+\]D.",I1@J+*5%#G!*9X1#L*:GG`IHCK;ZM51T='Y^"
M/PE)"5-]+M(>B7&>J//&UQPG-*8D:B``@,DSZ,S^7E4Q5KM`5P8;I[B8PM"C
MDS9E&JZ0+,?+E<%W)XNAG?;O5P/?N-4`)Q'2;F+&N,(*<#1-\\8LHRSF\Q9H
M2RC[<J;_3+`D8Q*C>],B>$*>L4QWMT.<A'EBOC!X4-"8:Y@)$I\W-!S-A=]_
M@D0+7%D,4=\R^(BD:9:011L6X:-OSQWMG)Z>MLVH-LQU1H2B1+87MB]!T@W/
MBR^&/AJYZN2#YG8M>$4DIHQN`1<(?,=P)7A"D@V1@K'?,5*9(!("TS8K$43V
M`C!M80#&(_UP/7;7A5Z#DS45Q(3P&ZIF/8:[E$,_A:CD\R37Z,F!@DA.HSE<
M^&XBMS5Q:>#"Q(=E_ZG3@6R&>E2&"9>Y(/!B78P=Y\H9!NC&#2Y1KS5L62W4
M=;TKI^?:U@#YWN`Z<+VACP9!K_6Q7=59_5PN2>2Q3^:Y$J'GPO,1SPFNAJK-
MY:I,W%QRN=HW%P%:$P%%!EDO-F]=L.0UY+$YBP@#]?`@>4(CK$C4Q8E.T/Z,
M$"5+Q`G#>HES='0,7/$!6,-?>+:]8<\9^DY//P%'W)X5P$O7&EA#VT'^I>,$
M_H$M;Y<M(PS6J!E1.OY4J)/5RYV3EW`'_6=DC2$N73J!CD,_';CTIKBTG$_I
MQ3:6LW["[U8CD`SC>FGT83,:^0'\IS.:C[P^LBW_$O4'WLTA&+U=`GE0PAG'
M*PSB]1+HW4L(Y(V<L64*H`.!=D>@-*7*D*5,$&BMM3HV1<Y*=6Q[5U=N8+AP
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M6^`#*W;&BAD7*B`B[6+VI4<R+NG*7EBJ250O*1[E#__2&P<H<,97P(SAKZCG
MC#S?/6R,=QPJUFU-I")?Z\TA[YX,$X=]QUMA0SZ1Y&L.WCFWE9,RF9/;>KGP
M_A$7KKL^,$#_D.Q\/IR7U42$C^W*G:FB8?5FE;Y71=,,$@1B3]XF6W>KJ[B(
M-N"AT?6,B'YK+N2:NJG9.6Z>=%KW,EK<B=C2BB7/MK1B(?<2*V(L)T9=+IM3
MC#-](:[3/.J`CK5F&!.>%&R31,E%2_-!U<M`B91HZULP;0:;=D'#S7"I2FE4
M3C4JG0^O-8.SY@M-X6SX<FO*4&MULJ9),KI>,DME#KXW;Y':F+0+`8W$^^T^
M*4G8FO+;=D3HQA!49?3#JYFI)['(,(Q,]='[9MXG0JQ(K2.#3E!G\ZNMQI3S
MAA7]E<OBYYZ`6U%DPCM.1IA&+K-Q1A5._!D6Y-$VR51$7F9^2AQ#,J10)A.?
MB%L:DA%0DD=C$O)ID3#TSPEY`C&MG"O_W,7'&4T@J^B[;DKH8R%S,?=L4ES7
M.&^$@H`9B^;,J`K,C;DH%_/MH83LKZ@RM\@N!,^S\T8Q'&Q(&ZBX8%>TI)P1
MA<4W%WJTFK57AY^^X+O1Q*V%SDVS'-C@,@494:HG@=]<>%^`TZ64/@WR-"]N
M]7U&<&K(%1F31"^>@'<)@THGI#@I1NC[Z7V"%51?)0Q?J>=OX(S(Y)^!YC,G
M\!;8)W!8)MYFPZO8X'G/*E:O1@644C:M'Y/*TG'N==@J4V?=@#WAA"MEKBWV
M8A.F8:YOL!#81/DNT;TDZG,Q#]?2$W:":5I.#"_6L"<(C@0/"8ED7_`4$AFA
MF9(>FQ]C`R@Z)\H%2&7@MA7<$[S6NEIB3@FES8;O2\(K7+.UU4E"HN*UA,::
M_J?=?WW0+2CX__:R\J-?U<EY]Y[0WP3)(BKV<IW3BA*X\-F+8Z+;;"Y7%L$V
M0O\T+CSGVB)I;`K%P_A]1&%,6`1%2+0M&@]R^X&*"0A;+I6G9/8F:3SC\N8K
MJ#+\>P)G\X6U1FQ?P+HA=#J#W8X%.V`\)<,\G1#AQ5TL:0CU5H\F>B]41)=K
MJ7=%^J`G+P[=O7C`I02<3'\)RUJUOMD09GZ"*$X`X>U_4$L!`AX#%`````@`
MM8*$0&J)8?EM0```@JX"`!$`&````````0```*2!`````&]R;7`M,C`Q,C`R
M,CDN>&UL550%``-5K7Q/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`M8*$
M0-K8L;,C#```=I<``!4`&````````0```*2!N$```&]R;7`M,C`Q,C`R,CE?
M8V%L+GAM;%54!0`#5:U\3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+6"
MA$"MW6?_^@<``*)1```5`!@```````$```"D@2I-``!O<FUP+3(P,3(P,C(Y
M7V1E9BYX;6Q55`4``U6M?$]U>`L``00E#@``!#D!``!02P$"'@,4````"`"U
M@H1`OJOB%>Y"```EN`,`%0`8```````!````I(%S50``;W)M<"TR,#$R,#(R
M.5]L86(N>&UL550%``-5K7Q/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
MM8*$0%ILFZ!A&@``DWH!`!4`&````````0```*2!L)@``&]R;7`M,C`Q,C`R
M,CE?<')E+GAM;%54!0`#5:U\3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`+6"A$"TV^XJ?@<``'D_```1`!@```````$```"D@6"S``!O<FUP+3(P,3(P
M,C(Y+GAS9%54!0`#5:U\3W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"
(```INP``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> <!--StartFragment--> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> NOTE 3 - FAIR VALUE:</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</div> </td> </tr> </table> </div> <div>&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> &middot;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> &middot;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; font-family: Symbol, serif; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> &middot;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="text-align: left"> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify; TEXT-INDENT: 0pt"> Marketable securities consist wholly of equity securities of D.N.A Biomedical Solutions Ltd. which were received in March 2011 as part of the consideration for selling the Company&#39;s equity method investee Entera. Those securities are classified as available-for-sale and are recorded at fair value.&nbsp;&nbsp;The D.N.A Shares are listed on the Tel Aviv Stock Exchange ("TASE") and their tradability was restricted for a period of 6 months from the closing date of the transaction according to TASE policy with regards to private placements. Until September 30, 2011, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market. As of October 1, 2011, the securities are not restricted and the fair value of the securities is measured based on the quoted prices of the securities on an active market.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> Transfers in and/or out of Level 3 are recognized in the beginning of the reporting period.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Financial items carried at fair value as of February 29, 2012 and August&nbsp;31, 2011 are classified in the tables below in one of the three categories described above:</div> </td> </tr> </table> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"> &nbsp;</div> <div style="text-align: right"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="90%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="46%" colspan="14"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Fair value measurements at&nbsp;reporting</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> date using</div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Level 1</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Level 2</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Level 3</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Total</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr bgcolor="#cceeff"> <td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> Marketable securities:</div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="10%" colspan="2"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> </tr> <tr bgcolor="white"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> February 29, 2012</div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">341,454</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">-</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">-</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">341,454</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> </tr> <tr bgcolor="#cceeff"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="52%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> August 31, 2011</div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">-</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">-</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">384,565</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%">384,565</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="text-align: center"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="75%"> <tr> <td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td valign="bottom" width="13%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Six months ended</div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr> <td valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td valign="bottom" width="13%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> February 29,</div> </td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> 2012</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"> Unaudited</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> &nbsp;</font> </td> </tr> <tr bgcolor="#cceeff"> <td valign="bottom" width="85%" align="left"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"> Carrying value at the beginning of the period</div> </td> <td valign="bottom" width="1%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%">384,565</td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="85%" align="left"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"> Reclassification to level 1</div> </td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%">(384,565</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap">)</td> </tr> <tr bgcolor="#cceeff"> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="85%" align="left"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: -18pt"> Carrying value at the end of the period</div> </td> <td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%">-</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &nbsp;</font> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt; WIDTH: 100%"> &nbsp;</div> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T
M,3`W-3-F9F,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U
M-3,T,3`W-3-F9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]"04Q!3D-%,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%
M1%]#3TY33TQ)1$%4141?4U1!5$5-13PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]35$%414U%3E137T]&7T-(04Y'
M13PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/3D1%
M3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-13$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/
M3$E#244\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M3TU-251-14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9!25)?5D%,544\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%52519/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\
M+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B
M5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\
M+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\
M+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L
M<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\
M+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4
M:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E
M;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T,3`W
M-3-F9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V9C<T9CE?
M93(X,%\T9F0R7SEB9C1?-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O4VAE970P
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13%!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,#,L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD
M($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&
M;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y&96(@,CDL#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D]204U%1"!02$%2
M34%#155424-!3%,@24Y#+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`Q,3<V,S`Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R
M96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XM+3`X+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O
M8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N
M>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PS,C`L-3@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,39F-S1F.5]E
M,C@P7S1F9#)?.6)F-%\U-3,T,3`W-3-F9F,-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C$V9C<T9CE?93(X,%\T9F0R7SEB9C1?-34S-#$P-S4S
M9F9C+U=O<FMS:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]+04<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!"
M04Q!3D-%(%-(14544R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($%3
M4T544SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#@R-"PQ-#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-3$S+#,V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAO<G0@
M=&5R;2!D97!O<VET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#,X+#<S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.#`Q+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36%R:V5T86)L92!S96-U<FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#$L-#4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@T+#4V-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4@+2!O=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L-C8X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30R+#@Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L.#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PV-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E;&%T960@<&%R=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=',@<F5C96EV86)L92!F<F]M('1H
M92!#:&EE9B!38VEE;G1I<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(X+#`T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T+#$Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E0@;R!T(&$@;"!C=7)R96YT(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,#@L,C@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR.#0L
M,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,3TY'(%1%4DT@1$503U-)5%,@04Y$($E.5D535$U%3E0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-#$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3@V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!34]53E13
M($953D1%1"!)3B!215-014-4($]&($5-4$Q/645%(%))1TA44R!54$].(%)%
M5$E214U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#$P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T+#(Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4%)/4$525%D@04Y$($5154E0345.5"P@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#<Y,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#,W-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E0@;R!T(&$@
M;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,30R
M+#4X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,S(U+#DS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($Q)04))3$E42453.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,S0L.3`W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<U+#4S.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!P
M87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ."PU,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G0@<&%Y86)L92!W:71H(&9O<FUE<B!S:&%R
M96AO;&1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<L,C4R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<L,C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5"!O('0@82!L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X,BPQ-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#$L,CDR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQ/3D<@5$5232!,24%"24Q)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@<FEG:'1S('5P;VX@
M<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M.3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C(L-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R('5N8V5R=&%I;B!T87@@<&]S:71I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S."PP-30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@L
M,#4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&]N9R!T97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-C(L,#,V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P+#<R.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4345.
M5%,@*&YO=&4@,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T-"PQ-#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#(L,#(Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-43T-+2$],1$524R<@15%52519.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@;V8@)"`P
M+C`P,2!P87(@=F%L=64@+2!A=71H;W)I>F5D.B`R,#`L,#`P+#`P,"!S:&%R
M97,@870@1F5B<G5A<GD@,CDL(#(P,3(@86YD($%U9W5S="`S,2P@,C`Q,3L@
M:7-S=65D(&%N9"!O=71S=&%N9&EN9SH@-S`L,3@W+#4X,R!S:&%R97,@870@
M1F5B<G5A<GD@,CDL(#(P,3(@86YD(#<P+#$P-"PU.#,@870@075G=7-T(#,Q
M+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PQ.#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M,"PQ,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ."PS,SDL,SDY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L,C`Q+#$Q,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E=F5L;W!M96YT('-T86=E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPP,3$L,3DS*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T
M+#4T-RPR.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5"!O('0@82!L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,Y."PS.3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<R,RPY
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4(&\@="!A(&P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@
M97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,30R
M+#4X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-"PS,C4L.3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T,3`W-3-F
M9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V9C<T9CE?93(X
M,%\T9F0R7SEB9C1?-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O4VAE970P,RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P139&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].
M1$5.4T5$($-/3E-/3$E$051%1"!"04Q!3D-%(%-(14544R`H4$%214Y42$54
M24-!3"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%U9RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$
M051%1"!"04Q!3D-%(%-(14544R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R
M('9A;'5E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO
M<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L,3@W+#4X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#$P
M-"PU.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PQ.#<L-3@S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`L,3`T+#4X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C$V
M9C<T9CE?93(X,%\T9F0R7SEB9C1?-34S-#$P-S4S9F9C#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q-F8W-&8Y7V4R.#!?-&9D,E\Y8F8T7S4U
M,S0Q,#<U,V9F8R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$54
M3T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)
M1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$Q.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1F5B+B`R.2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y&96(N(#(X+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)
M1$%4140@4U1!5$5-14Y44R!/1B!/4$52051)3TX@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y215-%05)#
M2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-S$P+#8T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0Q+#,R.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#DT+#8V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C(W
M+#@Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@."PW-#8L-3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)35!!25)-14Y4($]&($E.5D535$U%3E0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S-"PX-S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=%3D52
M04P@04Y$($%$34E.25-44D%4259%($584$5.4T53/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,CDL-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`U+#@X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q,2PV,#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C$L,#$V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPT-CDL.3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3U!%4D%424Y'($Q/4U,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDT,"PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-#<L,C$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#8L,C8X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-#@L.#,R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38L-C4Q+#,W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1DE.04Y#24%,($E.0T]-13PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-RPU-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-RPX-38I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L-3(X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#`T-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,#@L
M-38P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1DE.04Y#24%,($584$5.4T53/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#0X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L-#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL,#0S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW.#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3`L,S`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'04E.
M($].(%-!3$4@3T8@24Y615-4345.5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PP,S,L,#`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24U004E2345.5"!/1B!!5D%)3$%"
M3$4M($9/4BU304Q%(%-%0U52251)15,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0S+#$Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#$Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(T,"PU,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,3U-3($)%1D]212!405A%4R!/3B!)3D-/344\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX-2PS-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#(L-SDQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-C,L
M.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR-#4L-3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34L.#8P+#8S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$%815,@3TX@24Y#3TU%/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L-34X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/
M4U,@1D]2(%1(12!015))3T0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.3@U+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-C0R+#<Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PT-C,L.#DT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(T-2PU-S4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$V+#`Q,2PQ.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)!4TE#($%.1"!$24Q55$5$($Q/4U,@4$52($-/34U/
M3B!32$%213PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y714E'2%1%1"!!5D5204=%($Y534)%4B!/
M1B!#3TU-3TX@4U1/0TL@55-%1"!)3B!#3TU0551)3D<@0D%324,@04Y$($1)
M3%54140@3$]34R!015(@0T]-34].(%-43T-+/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,"PQ-S8L-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L.#`T+#<Y.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#$T,"PV,3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,"PS-#0L.#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T,3`W-3-F9F,-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V9C<T9CE?93(X,%\T9F0R
M7SEB9C1?-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15E01$D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].1$5.4T5$
M(%-4051%345.5%,@3T8@0TA!3D=%4R!)3B!35$]#2TA/3$1%4E,G($5154E4
M62`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E1O=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$969I8VET(&%C
M8W5M=6QA=&5D(&1U<FEN9R!T:&4@9&5V96QO<&UE;G0@<W1A9V4@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3W1H97(@8V]M
M<')E:&5N<VEV92!L;W-S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%(&%T($%P<BX@,3$L(#(P,#(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3,L-S`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-"PX,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$X+#@W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0D%,04Y#12P@<VAA<F5S(&%T($%P<BX@,3$L(#(P,#(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#@R."PR,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%
M4R!#04Y#14Q,140\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y
M+#@P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.2PX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-(05)%4R!#04Y#14Q,140L('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL.#`P+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%4R!)
M4U-5140@1D]2($E.5D535$U%3E0@24X@25-422U.2CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#,T+#@W-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,S+#<S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TA!4D53
M($E34U5%1"!&3U(@24Y615-4345.5"!)3B!)4U1)+4Y*+"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30T+#0Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TA!4D53
M($E34U5%1"!&3U(@3T9&15))3D<@0T]35%,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-S4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PW-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y32$%215,@25-3545$($9/4B!/
M1D9%4DE.1R!#3U-44RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#<U,BPY-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%4R!!3D0@5T%24D%.5%,@25-3545$
M($9/4B!#05-(+2!.150@3T8@25-354%.0T4@15A014Y315,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.3`W+#<X,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#,U.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#<P+#0R
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4TA!4D53($%.1"!705)204Y44R!)4U-5140@1D]2($-!4T@M($Y%5"!/
M1B!)4U-504Y#12!%6%!%3E-%4RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-RPS-3DL,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y32$%215,@25-3545$($9/4B!3
M15)624-%4R!214Y$15)%1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#(Q+#,S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-S,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#$Y+#8P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TA!4D53($E34U5%1"!&3U(@4T52
M5DE#15,@4D5.1$52140L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW,S`L-30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#3TY44DE"551)3TY3(%1/(%!!240@24X@
M0T%0251!3#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L.3DQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y214-%25!44R!/3B!!0T-/54Y4($]&(%-(05)%4R!!3D0@5T%2
M4D%.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#8Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP
M-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-(05)%4R!)4U-5140@1D]2($-/3E9%4E-)3TX@3T8@0T].5D525$E"
M3$4@3D]413PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(W-"PT-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-(05)%4R!)4U-5140@1D]2($-/3E9%4E-)3TX@3T8@
M0T].5D525$E"3$4@3D]412P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y35$]#2R!"05-%1"!#3TU014Y3051)3TX@
M4D5,051%1"!43R!/4%1)3TY3($=204Y4140@5$\@14U03$]91453($%.1"!$
M25)%0U1/4E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-34T
M+#DR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-34T+#DR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4U1/0TL@0D%3140@0T]-4$5.4T%424].(%)%3$%4
M140@5$\@3U!424].4R!'4D%.5$5$(%1/($-/3E-53%1!3E13/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,34L.#@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$U+#@X,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1$E30T]5
M3E0@3TX@0T].5D525$E"3$4@3D]412!214Q!5$5$(%1/($)%3D5&24-)04P@
M0T].5D524TE/3B!&14%455)%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3U1(15(@0T]-4%)%2$5.4TE612!)3D-/
M344@*$Q/4U,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DE-4%54140@24Y415)%4U0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Y+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Y+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$R+#DX-BPP,S@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L.3@V+#`S."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.
M0T4@870@075G+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#,P+#(W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4W+#4V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S+#<U."PW-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPY.#8L,#,X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0D%,04Y#12P@<VAA<F5S(&%T($%U9RX@,S$L(#(P,3`\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4W+#4V-2PS,C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%4R!!3D0@5T%2
M4D%.5%,@25-3545$($9/4B!#05-(+2!.150@3T8@25-354%.0T4@15A014Y3
M15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-CDT+#(Q,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q
M+#@P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-C@R+#0P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4TA!4D53($%.1"!705)204Y44R!)4U-5140@1D]2
M($-!4T@M($Y%5"!/1B!)4U-504Y#12!%6%!%3E-%4RP@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PX,#@L-C(V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y32$%215,@
M25-3545$($9/4B!315)624-%4R!214Y$15)%1#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C(W+#4V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<S,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R-BPX,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%4R!)4U-5
M140@1D]2(%-%4E9)0T53(%)%3D1%4D5$+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<S,"PV,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-+($)!4T5$($-/35!%
M3E-!5$E/3B!214Q!5$5$(%1/($]05$E/3E,@1U)!3E1%1"!43R!%35!,3UE%
M15,@04Y$($1)4D5#5$]24SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3`R+#4Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P,BPU.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-43T-+($)!4T5$($-/35!%3E-!5$E/3B!2
M14Q!5$5$(%1/($]05$E/3E,@1U)!3E1%1"!43R!#3TY354Q404Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-S,S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-S,S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)35!5
M5$5$($E.5$5215-4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#<X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.150@3$]34SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,2PU-C$L,C0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L-38Q+#(T-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.0T4@870@075G+B`S
M,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW,C,L
M.3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S`L,3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@L,C`Q+#$Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$T+#4T-RPR.#,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,38I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%+"!S
M:&%R97,@870@075G+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S`L,3`T+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<P+#$P-"PU.#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(05)%4R!)4U-5140@
M1D]2(%-%4E9)0T53(%)%3D1%4D5$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-"PY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T+#@Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TA!4D53($E34U5%1"!&3U(@4T52
M5DE#15,@4D5.1$52140L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y32$%215,@5$\@0D4@25-3545$($9/4B!315)6
M24-%4R!214Y$15)%1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`L-#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`L-#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y35$]#2R!"05-%1"!#3TU014Y3051)3TX@4D5,051%
M1"!43R!/4%1)3TY3($=204Y4140@5$\@14U03$]91453($%.1"!$25)%0U1/
M4E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#$S-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#$S
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4U1/0TL@0D%3140@0T]-4$5.4T%424].(%)%3$%4140@5$\@3U!424].
M4R!'4D%.5$5$(%1/($-/3E-53%1!3E13/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-BPY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!,3U-3/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0V,RPX.30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT-C,L.#DT*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%,
M04Y#12!A="!&96(N(#(Y+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,SDX+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-S`L,3@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."PS,SDL,SDY/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-BPP
M,3$L,3DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0D%,04Y#12P@<VAA<F5S(&%T($9E8BX@,CDL(#(P,3(\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#$X-RPU.#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,"PQ.#<L
M-3@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V
M,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T,3`W-3-F9F,-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V9C<T9CE?93(X,%\T9F0R7SEB9C1?
M-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14I:0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/
M3$E$051%1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$Q.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B
M+B`R.2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&
M96(N(#(X+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!5$E.1R!!0U1)
M5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@Q+#0V,RPX.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q+#(T-2PU-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-BPP,3$L,3DS*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!9&IU<W1M96YT<R!R97%U:7)E9"!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW,3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,3<L.#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C;W5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AC:&%N9V4@9&EF9F5R96YC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.38S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3<P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,RPP,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,S4L-SDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PW.#,L,38U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S
M=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C0L.3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$Y+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#<R+#DY-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('1O(&)E
M(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P+#0S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#0S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!S86QE
M(&]F(&EN=F5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#,S+#`P-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE
M;G0@;V8@:6YV97-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,T+#@W-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N
M="!O9B!A=F%I;&%B;&4@9F]R('-A;&5S('-E8W5R:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#$Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T,"PU
M,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEM<'5T960@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-34Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG
M97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"PX,#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.2PQ,C0I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#<L,30P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,38L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30P+#@V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P-RPR-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,S0L.3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI='D@;V8@96UP;&]Y964@
M<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PS,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPY.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F
M;W(@=6YC97)T86EN('1A>"!P;W-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X+#`U-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#DT+#<V,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V.34L
M-#`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#DL-C,X+#<R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D53
M5$E.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$R.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0W
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,C4L-C$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-Q=6ES:71I;VX@;V8@<VAO<G0M=&5R;2!I;G9E<W1M
M96YT<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C$L
M,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PV-S<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0L-#8W+#$R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U;F1S(&EN(')E<W!E8W0@;V8@
M96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPU.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#DP*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!S86QE(&]F(&EN=F5S=&UE;G0@:6X@16YT97)A/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F(%-H;W)T('1E<FT@
M:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C(X+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@9&5P;W-I
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#<L-3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&YE="!C87-H(&1E<FEV960@
M9G)O;2`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#`U+#4S-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-C<X+#0W-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-#`L
M,3,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@1DE.04Y#24Y'($%#5$E6
M251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&%N
M9"!W87)R86YT<R`M(&YE="!O9B!I<W-U86YC92!E>'!E;G-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,#8L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$L-C4U+#8Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5C96EP=',@;VX@86-C;W5N="!O9B!S:&%R97,@:7-S
M=6%N8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV+#`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VYV97)T
M:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S
M:&]R="!T97)M(&YO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y
M;65N=',@;V8@<VAO<G0@=&5R;2!N;W1E('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R
M,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R96AO;&1E<B!A9'9A;F-E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L,C0S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,3`V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#`P,BPY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)3D-214%312!)3B!#05-(($%.1"!#05-(
M($5154E604Q%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,3`L-S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S,R+#$R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L.#(T+#$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T%32"!!3D0@0T%32"!%455)5D%,
M14Y44R!!5"!"14=)3DY)3D<@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#4Q,RPS-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Y.2PV,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,@050@14Y$($]&(%!%4DE/1#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,C0L,30Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,S$L
M-S8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PX,C0L,30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;B!C87-H(&EN=F5S=&EN9R!A;F0@
M9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R(&]F9F5R:6YG
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')I8G5T:6]N('1O('!A:60@
M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L.3DQ/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;W5N="!O;B!C;VYV
M97)T:6)L92!N;W1E(')E;&%T960@=&\@8F5N969I8VEA;"!C;VYV97)S:6]N
M(&9E871U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C$V9C<T9CE?93(X,%\T9F0R7SEB
M9C1?-34S-#$P-S4S9F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8Q-F8W-&8Y7V4R.#!?-&9D,E\Y8F8T7S4U,S0Q,#<U,V9F8R]7;W)K<VAE
M971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,CDL(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4TE'
M3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-)1TY)1DE#
M04Y4($%#0T]53E1)3D<@4$],24-)15,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14
M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM
M/@T*/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U!3$E'3CH@
M;&5F=#L@5$585"U)3D1%3E0Z(#!P="<^($Y/5$4@,2`M(%-)1TY)1DE#04Y4
M($%#0T]53E1)3D<@4$],24-)15,Z/"]D:78^(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/B`\+V1I=CX@
M/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E
M;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S
M.2XV.3EP="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F
M;F)S<#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@
M/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!4
M15A4+4E.1$5.5#H@,'!T)SX@82X\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^($=E;F5R86PZ/"]D:78^(#PO=&0^(#PO
M='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX@/"]D:78^(#QD:78^(#QT
M86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^(#QT
M<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=724142#H@-S8N-35P="<^
M(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I=B!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0G/B`Q+CPO9&EV/B`\
M+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/B!/<F%M960@4&AA<FUA8V5U=&EC86QS+"!);F,N
M("AT:&4@(D-O;7!A;GDB*2!W87,@:6YC;W)P;W)A=&5D(&]N($%P<FEL(#$R
M+"`R,#`R+"!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@4W1A=&4@;V8@3F5V861A
M+B!&<F]M(&EN8V]R<&]R871I;VX@=6YT:6P@36%R8V@@,RP@,C`P-BP@=&AE
M($-O;7!A;GD@=V%S(&%N(&5X<&QO<F%T:6]N('-T86=E(&-O;7!A;GD@96YG
M86=E9"!I;B!T:&4@86-Q=6ES:71I;VX@86YD(&5X<&QO<F%T:6]N(&]F(&UI
M;F5R86P@<')O<&5R=&EE<RX@3VX@1F5B<G5A<GD@,3<L(#(P,#8L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A;B!A9W)E96UE;G0@*'1H92`B1FER<W0@
M06=R965M96YT(BD@=VET:"!(861A<VET($UE9&EC86P@4V5R=FEC97,@86YD
M($1E=F5L;W!M96YT($QT9"`H(DAA9&%S:70B*2!T;R!A8W%U:7)E('1H92!P
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M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/D]N($UA<F-H(#$Q+"`R
M,#$Q+"!/<F%M960@=V%S(')E:6YC;W)P;W)A=&5D(&9R;VT@=&AE(%-T871E
M(&]F($YE=F%D82!T;R!T:&4@4W1A=&4@;V8@1&5L87=A<F4N/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^(#PO
M9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#$Q,G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B!/;B!-87D@,30L(#(P
M,#<L('1H92!#;VUP86YY(&EN8V]R<&]R871E9"!A('=H;VQL>2UO=VYE9"!S
M=6)S:61I87)Y(&EN($ES<F%E;"P@3W)A;65D($QT9"XL('=H:6-H(&ES(&5N
M9V%G960@:6X@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT+B!5;FQE<W,@=&AE
M(&-O;G1E>'0@:6YD:6-A=&5S(&]T:&5R=VES92P@=&AE('1E<FT@(D=R;W5P
M(B!R969E<G,@=&\@3W)A;65D(%!H87)M86-E=71I8V%L<R!);F,N(&%N9"!I
M=',@27-R865L:2!S=6)S:61I87)Y+"!/<F%M960@3'1D("AT:&4@(E-U8G-I
M9&EA<GDB*2X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#QD
M:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG
M/B9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#$Q,G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B!4:&4@
M1W)O=7`@:7,@96YG86=E9"!I;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M:6X@=&AE(&)I;W1E8VAN;VQO9WD@9FEE;&0@86YD(&ES(&-O;G-I9&5R960@
M82!D979E;&]P;65N="!S=&%G92!C;VUP86YY(&EN(&%C8V]R9&%N8V4@=VET
M:"!!8V-O=6YT:6YG(%-T86YD87)D($-O9&EF:6-A=&EO;B`H(D%30R(I($YO
M+B`Y,34L(")$979E;&]P;65N="!3=&%G92!%;G1I=&EE<R(N/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX@/"]D:78^(#QD
M:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT
M97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=724142#H@-S8N
M-35P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S
M<#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I
M=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0G/B`R+CPO
M9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B!4:&4@86-C;VUP86YY:6YG('5N875D
M:71E9"!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&%S(&]F($9E8G)U87)Y(#(Y+"`R,#$R(&%N9"!F;W(@=&AE('-I>"!M
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M;'1S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!&96)R=6%R>2`R.2P@,C`Q
M,BP@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H92!R97-U
M;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D(&9O<B!T:&4@>65A<B!E;F1I;F<@
M075G=7-T(#,Q+"`R,#$R+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M+V1I=CX@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:R<^/&)R("\^(#PO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V+C4U<'0G/B`\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@,S9P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M.R!415A4+4E.1$5.5#H@,'!T)SX@,RX\+V1I=CX@/"]T9#X@/'1D/B`\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T
M)SX@1V]I;F<@8V]N8V5R;B!C;VYS:61E<F%T:6]N<SPO9&EV/B`\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B9N8G-P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3BU,1494.B`P<'0[($U!
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M;F-E<'1I;VX@*$%P<FEL)FYB<W`[,3(L(#(P,#(I('1H<F]U9V@@1F5B<G5A
M<GD@,CDL(#(P,3(@;V8@)#$V+#`Q,2PQ.3,@87,@=V5L;"!A<R!N96=A=&EV
M92!C87-H(&9L;W<@9G)O;2!O<&5R871I;F<@86-T:79I=&EE<RX@4')E<V5N
M=&QY+"!T:&4@0V]M<&%N>2!D;V5S(&YO="!H879E('-U9F9I8VEE;G0@8V%S
M:"!R97-O=7)C97,@=&\@;65E="!I=',@<F5Q=6ER96UE;G1S(&EN('1H92!T
M=V5L=F4@;6]N=&AS(&9O;&QO=VEN9R!&96)R=6%R>2`R.2P@,C`Q,BX@5&AE
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M86)L93X@/"]D:78^(#QD:78^)FYB<W`[/"]D:78^(#QD:78^(#QT86)L92!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^(#QT<B!V86QI
M9VX],T1T;W`^(#QT9"!S='EL93TS1"=724142#H@,3$R<'0G/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]D:78^(#PO=&0^
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M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SXN/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^/&)R("\^(#PO9&EV
M/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$
M8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#,Y+C8Y.7!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G
M/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[
M(%1%6%0M24Y$14Y4.B`P<'0G/B!B+CPO9&EV/B`\+W1D/B`\=&0^(#QD:78@
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M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/B`\+V1I=CX@
M/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E
M;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`W
M-BXU-7!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N
M8G-P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P="<^(#$N
M/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^($EN($UA>2`R,#$Q+"!T:&4@1FEN
M86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F0@0F]A<F0@*")&05-"(BD@:7-S
M=65D(&%N(&%C8V]U;G1I;F<@=7!D871E('1H870@86UE;F1S($%30R!.;RX@
M.#(P+"`B1F%I<B!686QU92!-96%S=7)E;65N="(@<F5G87)D:6YG(&9A:7(@
M=F%L=64@;65A<W5R96UE;G1S(&%N9"!D:7-C;&]S=7)E(')E<75I<F5M96YT
M<RX@5&AE(&%M96YD;65N=',@87)E(&5F9F5C=&EV92!D=7)I;F<@:6YT97)I
M;2!A;F0@86YN=6%L('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R
M)FYB<W`[,34L(#(P,3$@86YD(&%R92!T;R!B92!A<'!L:65D('!R;W-P96-T
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M=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV/B9N8G-P.SPO9&EV/B`\
M9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N
M=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V
M+C4U<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB
M<W`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,S9P="<^(#QD
M:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T)SX@,BX\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^($EN($IU;F4@
M,C`Q,2P@=&AE($9!4T(@:7-S=65D(&%N('5P9&%T92!T;R!!4T,@3F\N)FYB
M<W`[,C(P+"`B4')E<V5N=&%T:6]N(&]F($-O;7!R96AE;G-I=F4@26YC;VUE
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M96=I;FYI;F<@869T97(@1&5C96UB97(F;F)S<#LQ-2P@,C`Q,2P@=VET:"!E
M87)L:65R(&%D;W!T:6]N('!E<FUI='1E9"X@26X@1&5C96UB97(@,C`Q,2P@
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M,C`Q,BX@5&AE(&%D;W!T:6]N(&]F('1H92!N97<@9W5I9&%N8V4@:7,@;F]T
M(&5X<&5C=&5D('1O(&AA=F4@82!M871E<FEA;"!I;7!A8W0@;VX@=&AE(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+V1I=CX@/"]T9#X@
M/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/B9N8G-P.SPO9&EV/B`\(2TM16YD
M1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U
M-3,T,3`W-3-F9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V
M9C<T9CE?93(X,%\T9F0R7SEB9C1?-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O
M4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-/34U)5$U%3E13/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0T]-34E4345.5%,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-
M14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H\9&EV/B`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)SX@/"$M+5-T87)T1G)A9VUE;G0M+3X@/&1I=B!S='EL
M93TS1"=$25-03$%9.B!B;&]C:SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#@N,7!T.R!T97AT+6%L:6=N.B!L969T.R!415A4+4E.1$5.
M5#H@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+5=%24=(5#H@8F]L9"<^3D]412`R("T\+V9O;G0^(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^0T]-34E4345.5%,\+V9O;G0^.CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z
M(#!P="<^("9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y+C8Y.7!T)SX@/&1I=B!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#,V<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0G/B!A+CPO9&EV
M/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
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M9W)E96UE;G0L($AA9&%S:70@:7,@96YT:71L960@=&\@)#(P,"PP,#`N(%1H
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M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,'!T)SX@)FYB<W`[/"]D:78^(#QD
M:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT
M97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=724142#H@-S4N
M-W!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P
M.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL
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M9"!A;F0@87-S:6=N960@86QL(&]F(&ET<R!O=VYE<G-H:7`@<FEG:'1S(&EN
M('1H92!P871E;G1S(&%C<75I<F5D('5N9&5R('1H92!&:7)S="!!9W)E96UE
M;G0@=&\@=&AE($-O;7!A;GDL(&%N9"!C97)T86EN(&]T:&5R('!A=&5N=',@
M9FEL960@8GD@=&AE($-O;7!A;GD@869T97(@=&AE($9I<G-T($%G<F5E;65N
M="!A<R!A(')E<W5L="!O9B!T:&4@8V]L;&%B;W)A=&EO;B!B971W965N('1H
M92!#;VUP86YY(&%N9"!(861A<VET+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\+V1I=CX@/&1I
M=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E
M<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`W-2XW
M<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[
M/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^($]N($IU;'D@."P@,C`P.2!T:&4@
M0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!T:&ER9"!A9W)E96UE;G0@=VET:"!(
M861A<VET+"!0<F]F+B!)=&%M87(@4F%Z(&%N9"!$<BX@36ER:6%M($MI9')O
M;B`H(G1H92!4:&ER9"!!9W)E96UE;G0B*2P@=&\@<F5T86EN(&-O;G-U;'1I
M;F<@86YD(&-L:6YI8V%L('1R:6%L('-E<G9I8V5S(&9R;VT@2&%D87-I="X@
M06-C;W)D:6YG('1O('1H92!4:&ER9"!!9W)E96UE;G0L($AA9&%S:70@=VEL
M;"!B92!E;G1I=&QE9"!T;R!T;W1A;"!C;VYS:61E<F%T:6]N(&]F("0T,#`L
M,#`P('1O(&)E('!A:60@8GD@3W)A;65D+B`D,C`P+#`P,"!O9B!T:&ES(&%M
M;W5N="!W87,@86=R965D(&EN('1H92!T97)M<R!O9B!T:&4@1FER<W0@06=R
M965M96YT+"!A;F0@=&AE(')E;6%I;FEN9R!O9B`D,C`P+#`P,"!W:6QL(&)E
M('!A:60@:6X@86-C;W)D86YC92!W:71H('1H92!A8W1U86P@<')O9W)E<W,@
M;V8@=&AE('-T=61Y+B!4:&4@=&]T86P@86UO=6YT('1H870@=V%S('!A:60@
M=&AR;W5G:"!&96)R=6%R>2`R.2P@,C`Q,B!W87,@)#0P,"PP,#`N/"]D:78^
M(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^
M("9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#<U+C=P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX@3VX@
M4V5P=&5M8F5R(#$Q+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
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M(&]F("0R,#`L,#`P('1O(&)E('!A:60@8GD@=&AE($-O;7!A;GDL(&YO;F4@
M;V8@=VAI8V@@=V%S(')E8V]G;FEZ960@;W(@<&%I9"!T:')O=6=H($9E8G)U
M87)Y(#(Y+"`R,#$R+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I
M=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\+V1I=CX@/&1I=CX@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX@/'1R('9A
M;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XV.3EP="<^(#QD
M:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I=B!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4E.1$5.5#H@
M,'!T)SX@8BX\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX@3VX@36%R8V@@,3@L
M(#(P,3(L('1H92!3=6)S:61I87)Y(&5N=&5R960@:6YT;R!A(&QE87-E(&%G
M<F5E;65N="!F;W(@:71S(&]F9FEC92!F86-I;&ET:65S(&EN($ES<F%E;"X@
M5&AE(&QE87-E(&%G<F5E;65N="!I<R!F;W(@82!P97)I;V0@;V8@-3<@;6]N
M=&AS(&-O;6UE;F-I;F<@2F%N=6%R>2`Q+"`R,#$R+B!4:&4@;6]N=&AL>2!L
M96%S92!P87EM96YT('=I;&P@8F4@3DE3(#,L-#`P(&EN(#(P,3(L($Y)4R`T
M+#(R-2!I;B`R,#$S(&%N9"!.25,@-2PV,3`@9G)O;2`R,#$T(&]N=V%R9',L
M(&%N9"!W:6QL(&)E(&QI;FME9"!T;R!T:&4@:6YC<F5A<V4@:6X@=&AE($ES
M<F%E;&D@8V]N<W5M97(@<')I8V4@:6YD97@@*&%S(&]F($9E8G)U87)Y(#(Y
M+"`R,#$R+"!T:&4@;6]N=&AL>2!P87EM96YT(&EN('1H92!#;VUP86YY)B,S
M.3MS(&9U;F-T:6]N86P@8W5R<F5N8WD@:7,@)#DP,RP@=&AE(&9U='5R92!A
M;FYU86P@;&5A<V4@<&%Y;65N=',@=6YD97(@=&AE(&%G<F5E;65N="!W:6QL
M(&)E("0Q,"PX,S8@+2`D,3<L.#<X*2X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VLG/B9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N
M/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<U+C=P="<^(#QD:78@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX@07,@<V5C=7)I='D@9F]R(&ET<R!O8FQI9V%T:6]N('5N
M9&5R('1H92!L96%S92!A9W)E96UE;G1S('1H92!3=6)S:61I87)Y('!R;W9I
M9&5D(&$@8F%N:R!G=6%R86YT964@:6X@86X@86UO=6YT(&5Q=6%L('1O('1H
M<F5E(&UO;G1H;'D@;&5A<V4@<&%Y;65N=',N('9A;&ED('5N=&EL($YO=F5M
M8F5R(#,P+"`R,#$V+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I
M=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\+V1I=CX@/&1I=CX@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX@/'1R('9A
M;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XV.3EP="<^(#QD
M:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I=B!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4E.1$5.5#H@
M,'!T)SX@8RX\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^
M($]N($%P<FEL(#(Q+"`R,#`Y+"!T:&4@4W5B<VED:6%R>2!E;G1E<F5D(&EN
M=&\@82!C;VYS=6QT:6YG('-E<G9I8V4@86=R965M96YT('=I=&@\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SXF
M;F)S<#L\+V9O;G0^($%$4D53($%D=F%N8V5D(%)E9W5L871O<GD@4V5R=FEC
M97,@3'1D+B`H(D%$4D53(BD@*'1H92`B3W)I9VEN86P@06=R965M96YT(BD@
M<'5R<W5A;G0@=&\@=VAI8V@@041215,@=VEL;"!P<F]V:61E(&-O;G-U;'1I
M;F<@<V5R=FEC97,@<F5L871I;F<@=&\@<75A;&ET>2!A<W-U<F%N8V4@86YD
M(')E9W5L871O<GD@<')O8V5S<V5S(&%N9"!P<F]C961U<F5S(&EN(&]R9&5R
M('1O(&%S<VES="!T:&4@4W5B<VED:6%R>2!I;B!S=6)M:7-S:6]N(&]F(&$@
M52Y3+B!);G9E<W1I9V%T:6]N86P@3F5W($1R=6<@*"))3D0B*2!A8V-O<F1I
M;F<@=&\@=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H
M=&AE(")&1$$B*2!R96=U;&%T:6]N<RX@26X@8V]N<VED97)A=&EO;B!F;W(@
M=&AE('-E<G9I8V5S('!R;W9I9&5D('5N9&5R('1H92!A9W)E96UE;G0L($%$
M4D53('=I;&P@8F4@96YT:71L960@=&\@=&]T86P@8V%S:"!C;VUP96YS871I
M;VX@;V8@)#(Q,2PP,#`L(&]F('=H:6-H('1H92!A;6]U;G0@;V8@)#$Q,"PP
M,#`@=VEL;"!B92!P86ED(&%S(&$@;6]N=&AL>2!F:7AE9"!F964@;V8@)#$P
M+#`P,"!E86-H(&UO;G1H(&9O<B`Q,2!M;VYT:',@8V]M;65N8VEN9R!-87D@
M,C`P.2P@86YD('1H92!R96UA:6YI;F<@)#$P,2PP,#`@=VEL;"!B92!P86ED
M(&)A<V5D(&]N(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@;6EL97-T;VYE<RX@
M)#$V,"PP,#`@;V8@=&AE('1O=&%L(&%M;W5N="!W87,@<&%I9"!T:')O=6=H
M($YO=F5M8F5R(#,P+"`R,#$Q+"`D-3`L,#`P(&]F('=H:6-H('=A<R!P86ED
M(&9O<B!C;VUP;&5T:6YG('1H92!F:7)S="!T:')E92!M:6QE<W1O;F5S+CPO
M9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS
M1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)FYB<W`[/"]D
M:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX]
M,T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=72414
M2#H@-S4N-W!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B!/;B!&96)R=6%R>2`R
M-BP@,C`Q,BP@=&AE('!A<G1I97,@96YT97)E9"!I;G1O(&%N(&%M96YD;65N
M="!A9W)E96UE;G0L(&%C8V]R9&EN9R!T;R!W:&EC:"!T:&4@4W5B<VED:6%R
M>2!W:6QL('!A>2!T:&4@<F5M86EN:6YG("0U,2PP,#`@;V8@=&AE($]R:6=I
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M5"U325I%.B`Q,'!T)SXN/"]F;VYT/B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D
M('1H92`D-3$L,#`P(&%S(&%N(&5X<&5N<V4@=&AR;W5G:"!&96)R=6%R>2`R
M.2P@,C`Q,BX\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#QD
M:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!415A4
M+4E.1$5.5#H@,'!T)SX@)FYB<W`[/"]D:78^(#QD:78^(#QT86)L92!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^(#QT<B!V86QI9VX]
M,T1T;W`^(#QT9"!S='EL93TS1"=724142#H@,SDN-CDY<'0G/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]D:78^(#PO=&0^
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M13H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^($]N($9E8G)U87)Y(#$P+"`R
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M<F\[,3`W+#$P,"`H)#$T,RPX,S$I(&]F('=H:6-H("9E=7)O.S@Y+#(Y,R`H
M)#$R,"PP,CDI('=A<R!P86ED('1H<F]U9V@@1F5B<G5A<GD@,CDL(#(P,3(N
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF;F)S<#L\
M+V1I=CX@/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG
M;CTS1&-E;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`S.2XV.3EP="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S
M-G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T.R!415A4+4E.1$5.5#H@,'!T)SX@92X\+V1I=CX@/"]T9#X@/'1D/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M5$585"U)3D1%3E0Z(#!P="<^($]N($9E8G)U87)Y(#$U+"`R,#$Q+"!T:&4@
M4W5B<VED:6%R>2!E;G1E<F5D(&EN=&\@82!C;VYS=6QT:6YG(&%G<F5E;65N
M="!W:71H(&$@=&AI<F0@<&%R='D@*'1H92`B0V]N<W5L=&%N="(I(&9O<B!A
M('!E<FEO9"!O9B!F:79E('EE87)S+"!P=7)S=6%N="!T;R!W:&EC:"!T:&4@
M0V]N<W5L=&%N="!W:6QL('!R;W9I9&4@8V]N<W5L=&%T:6]N(&]N('-C:65N
M=&EF:6,@86YD(&-L:6YI8V%L(&UA='1E<G,N(%1H92!#;VYS=6QT86YT(&ES
M(&5N=&ET;&5D('1O(&$@9FEX960@;6]N=&AL>2!F964@;V8@)#@L,#`P+"!R
M;WEA;'1I97,@;V8@."4@;V8@=&AE(&YE="!R;WEA;'1I97,@86-T=6%L;'D@
M<F5C96EV960@8GD@=&AE(%-U8G-I9&EA<GD@:6X@<F5S<&5C="!O9B!T:&4@
M<&%T96YT('1H870@=V%S('-O;&0@=&\@16YT97)A(&]N($9E8G)U87)Y(#(R
M+"`R,#$Q(&%N9"!A;B!O<'1I;VX@=&\@<'5R8VAA<V4@=7`@=&\@,C4P+#`P
M,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!P87(@=F%L=64@)#`N,#`Q('!E
M<B!S:&%R92P@;V8@=&AE($-O;7!A;GD@870@86X@97AE<F-I<V4@<')I8V4@
M;V8@)#`N-3`@<&5R('-H87)E+B!4:&4@;W!T:6]N('9E<W0@:6X@9FEV92!A
M;FYU86P@:6YS=&%L;&UE;G1S(&-O;6UE;F-I;F<@1F5B<G5A<GD@,38L(#(P
M,3(@86YD(&5X<&ER92!O;B!&96)R=6%R>2`Q-BP@,C`R,2X@5&AE(&EN:71I
M86P@9F%I<B!V86QU92!O9B!T:&4@;W!T:6]N(&]N('1H92!D871E(&]F(&=R
M86YT('=A<R`D-S$L-#DU+"!U<VEN9R!T:&4@0FQA8VL@4V-H;VQE<R!O<'1I
M;VXM<')I8VEN9R!M;V1E;"!A;F0@=V%S(&)A<V5D(&]N('1H92!F;VQL;W=I
M;F<@87-S=6UP=&EO;G,Z(&1I=FED96YD('EI96QD(&]F(#`E(&9O<B!A;&P@
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M97)I;V0@=7-I;F<@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D+CPO9&EV/B`\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P<'0G/B`F
M;F)S<#L\+V1I=CX@/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$
M,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)2!A;&EG;CTS1&-E;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE
M/3-$)U=)1%1(.B`S.2XV.3EP="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`S-G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T)SX@9BX\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX@3VX@36%Y(#$S+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!C;VYS=6QT:6YG(&%G<F5E;65N="!W:71H(&$@=&AI<F0@
M<&%R='D@*'1H92`B0V]N<W5L=&%N="(I(&9O<B!A('!E<FEO9"!O9B`Q,B!M
M;VYT:',L('!U<G-U86YT('1O('=H:6-H('1H92!#;VYS=6QT86YT('=I;&P@
M<')O=FED92!I;G9E<W1O<B!R96QA=&EO;G,@<V5R=FEC97,@86YD('=I;&P@
M8F4@96YT:71L960@=&\@82!C87-H(&UO;G1H;'D@9F5E(&]F("0T+#`P,"P@
M=&AA="!M87D@8F4@:6YC<F5A<V5D('5P('1O("0Q,"PP,#`@=7!O;B!T:&4@
M8V]M<&QE=&EO;B!O9B!A("0U+#`P,"PP,#`@8V%P:71A;"!R86ES92!B>2!T
M:&4@0V]M<&%N>2X@26X@861D:71I;VXL('1H92!#;VYS=6QT86YT(')E8V5I
M=F5D(&$@=V%R<F%N="!T;R!P=7)C:&%S92!U<"!T;R`S,BPP,#`@<VAA<F5S
M(&]F('1H92!#;VUP86YY+B!4:&4@=V%R<F%N="!H87,@82!T97)M(&]F(&9I
M=F4@>65A<G,@86YD(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C4P('!E<B!3
M:&%R92!A;F0@=VEL;"!V97-T(&EN(#$R(&EN<W1A;&QM96YT<R!I;B!T:&4@
M<&5R:6]D(&9R;VT@3V-T;V)E<B`R,#$Q('1O($UA>2`R,#$V+B!4:&4@0V]M
M<&%N>2!R96-O<F1S(&5X<&5N<V5S(&EN(')E<W!E8W0@;V8@=&AI<R!W87)R
M86YT(&1U<FEN9R!T:&4@=&5R;2!O9B!T:&4@<V5R=FEC97,N/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@-S)P=#L@34%21TE.+5))1TA4.B`W
M,G!T.R!T97AT+6%L:6=N.B!L969T.R!415A4+4E.1$5.5#H@,'!T)SX@)FYB
M<W`[/"]D:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@
M86QI9VX],T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS
M1"=724142#H@,SDN-CDY<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX@)FYB<W`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=72414
M2#H@,S9P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P="<^(&<N/"]D:78^(#PO=&0^(#QT
M9#X@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^($]N($IU;F4@,C(L(#(P,3$L('1H92!3=6)S:61I87)Y(&ES
M<W5E9"!A('!U<F-H87-E(&]R9&5R('1O(%-!1D,@4&AA<FUA(&9O<B!P<F]D
M=6-I;F<@;VYE(&]F(&ET<R!O<F%L(&-A<'-U;&4@:6YG<F5D:65N=',@:6X@
M=&AE(&%M;W5N="!O9B`D-C`P+#`P,"P@)#$W,"PP,#`@;V8@=VAI8V@@=V%S
M(')E8V]G;FEZ960@=&AR;W5G:"!&96)R=6%R>2`R.2P@,C`Q,BX\+V1I=CX@
M/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/B9N8G-P.SPO9&EV/B`\
M9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N
M=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y
M+C8Y.7!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N
M8G-P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0G/B!H+CPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y
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M(&$@8V%S:"!M;VYT:&QY(&9E92!O9B`D-"PP,#`L(&%N9"!A;B!A9&1I=&EO
M;F%L("0S+#`P,"!I;B!T:&4@9FER<W0@;6]N=&@N($EN(&%D9&ET:6]N+"!T
M:&4@061V:7-O<B!W:6QL(&)E(&ES<W5E9"`R-#DL,#`P('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C,SD[<R!C;VUM;VX@<W1O8VL@:6X@=&AR964@97%U86P@
M:6YS=&%L;&UE;G1S(&]V97(@=&AE(&5N9V%G96UE;G0@<&5R:6]D+"!C;VUM
M96YC:6YG($YO=F5M8F5R(#(P,3$N(%-E92!A;'-O(&YO=&5S(#0@86YD(#4N
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF;F)S<#L\
M+V1I=CX@/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG
M;CTS1&-E;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`S.2XV.3EP="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S
M-G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T.R!415A4+4E.1$5.5#H@,'!T)SX@:2X\+V1I=CX@/"]T9#X@/'1D/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX@3VX@1&5C96UB97(@,3(L(#(P,3$L('1H92!3=6)S:61I87)Y(&5N
M=&5R960@:6YT;R!A(%-U<'!L>2!!9W)E96UE;G0@=VET:"!3=VES<R!#87!S
M($%'("@B4W=I<W,@0V%P<R(I+"!A8V-O<F1I;F<@=&\@=VAI8V@L(%-W:7-S
M($-A<',@=VEL;"!M86YU9F%C='5R92!I;G-U;&EN(&-A<'-U;&5S(&9O<B!A
M('1O=&%L(&-O;G-I9&5R871I;VX@;V8@0TA&(#,Y-2PP,#`@*&%P<')O>&EM
M871E;'D@)#0T,"PV,#`I(&]F('=H:6-H($-(1B`Q.#`L,#`P("AA<'!R;WAI
M;6%T96QY("0Q.34L-C`P*2!W87,@<&%I9"!T:')O=6=H($9E8G)U87)Y(#(Y
M+"`R,#$R+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I
M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^
M)FYB<W`[/"]D:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4@86QI9VX],T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL
M93TS1"=724142#H@,SDN-CDY<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX@)FYB<W`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=7
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M;&EG;CH@;&5F="<^($]N($9E8G)U87)Y(#$U+"`R,#$R+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@86X@861V:7-O<GD@86=R965M96YT('=I=&@@82!T
M:&ER9"!P87)T>2!F;W(@82!P97)I;V0@;V8@;VYE('EE87(L('!U<G-U86YT
M('1O('=H:6-H('-U8V@@=&AI<F0@<&%R='D@=VEL;"!P<F]V:61E(&EN=F5S
M=&]R<R!R96QA=&EO;G,@<V5R=FEC97,@86YD('=I;&P@8F4@96YT:71L960@
M=&\@82!S:&%R92!B87-E9"!C;VUP96YS871I;VX@87,@9F]L;&]W<SH@,S`P
M+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F('1H92!#;VUP86YY('=I
M;&P@8F4@:7-S=65D(&EN('-I>"!I;G-T86QL;65N=',@;W9E<B!T:&4@96YG
M86=E;65N="!P97)I;V0L(&-O;6UE;F-I;F<@1F5B<G5A<GD@,34L(#(P,3(L
M(&%N9"!A('=A<G)A;G0@=&\@<'5R8VAA<V4@-S4P+#`P,"!S:&%R97,@;V8@
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M9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K)SXF;F)S<#L\+V1I=CX@/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@
M/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XV.3EP="<^(#QD:78@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T)SX@:RX\+V1I
M=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX@1W)A;G1S(&9R;VT@0FEO+4IE<G5S86QE
M;3PO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL
M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^)FYB<W`[
M/"]D:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI
M9VX],T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=7
M24142#H@-S4N-W!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B!4:&4@4W5B<VED
M:6%R>2!I<R!C;VUM:71T960@=&\@<&%Y(')O>6%L=&EE<R!T;R!":6\M2F5R
M=7-A;&5M(&9U;F0@;VX@<')O8V5E9',@9G)O;2!F=71U<F4@<V%L97,@870@
M82!R871E(&]F(#0E(&%N9"!U<"!T;R`Q,#`E(&]F('1H92!A;6]U;G0@;V8@
M=&AE(&=R86YT(')E8V5I=F5D(&)Y('1H92!#;VUP86YY("A)<W)A96QI($-0
M22!L:6YK960I(&%T('1H92!T;W1A;"!A;6]U;G0@;V8@)#4R+#<S,RXF;F)S
M<#LF;F)S<#M!<R!O9B!&96)R=6%R>2`R.2P@,C`Q,BP@=&AE(%-U8G-I9&EA
M<GD@:&%D(&YO="!Y970@<F5A;&EZ960@86YY(')E=F5N=65S(&%N9"!D:60@
M;F]T(&EN8W5R(&%N>2!R;WEA;'1Y(&QI86)I;&ET>2X\+V1I=CX@/"]T9#X@
M/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,'!T)SX@)FYB<W`[
M/"]D:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI
M9VX],T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=7
M24142#H@-S4N-W!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E3
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M/B9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#,Y+C8Y.7!T)SX@/&1I=B!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#,V<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0G/B!L+CPO9&EV/B`\+W1D
M/B`\=&0^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B!'<F%N=',@9G)O;2!T:&4@3V9F:6-E(&]F('1H92!#
M:&EE9B!38VEE;G1I<W0@*")/0U,B*3PO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:R<^)FYB<W`[/"]D:78^(#QD:78^(#QT86)L92!S='EL
M93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^(#QT<B!V86QI9VX]
M,T1T;W`^(#QT9"!S='EL93TS1"=724142#H@-S4N-W!T)SX@/&1I=B!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9&EV/B`\+W1D/B`\
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M8VEP871E<R!B>2!W87D@;V8@9W)A;G1S+CPO9&EV/B`\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\+V1I=CX@
M/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E
M;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`W
M-2XW<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB
M<W`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=$25-03$%9.B!I
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M='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^("9N8G-P.SPO
M9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N
M/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#<U+C=P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX@56YD97(@=&AE('1E
M<FUS(&]F('1H92!3=6)S:61I87)Y)B,S.3MS(&9U;F1I;F<@9G)O;2!T:&4@
M27-R865L:2!';W9E<FYM96YT+"!R;WEA;'1I97,@;V8@,R4M,RXU)2!A<F4@
M<&%Y86)L92!O;B!S86QE<R!O9B!P<F]D=6-T<R!D979E;&]P960@9G)O;2!A
M('!R;VIE8W0@<V\@9G5N9&5D+"!U<"!T;R`Q,#`E(&]F('1H92!A;6]U;G0@
M;V8@=&AE(&=R86YT(')E8V5I=F5D(&)Y('1H92!3=6)S:61I87)Y("AD;VQL
M87(@;&EN:V5D*2!W:71H('1H92!A9&1I=&EO;B!O9B!A;FYU86P@:6YT97)E
M<W0@870@82!R871E(&)A<V5D(&]N($Q)0D]2+CPO9&EV/B`\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\+V1I
M=CX@/&1I=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS
M1&-E;G1E<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`W-2XW<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@
M)FYB<W`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^($%S(&]F($9E8G)U87)Y
M(#(Y+"`R,#$R+"!T:&4@4W5B<VED:6%R>2!H860@;F]T('EE="!R96%L:7IE
M9"!A;GD@<F5V96YU97,@9G)O;2!S=6-H('!R;V1U8W0@86YD(&1I9"!N;W0@
M:6YC=7(@86YY(')O>6%L='D@;&EA8FEL:71Y+B!4:&4@=&]T86P@86UO=6YT
M(')E8V5I=F5D('1H<F]U9V@@1F5B<G5A<GD@,CDL(#(P,3(@=V%S("0Q+#`W
M."PU-#4N/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@5$585"U)
M3D1%3E0Z(#!P="<^("9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$
M=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<U+C=P="<^(#QD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D
M/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)SX@1F]R('1H92!S:7@@;6]N=&@@<&5R:6]D(&5N9&5D($9E8G)U
M87)Y(#(Y+"`R,#$R+"!T:&4@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X
M<&5N<V5S(&%R92!P<F5S96YT960@;F5T(&]F($]#4R!G<F%N=',L(&EN('1H
M92!T;W1A;"!A;6]U;G0@;V8@)#4W+#`S."X\+V1I=CX@/"]T9#X@/"]T<CX@
M/"]T86)L93X@/"]D:78^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8Q
M-F8W-&8Y7V4R.#!?-&9D,E\Y8F8T7S4U,S0Q,#<U,V9F8PT*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U
M-3,T,3`W-3-F9F,O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1D%)4B!604Q513QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9!25(@
M5D%,544@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&04E2(%9!3%5%/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$
M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S
M+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M
M+3X-"CQD:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!415A4+4E.1$5.5#H@,'!T)SX@/"$M+5-T87)T1G)A9VUE;G0M
M+3X@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0G/B!.3U1%(#,@
M+2!&04E2(%9!3%5%.CPO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SXF;F)S<#L\+V1I=CX@/&1I=CX@/'1A
M8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX@/'1R
M('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XW<'0G/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]D:78^
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M=&%B;&4^(#PO9&EV/B`\9&EV/B9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L
M:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y+C=P="<^(#QD:78@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T
M9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT
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M=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SXF;F)S<#L\+V1I=CX@/&1I=CX@/'1A8FQE('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E<CX@/'1R('9A;&EG
M;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XV.3EP="<^(#QD:78@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S-G!T)SX@/&1I=B!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E<FEF.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4E.
M1$5.5#H@,'!T)SX@)FUI9&1O=#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX@
M3&5V96P@,3H@475O=&5D('!R:6-E<R`H=6YA9&IU<W1E9"D@:6X@86-T:79E
M(&UA<FME=',@=&AA="!A<F4@86-C97-S:6)L92!A="!T:&4@;65A<W5R96UE
M;G0@9&%T92!F;W(@87-S971S(&]R(&QI86)I;&ET:65S+B!4:&4@9F%I<B!V
M86QU92!H:65R87)C:'D@9VEV97,@=&AE(&AI9VAE<W0@<')I;W)I='D@=&\@
M3&5V96P@,2!I;G!U=',N/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO
M9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@5$585"U)3D1%3E0Z(#!P="<^("9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@
M=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y+C8Y.7!T)SX@
M/&1I=B!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,V<'0G/B`\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@9F]N="UF86UI;'DZ(%-Y;6)O;"P@<V5R
M:68[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%
M6%0M24Y$14Y4.B`P<'0G/B`F;6ED9&]T.SPO9&EV/B`\+W1D/B`\=&0^(#QD
M:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B!,979E;"`R.B!/8G-E<G9A8FQE('!R:6-E<R!T:&%T(&%R92!B87-E
M9"!O;B!I;G!U=',@;F]T('%U;W1E9"!O;B!A8W1I=F4@;6%R:V5T<RP@8G5T
M(&-O<G)O8F]R871E9"!B>2!M87)K970@9&%T82X\+V1I=CX@/"]T9#X@/"]T
M<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,'!T)SX@)FYB<W`[/"]D
M:78^(#QD:78^(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX]
M,T1C96YT97(^(#QT<B!V86QI9VX],T1T;W`^(#QT9"!S='EL93TS1"=72414
M2#H@,SDN-CDY<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX@)FYB<W`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,S9P
M="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@4WEM8F]L+"!S97)I9CL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
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M(&QO=V5S="!P<FEO<FET>2!T;R!,979E;"`S(&EN<'5T<RX\+V1I=CX@/"]T
M9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/B`\+V1I=CX@/&1I
M=CX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2!A;&EG;CTS1&-E;G1E
M<CX@/'1R('9A;&EG;CTS1'1O<#X@/'1D('-T>6QE/3-$)U=)1%1(.B`S.2XW
M<'0G/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[
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M=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX@/"]D:78^(#QD:78^(#QT86)L92!S
M='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@86QI9VX],T1C96YT97(^(#QT<B!V86QI
M9VX],T1T;W`^(#QT9"!S='EL93TS1"=724142#H@,SDN-W!T)SX@/&1I=B!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9&EV/B`\+W1D
M/B`\=&0^(#QD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^(#QD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&IU<W1I9GD[(%1%6%0M
M24Y$14Y4.B`P<'0G/B!-87)K971A8FQE('-E8W5R:71I97,@8V]N<VES="!W
M:&]L;'D@;V8@97%U:71Y('-E8W5R:71I97,@;V8@1"Y.+D$@0FEO;65D:6-A
M;"!3;VQU=&EO;G,@3'1D+B!W:&EC:"!W97)E(')E8V5I=F5D(&EN($UA<F-H
M(#(P,3$@87,@<&%R="!O9B!T:&4@8V]N<VED97)A=&EO;B!F;W(@<V5L;&EN
M9R!T:&4@0V]M<&%N>28C,SD[<R!E<75I='D@;65T:&]D(&EN=F5S=&5E($5N
M=&5R82X@5&AO<V4@<V5C=7)I=&EE<R!A<F4@8VQA<W-I9FEE9"!A<R!A=F%I
M;&%B;&4M9F]R+7-A;&4@86YD(&%R92!R96-O<F1E9"!A="!F86ER('9A;'5E
M+B9N8G-P.R9N8G-P.U1H92!$+DXN02!3:&%R97,@87)E(&QI<W1E9"!O;B!T
M:&4@5&5L($%V:78@4W1O8VL@17AC:&%N9V4@*")405-%(BD@86YD('1H96ER
M('1R861A8FEL:71Y('=A<R!R97-T<FEC=&5D(&9O<B!A('!E<FEO9"!O9B`V
M(&UO;G1H<R!F<F]M('1H92!C;&]S:6YG(&1A=&4@;V8@=&AE('1R86YS86-T
M:6]N(&%C8V]R9&EN9R!T;R!405-%('!O;&EC>2!W:71H(')E9V%R9',@=&\@
M<')I=F%T92!P;&%C96UE;G1S+B!5;G1I;"!397!T96UB97(@,S`L(#(P,3$L
M('1H92!F86ER('9A;'5E(&]F('1H92!R97-T<FEC=&5D('-E8W5R:71I97,@
M=V%S(&UE87-U<F5D(&)A<V5D(&]N('1H92!Q=6]T960@<')I8V5S(&]F('1H
M92!O=&AE<G=I<V4@:61E;G1I8V%L('5N<F5S=')I8W1E9"!S96-U<FET:65S
M+"!A9&IU<W1E9"!F;W(@=&AE(&5F9F5C="!O9B!T:&4@<F5S=')I8W1I;VX@
M8GD@87!P;'EI;F<@82!P<F]P97(@9&ES8V]U;G0N(%1H92!D:7-C;W5N="!W
M87,@9&5T97)M:6YE9"!W:71H(')E9F5R96YC92!T;R!O=&AE<B!S:6UI;&%R
M(')E<W1R:6-T960@:6YS=')U;65N=',N(%-I;6EL87(@<V5C=7)I=&EE<RP@
M=VET:"!N;R!R97-T<FEC=&EO;B!O;B!T<F%D86)I;&ET>2P@87)E('%U;W1E
M9"!O;B!A;B!A8W1I=F4@;6%R:V5T+B!!<R!O9B!/8W1O8F5R(#$L(#(P,3$L
M('1H92!S96-U<FET:65S(&%R92!N;W0@<F5S=')I8W1E9"!A;F0@=&AE(&9A
M:7(@=F%L=64@;V8@=&AE('-E8W5R:71I97,@:7,@;65A<W5R960@8F%S960@
M;VX@=&AE('%U;W1E9"!P<FEC97,@;V8@=&AE('-E8W5R:71I97,@;VX@86X@
M86-T:79E(&UA<FME="X\+V1I=CX@/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P<'0G/B`F;F)S<#L\
M+V1I=CX@/"]D:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[('1E>'0M86QI
M9VXZ(&QE9G0[(%1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0G
M/B!4<F%N<V9E<G,@:6X@86YD+V]R(&]U="!O9B!,979E;"`S(&%R92!R96-O
M9VYI>F5D(&EN('1H92!B96=I;FYI;F<@;V8@=&AE(')E<&]R=&EN9R!P97)I
M;V0N/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@-31P=#L@34%2
M1TE.+5))1TA4.B`X+C%P=#L@=&5X="UA;&EG;CH@;&5F=#L@5$585"U)3D1%
M3E0Z(#!P="<^("9N8G-P.SPO9&EV/B`\9&EV/B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N=&5R/B`\='(@=F%L:6=N/3-$=&]P
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y+C=P="<^(#QD:78@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V1I=CX@/"]T9#X@/'1D/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!T97AT+6%L:6=N.B!L
M969T)SX@1FEN86YC:6%L(&ET96US(&-A<G)I960@870@9F%I<B!V86QU92!A
M<R!O9B!&96)R=6%R>2`R.2P@,C`Q,B!A;F0@075G=7-T)FYB<W`[,S$L(#(P
M,3$@87)E(&-L87-S:69I960@:6X@=&AE('1A8FQE<R!B96QO=R!I;B!O;F4@
M;V8@=&AE('1H<F5E(&-A=&5G;W)I97,@9&5S8W)I8F5D(&%B;W9E.CPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=$
M25-03$%9.B!B;&]C:SL@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P="<^
M("9N8G-P.SPO9&EV/B`\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SX@/'1A8FQE('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#DP)3X@/'1R/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/CQF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]F;VYT
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@)FYB<W`[/"]F;VYT
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-B4@8V]L<W!A;CTS
M1#$T/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^
M(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T
M97AT+6%L:6=N.B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0G/B!&86ER('9A
M;'5E(&UE87-U<F5M96YT<R!A="9N8G-P.W)E<&]R=&EN9SPO9&EV/B`\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@9&%T92!U<VEN9SPO
M9&EV/B`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`F;F)S<#L\+V9O;G0^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9F]N=#X@/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/B`\9&EV
M('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@3&5V96P@,3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/B`\9&EV('-T
M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@3&5V96P@,CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/B`\9&EV('-T>6QE
M/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@3&5V96P@,SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@5&]T86P\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#PO='(^(#QT<B!B9V-O
M;&]R/3-$(V-C965F9CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4^(#QD:78@
M<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,
M24=..B!L969T.R!415A4+4E.1$5.5#H@,'!T)SX@36%R:V5T86)L92!S96-U
M<FET:65S.CPO9&EV/B`\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S
M<#L\+V9O;G0^(#PO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,"4@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F
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M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[
M/"]F;VYT/B`\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB
M<W`[/"]F;VYT/B`\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\
M+V9O;G0^(#PO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@
M8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S
M<#L\+V9O;G0^(#PO=&0^(#PO='(^(#QT<B!B9V-O;&]R/3-$=VAI=&4^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M-'!X.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/B`\
M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T.R!415A4
M+4E.1$5.5#H@,'!T)SX@1F5B<G5A<GD@,CDL(#(P,3(\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/B0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3XS-#$L-#4T/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T
M<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO
M9F]N=#X@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
M8FQE.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE/BT\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]F;VYT/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
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M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N
M8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3XD/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[
M($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24^,S0Q+#0U-#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO
M=&0^(#PO='(^(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@[(%1%6%0M
M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4^(#QD:78@<W1Y;&4]
M,T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P
M<'0G/B!!=6=U<W0@,S$L(#(P,3$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[
M/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M/BT\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U
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M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^+3PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\
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M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3XD/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#1P>"!D;W5B;&4[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^,S@T
M+#4V-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
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M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3XD/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[($1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24^,S@T+#4V-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#PO='(^(#PO
M=&%B;&4^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^("9N8G-P.SPO9&EV/B`\
M9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E(&%L:6=N/3-$8V5N
M=&5R/B`\='(@=F%L:6=N/3-$=&]P/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#,Y
M+C=P="<^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S
M<#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)SX@5&AE(&9O;&QO=VEN9R!T86)L
M92!S=6UM87)I>F5S('1H92!A8W1I=FET>2!F;W(@=&AO<V4@9FEN86YC:6%L
M(&%S<V5T<R!W:&5R92!F86ER('9A;'5E(&UE87-U<F5M96YT<R!A<F4@97-T
M:6UA=&5D('5T:6QI>FEN9R!,979E;"`S(&EN<'5T<SH\+V1I=CX@/"]T9#X@
M/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/CQB<B`O/B`\+V1I=CX@/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B`\=&%B;&4@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S4E
M/B`\='(^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X-24^/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO
M=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`F
M;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO
M8VL[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!C96YT97([(%1%6%0M24Y$
M14Y4.B`P<'0G/B!3:7@@;6]N=&AS(&5N9&5D/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@)FYB<W`[/"]F;VYT
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0X-24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S
M<#L\+V9O;G0^(#PO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G
M1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!C96YT
M97([(%1%6%0M24Y$14Y4.B`P<'0G/B!&96)R=6%R>2`R.2P\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`F;F)S
M<#L\+V9O;G0^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@U)3X\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^("9N8G-P.SPO9F]N
M=#X@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N
M=#X@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X]
M,T0R/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M=#L@=&5X="UA;&EG;CH@8V5N=&5R.R!415A4+4E.1$5.5#H@,'!T)SX@,C`Q
M,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^("9N8G-P.SPO9F]N=#X@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#4E/CQF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^(#QD:78@<W1Y
M;&4],T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N
M.B!C96YT97([(%1%6%0M24Y$14Y4.B`P<'0G/B!5;F%U9&ET960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#PO='(^
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M/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=$25-03$%9.B!I
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M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
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M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX@
M)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
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M,T0Q,B4^*#,X-"PU-C4\+W1D/B`\=&0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R<'@[(%1%6%0M04Q)1TXZ(&QE9G0G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#XI
M/"]T9#X@/"]T<CX@/'1R(&)G8V]L;W(],T0C8V-E969F/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.#4E(&%L:6=N/3-$;&5F=#X@/&1I=B!S='EL93TS1"=$25-03$%9.B!B
M;&]C:SL@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0[
M('1E>'0M86QI9VXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,3AP="<^($-A<G)Y
M:6YG('9A;'5E(&%T('1H92!E;F0@;V8@=&AE('!E<FEO9#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`F;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
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M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/BT\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX@)FYB<W`[/"]F;VYT/B`\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:R<^/&)R("\^(#PO9&EV/B`\9&EV('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T.R!T97AT+6%L:6=N.B!L969T.R!415A4+4E.1$5.5#H@,'!T
M.R!724142#H@,3`P)2<^("9N8G-P.SPO9&EV/B`\(2TM16YD1G)A9VUE;G0M
M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,39F-S1F.5]E,C@P7S1F9#)?.6)F-%\U-3,T,3`W-3-F
M9F,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C$V9C<T9CE?93(X
M,%\T9F0R7SEB9C1?-34S-#$P-S4S9F9C+U=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-43T-+
M2$],1$524R<@15%52519/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D9E8BX@,CDL(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4U1/0TL@2$],1$524R<@15%52519(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4U1/0TL@2$],1$524R<@15%52519/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$
M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S
M+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M
M+3X-"CQD:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!415A4+4E.1$5.5#H@,'!T)SX@/"$M+5-T87)T1G)A9VUE;G0M
M+3X@/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0G/B!.3U1%(#0@
M+2!35$]#2R!(3TQ$15)3)B,S.3L@15%52519.CPO9&EV/B`\9&EV('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX@
M/"]D:78^(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`P<'0G/B`\9F]N="!S='EL93TS1"=,151415(M
M4U!!0TE.1SH@.7!T)SXF;F)S<#LF;F)S<#LF;F)S<#L\+V9O;G0^("9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R!/;B!$96-E;6)E<B`Q,BP@,C`Q
M,2P@=&AE($-O;7!A;GD@:7-S=65D(#@S+#`P,"!S:&%R97,@;V8@:71S(&-O
M;6UO;B!S=&]C:R!T;R!T:&4@061V:7-O<B!A<R!R96UU;F5R871I;VX@9F]R
M('-E<G9I8V5S('!R;W9I9&5D+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@<VAA
M<F5S(&%T('1H92!D871E(&]F(&=R86YT('=A<R`D,C0L.3`P+B!3964@86QS
M;R!N;W1E(#)H+CPO9&EV/B`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SXF;F)S<#L\+V1I=CX@/"$M+45N9$9R86=M
M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C$V9C<T9CE?93(X,%\T9F0R7SEB9C1?-34S-#$P
M-S4S9F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q-F8W-&8Y
M7V4R.#!?-&9D,E\Y8F8T7S4U,S0Q,#<U,V9F8R]7;W)K<VAE971S+U-H965T
M,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M54)315%514Y4($5614Y44SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-50E-%455%3E0@159%3E0@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M54)315%514Y4($5614Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"CQD:78^
M(#QD:78@<W1Y;&4],T0G1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!4
M15A4+4E.1$5.5#H@,'!T)SX@/"$M+5-T87)T1G)A9VUE;G0M+3X@/&1I=B!S
M='EL93TS1"=$25-03$%9.B!B;&]C:SL@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`X+C%P=#L@=&5X="UA
M;&EG;CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P="<^($Y/5$4@-2`M(%-50E-%
M455%3E0@159%3E13.CPO9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P=#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#!P="<^("9N8G-P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T.R!415A4+4%,24=..B!L969T
M.R!415A4+4E.1$5.5#H@,'!T)SX@/&9O;G0@<W1Y;&4],T0G3$545$52+5-0
M04-)3D<Z(#EP="<^)FYB<W`[)FYB<W`[)FYB<W`[/"]F;VYT/B`F;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@3VX@36%R8V@@,30L(#(P,3(L('1H
M92!#;VUP86YY(&ES<W5E9"`X,RPP,#`@86YD(#4P+#`P,"!S:&%R97,@;V8@
M:71S(&-O;6UO;B!S=&]C:RP@<F5S<&5C=&EV96QY+"!T;R!T=V\@861V:7-O
M<GD@8V]M<&%N:65S(&%S(')E;75N97)A=&EO;B!F;W(@<V5R=FEC97,@<')O
M=FED960N(%1H92!F86ER('9A;'5E<R!O9B!T:&4@<VAA<F5S(&%T('1H92!D
M871E(&]F(&=R86YT('=E<F4@)#(T+#`W,"!A;F0@)#$T+#4P,"!R97-P96-T
M:79E;'DN(%-E92!A;'-O(&YO=&5S(#)H(&%N9"`R:BX\+V1I=CX@/"$M+45N
M9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C$V9C<T9CE?93(X,%\T9F0R7SEB9C1?
M-34S-#$P-S4S9F9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8Q
M-F8W-&8Y7V4R.#!?-&9D,E\Y8F8T7S4U,S0Q,#<U,V9F8R]7;W)K<VAE971S
M+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M
M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(
M4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*/"]X
M;6P^#0HM+2TM+2T]7TYE>'1087)T7S8Q-F8W-&8Y7V4R.#!?-&9D,E\Y8F8T
17S4U,S0Q,#<U,V9F8RTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <!--StartFragment--> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"> <font style="DISPLAY: inline; FONT-WEIGHT: bold">NOTE 2 -</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMMITMENTS</font>:</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> a.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Under the terms of the First Agreement with Hadasit (note 1a(1) above), the Company retained Hadasit to provide consulting and clinical trial services. As remuneration for the services provided under the agreement, Hadasit is entitled to $200,000. The primary researcher for Hadasit is Dr. Miriam Kidron, a director and officer of the Company. The funds paid to Hadasit under the agreement are deposited by Hadasit into a research fund managed by Dr. Kidron. Pursuant to the general policy of Hadasit with respect to its research funds, Dr. Kidron receives from Hadasit a management fee in the rate of 10% of all the funds deposited into this research fund. The total amount paid to Dr. Kidron out of this fund was $10,214.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On January 7, 2009, the Company entered into a second agreement with Hadasit (the "Second Agreement") which confirms that Hadasit has conveyed, transferred and assigned all of its ownership rights in the patents acquired under the First Agreement to the Company, and certain other patents filed by the Company after the First Agreement as a result of the collaboration between the Company and Hadasit.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On July 8, 2009 the Company entered into a third agreement with Hadasit, Prof. Itamar Raz and Dr. Miriam Kidron ("the Third Agreement"), to retain consulting and clinical trial services from Hadasit. According to the Third Agreement, Hadasit will be entitled to total consideration of $400,000 to be paid by Oramed. $200,000 of this amount was agreed in the terms of the First Agreement, and the remaining of $200,000 will be paid in accordance with the actual progress of the study. The total amount that was paid through February 29, 2012 was $400,000.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On September 11, 2011, the Company entered into a fourth agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr ("the Fourth Agreement"), to retain consulting and clinical trial services. According to the Fourth Agreement, Hadasit will be entitled to consideration of $200,000 to be paid by the Company, none of which was recognized or paid through February 29, 2012.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> b.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On March 18, 2012, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012. The monthly lease payment will be NIS 3,400 in 2012, NIS 4,225 in 2013 and NIS 5,610 from 2014 onwards, and will be linked to the increase in the Israeli consumer price index (as of February 29, 2012, the monthly payment in the Company&#39;s functional currency is $903, the future annual lease payments under the agreement will be $10,836 - $17,878).</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> As security for its obligation under the lease agreements the Subsidiary provided a bank guarantee in an amount equal to three monthly lease payments. valid until November 30, 2016.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> c.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> On April 21, 2009, the Subsidiary entered into a consulting service agreement with<font style="DISPLAY: inline; FONT-WEIGHT: bold">&nbsp;</font> ADRES Advanced Regulatory Services Ltd. ("ADRES") (the "Original Agreement") pursuant to which ADRES will provide consulting services relating to quality assurance and regulatory processes and procedures in order to assist the Subsidiary in submission of a U.S. Investigational New Drug ("IND") according to the U.S. Food and Drug Administration (the "FDA") regulations. In consideration for the services provided under the agreement, ADRES will be entitled to total cash compensation of $211,000, of which the amount of $110,000 will be paid as a monthly fixed fee of $10,000 each month for 11 months commencing May 2009, and the remaining $101,000 will be paid based on achievement of certain milestones. $160,000 of the total amount was paid through November 30, 2011, $50,000 of which was paid for completing the first three milestones.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On February 26, 2012, the parties entered into an amendment agreement, according to which the Subsidiary will pay the remaining $51,000 of the Original Agreement upon issuance the amendment agreement. In addition, beginning March 1, 2012 and until submission of the IND, the Subsidiary will pay ADRES a monthly fee of approximately $3,600<font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font> The Company recognized the $51,000 as an expense through February 29, 2012.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> d.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On February 10, 2010, the Subsidiary entered into an agreement with Vetgenerics Research G. Ziv Ltd, a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. The total cost estimated for the studies is &euro;107,100 ($143,831) of which &euro;89,293 ($120,029) was paid through February 29, 2012.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> e.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on February 22, 2011 and an option to purchase up to 250,000 shares of common stock, par value $0.001 per share, of the Company at an exercise price of $0.50 per share. The option vest in five annual installments commencing February 16, 2012 and expire on February 16, 2021. The initial fair value of the option on the date of grant was $71,495, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 113.80%; risk-free interest rates of 3.42%; and the remaining contractual life of 10 years. The fair value of the options granted is measured on a final basis at each balance sheet reporting date and is recognized over the related service period using the straight-line method.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> f.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On May 13, 2011, the Company entered into a consulting agreement with a third party (the "Consultant") for a period of 12 months, pursuant to which the Consultant will provide investor relations services and will be entitled to a cash monthly fee of $4,000, that may be increased up to $10,000 upon the completion of a $5,000,000 capital raise by the Company. In addition, the Consultant received a warrant to purchase up to 32,000 shares of the Company. The warrant has a term of five years and an exercise price of $0.50 per Share and will vest in 12 installments in the period from October 2011 to May 2016. The Company records expenses in respect of this warrant during the term of the services.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 72pt; text-align: left; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> g.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On June 22, 2011, the Subsidiary issued a purchase order to SAFC Pharma for producing one of its oral capsule ingredients in the amount of $600,000, $170,000 of which was recognized through February 29, 2012.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> h.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On August 15, 2011, the Company entered into an advisory agreement with a third party (the "Advisor") for a period of nine months, pursuant to which the Advisor will provide investors relations services and will be entitled to a cash monthly fee of $4,000, and an additional $3,000 in the first month. In addition, the Advisor will be issued 249,000 shares of the Company&#39;s common stock in three equal installments over the engagement period, commencing November 2011. See also notes 4 and 5.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> i.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On December 12, 2011, the Subsidiary entered into a Supply Agreement with Swiss Caps AG ("Swiss Caps"), according to which, Swiss Caps will manufacture insulin capsules for a total consideration of CHF 395,000 (approximately $440,600) of which CHF 180,000 (approximately $195,600) was paid through February 29, 2012.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> j.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 300,000 shares of common stock of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 750,000 shares of common stock of the Company. The warrant has a term of five years and an exercise price of $0.50 per share and will vest in 12 monthly installments over the term of the agreement. The Company records expenses in respect of this warrant during the term of the services. See also note 5.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> k.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Grants from Bio-Jerusalem</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The Subsidiary is committed to pay royalties to Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $52,733.&nbsp;&nbsp;As of February 29, 2012, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> For the six month period ended February 29, 2012, there were no grants received from the Bio-Jerusalem fund.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> l.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Grants from the Office of the Chief Scientist ("OCS")</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The Subsidiary is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> At the time the grants were received, successful development of the related products was not assured. In case of failure of a product that was partly financed as above, the Subsidiary is not obligated to pay any such royalties.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Under the terms of the Subsidiary&#39;s funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Subsidiary (dollar linked) with the addition of annual interest at a rate based on LIBOR.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> As of February 29, 2012, the Subsidiary had not yet realized any revenues from such product and did not incur any royalty liability. The total amount received through February 29, 2012 was $1,078,545.</div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 75.7pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> For the six month period ended February 29, 2012, the research and development expenses are presented net of OCS grants, in the total amount of $57,038.</div> </td> </tr> </table> </div> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EOKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 1,824,141<span></span></td>
        <td class="nump">$ 1,513,365<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short term deposits</a></td>
        <td class="nump">838,738<span></span></td>
        <td class="nump">1,801,400<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">341,454<span></span></td>
        <td class="nump">384,565<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">16,000<span></span></td>
        <td class="nump">16,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - other</a></td>
        <td class="nump">46,668<span></span></td>
        <td class="nump">542,891<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">12,805<span></span></td>
        <td class="nump">1,670<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Related parties</a></td>
        <td class="nump">432<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Grants receivable from the Chief Scientist</a></td>
        <td class="nump">28,045<span></span></td>
        <td class="nump">24,191<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">T o t a l current assets</a></td>
        <td class="nump">3,108,283<span></span></td>
        <td class="nump">4,284,082<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">LONG TERM DEPOSITS AND INVESTMENT</a></td>
        <td class="nump">9,412<span></span></td>
        <td class="nump">10,186<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidPensionCosts', window );">AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">17,101<span></span></td>
        <td class="nump">14,293<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, net</a></td>
        <td class="nump">7,792<span></span></td>
        <td class="nump">17,376<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">T o t a l assets</a></td>
        <td class="nump">3,142,588<span></span></td>
        <td class="nump">4,325,937<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">534,907<span></span></td>
        <td class="nump">375,538<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related parties</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">18,502<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Account payable with former shareholder</a></td>
        <td class="nump">47,252<span></span></td>
        <td class="nump">47,252<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">T o t a l current liabilities</a></td>
        <td class="nump">582,159<span></span></td>
        <td class="nump">441,292<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee rights upon retirement</a></td>
        <td class="nump">23,982<span></span></td>
        <td class="nump">22,675<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Provision for uncertain tax position</a></td>
        <td class="nump">138,054<span></span></td>
        <td class="nump">138,054<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">162,036<span></span></td>
        <td class="nump">160,729<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS (note 2)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">744,145<span></span></td>
        <td class="nump">602,021<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $ 0.001 par value - authorized: 200,000,000 shares at February 29, 2012 and August 31, 2011; issued and outstanding: 70,187,583 shares at February 29, 2012 and 70,104,583 at August 31, 2011</a></td>
        <td class="nump">70,187<span></span></td>
        <td class="nump">70,104<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">18,339,399<span></span></td>
        <td class="nump">18,201,111<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(16,011,193)<span></span></td>
        <td class="num">(14,547,299)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">T o t a l stockholders' equity</a></td>
        <td class="nump">2,398,393<span></span></td>
        <td class="nump">3,723,916<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">T o t a l liabilities and stockholders' equity</a></td>
        <td class="nump">$ 3,142,588<span></span></td>
        <td class="nump">$ 4,325,937<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due within 1 year (or 1 business cycle) from other related parties which are not otherwise stated in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueFromOtherRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of investments and other noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsAndOtherNoncurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Interpretation (FIN)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability for underfunded plans recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement defined benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6410544&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidPensionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative employer's contributions in excess of net pension cost recognized, before the adoption of the recognition provisions of FAS 158. Under FAS 158, prepaid pension costs are no longer recognized in the statement of financial position. Note that there is a separate concept for noncurrent assets relating to defined benefit pension and other defined benefit postretirement plans for use under the recognition provisions of FAS 158.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c(4)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6410544&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidPensionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Chapter 4<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-8, 3<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJZBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">119 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,463,894)<span></span></td>
        <td class="num">$ (1,245,575)<span></span></td>
        <td class="num">$ (16,011,193)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">11,713<span></span></td>
        <td class="nump">15,122<span></span></td>
        <td class="nump">117,820<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">108,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange differences</a></td>
        <td class="nump">2,963<span></span></td>
        <td class="num">(570)<span></span></td>
        <td class="nump">295<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">83,036<span></span></td>
        <td class="nump">335,797<span></span></td>
        <td class="nump">4,783,165<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for services</a></td>
        <td class="nump">24,900<span></span></td>
        <td class="nump">119,800<span></span></td>
        <td class="nump">1,072,996<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims', window );">Common stock to be issued for services</a></td>
        <td class="nump">30,435<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">30,435<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments', window );">Gain on sale of investment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,033,004)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet', window );">Impairment of investment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">434,876<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities', window );">Impairment of available for sales securities</a></td>
        <td class="nump">43,111<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">240,523<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_ImputedInterestExpense', window );">Imputed interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,891<span></span></td>
        <td class="nump">23,559<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">30,802<span></span></td>
        <td class="num">(29,124)<span></span></td>
        <td class="num">(87,140)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="num">(16,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">140,867<span></span></td>
        <td class="nump">107,249<span></span></td>
        <td class="nump">534,907<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations', window );">Liability of employee rights upon retirement</a></td>
        <td class="nump">1,307<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">23,982<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Provision for uncertain tax position</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">138,054<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Total net cash used in operating activities</a></td>
        <td class="num">(1,094,760)<span></span></td>
        <td class="num">(695,402)<span></span></td>
        <td class="num">(9,638,725)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(2,129)<span></span></td>
        <td class="num">(1,475)<span></span></td>
        <td class="num">(125,612)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Acquisition of short-term investments, net</a></td>
        <td class="nump">961,262<span></span></td>
        <td class="num">(1,677,000)<span></span></td>
        <td class="num">(4,467,120)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Funds in respect of employee rights upon retirement</a></td>
        <td class="num">(3,597)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(17,890)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of investment in Entera</a></td>
        <td class="nump">450,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">450,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from sale of Short term investments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,628,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Lease deposits</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(7,509)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Total net cash derived from (used in) investing activities</a></td>
        <td class="nump">1,405,536<span></span></td>
        <td class="num">(1,678,475)<span></span></td>
        <td class="num">(540,131)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants - net of issuance expenses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,106,000<span></span></td>
        <td class="nump">11,655,693<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances', window );">Receipts on account of shares issuances</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">6,061<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">275,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from short term note payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">120,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of short term note payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(120,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Shareholder advances</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">66,243<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,106,000<span></span></td>
        <td class="nump">12,002,997<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">310,776<span></span></td>
        <td class="nump">732,123<span></span></td>
        <td class="nump">1,824,141<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">1,513,365<span></span></td>
        <td class="nump">1,199,638<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">1,824,141<span></span></td>
        <td class="nump">1,931,761<span></span></td>
        <td class="nump">1,824,141<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued for offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,753<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Contribution to paid in capital</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">18,991<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature', window );">Discount on convertible note related to beneficial conversion feature</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 108,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Discount on convertible note related to beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_ImputedInterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Imputed Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_ImputedInterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of stock and warrants to be issued for services or claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Receipts On Account Of Shares Issuances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_ProceedsFromReceiptsOnAccountOfSharesIssuances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of interest expense representing the noncash expenses charged against earnings in the period to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate caption: Noncash Interest Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of property contributed in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContributionOfProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due to fund pension and non-pension benefits to employees, retired and disabled former employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPensionAndPostretirementObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 16B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 7<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15C<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of other than temporary impairment losses on investments in debt and equity securities categorized as Available-for-sale which have been recognized in earnings during the period. Such impairment losses consist of other than temporary impairments (OTTI) on equity securities, credit losses on investments in debt securities, and when the entity intends to sell an impaired debt security or it is more likely than not that the entity will be required to sell the impaired debt security before recovery of its amortized cost basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 7<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15C<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Section Appendix C<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> a.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> General:</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 76.55pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 1.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Oramed Pharmaceuticals, Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement (the "First Agreement") with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. The Company has been in the development stage since its formation and has not yet realized any revenues from its planned operations. <font style="DISPLAY: inline; FONT-SIZE: 10pt">On March 11, 2011, Oramed was reincorporated from the State of Nevada to the State of Delaware.</font></div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 112pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd (the "Subsidiary").</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 112pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with Accounting Standard Codification ("ASC") No. 915, "Development Stage Entities".</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 76.55pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 2.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> The accompanying unaudited condensed consolidated financial statements as of February 29, 2012 and for the six months then ended, have been prepared in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required for annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. The accounting principles applied in the preparation of the condensed statements are consistent with those applied in the preparation of the annual financial statements, however the condensed statements do not include all the information and explanations required for the annual financial statements. Operating results for the six months ended February 29, 2012, are not necessarily indicative of the results that may be expected for the year ending August 31, 2012.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 76.55pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 3.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> Going concern considerations</div> <div style="text-align: left">&nbsp;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (April&nbsp;12, 2002) through February 29, 2012 of $16,011,193 as well as negative cash flow from operating activities. Presently, the Company does not have sufficient cash resources to meet its requirements in the twelve months following February 29, 2012. These factors raise substantial doubt about the Company&#39;s ability to continue as a going concern. Management is in the process of evaluating various financing alternatives as the Company will need to finance future research and development activities and general and administrative expenses through fund raising<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&nbsp;</font> in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders, as well as on going funding from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel ("OCS").</div> </td> </tr> </table> </div> <div>&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 112pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> These condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company&#39;s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability<font style="DISPLAY: inline; FONT-SIZE: 10pt">.</font></div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 39.699pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> b.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; text-align: justify"> Newly issued and recently adopted Accounting Pronouncements</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 76.55pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 1.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; text-align: left"> In May 2011, the Financial Accounting Standard Board ("FASB") issued an accounting update that amends ASC No. 820, "Fair Value Measurement" regarding fair value measurements and disclosure requirements. The amendments are effective during interim and annual periods beginning after December&nbsp;15, 2011 and are to be applied prospectively. The accounting update will be applicable to the Company beginning in the third quarter of fiscal year 2012. As applicable to the Company, the adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.</div> </td> </tr> </table> </div> <div>&nbsp;</div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 76.55pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> &nbsp;</div> </td> <td style="WIDTH: 36pt"> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt"> 2.</div> </td> <td> <div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> In June 2011, the FASB issued an update to ASC No.&nbsp;220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders&#39; equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The accounting update will be applicable to the Company beginning on September 1, 2012. The adoption of the new guidance is not expected to have a material impact on the consolidated financial statements.</div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">70,187,583<span></span></td>
        <td class="nump">70,104,583<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">70,187,583<span></span></td>
        <td class="nump">70,104,583<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 03, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Feb. 29,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ORAMED PHARMACEUTICALS INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001176309<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--08-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">70,320,583<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETOAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="1">119 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATION [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="nump">$ 710,647<span></span></td>
        <td class="nump">$ 341,328<span></span></td>
        <td class="nump">$ 894,663<span></span></td>
        <td class="nump">$ 627,816<span></span></td>
        <td class="nump">$ 8,746,512<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet', window );">IMPAIRMENT OF INVESTMENT</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">434,876<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="nump">229,704<span></span></td>
        <td class="nump">305,887<span></span></td>
        <td class="nump">511,605<span></span></td>
        <td class="nump">621,016<span></span></td>
        <td class="nump">7,469,988<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="nump">940,351<span></span></td>
        <td class="nump">647,215<span></span></td>
        <td class="nump">1,406,268<span></span></td>
        <td class="nump">1,248,832<span></span></td>
        <td class="nump">16,651,376<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
        <td class="num">(7,574)<span></span></td>
        <td class="num">(7,856)<span></span></td>
        <td class="num">(14,528)<span></span></td>
        <td class="num">(10,045)<span></span></td>
        <td class="num">(208,560)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
        <td class="nump">9,487<span></span></td>
        <td class="nump">3,432<span></span></td>
        <td class="nump">29,043<span></span></td>
        <td class="nump">6,788<span></span></td>
        <td class="nump">210,300<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments', window );">GAIN ON SALE OF INVESTMENT</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,033,004)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities', window );">IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES</a></td>
        <td class="nump">43,111<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">43,111<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">240,523<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE TAXES ON INCOME</a></td>
        <td class="nump">985,375<span></span></td>
        <td class="nump">642,791<span></span></td>
        <td class="nump">1,463,894<span></span></td>
        <td class="nump">1,245,575<span></span></td>
        <td class="nump">15,860,635<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">150,558<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="nump">$ 985,375<span></span></td>
        <td class="nump">$ 642,791<span></span></td>
        <td class="nump">$ 1,463,894<span></span></td>
        <td class="nump">$ 1,245,575<span></span></td>
        <td class="nump">$ 16,011,193<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare', window );">WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK</a></td>
        <td class="nump">70,176,638<span></span></td>
        <td class="nump">62,804,799<span></span></td>
        <td class="nump">70,140,610<span></span></td>
        <td class="nump">60,344,880<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 22<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 28<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a, b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A7<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 10, 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 87-21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 28, 29, 30<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Chapter 4<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-4<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 16B<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15C<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of other than temporary impairment losses on investments in debt and equity securities categorized as Available-for-sale which have been recognized in earnings during the period. Such impairment losses consist of other than temporary impairments (OTTI) on equity securities, credit losses on investments in debt securities, and when the entity intends to sell an impaired debt security or it is more likely than not that the entity will be required to sell the impaired debt security before recovery of its amortized cost basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15C<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141<br><br><br><br> -Paragraph 51<br><br><br><br> -Subparagraph g<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 2<br><br><br><br> -Paragraph 12, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 86<br><br><br><br> -Paragraph 11, 12<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> <!--StartFragment--> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 8.1pt; text-align: left; TEXT-INDENT: 0pt"> NOTE 5 - SUBSEQUENT EVENTS:</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> &nbsp;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> <font style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On March 14, 2012, the Company issued 83,000 and 50,000 shares of its common stock, respectively, to two advisory companies as remuneration for services provided. The fair values of the shares at the date of grant were $24,070 and $14,500 respectively. See also notes 2h and 2j.</div> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYPDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional paid-in capital [Member]</div>
        </th>
        <th class="th">
          <div>Deficit accumulated during the development stage [Member]</div>
        </th>
        <th class="th">
          <div>Other comprehensive loss [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Apr. 11, 2002</a></td>
        <td class="nump">$ 53,700<span></span></td>
        <td class="nump">$ 34,828<span></span></td>
        <td class="nump">$ 18,872<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE, shares at Apr. 11, 2002</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,828,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_SharesCancelledValue', window );">SHARES CANCELLED</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19,800)<span></span></td>
        <td class="nump">19,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_SharesCancelledShares', window );">SHARES CANCELLED, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19,800,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">SHARES ISSUED FOR INVESTMENT IN ISTI-NJ</a></td>
        <td class="nump">434,876<span></span></td>
        <td class="nump">1,144<span></span></td>
        <td class="nump">433,732<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">SHARES ISSUED FOR INVESTMENT IN ISTI-NJ, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,144,410<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodValueOfferingCosts', window );">SHARES ISSUED FOR OFFERING COSTS</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,753<span></span></td>
        <td class="num">(1,753)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodSharesOfferingCosts', window );">SHARES ISSUED FOR OFFERING COSTS, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,752,941<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES</a></td>
        <td class="nump">7,907,781<span></span></td>
        <td class="nump">37,359<span></span></td>
        <td class="nump">7,870,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">37,359,230<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodValueServices', window );">SHARES ISSUED FOR SERVICES RENDERED</a></td>
        <td class="nump">821,337<span></span></td>
        <td class="nump">1,731<span></span></td>
        <td class="nump">819,606<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodSharesServices', window );">SHARES ISSUED FOR SERVICES RENDERED, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,730,540<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">CONTRIBUTIONS TO PAID IN CAPITAL</a></td>
        <td class="nump">18,991<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,991<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_ReceiptsOnAccountOfSharesAndWarrants', window );">RECEIPTS ON ACCOUNT OF SHARES AND WARRANTS</a></td>
        <td class="nump">6,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE</a></td>
        <td class="nump">275,000<span></span></td>
        <td class="nump">550<span></span></td>
        <td class="nump">274,450<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">550,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</a></td>
        <td class="nump">3,554,921<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,554,921<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</a></td>
        <td class="nump">615,882<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">615,882<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">DISCOUNT ON CONVERTIBLE NOTE RELATED TO BENEFICIAL CONVERSION FEATURE</a></td>
        <td class="nump">108,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">108,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">OTHER COMPREHENSIVE INCOME (LOSS)</a></td>
        <td class="num">(16)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(16)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest', window );">IMPUTED INTEREST</a></td>
        <td class="nump">19,777<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,777<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
        <td class="num">(12,986,038)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,986,038)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Aug. 31, 2010</a></td>
        <td class="nump">830,272<span></span></td>
        <td class="nump">57,565<span></span></td>
        <td class="nump">13,758,761<span></span></td>
        <td class="num">(12,986,038)<span></span></td>
        <td class="num">(16)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE, shares at Aug. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,565,321<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES</a></td>
        <td class="nump">3,694,212<span></span></td>
        <td class="nump">11,808<span></span></td>
        <td class="nump">3,682,404<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,808,626<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodValueServices', window );">SHARES ISSUED FOR SERVICES RENDERED</a></td>
        <td class="nump">227,569<span></span></td>
        <td class="nump">731<span></span></td>
        <td class="nump">226,838<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodSharesServices', window );">SHARES ISSUED FOR SERVICES RENDERED, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">730,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</a></td>
        <td class="nump">502,593<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">502,593<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</a></td>
        <td class="nump">26,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,733<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest', window );">IMPUTED INTEREST</a></td>
        <td class="nump">3,782<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,782<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
        <td class="num">(1,561,245)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,561,245)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Aug. 31, 2011</a></td>
        <td class="nump">3,723,916<span></span></td>
        <td class="nump">70,104<span></span></td>
        <td class="nump">18,201,111<span></span></td>
        <td class="num">(14,547,283)<span></span></td>
        <td class="num">(16)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE, shares at Aug. 31, 2011</a></td>
        <td class="nump">70,104,583<span></span></td>
        <td class="nump">70,104,583<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodValueServices', window );">SHARES ISSUED FOR SERVICES RENDERED</a></td>
        <td class="nump">24,900<span></span></td>
        <td class="nump">83<span></span></td>
        <td class="nump">24,817<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodSharesServices', window );">SHARES ISSUED FOR SERVICES RENDERED, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_StockIssuedDuringPeriodValueServicesRendered', window );">SHARES TO BE ISSUED FOR SERVICES RENDERED</a></td>
        <td class="nump">30,435<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,435<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS</a></td>
        <td class="nump">66,136<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66,136<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants', window );">STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS</a></td>
        <td class="nump">16,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
        <td class="num">(1,463,894)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,463,894)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Feb. 29, 2012</a></td>
        <td class="nump">$ 2,398,393<span></span></td>
        <td class="nump">$ 70,187<span></span></td>
        <td class="nump">$ 18,339,399<span></span></td>
        <td class="num">$ (16,011,193)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE, shares at Feb. 29, 2012</a></td>
        <td class="nump">70,187,583<span></span></td>
        <td class="nump">70,187,583<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustments To Additional Paid In Capital Share Based Compensation, Stock Options, Requisite Service Period Recognition, Consultants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment To Additional Paid In Capital Imputed Interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_ReceiptsOnAccountOfSharesAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Receipts On Account Of Shares And Warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_ReceiptsOnAccountOfSharesAndWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_SharesCancelledShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares Cancelled, Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_SharesCancelledShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_SharesCancelledValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares Cancelled, Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_SharesCancelledValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_StockIssuedDuringPeriodSharesOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period, Shares, Offering Costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_StockIssuedDuringPeriodSharesOfferingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_StockIssuedDuringPeriodSharesServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period, Shares, Services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_StockIssuedDuringPeriodSharesServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_StockIssuedDuringPeriodValueOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period, Value, Offering Costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_StockIssuedDuringPeriodValueOfferingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_StockIssuedDuringPeriodValueServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period, Value, Services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_StockIssuedDuringPeriodValueServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ormp_StockIssuedDuringPeriodValueServicesRendered">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period, Value, Services Rendered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ormp_StockIssuedDuringPeriodValueServicesRendered</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ormp_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 51<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909077&amp;loc=d3e34017-109320<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 05-8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents increases or decreases in additional paid in capital not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK HOLDERS' EQUITY [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK HOLDERS' EQUITY</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"> <!--StartFragment--> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> NOTE 4 - STOCK HOLDERS&#39; EQUITY:</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"> <font style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On December 12, 2011, the Company issued 83,000 shares of its common stock to the Advisor as remuneration for services provided. The fair value of the shares at the date of grant was $24,900. See also note 2h.</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block">&nbsp;</div> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>36</ContextCount>
  <ElementCount>110</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/CondensedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>102 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>103 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/FairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>104 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>105 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oramed.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Feb. 28, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Aug. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Apr. 11, 2002'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Aug. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '101 Months Ended
Aug. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>ormp-20120229.xml</File>
    <File>ormp-20120229.xsd</File>
    <File>ormp-20120229_cal.xml</File>
    <File>ormp-20120229_def.xml</File>
    <File>ormp-20120229_lab.xml</File>
    <File>ormp-20120229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
